0001493152-23-017496.txt : 20230515 0001493152-23-017496.hdr.sgml : 20230515 20230515170346 ACCESSION NUMBER: 0001493152-23-017496 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OZOP ENERGY SOLUTIONS, INC. CENTRAL INDEX KEY: 0001679817 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 352540672 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55976 FILM NUMBER: 23924033 BUSINESS ADDRESS: STREET 1: 55 RONALD REAGAN BLVD. CITY: WARWICK STATE: NY ZIP: 10990 BUSINESS PHONE: (845) 544-5112 MAIL ADDRESS: STREET 1: 55 RONALD REAGAN BLVD. CITY: WARWICK STATE: NY ZIP: 10990 FORMER COMPANY: FORMER CONFORMED NAME: OZOP SURGICAL CORP. DATE OF NAME CHANGE: 20180521 FORMER COMPANY: FORMER CONFORMED NAME: Newmarkt Corp. DATE OF NAME CHANGE: 20160715 10-Q 1 form10-q.htm
0001679817 false --12-31 Q1 P5Y P5Y 0001679817 2023-01-01 2023-03-31 0001679817 2023-05-15 0001679817 2023-03-31 0001679817 2022-12-31 0001679817 us-gaap:SeriesDPreferredStockMember 2023-03-31 0001679817 us-gaap:SeriesDPreferredStockMember 2022-12-31 0001679817 us-gaap:SeriesEPreferredStockMember 2023-03-31 0001679817 us-gaap:SeriesEPreferredStockMember 2022-12-31 0001679817 us-gaap:SeriesCPreferredStockMember 2022-12-31 0001679817 us-gaap:SeriesCPreferredStockMember 2023-03-31 0001679817 2022-01-01 2022-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2022-12-31 0001679817 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-12-31 0001679817 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-12-31 0001679817 us-gaap:CommonStockMember 2022-12-31 0001679817 us-gaap:TreasuryStockCommonMember 2022-12-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001679817 us-gaap:RetainedEarningsMember 2022-12-31 0001679817 us-gaap:NoncontrollingInterestMember 2022-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2021-12-31 0001679817 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-12-31 0001679817 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-12-31 0001679817 us-gaap:CommonStockMember 2021-12-31 0001679817 us-gaap:TreasuryStockCommonMember 2021-12-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001679817 us-gaap:RetainedEarningsMember 2021-12-31 0001679817 us-gaap:NoncontrollingInterestMember 2021-12-31 0001679817 2021-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2023-01-01 2023-03-31 0001679817 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-01-01 2023-03-31 0001679817 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2023-01-01 2023-03-31 0001679817 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001679817 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001679817 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001679817 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2022-01-01 2022-03-31 0001679817 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001679817 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001679817 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2023-03-31 0001679817 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-03-31 0001679817 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2023-03-31 0001679817 us-gaap:CommonStockMember 2023-03-31 0001679817 us-gaap:TreasuryStockCommonMember 2023-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001679817 us-gaap:RetainedEarningsMember 2023-03-31 0001679817 us-gaap:NoncontrollingInterestMember 2023-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2022-03-31 0001679817 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-03-31 0001679817 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-03-31 0001679817 us-gaap:CommonStockMember 2022-03-31 0001679817 us-gaap:TreasuryStockCommonMember 2022-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001679817 us-gaap:RetainedEarningsMember 2022-03-31 0001679817 us-gaap:NoncontrollingInterestMember 2022-03-31 0001679817 2022-03-31 0001679817 OZSC:FirstSecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember 2022-04-01 2022-04-04 0001679817 OZSC:GHSInvestmentsLLCMember OZSC:FirstSecuritiesPurchaseAgreementMember 2022-10-16 2022-10-17 0001679817 OZSC:FirstSecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001679817 OZSC:FirstSecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001679817 OZSC:FirstSecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember 2023-01-01 2023-01-23 0001679817 OZSC:SecondSecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember 2023-01-01 2023-01-18 0001679817 OZSC:SecondSecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001679817 OZSC:FirstSecuritiesPurchaseAgreementMember OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2023-04-01 2023-04-02 0001679817 2021-04-30 0001679817 OZSC:SuppliersOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:SuppliersOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:SuppliersTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:SuppliersThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:SuppliersFourMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:TwoVendorMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:CustomerAMember 2023-03-31 0001679817 OZSC:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:CustomerBMember 2023-03-31 0001679817 OZSC:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:CustomerCMember 2023-03-31 0001679817 OZSC:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:CustomerDMember 2023-03-31 0001679817 OZSC:CustomerEMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:CustomerEMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:CustomerEMember 2023-03-31 0001679817 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2023-03-31 0001679817 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2023-03-31 0001679817 srt:MinimumMember OZSC:OfficeFurnitureAndEquipmentMember 2023-03-31 0001679817 srt:MaximumMember OZSC:OfficeFurnitureAndEquipmentMember 2023-03-31 0001679817 OZSC:WarehouseEquipmentMember 2023-03-31 0001679817 OZSC:SourcedAndDistributedProductsMember 2023-01-01 2023-03-31 0001679817 OZSC:SourcedAndDistributedProductsMember 2022-01-01 2022-03-31 0001679817 OZSC:OEDInstallationsMember 2023-01-01 2023-03-31 0001679817 OZSC:OEDInstallationsMember 2022-01-01 2022-03-31 0001679817 us-gaap:FairValueInputsLevel1Member 2023-03-31 0001679817 us-gaap:FairValueInputsLevel2Member 2023-03-31 0001679817 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001679817 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001679817 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001679817 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001679817 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001679817 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001679817 OZSC:UnexercisedCommonStockPurchaseWarrantsMember 2023-01-01 2023-03-31 0001679817 OZSC:UnexercisedCommonStockPurchaseWarrantsMember 2022-01-01 2022-03-31 0001679817 us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-03-31 0001679817 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-03-31 0001679817 OZSC:PromissoryNotePayableMember 2023-01-01 2023-03-31 0001679817 OZSC:PromissoryNotePayableMember 2022-01-01 2022-03-31 0001679817 us-gaap:OfficeEquipmentMember 2023-03-31 0001679817 us-gaap:OfficeEquipmentMember 2022-12-31 0001679817 us-gaap:BuildingAndBuildingImprovementsMember 2023-03-31 0001679817 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0001679817 OZSC:FifteenPercentPromissoryNoteMember 2023-03-31 0001679817 OZSC:FifteenPercentPromissoryNoteMember 2022-12-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001679817 us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001679817 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001679817 2022-01-01 2022-12-31 0001679817 us-gaap:MeasurementInputExercisePriceMember 2022-12-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2023-03-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2023-03-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2022-12-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2022-12-31 0001679817 OZSC:MeasurementInputPriceVolatilityOneMember srt:MinimumMember 2023-03-31 0001679817 OZSC:MeasurementInputPriceVolatilityOneMember srt:MaximumMember 2023-03-31 0001679817 OZSC:MeasurementInputPriceVolatilityOneMember srt:MinimumMember 2022-12-31 0001679817 OZSC:MeasurementInputPriceVolatilityOneMember srt:MaximumMember 2022-12-31 0001679817 us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2023-03-31 0001679817 us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2023-03-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2022-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2022-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2023-01-01 2023-03-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2023-01-01 2023-03-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2023-03-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2023-03-31 0001679817 OZSC:NotePayableMember 2023-03-31 0001679817 OZSC:NotePayableMember 2022-12-31 0001679817 OZSC:NotePayableMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableMember 2022-01-01 2022-12-31 0001679817 OZSC:OtherMember 2023-03-31 0001679817 OZSC:OtherMember 2022-12-31 0001679817 OZSC:NotePayableOneMember 2023-03-31 0001679817 OZSC:NotePayableOneMember 2022-12-31 0001679817 OZSC:NotePayableOneMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableOneMember 2022-01-01 2022-12-31 0001679817 OZSC:NotePayableTwoMember 2023-03-31 0001679817 OZSC:NotePayableTwoMember 2022-12-31 0001679817 OZSC:NotePayableTwoMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableTwoMember 2022-01-01 2022-12-31 0001679817 OZSC:NotePayableThreeMember 2023-03-31 0001679817 OZSC:NotePayableThreeMember 2022-12-31 0001679817 OZSC:NotePayableThreeMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableThreeMember 2022-01-01 2022-12-31 0001679817 OZSC:NotePayableFourMember 2023-03-31 0001679817 OZSC:NotePayableFourMember 2022-12-31 0001679817 OZSC:NotePayableFourMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableFourMember 2022-01-01 2022-12-31 0001679817 OZSC:NotePayableFiveMember 2023-03-31 0001679817 OZSC:NotePayableFiveMember 2022-12-31 0001679817 OZSC:NotePayableFiveMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableFiveMember 2022-01-01 2022-12-31 0001679817 OZSC:NotePayableSixMember 2023-03-31 0001679817 OZSC:NotePayableSixMember 2022-12-31 0001679817 OZSC:NotePayableSixMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableSixMember 2022-01-01 2022-12-31 0001679817 OZSC:NotePayableSevenMember 2023-03-31 0001679817 OZSC:NotePayableSevenMember 2022-12-31 0001679817 OZSC:NotePayableSevenMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableSevenMember 2022-01-01 2022-12-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2022-11-11 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:MarchThirtyOneTwoThousandTwentyThreeMember 2022-11-11 2022-11-11 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:MarchThirtyOneTwoThousandTwentyThreeMember 2022-11-11 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:MarchThirtyOneTwoThousandTwentyThreeMember 2023-01-01 2023-03-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:MarchThirtyOneTwoThousandTwentyThreeMember 2023-03-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:MarchThirtyOneTwoThousandTwentyThreeMember 2022-12-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2021-12-07 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2021-12-05 2021-12-07 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2021-12-12 2021-12-13 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2022-10-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2023-01-01 2023-03-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2023-03-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember 2022-12-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember 2021-03-17 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember 2021-03-16 2021-03-17 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember 2021-03-22 2021-03-23 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember 2022-10-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:MarchSeventeenTwoThousandTwentyTwoMember 2023-01-01 2023-03-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:MarchSeventeenTwoThousandTwentyTwoMember 2023-03-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember 2023-03-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember 2022-12-31 0001679817 OZSC:PromissoryNoteOneMember OZSC:LenderMember 2021-02-09 0001679817 OZSC:PromissoryNoteOneMember OZSC:LenderMember 2021-02-08 2021-02-09 0001679817 OZSC:PromissoryNoteOneMember OZSC:LenderMember 2021-02-15 2021-02-16 0001679817 OZSC:PromissoryNoteTwoMember OZSC:LenderMember 2022-10-31 0001679817 OZSC:PromissoryNoteTwoMember OZSC:LenderMember 2022-10-28 2022-10-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:FebruaryNineTwoThousandTwentyTwoMember 2023-01-01 2023-03-31 0001679817 OZSC:PromissoryNoteMember OZSC:LenderMember OZSC:FebruaryNineTwoThousandTwentyTwoMember 2023-03-31 0001679817 OZSC:PromissoryNoteOneMember OZSC:LenderMember 2023-03-31 0001679817 OZSC:PromissoryNoteOneMember OZSC:LenderMember 2022-12-31 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-11-13 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-11-12 2020-11-13 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-11-17 2020-11-20 0001679817 OZSC:HolderMember 2023-03-31 0001679817 OZSC:PromissoryNoteOneMember OZSC:HolderMember 2023-01-01 2023-03-31 0001679817 OZSC:PromissoryNoteOneMember OZSC:HolderMember 2022-01-01 2022-12-31 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2023-03-31 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2022-12-31 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-11-06 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-11-05 2020-11-06 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-07-23 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-07-20 2020-07-23 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-08-24 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-08-23 2020-08-24 0001679817 OZSC:PromissoryNoteMember OZSC:HolderMember 2020-08-22 2020-08-25 0001679817 OZSC:PromissoryNoteMember 2021-12-31 0001679817 OZSC:PromissoryNoteMember 2021-05-03 0001679817 OZSC:PromissoryNoteMember 2023-03-31 0001679817 OZSC:PromissoryNoteMember 2022-12-31 0001679817 OZSC:PCTIMember OZSC:ExchangeAgreementMember 2020-09-02 0001679817 OZSC:PCTIMember OZSC:ExchangeAgreementMember 2020-08-30 2020-09-02 0001679817 OZSC:PCTIMember OZSC:ExchangeAgreementMember 2021-02-25 2021-02-26 0001679817 2022-11-10 2022-11-11 0001679817 OZSC:PromissoryNoteMember 2022-11-10 2022-11-11 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2020-07-01 2020-07-10 0001679817 OZSC:MrConwayMember OZSC:EmploymentAgreementMember 2021-12-29 2022-01-02 0001679817 OZSC:EmploymentAgreementMember 2021-12-29 2022-01-02 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2022-01-01 2022-01-31 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2022-03-01 2022-03-31 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2022-04-01 2022-04-30 0001679817 srt:ChiefExecutiveOfficerMember 2023-01-01 2023-03-31 0001679817 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-03-31 0001679817 OZSC:ChiefExecutiveOfficerBonusMember 2023-01-01 2023-03-31 0001679817 OZSC:ChiefExecutiveOfficerBonusMember 2022-01-01 2022-03-31 0001679817 OZSC:RMAAgreementMember 2021-08-28 2021-09-02 0001679817 OZSC:RMAAgreementMember 2021-09-03 2021-09-30 0001679817 OZSC:PJNStrategiesMember 2021-04-12 2021-04-13 0001679817 OZSC:PJNStrategiesMember 2021-08-30 2021-09-01 0001679817 OZSC:PJNStrategiesMember 2023-01-01 2023-03-31 0001679817 OZSC:PJNStrategiesMember 2022-01-01 2022-03-31 0001679817 OZSC:CoDirectorsOfSalesMember 2021-03-29 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember us-gaap:RestrictedStockMember 2021-03-29 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember us-gaap:RestrictedStockMember 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember 2021-06-29 2021-07-02 0001679817 OZSC:CoDirectorsOfSalesMember 2021-07-01 0001679817 OZSC:CoDirectorsOfSalesMember 2021-09-28 2021-10-01 0001679817 OZSC:CoDirectorsOfSalesMember 2021-10-01 0001679817 OZSC:CoDirectorsOfSalesMember 2022-01-01 2022-01-14 0001679817 OZSC:CoDirectorsOfSalesMember 2023-03-31 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2021-03-14 2021-03-15 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2023-01-01 2023-03-31 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2022-01-01 2022-03-31 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-05 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2021-01-05 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2021-01-06 0001679817 OZSC:MrAllenSosisMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember us-gaap:RelatedPartyMember 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001679817 OZSC:SalmanJChaudhryMember OZSC:SeparationAgreementMember us-gaap:RelatedPartyMember 2019-03-04 0001679817 OZSC:SalmanJChaudhryMember OZSC:SeparationAgreementMember us-gaap:RelatedPartyMember 2023-03-31 0001679817 OZSC:SalmanJChaudhryMember OZSC:SeparationAgreementMember us-gaap:RelatedPartyMember 2022-12-31 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2020-09-01 2020-09-02 0001679817 us-gaap:RestrictedStockMember OZSC:LeaseAgreementMember 2022-01-01 2022-03-31 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-07 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-06 2020-07-07 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:SeriesDAmendmentMember 2021-07-27 0001679817 us-gaap:InvestorMember us-gaap:SeriesDPreferredStockMember OZSC:SeriesDSPAMember 2021-06-28 2021-07-28 0001679817 us-gaap:InvestorMember us-gaap:SeriesDPreferredStockMember OZSC:SeriesDSPAMember 2021-07-28 0001679817 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001679817 OZSC:RemainingWarrantSharesMember 2023-01-01 2023-03-31 0001679817 us-gaap:SeriesEPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-07 0001679817 OZSC:BrianConwayMember 2021-08-19 0001679817 OZSC:PJNStrategiesMember 2021-08-19 0001679817 OZSC:PJNStrategiesMember 2022-09-12 2022-09-13 0001679817 OZSC:PJNStrategiesMember 2022-09-13 0001679817 2021-04-14 0001679817 stpr:CA 2021-04-11 2021-04-14 0001679817 OZSC:ThereafterMember 2021-04-14 0001679817 stpr:CA 2021-04-14 0001679817 us-gaap:AccountingStandardsUpdate201602Member 2021-12-31 0001679817 OZSC:CatherineChisMember us-gaap:LineOfCreditMember 2022-05-16 0001679817 OZSC:CatherineChisMember us-gaap:LineOfCreditMember us-gaap:LineOfCreditMember 2022-05-16 0001679817 OZSC:CatherineChisMember us-gaap:ShortTermDebtMember 2022-05-16 0001679817 OZSC:PowerConversionTechnologiesIncMember us-gaap:LineOfCreditMember 2022-06-24 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2023-04-01 2023-04-01 0001679817 OZSC:FinancingAndRegistrationRightsAgreementMember us-gaap:SubsequentEventMember 2023-05-02 2023-05-02 0001679817 us-gaap:SubsequentEventMember 2023-05-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:sqft xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarter ended March 31, 2023

 

Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from __________ to __________

 

Commission file number 000-55976

 

OZOP ENERGY SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   3841   35-2540672

(State or Other Jurisdiction of

Incorporation or Organization)

 

(Primary Standard Industrial

Classification Number)

 

(IRS Employer

Identification Number)

 

55 Ronald Reagan Blvd.

Warwick, NY 10990

(877) 785-6967

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Securities registered under Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicated by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. :

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer Smaller reporting company
Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use to the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 USC. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

As of May 15, 2023, 4,894,080,751 shares of common stock of the registrant were outstanding.

 

 

 

 

 

 

OZOP ENERGY SOLUTIONS, INC.

CONSOLIDATED FINANCIAL STATEMENTS

Table of Contents

 

  Page
   
Consolidated Balance Sheets as of March 31, 2023, and December 31, 2022 (Unaudited) F-1
   
Consolidated Statements of Operations for the three months ended March 31, 2023, and 2022 (Unaudited) F-2
   
Consolidated Statements of Stockholders’ Deficit for the three months ended March 31, 2023, and 2022 (Unaudited) F-3
   
Consolidated Statements of Cash Flows for the three months ended March 31, 2023, and 2022 (Unaudited) F-5
   
Notes to Consolidated Financial Statements (unaudited) F-6

 

  2 
 

 

OZOP ENERGY SOLUTIONS, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

   March 31, 2023   December 31, 2022 
ASSETS          
Current Assets          
Cash  $1,954,814   $1,369,210 
Prepaid expenses   69,319    59,405 
Accounts receivable   209,421    173,151 
Inventory   1,648,182    3,601,026 
Vendor deposits   3,687,266    3,053,821 
Total Current Assets   7,569,002    8,256,613 
           
Operating lease right-of-use asset, net   474,817    507,706 
Property and equipment, net   690,755    711,615 
Other assets   13,408    13,408 
TOTAL ASSETS  $8,747,982   $9,489,342 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Liabilities          
Current Liabilities          
Accounts payable and accrued expenses  $5,797,368   $5,089,009 
Convertible notes payable, net of discounts   25,000    25,000 
Current portion of notes payable, net of discounts   4,079,423    4,447,605 
Customer deposits   250,000    250,000 
Deferred liability   

490,000

    

490,000

 
Derivative liabilities   4,952,388    4,314,270 
Operating lease liability, current portion   137,011    133,508 
Liabilities of discontinued operations   1,054,473    1,059,837 
Total Current Liabilities   16,785,663    15,809,229 
           
Long Term Liabilities          
Note payable, net of discount   14,591,250    14,272,500 
Operating lease liability, net of current portion   348,997    384,382 
TOTAL LIABILITIES   31,725,910    30,466,111 
           
COMMITMENTS AND CONTINGENCIES   -    - 
           
Stockholders’ Deficit          
Preferred stock (10,000,000 shares authorized, par value $0.001) Series C Preferred Stock (50,000 shares authorized and 2,500 shares issued and outstanding, par value $0.001)   3    3 
Series D Preferred Stock (4,570 shares authorized and 1,334 shares issued and outstanding, par value $0.001)   1    1 
Series E Preferred Stock (3,000 shares authorized, -0- issued and outstanding, par value $0.001)   -    - 
Common stock (4,990,000,000 shares authorized par value $0.001; 4,879,032,132 and 4,771,275,349 shares issued and outstanding as of March 31, 2023, and December 31, 2022, respectively)   4,879,032    4,771,275 
Treasury stock, at cost, 47,500 shares of Sereis C Preferred Stock and 18,667 shares of Series D Preferred Stock   (11,249,934)   (11,249,934)
Common stock to be issued; 637,755 shares as of March 31, 2023 and December 31, 2022   638    638 
Additional paid in capital   198,005,460    197,586,824 
Accumulated deficit   (213,828,351)   (211,300,799)
Total Ozop Energy Solutions, Inc. stockholders’ deficit   (22,193,151)   (20,191,992)
Noncontrolling interest   (784,777)   (784,777)
TOTAL STOCKHOLDERS’ DEFICIT   (22,977,928)   (20,976,769)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $8,747,982   $9,489,342 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

  F-1 
 

 

OZOP ENERGY SOLUTIONS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   2023   2022 
   For the Three Months Ended March 31, 
   2023   2022 
Revenue  $2,791,198   $2,919,322 
Cost of goods sold   2,394,700    2,749,349 
Gross profit   396,498    169,973 
           
Operating expenses:          
General and administrative, related parties   240,000    390,000 
General and administrative, other   829,762    1,375,567 
Total operating expenses   1,069,762    1,765,567 
           
Loss from continuing operations   (673,264)   (1,595,594)
           
Other (income) expenses:          
Interest expense   1,221,533    3,966,898 
(Gain) loss on change in fair value of derivatives   638,118    (4,365,203)
Total Other (Income) Expenses   1,859,651    (398,305)
           
Loss from continuing operations before income taxes   (2,532,915)   (1,197,289)
Income tax provision   -    - 
Net loss from continuing operations   (2,532,915)   (1,197,289)
Discontinued Operations:          
Income (loss) from discontinued operations, net of tax   5,363    (184,180)
Net loss   (2,527,552)   (1,381,469)
Less: net loss attributable to noncontrolling interest   -    (187,708)
Net loss attributable to Ozop Energy Solutions, Inc.  $(2,527,552)  $(1,193,761)
           
Loss from contuining operations per share of common stock          
basic and fully diluted  $(0.00)  $(0.00)
Income (loss) from discontinued operations per share of common stock          
basic and fully diluted  $0.00   $(0.00)
Loss per share basic and fully diluted  $(0.00)  $(0.00)
           
Weighted average shares outstanding          
Basic and diluted   4,834,943,957    4,619,807,422 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

  F-2 
 

 

OZOP ENERGY SOLUTIONS, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2023

(Unaudited)

 

    Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Stock     Capital     Deficit     Interest     (Deficit)  
    Common stock to be issued     Series C Preferred Stock     Series D Preferred Stock     Common Stock     Treasury     Additional Paid-in     Accumulated     Noncontrolling    

Total

Stockholders’ Equity

 
    Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Stock     Capital     Deficit     Interest     (Deficit)  
Balances January 1, 2023     637,755     $ 638       2,500     $ 3       1,334     $ 1       4,771,275,349     $ 4,771,275     $ (11,249,934 )   $ 197,586,824     $ (211,300,799 )   $ (784,777 )   $ (20,976,769 )
                                                                                                         
Issuance of shares of common stock sold, net of issuance costs of $19,110     -       -       -       -       -       -       107,756,783       107,757       -       418,636       -       -       526,393  
                                                                                                         
Net loss     -       -       -       -       -       -       -       -       -       -       (2,527,552 )     -       (2,527,552 )
Balances March 31, 2023     637,755     $ 638       2,500     $ 3       1,334     $ 1       4,879,032,132     $ 4,879,032     $ (11,249,934 )   $ 198,005,460     $ (213,828,351 )   $ (784,777 )   $ (22,977,928 )

 

The accompanying notes are an integral part of these consolidated financial statements.

 

  F-3 
 

 

OZOP ENERGY SOLUTIONS, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2022

(Unaudited)

 

    Common stock to be issued     Series C Preferred Stock     Series D Preferred Stock     Common Stock     Treasury    Additional Paid-in     Accumulated     Noncontrolling    

Total

Stockholders’ Equity

 
      Shares       Amount       Shares       Amount       Shares       Amount       Shares       Amount       Stock       Capital       Deficit       Interest       (Deficit)  
Balances January 1, 2022     637,755     $ 638       2,500     $ 3       1,334     $ 1       4,617,362,977     $ 4,617,363     $ (11,249,934 )   $ 196,464,222     $ (217,326,611 )   $ (255,105 )   $ (27,749,423 )
                                                                                                         
Issuance of common stock for services     -       -       -       -       -       -       5,000,000       5,000       -       130,000       -       -       135,000  
                                                                                                         
Net loss     -       -       -       -       -       -       -       -       -       -       (1,193,761 )     (187,708 )     (1,381,469 )
Balances March 31, 2022     637,755     $ 638       2,500     $ 3       1,334     $ 1       4,622,362,977     $ 4,622,363     $ (11,249,934 )   $ 196,594,222     $ (218,520,372 )   $ (442,813 )   $ (28,995,892 )

 

The accompanying notes are an integral part of these consolidated financial statements.

 

  F-4 
 

 

OZOP ENERGY SOLUTIONS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   2023   2022 
   For the Three Months Ended March 31, 
   2023   2022 
Cash flows from operating activities:          
Net loss from continuing operations  $(2,532,915)  $(1,197,289)
Net income (loss) from discontinued operations   5,363    (184,180)
Net loss   (2,527,552)   (1,381,469)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities          
Non-cash interest expense   500,568    3,379,121 
Amortization and depreciation   55,912    41,421 
(Gain) loss on fair value change of derivatives   638,118    (4,365,203)
Stock compensation expense   -    136,249 
Changes in operating assets and liabilities:          
Accounts receivable   (36,270)   166,822 
Inventory   1,952,844    (1,253,333)
Prepaid expenses   (9,915)   (19,400)
Vendor deposits   (633,445)   (621,373)
Accounts payable and accrued expenses   708,358    542,507 
Operating lease liabilities   (31,882)   (28,658)
Customer deposits   -    400,769 
Net cash provided by (used in) continuing operations   616,736    (3,002,547)
Net cash used in discontinued operations   (5,363)   (57,909)
Net cash provided by (used in) operating activities   611,373    (3,060,456)
           
Cash flows from investing activities:          
Purchase of office and computer equipment   (2,162)   (40,000)
Net cash used in investing activities   (2,162)   (40,000)
           
Cash flows from financing activities:          
Proceeds from sale of common stock, net of costs   526,393    - 
Payments of principal of convertible note payable and notes payable   (550,000)   - 
Net cash used in financing activities   (23,607)   - 
           
Net increase (decrease) in cash   585,604    (3,100,456)
           
Cash, Beginning of period   1,369,210    6,632,194 
           
Cash, End of period  $1,954,814   $3,531,738 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $-   $10,075 
Cash paid for income taxes  $-   $- 
           
Schedule of non-cash Investing or Financing Activity:          
Issuance of common stock and preferred stockfor consulting fees and compensation  $-   $136,249 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

  F-5 
 

 

OZOP ENERGY SOLUTIONS, INC.

Notes to Consolidated Financial Statements

March 31, 2023

 

NOTE 1 - ORGANIZATION

 

Business

 

Ozop Energy Solutions, Inc. (the” Company,” “we,” “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada.

 

On October 29, 2020, the Company formed a new wholly owned subsidiary, Ozop Surgical Name Change Subsidiary, Inc., a Nevada corporation (“Merger Sub”). The Merger Sub was formed under the Nevada Revised Statutes for the sole purpose and effect of changing the Company’s name to “Ozop Energy Solutions, Inc.” That same day the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with the Merger Sub and filed Articles of Merger (the “Articles of Merger”) with the Nevada Secretary of State, merging the Merger Sub into the Company, which were stamped effective as of November 3, 2020. As permitted by the Section 92.A.180 of the Nevada Revised Statutes, the sole purpose and effect of the filing of Articles of Merger was to change the name of the Company from Ozop Surgical Corp to “Ozop Energy Solutions, Inc.”

 

On December 11, 2020, the Company formed Ozop Energy Systems, Inc. (“OES”), a Nevada corporation and a wholly owned subsidiary of the Company. OES was formed to be a manufacturer and distributor of renewable energy products.

 

On August 19, 2021, the Company formed Ozop Capital Partners, Inc. (“Ozop Capital”), a Delaware corporation and a wholly owned subsidiary of the Company. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital.

 

On October 29, 2021, EV Insurance Company, Inc. (“EVCO”) was formed as a captive insurance company in the State of Delaware. EVCO is a wholly owned subsidiary of Ozop Capital. On January 7, 2022, EVCO filed with New Castle County, Delaware DBA OZOP Plus.

 

On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners offer the resources needed for lighting, solar and electrical design projects. OED provides its customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs. We work with architects, engineers, facility managers, electrical contractors, and engineers.

 

NOTE 2 – GOING CONCERN AND MANAGEMENT’S PLANS

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2023, the Company had an accumulated deficit of $213,828,351 and a working capital deficit of $9,216,661 (including derivative liabilities of $4,952,388). As of March 31, 2023, the Company was in default of $3,690,000 plus accrued interest on debt instruments due to non-payment upon maturity dates. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date of the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

In December 2019, a novel strain of coronavirus (COVID-19) emerged. Because COVID-19 infections have been reported throughout the United States, certain federal, state and local governmental authorities have issued stay-at-home orders, proclamations and/or directives aimed at minimizing the spread of COVID-19. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but it may have a material adverse impact on our business, financial condition and results of operations. Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.

 

  F-6 
 

 

Management’s Plans

 

As a public company, Management believes it will be able to access the public equities market for fund raising for product development, sales and marketing and inventory requirements as we expand our distribution in the U.S. market.

 

On April 4, 2022, the Company, and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “1st GHS Purchase Agreement”) for the sale of up to Two Hundred Million (200,000,000) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending October 4, 2022, at our sole discretion, to GHS under the GHS Purchase Agreement. On October 17, 2022, the Company and GHS extended the Maturity Date to April 4, 2023. The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement. During the three months ended March 31, 2023, the Company sold GHS 51,087,628 shares of common stock and received $205,443, net of offering costs. During the year ended December 31, 2022, the Company sold to GHS 148,912,372 shares of common stock and received $1,141,514, net of offering costs. As of January 23, 2023, the Company sold GHS 200,000,000 shares of common stock.

 

On January 18, 2023, the Company and GHS signed a Securities Purchase Agreement (the “2nd GHS Purchase Agreement”) for the sale of up to One Hundred Fifty Million (150,000,000) shares of the Company’s common stock to GHS. The terms and conditions of the 2nd GHS Purchase Agreement are similar to the terms and conditions of the 1st GHS Purchase Agreement. During the quarter ended March 31, 2023, the Company sold to GHS 56,669,155 shares of common stock and received $320,950, net of offering costs. Subsequent to March 31, 2023, the Company has sold GHS 15,048,619 shares of common stock for proceeds of $71,827, net of offering costs.

 

OES is actively engaged in the renewable, electric vehicle (“EV”), energy storage and energy resiliency sectors. We are engaged in multiple business lines that include project development as well as equipment distribution. Our solar and energy storage projects involve large-scale battery and solar photovoltaics (PV) installations. Our utility-scale storage business model is based on an arbitrage business model in which we install multiple 1+ megawatt batteries, charge them with off-peak grid electricity under contract with the utility, then sell the power back during peak load hours at a premium, as dictated by prevailing electricity tariffs.

 

Equipment Distributor: OES has entered the component supply/distribution side of the renewable, resiliency and energy storage industries distributing the core components associated with residential and commercial solar PV systems as well as onsite battery storage and power generation. In April 2021, the Company signed a five- year lease (beginning June 1, 2021) of approximately 8,100 SF in California, for office and warehouse space to support the sales and distribution of our west coast operations. On February 22, 2023, with an effective date of March 1, 2023, the Company entered into a Sublease for a Single Subleasee Agreement (the “Sublease”) with the landlord and a third party for the office and warehouse in Carlsbad California. Pursuant to the Sublease agreement, the third party will be responsible for all of the Company’s lease obligations through May 31, 2026, the lease termination date. The Company and the subleasee have agreed to work together regarding any existing Company inventory in the facility. OES currently is focused on solar panel sales to other distributors and large installation companies.

 

Solar PV: Our PV business model involves the design and construction of electrical generating PV systems that can sell power to the utilities or be used for off grid use as part of our developing Neo-Grids solution. The Neo-Grids proprietary program, patent pending, was developed for the off-grid distribution of electricity to remove or reduce the dependency on utilities that currently burdens the EV Charging sectors. It will also reduce or eliminate the lengthy permitting processes and streamline the installations of those EV chargers.

 

Modular Energy Distribution System: The Neo-Grids, patent pending, is comprised of the design engineering, installation, and operational methodologies as well as the financial arbitrage of how we produce, capture and distribute electrical energy for the EV markets. OES has acquired the license rights to a proprietary system, the Neo-GridsTM System (patent pending), for the capture and distribution of electrical energy for the EV market. The Neo-GridsTM System will serve both the private auto and the commercial sectors. The exponential growth of the EV industry has been accelerated by the recent major commitments of most of the major car manufacturers. Our Neo-GridsTM System leverages this accelerated growth by offering (1) charging locations that can be installed with reduced delays, restricted areas or load limits and (2) EV charger electricity that is produced from renewable sources claiming little to no carbon footprint.

 

OES has developed a business plan for the Neo Grids distribution, a solution to the stress forthcoming to the existing grid infrastructure. The Company has completed its’ Neo Grid research and development as well as the first set of engineered technical drawings. This first stage of engineered technical drawings allows us to move forward with stage two, as well as to begin to construct the first prototype or proof of concept, (“PoC”). Our PoC design is partially reliant on auto manufacturers establishing standardizations of the actual charging/discharging protocols of the batteries such as on-board inverters as well as bi-directional capabilities in electric vehicles, which have only recently been established. As the market growth rate of EV’s continues to rise, the stress on the existing grid-tied infrastructure shows the need for the continued development of our Neo-Grid solution.

 

  F-7 
 

 

Ozop Plus markets vehicle service contracts (“VSC’s”) for electric vehicles (EV’s) that offer consumers to be able to purchase additional months and miles above the manufacturer’s warranty and to also bring added value to EV owners by utilizing our partnerships and strengths in the energy market to offer unique and innovative services. Among EV owners’ concerns are the EV battery repair and replacement costs, range anxiety, environmental responsibilities, roadside assistance, and the accelerated wear on additional components that EV vehicles experience. Management believes that the Ozop Plus marketed VSC’s will give “peace of mind” to the EV buyer.

 

  In May 2022, the Company entered into an agreement with GS Administrators, Inc., a member of Houston-based GSFSGroup. Under the agreement, the Company will market GSFSGroup’s EV VSC’s in all states (except, California, Florida, Massachusetts and Washington) to Ozop’s network of new and used franchised dealerships and other eligible entities. In addition to acting as an agent for the marketing, Ozop also has the right to white label the product under its’ Ozop Plus brand. Ozop’s role won’t be limited to marketing the product. GSFSGroup plans to tap into Ozop’s experience relative to battery collection and disposal and has agreed to insurance risk sharing in connection with the insurance policies that back the VSC’s. GSFSGroup is working on getting the approvals needed for the above four (4) states.
     
  On June 22, 2022, the Company entered into an Agent Agreement with Royal Administration Services, Inc. (“Royal”). Under the agreement, the Company will market Royal’s EV VSC’s and has the right to white label it under Ozop Plus. Royal has agreed to allow Ozop Plus on all VSC’s, marketed by Royal and the Company, to assume all the risk related to the electric battery at an agreed upon premium. The battery premium is dependent on the consumer’s selection of the duration of the VSC, the miles selected for coverage and the type of vehicle that the consumer has purchased, with a key component being the kWh size of the battery. These VSC’s have a maximum of 10 years and 150,000 miles and cover new and used cars from model year 2017 and newer. Royal’s VSCs are now effective in 46 states and the others have various waiting times or approvals needed.
     
  On October 13, 2022, EVCO entered into a Reinsurance Contract (the “Contract”) with American Bankers Insurance Company of Florida (“ABIC” or the “Ceding Company”). Royal is the Administrator of the Contract. Pursuant to the terms of the Contract, ABIC will cede 100% of the battery coverage portion of all electric vehicle service contracts to EVCO. On the same date ABIC and EVCO also entered into a Trust Agreement, whereas EVCO as the reinsurer agrees to deposit an amount equal to unearned premium reserves, plus losses reported but unpaid, plus the estimated amount of losses incurred but not reported to the trust account. Permissible investments (with a maturity of no more than five (5) years) of the assets of the Trust account include:

 

  U.S. Treasury Securities
  Cash or cash instruments
  U.S agency issues
  Other investments as Ceding Company approves

 

On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners offer the resources needed for lighting, solar and electrical design projects. OED will provide its’ customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs by working with architects, engineers, facility managers, electrical contractors and engineers.

 

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

 

Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2023, and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2023, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Current Report on Form 10-K filed on April 17, 2023.

 

The unaudited consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries Ozop Capital Partners, Inc., Ozop Engineering and Design, Inc., Power Conversion Technologies, Inc. (“PCTI”), Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”). All intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”).

 

  F-8 
 

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. The Company has no cash equivalents at March 31, 2023 and December 31, 2022.

 

Sales Concentration and credit risk

 

Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the three months ended March 31, 2023, and 2022, and their accounts receivable balance as of March 31, 2023:

 

   Sales % Three Months Ended March 31, 2023   Sales % Three Months Ended March 31, 2022   Accounts receivable balance March 31, 2023 
Customer A   97%   -   $149,040 
Customer B   -    19%  $- 
Customer C   -    15%  $- 
Customer D   -    15%  $- 
Customer E   -    14%  $- 

 

Accounts Receivable

 

The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.

 

Inventory

 

Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs consist of finished goods. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues. Finished goods inventories as of March 31, 2023, and December 31, 2022, were $1,648,182 and $3,601,026, respectively. As of March 31, 2023, the Company has on deposit with vendor(s) approximately $3,687,000 and has a balance due of approximately $10,264,000 for open purchase orders. The remaining balance is partially due when the vendor ships the product, with the final balance due prior to delivery.

 

Purchase concentration

 

OES purchases finished renewable energy products from its’ suppliers. For the three months ended March 31, 2023, there was one supplier that accounted for 100%. For the three months ended March 31, 2022, there were four suppliers that accounted for approximately 36%, 24%,13%, and 10%, respectively. There are only a handful of major suppliers, and we currently have supply arrangements with some of those vendors. One of these vendors requires a 20% down payment with the balances due on shipment and delivery, while other vendors’ terms are due immediately prior to delivery. We may also buy product from other distributors if we are not able to purchase direct from the manufacturer. While management believes its relationships with its vendors are good, if we are unable to continue to use and/or find alternative suppliers, when we cannot buy direct, it may have a material negative effect on our business.

 

  F-9 
 

 

Property, plant, and equipment

 

Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.

 

The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows:

 

  Building 10-25 years
  Office furniture and equipment 3-5 years
  Warehouse equipment 7 years

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. The Company has no outstanding contracts with any of its’ customers. The Company recognizes revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms.

 

For contracts with customers, ownership of the goods and associated revenue are transferred to customers at a point in time, generally upon shipment of a product to the customer or receipt of the product by the customer and without significant judgments. Any advance payments are recorded as current liability until revenue is recognized.

 

For the periods covered herein, we did not have post shipment obligations such as training or installation, customer acceptance provisions, credits and discounts, rebates and price protection, or other similar privileges.

 

The following table disaggregates our revenue by major source for the three months ended March 31, 2023, and 2022:

 

    2023     2022  
    Three months ended March 31,  
    2023     2022  
Sourced and distributed products   $ 2,758,798     $ 2,919,322  
OED Installations     32,400       -  
Total   $ 2,791,198     $ 2,919,322  

 

Revenues from sourced and distributed products are purchased from suppliers as finished goods and the Company currently brings the finished goods into a third-party warehouse to fill orders as well as to build inventory for future sales orders.

 

Advertising and Marketing Expenses

 

The Company expenses advertising and marketing costs as incurred. For the three months ended March 31, 2023, and 2022, the Company recorded advertising and marketing expenses of $17,772 and $2,478, respectively.

 

Convertible Instruments

 

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

 

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

 

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

 

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

 

  F-10 
 

 

Discontinued Operations

 

In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meet the criteria in paragraph 205-20-45-10. In the period in which the component meets held-for-sale or discontinued operations criteria the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations.

 

On September 1, 2022, the BOD of the Company authorized the filing of a Chapter 7 proceeding which meets the definition of a discontinued operation. Accordingly, the operating results of PCTI are reported as income (loss) from discontinued operations in the accompanying consolidated financial statements for the three months ended March 31, 2023, and 2022. For additional information, see Note 14- Discontinued Operations.

 

Distinguishing Liabilities from Equity

 

The Company relies on the guidance provided by ASC Topic 480, Distinguishing Liabilities from Equity, to classify certain redeemable and/or convertible instruments. The Company first determines whether a financial instrument should be classified as a liability. The Company will determine the liability classification if the financial instrument is mandatorily redeemable, or if the financial instrument, other than outstanding shares, embodies a conditional obligation that the Company must or may settle by issuing a variable number of its equity shares.

 

Once the Company determines that a financial instrument should not be classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet (“temporary equity”). The Company will determine temporary equity classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity.

 

Our CEO and Chairman holds sufficient shares of the Company’s voting preferred stock that give sufficient voting rights under the articles of incorporation and bylaws of the Company such that the CEO and Chairman can at any time unilaterally vote to increase the number of authorized shares of common stock of the Company, without the need to call a general meeting of common shareholders of the Company.

 

Initial Measurement

 

The Company records its financial instruments classified as liability, temporary equity, or permanent equity at issuance at the fair value, or cash received.

 

Subsequent Measurement – Financial Instruments Classified as Liabilities

 

The Company records the fair value of its financial instruments classified as liabilities at each subsequent measurement date. The changes in the fair value of its financial instruments classified as liabilities are recorded as other income (expenses).

 

Fair Value of Financial Instruments

 

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

  Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
  Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
  Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

  F-11 
 

 

From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.

 

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of March 31, 2023, and December 31, 2022, for each fair value hierarchy level:

 

March 31, 2023  Derivative Liabilities   Total 
Level I  $-   $- 
Level II  $-   $- 
Level III  $4,952,388   $4,952,388 

 

December 31, 2022  Derivative Liabilities   Total 
Level I  $-   $- 
Level II  $-   $- 
Level III  $4,314,270   $4,314,270 

 

Leases

 

The Company accounts for leases under ASU 2016-02 (see Note 13), applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

 

Operating lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company used an incremental borrowing rate of 7.5%, for the existing lease, based on the information available at the adoption date in determining the present value of future payments. Operating lease expense is recognized pursuant to on a straight-line basis over the lease term and is included in rent in the consolidated statements of operations.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.

 

Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.

 

  F-12 
 

 

Segment Policy

 

The Company has no reportable segments as it operates in one segment: renewable energy.

 

Earnings (Loss) Per Share

 

The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of March 31, 2023, and 2022, the Company’s dilutive securities are convertible into approximately 8,471,310,904 and 7,689,322,026, respectively, shares of common stock. The following table represents the classes of dilutive securities as of March 31, 2023, and 2022:

 

    March 31, 2023     March 31, 2022  
Convertible preferred stock (1)     7,318,548,198       6,933,544,496  
Unexercised common stock purchase warrants (1)     1,047,024,518       672,024,518  
Convertible notes payable (1)     11,025,635       2,461,916  
Promissory notes payable (1)     94,712,553       81,291,096  
TOTAL      8,471,310,904       7,689,322,026  

 

(1) The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than 4.99% of the then outstanding shares of common stock subsequent to any conversion or exercise. These shares were excluded from the diluted per share calculation because the effect of including these potential shares was anti-dilutive due to the Company’s net loss position.

 

Recent Accounting Pronouncements

 

In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging —Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company does not believe the adoption of the ASU will have a material impact on the Company’s financial position, results of operations or cash flows.

 

Other than the above, there have been no recent accounting pronouncements or changes in accounting pronouncements during the period ended March 31, 2023, that are of significance or potential significance to the Company.

 

NOTE 4 – PROPERTY AND EQUIPMENT

 

The following table summarizes the Company’s property and equipment:

 

    March 31, 2023     December 31, 2022  
Office equipment   $ 224,733     $ 222,571  
Building and building improvements     600,000       600,000  
Less: Accumulated Depreciation     (133,978 )     (110,956 )
Property and Equipment, Net   $ 690,755     $ 711,615  

 

Depreciation expenses were $23,022 and $10,805 for the three months ended March 31, 2023, and 2022, respectively.

 

NOTE 5 - CONVERTIBLE NOTES PAYABLE

 

On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a past-due 15% convertible note issued by the Company on September 13, 2017. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $25,000.

 

NOTE 6 – DERIVATIVE LIABILITIES

 

The Company determined the conversion feature of the convertible notes, which all contain variable conversion rates, represented an embedded derivative since the notes were convertible into a variable number of shares upon conversion. Accordingly, the notes are not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability.

 

  F-13 
 

 

At any given time, certain of the Company’s embedded conversion features on debt and outstanding warrants may be treated as derivative liabilities for accounting purposes under ASC 815-40 due to insufficient authorized shares to settle these outstanding contracts. Pursuant to SEC staff guidance that permits a sequencing approach based on the use of ASC 815-15-25 which provides guidance for contracts that permit partial net share settlement. The sequencing approach may be applied in one of two ways: contracts may be evaluated based on (1) earliest issuance date or (2) latest maturity date. Pursuant to the sequencing approach, the Company evaluates its contracts based upon the latest maturity date.

 

The Company valued the derivative liabilities as of March 31, 2023, and December 31, 2022, at $4,952,388 and $4,314,270 respectively. For the derivative liability associated with convertible notes, the Company used the Monte Carlo simulation valuation model with the following assumptions as of March 31, 2023, and December 31, 2022, risk free interest rates at 4.85% and 4.76%, respectively, and volatility of 86% and 71%, respectively. During the year ended December 31, 2022, the Company issued 375,000,000 warrants in conjunction with the extension of certain notes payable. The Company recorded a discount to notes payable of $2,550,000 with the offset to derivative liabilities for the initial fair value of the warrants based on the Black-Scholes option pricing model. The following assumptions were utilized in the initial Black-Scholes valuation of issued warrants during the year ended December 31, 2022, risk free interest rate of 4.45%, volatility of 509%, and an exercise price of $0.0067.

 

The following assumptions were utilized in the Black-Scholes valuation of outstanding warrants as of March 31, 2023, and December 31, 2022, risk free interest rate of 3.94% to 4.64%, and 4.39% to 4.73%, respectively, volatility of 112% to 168%, and 109% to 272%, respectively, and exercise prices of $0.0061 to $0.15.

 

A summary of the activity related to derivative liabilities for the three months ended March 31, 2023, is as follows:

 

   Derivative liabilities associated with warrants   Derivative liabilities associated with convertible notes   Total derivative liabilities 
             
Balance January 1, 2023  $4,285,400   $28,870   $4,314,270 
Change in fair value   636,213    1,905    638,118 
Balance March 31, 2023  $4,921,613   $30,775   $4,952,388 

 

NOTE 7 – NOTES PAYABLE

 

The Company has the following notes payable outstanding:

 

   March 31, 2023   December 31, 2022 
         
Note payable, interest at 8%, matured January 5, 2020, in default  $45,000   $45,000 
Other, due on demand, interest at 6%, currently in default   50,000    50,000 
Note payable $750,000 face value, interest at 12%, matured August 24, 2021, in default   375,000    375,000 
Note payable $389,423 face value, interest at 12%, matures November 6, 2023   389,423    389,423 
Note payable $1,000,000 face value, interest at 12%, matured November 13, 2021, in default   1,000,000    1,000,000 
Note payable $2,200,000 face value, interest at 15%, matures October 31, 2024, net of discount of $269,167 (2023) and $311,667 (2022)   1,930,833    1,888,333 
Note payable $11,110,000 face value, interest at 15%, matures October 31, 2024, net of discount of $1,345,833 (2023) and $1,558,333 (2022)   9,764,167    9,551,667 
Note payable $3,300,000 face value, interest at 15%, matures October 31, 2024, net of discount of $403,750 (2023) and $467,500 (2022)   2,896,250    2,832,500 
Note payable $3,020,000 face value, matured March 31, 2023, net of discount of $0 (2023) and $181,818 (2022), in default   2,220,000    2,588,182 
Sub- total notes payable, net of discount   18,670,673    18,720,105 
Less long-term portion, net of discount   14,591,250    14,272,500 
Current portion of notes payable, net of discount  $4,079,423   $4,447,605 

 

  F-14 
 

 

On November 11, 2022, the Company entered into a non-interest bearing, $3,020,000 face value promissory note with a third-party lender with scheduled weekly payments and a maturity date of March 31, 2023. In exchange for the issuance of the $3,020,000 note, inclusive of an original issue discount of $250,000, and the reclass of $260,000 from accounts payable and accrued expenses the Company received proceeds of $2,510,000 on November 11, 2022, from the lender. For the three months ended March 31, 2023, amortization of the original issue discount of $181,818 was charged to interest expense. During the three months ended March 31, 2023, the Company also repaid $550,000 of the principal of the note. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $2,220,000 and $2,770,000, respectively, with a carrying value as of March 31, 2023, and December 31, 2022, of $2,220,000 and $2,588,182, respectively, net of unamortized discounts of $181,818 as of December 31, 2022. The Company is in default on the weekly payments. The Company is currently in discussions with the lender regarding an extension of the maturity date.

 

On December 7, 2021, the Company entered into a 12%, $3,300,000 face value promissory note with a third- party lender with a maturity date of December 7, 2022. In exchange for the issuance of the $3,300,000 note, inclusive of an original issue discount of $300,000, the Company received proceeds of $3,000,000 on December 13, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 75,000,000 shares of common stock at $0.039 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. On October 31, 2022, the maturity date of the note was extended to October 31, 2024, and the interest rate was increased to 15% per annum. The Company issued 75,000,000 warrants at an exercise price of $0.0067 and with an expiration of October 31, 2025, in exchange for the extension. The warrants were valued at $510,000 by the Black-Scholes option pricing method and will be amortized through the new maturity date of the note. The Company determined that this transaction was a modification of the existing note. For the three months ended March 31, 2023, $63,750 was charged to interest expense. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $3,300,000 with carrying values of $2,896,250 and $2,832,500, respectively, net of unamortized discounts of $403,750 and $467,500 as of March 31, 2023 and December 31, 2022, respectively.

 

On March 17, 2021, the Company entered into a 12%, $11,110,000 face value promissory note with a third- party lender with a maturity date of March 17, 2022. In exchange for the issuance of the $11,110,000 note, inclusive of an original issue discount of $1,000,000 and lender costs of $110,000 the Company received proceeds of $10,000,000 on March 23, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 250,000,000 shares of common stock at $0.13 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. On October 31, 2022, the maturity date of the note was extended to October 31, 2024, and the interest rate was increased to 15% per annum. The Company issued 250,000,000 warrants at an exercise price of $0.0067 and with an expiration of October 31, 2025, in exchange for the extension. The warrants were valued at $1,700,000 by the Black-Scholes option pricing method and will be amortized through the new maturity date of the note. The Company determined that this transaction was a modification of the existing note. For the three months ended March 31, 2023, $212,500 was charged to interest expense. As of March 31, 2023 and December 31, 2022, the outstanding principal balance of this note was $11,110,000 with a carrying value of $9,764,167 and $9,551,667, respectively, net of unamortized discounts of $1,345,833 and $1,558,333, respectively.

 

On February 9, 2021, the Company entered into a 12%, $2,200,000 face value promissory note with a third- party lender with a maturity date of February 9, 2022. In exchange for the issuance of the $2,200,000 note, inclusive of an original issue discount of $200,000 the Company received proceeds of $2,000,000 on February 16, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 50,000,000 shares of common stock at $0.15 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. On October 31, 2022, the maturity date of the note was extended to October 31, 2024, and the interest rate was increased to 15% per annum. The Company issued 50,000,000 warrants at an exercise price of $0.0067 and with an expiration of October 31, 2025, in exchange for the extension. The warrants were valued at $340,000 by the Black-Scholes option pricing method and will be amortized through the new maturity date of the note. The Company determined that this transaction was a modification of the existing note. For the three months ended March 31, 2023, $42,500 was charged to interest expense. As of March 31, 2023 and December 31, 2022, the outstanding principal balance of this note was $2,200,000 with a carrying value of $1,930,833 and $1,888,333, respectively, net of unamortized discounts of $269,167 and $311,667, respectively.

 

On November 13, 2020, the Company entered into a 12%, $1,000,000 face value promissory note with a third-party due November 13, 2021. Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date. The Company received proceeds of $890,000 on November 20, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $110,000. In conjunction with this note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase 125,000,000 shares of common stock at an exercise price of $0.008, subject to adjustments and expires on the five-year anniversary of the issue date. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $1,000,000. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of March 31, 2023, and December 31, 2022, the accrued interest is $435,452 and $375,452, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

 

On November 6, 2020, the Company entered into a Settlement Agreement with the holder of $120,000 of convertible notes with accrued and unpaid interest of $8,716 and a $210,000 Promissory Noted dated June 23, 2020, with accrued and unpaid interest of $15,707. The Company issued a new 12% Promissory Note with a face value of $389,423 and a maturity date of November 6, 2023. In conjunction with this settlement, the Company issued a warrant to purchase 60,000,000 shares of common stock at an exercise price of $0.0075, subject to adjustments and expires on the five-year anniversary of the issue date. The Company analyzed the transaction and concluded that this was a modification to the existing debt. The investor exercised the warrant on January 14, 2021.

 

  F-15 
 

 

On August 24, 2020 (the “Issue Date”), the Company entered into a 12%, $750,000 face value promissory note with a third-party (the “Holder”) due August 24, 2021 (the “Maturity Date”). Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date. The Company received proceeds of $663,000 on August 25, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $87,000. In conjunction with this Note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase 122,950,819 shares of common stock at an exercise price of $0.0061, subject to adjustments and expires on the five-year anniversary of the Issue Date. During the year ended December 31, 2021, the Company paid $375,000 to the Holder. On May 3, 2021, the Company issued 75,000,000 shares of common stock to the Holder, upon the cashless exercise of a portion of the warrants. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $375,000. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of March 31, 2023, and December 31, 2022, the accrued interest is $202,747 and $180,247, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

 

NOTE 8 – DEFERRED LIABILITY

 

On September 2, 2020, PCTI entered into an agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $750,000, PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement. Payments are due ninety (90) days after each calendar quarter, with the first payment due on or before March 31, 2021, for revenues for the quarter ending December 31, 2020. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the note was amended, whereby in exchange for 175,000,000 shares of common stock, the royalty percentage was amended to 1.8%.

 

No payments have been made and the Company is in default of the agreement. On November 11, 2022, the third-party and the Company agreed to reduce the liability by $260,000 and add $260,000 to the promissory note issued on November 11, 2022. The deferred liability as of March 31, 2023, and December 31, 2022, on the consolidated balance sheet is $490,000.

 

NOTE 9 – RELATED PARTY TRANSACTIONS

 

Employment Agreement

 

On July 10, 2020, pursuant to the PCTI transaction, the Company assumed an employment contract entered into on February 28, 2020, between the Company and Mr. Conway (the “Employment Agreement”). Mr. Conway’s compensation as adjusted was $20,000 per month, and effective September 1, 2021, Mr. Conway received $10,000 per month from Ozop Capital. Effective January 1, 2022, the Company entered into a new employment agreement with Mr. Conway. Pursuant to the agreement, Mr. Conway received a $250,000 contract renewal bonus and will receive annual compensation of $240,000 from the Company and will also be eligible to receive bonuses and equity grants at the discretion of the BOD. The Company also agreed to compensate Mr. Conway for services provided directly to any of the Company’s subsidiaries. Ozop Capital increased Mr. Conway’s compensation to $20,000 per month in January 2022, OES began compensating Mr. Conway $20,000 in March 2022, and OED began compensation Mr. Conway $20,000 per month beginning in April 2022.

 

Management Fees and related party payables

 

For the three months ended March 31, 2023 and 2022, the Company recorded expenses to its officers in the following amounts:

 

   2023   2022 
   Three months ended March 31, 
   2023   2022 
CEO  $240,000   $140,000 
CEO bonus   -    250,000 
Total  $240,000   $390,000 

 

  F-16 
 

 

NOTE 10 – COMMITMENTS AND CONTINGENCIES

 

Agreements

 

On September 1, 2021, Ozop Capital entered into an advisory agreement (the “RMA Agreement”) with Risk Management Advisors, Inc. (“RMA”). Pursuant to the terms of the RMA Agreement, RMA will assist Ozop Capital in analyzing, structuring, and coordinating Ozop Capital’s participation in a captive insurance company. RMA will coordinate legal, accounting, tax, actuarial and other services necessary to implement the Company’s participation in a captive insurance company, including, but not limited to, the preparation of an actuarial feasibility study, filing of all required regulatory applications, domicile selection, structural selection, and coordination of the preparation of legal documentation. In connection with the services listed above, Ozop Capital agreed to pay $50,000 and to issue $50,000 of shares of restricted common stock. One-half of the cash and stock were due upon the signing of the RMA Agreement. Accordingly, RMA received $25,000 and 452,080 shares of restricted common stock of the Company in September 2021. The balance of the cash and stock became due on October 29, 2021, upon the issuance of the captive insurance company’s certificate of authority from the state of Delaware. The Company has paid the $25,000 balance and recorded 637,755 shares of common stock to be issued.

 

On April 13, 2021, the Company agreed to engage PJN Strategies, LLC (“PJN”) as a consultant. Pursuant to the agreement, the Company agreed to compensate PJN $20,000 per month. Effective September 1, 2021, a new agreement was entered into between PJN and Ozop Capital. Pursuant to the terms of the one- year agreement Ozop Capital agreed to compensate PJN $84,000 per month. For the three months ended March 31, 2023, and 2022, the Company recorded $-0- and $252,000, respectively, of consulting expenses.

 

On March 30, 2021, OES hired 2 individuals as Co-Directors of Sales. Pursuant to their respective offers of employment, the Company agreed to an annual salary of $130,000 with a signing bonus of $20,000 for each and to issue each 2,500,000 shares of restricted common stock upon the execution of the agreements and every 90 days thereafter for the first year as long as the employee is still employed. The Company valued the initial shares at $0.092 per share (the market price of the common stock on the date of the agreement). On July 1, 2021, the Company issued each of the Co-Directors the 2,500,000 shares due after the first ninety days of employment. The shares were valued at $0.0745 per share (the market price of the common stock on the date of the issuance). On October 1, 2021, the Company issued each of the Co-Directors the 2,500,000 shares due after the first one hundred eighty days of employment. The shares were valued at $0.0445 per share (the market price of the common stock on the date of the issuance). On January 14, 2022, the Company issued each of the Co-Directors their final 2,500,000 shares due. The shares were valued at $0.027 per share (the market price of the common stock on the date of the issuance), and $135,000 is included in stock-based compensation expense for the three months ended March 31, 2022. One of the individuals resigned on January 24, 2022, and the other was terminated for cause on November 3, 2022.

 

On March 15, 2021, the Company entered into a consulting agreement with Aurora Enterprises (“Aurora”). Mr. Steven Martello is a principal of Aurora. Pursuant to the agreement Mr. Martello will provide strategic analysis regarding existing markets and revenue streams as well as the development of new lines of revenue. The Company agreed to a monthly retainer fee of $10,000 and to issue to Aurora or their designee 5,000,000 shares of restricted common stock. For the three months ended March 31, 2023, and 2022, the Company has recorded consulting expenses of $-0- and $30,000, respectively.

 

On January 6, 2021, the Company entered into a consulting agreement with Ezra Green to begin on February 8, 2021. The Company agreed to issue 10,000,000 shares of restricted common stock to Mr. Green and to a monthly fee of $2,500. The Company valued the shares at $0.0076 per share (the market price of the common stock on the date of the agreement), and $76,000 was recorded as deferred stock-based compensation, to be amortized over the one-year term of the agreement. Effective April 1, 2021, the agreement was amended to $10,000 per month. Effective June 30, 2022, Mr. Green was no longer providing consulting services to the Company. For the three months ended March 31, 2023, and 2022, the Company recorded consulting expenses of $-0- and $30,000 of consulting expenses respectively.

 

On March 4, 2019, the Company entered into a Separation Agreement (the “Separation Agreement”) with Salman J. Chaudhry, pursuant to which the Company agreed to pay Mr. Chaudry $227,200 (the “Outstanding Fees”) in certain increments as set forth in the Separation Agreement. As of March 31, 2023, and December 31, 2022, the balance owed Mr. Chaudhry is $162,085.

 

On September 2, 2020, PCTI entered into an Agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $750,000, PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the agreement was amended, whereby in exchange for 175,000,000 shares of common stock, the royalty percentage was amended to 1.8% (see Note 8). As of March 31, 2023, and December 31, 2022, the Company has recorded $243,272, respectively, and is included in accounts payable and accrued expenses on the consolidated balance sheet presented herein.

 

Legal matters

 

We know of no material, existing or pending legal proceedings against our Company.

 

We are involved as a plaintiff in a Complaint filed in the SUPERIOR COURT OF THE STATE OF CALIFORNIA FOR THE COUNTY OF SAN DIEGO NORTH COUNTY (the “Complaint”) on November 14, 2022. The Complaint alleges that former employees would place an order from a customer for purchase of product from OZOP with funds the exact source of which is presently unknown. OZOP alleges that next, the customer would sell that product to OZOP’s customers at a price marked up from the price for which the customer purchased from OZOP – to the benefit of Defendants and to the detriment of OZOP, their employer at the time. The Complaint further alleges that the former employees falsely represented that the price the customer was obtaining from other suppliers and therefore was willing to pay for OZOP product decreased, which allowed them to use the customer to then sell additional product to OZOP’s customers at increasingly larger margins, thus further wrongfully enriching themselves to the detriment of their employer, OZOP. The lawsuit also alleges that the employees were also making false statements to Ozop’s customers regarding the financial condition of Ozop and the lack of module inventory.

 

  F-17 
 

 

There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

 

NOTE 11– STOCKHOLDERS’ EQUITY

 

Common stock

 

During the three months ended March 31, 2023, the Company issued 107,756,783 shares of common stock and received net proceeds of $526,393 after issuance costs of $19,110.

 

During the three months ended March 31, 2022, the Company issued 5,000,000 shares of restricted common stock in the aggregate for services.

 

As of March 31, 2023, the Company has 4,990,000,000 shares of $0.001 par value common stock authorized and there are 4,879,032,132 shares of common stock issued and outstanding.

 

Preferred stock

 

As of March 31, 2023, 10,000,000 shares have been authorized as preferred stock, par value $0.001 (the “Preferred Stock”), which such Preferred Stock shall be issuable in such series, and with such designations, rights and preferences as the Board of Directors may determine from time to time.

 

Series C Preferred Stock

 

On July 7, 2020, the Company filed an Amended and Restated Certificate of Designation with the State of Nevada of the Company’s Series C Preferred Stock. Under the terms of the Amendment to Certificate of Designation of Series C Preferred Stock, 50,000 shares of the Company’s preferred remain designated as Series C Preferred Stock. The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote. As of March 31, 2023, and December 31, 2022, there were 2,500 shares of Series C Preferred Stock issued and outstanding and the shares are held by Mr. Conway.

 

Series D Preferred Stock

 

On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series D Preferred Stock.

 

On July 27, 2021, the Company filed with the Secretary of State of the State of Nevada an Amended and Restated Certificate of Designation of Series D Preferred Stock (the “Series D Amendment”). Under the terms of the Series D Amendment, 4,570 shares of the Company’s preferred stock will be designated as Series D Convertible Preferred Stock. The holders of the Series D Convertible Preferred Stock shall not be entitled to receive dividends. Any holder may, at any time convert any number of shares of Series D Convertible Preferred Stock held by such holder into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion, by 1.5 and dividing that number by the number of authorized shares of Series D Convertible Preferred Stock and multiply that result by the number of shares of Series D Convertible Preferred Stock being converted. Except as provided in the Series D Amendment or as otherwise required by law, no holder of the Series D Convertible Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. The Series D Convertible Preferred Stock shall not bear any liquidation rights. On July 28, 2021, the Company closed on a Stock and Warrant Purchase Agreement (the “Series D SPA”). Pursuant to the terms of Series D SPA, an investor in exchange for $13,200,000 purchased one share of Series D Preferred Stock, and a warrant to acquire 3,236 shares of Series D Preferred Stock. As of March 31, 2023, and December 31, 2022, there were 1,334 shares, respectively, of Series D Preferred Stock issued and outstanding and a warrant to purchase 3,236 shares of Series D Preferred Stock are outstanding as of March 31, 2023, and December 31, 2022.

 

  F-18 
 

 

The warrant has a 15- year term and Partial Warrant Lock Up and Leak-Out Period. The Holder may only exercise the Warrant and purchase Warrant Shares as follows:

 

  i. Up to 162 (one hundred and sixty-two) Warrant Shares, at any time or times on or after five (5) business days from the closing of the Series D SPA (“the Initial Exercise Date”) subject to up to a maximum number of Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company and no later than on or before the 15th year anniversary of the Initial Exercise Date (“the Termination Date”); and
     
  ii. The Remainder of the Warrant representing up to 3,074 (three thousand and seventy-four) Warrant Shares (“Remaining Warrant Shares”) shall be locked up for a period of 36 (thirty-six) months from the Initial Exercise Date (“Lock Up Period”) and shall become exercisable at any time or times from the date that is the 36 (thirty-six) month anniversary of the Initial Exercise Date (“Lock Up Period Termination Date”) and no later than on or before the Termination Date, as follows:

 

  a. During every 1 (one) year period, starting on the day that is the Lock Up Period Termination Date, the Holder shall have the right to exercise the Remainder of the Warrant up to a maximum number of Remaining Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company during such given year (“Leak-Out Period”). The Leak-Out Period shall come into effect on the day that is the Lock Up Period Termination Date and remain effective on a yearly basis, for a period of 10 (ten) years thereafter, after which the Leak-Out Period will automatically terminate and become null and void. For clarity purposes the Remainder of the Warrant shall become freely exercisable at any time or times beginning on June 29, 2034, and until the Termination Date.

 

Series E Preferred Stock

 

On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series E Preferred Stock. Under the terms of the Certificate of Designation of Series E Preferred Stock, 3,000 shares of the Company’s preferred stock have been designated as Series E Preferred Stock. The holders of the Series E Convertible Preferred Stock shall not be entitled to receive dividends. No holder of the Series E Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, except as may be otherwise expressly required by law. At any time, the Corporation may redeem for cash out of funds legally available therefor, any or all of the outstanding Preferred Stock (“Optional Redemption”) at $1,000 (one thousand dollars) per share. The shares of Series E Preferred Stock have not been registered under the Securities Act of 1933 or the laws of any state of the United States and may not be transferred without such registration or an exemption from registration. As of March 31, 2023, and December 31, 2022, there were -0- shares of Series E Preferred Stock issued and outstanding, respectively.

 

NOTE 12 – NONCONTROLLING INTEREST

 

On August 19, 2021, the Company formed Ozop Capital. The Company initially owned 51% with PJN Holdings, LLC (“PJN”) owning 49%. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital. The Company presents interest held by noncontrolling interest holders within noncontrolling interest in the consolidated financial statements. On September 13, 2022, there was a change in the ownership percentages, as PJN returned 490,000 shares, representing their 49% ownership. As of that date, Ozop Capital is a wholly owned subsidiary of the Company. As of March 31, 2023, and December 31, 2022, the accumulative noncontrolling interest is $784,777.

 

NOTE 13 - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES

 

On April 14, 2021, the Company entered into a five-year lease which began on June 1, 2021, for approximately 8,100 square feet of office and warehouse space in Carlsbad, California, expiring May 31, 2026. Initial lease payments of $13,481 begin on June 1, 2021, and increase by approximately 2.4% annually thereafter. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 7.5%, as the interest rate implicit in most of our leases is not readily determinable. During the year ended December 31, 2021, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $702,888 for this lease. On February 22, 2023, with an effective date of March 1, 2023, the Company entered into a Sublease for a Single Subleasee Agreement (the “Sublease”) with the landlord and a third party for the office and warehouse in Carlsbad California. Pursuant to the Sublease agreement, the third party will be responsible for all of the Company’s lease obligations through May 31, 2026, the lease termination date. The Company and the subleasee have agreed to work together regarding any existing Company inventory in the facility.

 

In adopting Topic 842, the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less.

 

  F-19 
 

 

Right-of- use assets are summarized below:

 

   March 31, 2023   December 31, 2022 
Office and warehouse lease  $702,888   $702,888 
Less: Accumulated amortization   (228,071)   (195,182)
Right-of-use assets, net  $474,817   $507,706 

 

Operating lease liabilities are summarized as follows:

 

   March 31, 2023   December 31, 2022 
Lease liability  $486,008   $517,890 
Less current portion   (137,011)   (133,508)
Long term portion  $348,997   $384,382 

 

Maturity of lease liabilities are as follows:

 

   Amount 
For the year ending December 31, 2023  $126,464 
For the year ending December 31, 2024   171,840 
For the year ending December 31, 2025   175,942 
For the year ending December 31, 2026   74,030 
Total  $548,276 
Less: present value discount   (62,268)
Lease liability  $486,008 

 

NOTE 14 – DISCONTINUED OPERATIONS

 

On September 1, 2022, the BOD of the Company authorized the filing of a Chapter 7 proceeding which meets the definition of a discontinued operation. Accordingly, the operating results of PCTI are reported as income (loss) from discontinued operations in the accompanying consolidated financial statements for the three months ended March 31, 2023, and 2022. On October 3, 2022, PCTI filed a Voluntary Petition for Non- Individuals Filing for Bankruptcy. On November 30, 2022, the Trustee filed a Notice of Abandonment of Estate Property, as it is over encumbered by the secured creditors. No objections were filed, and as such the inventory and equipment is now considered abandoned to the secured creditors to do with what they wish. In March 2023, the Trustee declared this a no-asset case and closed the bankruptcy.

 

The results of operations of this component, for all periods, are separately reported as “discontinued operations”. A reconciliation of the major classes of line items constituting the income (loss) from discontinued operations, net of income taxes as is presented in the Consolidated Statements of Operations for the three months ended March 31, 2023, and 2022 are summarized below:

 

   2023   2022 
   Three months ended March 31, 
   2023   2022 
Revenues  $5,363   $162,916 
Cost of goods sold   -    126,482 
Gross profit   5,363    36,434 
Operating expenses   -    212,290 
Interest expense   -    8,324 
Income (loss) from discontinued operations  $5,363   $(184,180)

 

There are no assets as of March 31, 2023, and December 31, 2022, as the secured lender has taken possession. Liabilities of discontinued operations are separately reported as “liabilities held for disposal” as of March 31, 2023, and December 31, 2022. All liabilities are classified as current. The following tables present the reconciliation of carrying amounts of the major classes of liabilities of the Company classified as discontinued operations in the consolidated balance sheets at March 31, 2023, and December 31, 2022:

 

  F-20 
 

 

Current liabilities

 

         
  

March 31,

2023
   December 31,
2022
 
Accounts payable and accrued liabilities  $445,565   $445,565 
Current portion of notes payable   589,246    589,246 
Operating lease liability   -    3,575 
Deferred revenues   19,662    21,451 
Total current liabilities of discontinued operations  $1,054,473   $1,059,837 

 

On May 16, 2022, Huntington National Bank (“Huntington”) filed a Complaint for Confession of Judgment (“COJ”) against Catherine Chis (“Chis”). Chis was the former CEO of PCTI and a Guarantor on Huntington’s Letter of Credit financing (“LOC”) and a Term Loan (“Term Loan”). The Chis COJ for the LOC was for $352,415 and accrues per diem interest of $63.65, and the Chis COJ for the Term Loan was for $141,415 and accrues per diem interest of $28.60. On June 24, 2022, Huntington filed a COJ against Power Conversion Technologies, Inc (“PCTI”). The PCTI COJ for the LOC was for $354,774 and accrues per diem interest of $63.65 and the PCTI COJ for the LOC was for $142,473 and accrues per diem interest of $28.60. On July 20, 2022, Huntington assigned the PCTI judgment against PCTI to Meraki Advisors, LLC. (“Meraki”). The Company’s understanding is Meraki is a Pennsylvania limited liability company, controlled by Chis.

 

The Company wrote off the book value of the inventory of $237,091 and fixed assets of $15,447 during the year ended December 31, 2022, with the offset to Loss on Disposal of Assets of Discontinued Operations. Included in the Current portion of notes payable are the principal balances of Huntington’s LOC of $344,166 and Term Loan of $134,681. Accrued interest and fees on the LOC and Term Loan debt $54,256 is included in accounts payable and accrued liabilities.

 

NOTE 15 - INCOME TAXES

 

The Company provides for income taxes under ASC 740, Accounting for Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely- than not that some or all of the deferred tax assets will not be realized.

 

In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future income, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability.

 

NOTE 16 – SUBSEQUENT EVENTS

 

From April 1, 2023, through the filing of this report, the Company sold GHS 15,048,619 shares of common stock for proceeds of $71,827 net of offering costs. These sales were under the January 20, 2023, GHS SPA.

 

On May 2, 2023, the Company entered into an Equity Financing Agreement (the “Financing Agreement”) and Registration Rights Agreement (the “Registration Rights Agreement”) with GHS. Under the terms of the Financing Agreement, GHS has agreed to provide the Company with up to $10,000,000 of funding upon effectiveness of a registration statement on Form S-1. Following effectiveness of the registration statement, the Company shall have the right to deliver puts to GHS and GHS will be obligated to purchase shares of our common stock based on the investment amount specified in each put notice. The maximum amount that the Company shall be entitled to put to GHS in each put notice will not exceed two hundred fifty percent (250%) of the average of the daily trading dollar volume of the Company’s common stock during the ten (10) trading days preceding the put, so long as such amount does not exceed 4.99% of the outstanding shares of the Company. Pursuant to the Financing Agreement, GHS and its affiliates will not be permitted to purchase, and the Company may not put shares of the Company’s common stock to GHS that would result in GHS’s beneficial ownership equaling more than 4.99% of the Company’s outstanding common stock. The price of each put share shall be equal to eighty percent (80%) of the lowest daily volume weighted average price of the Company’s common stock for the ten (10) consecutive trading days preceding the date on which the applicable put is delivered to GHS. No put will be made in an amount equaling less than $10,000 or greater than $750,000. Puts may be delivered by the Company to GHS until the earlier of twenty-four (24) months after the effectiveness of the registration statement on Form S-1 or the date on which GHS has purchased an aggregate of $10,000,000 worth of put shares.

 

On May 5, 2023, the Board of Directors of the Company approved to amend the Company’s Articles of Incorporation (the “Amendment”) to increase the authorized capital stock of the Company to 7,000,000,000 shares, of which 6,990,000,000 shall be authorized as common shares and 10,000,000 shall be authorized as preferred shares. The Company is in the process of filing the Amendment with the State of Nevada,

 

The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no other such events that warrant disclosure or recognition in the financial statements, except as stated herein.

 

  F-21 
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following is management’s discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying consolidated financial statements, as well as information relating to the plans of our current management. This report includes forward-looking statements. Generally, the words “believes,” “anticipates,” “may,” “will,” “should,” “expect,” “intend,” “estimate,” “continue,” and similar expressions or the negative thereof or comparable terminology are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including the matters set forth in this report or other reports or documents we file with the Securities and Exchange Commission from time to time, which could cause actual results or outcomes to differ materially from those projected. Undue reliance should not be placed on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to update these forward-looking statements.

 

While our financial statements are presented on the basis that we are a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business over a reasonable length of time, our auditors have raised a substantial doubt about our ability to continue as a going concern.

 

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

 

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments, and assumptions. We believe that the estimates, judgments, and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments, and assumptions are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates.

 

The following discussion should be read in conjunction with our unaudited financial statements and the related notes that appear elsewhere in this Quarterly Report on Form 10-Q.

 

THE COMPANY

 

Ozop Energy Solutions, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada.

 

On December 11, 2020, the Company formed Ozop Energy Systems, Inc. (“OES”), a Nevada corporation and a wholly owned subsidiary of the Company. OES was formed to be a manufacturer and distributor of renewable energy products.

 

On October 29, 2020, the Company formed a new wholly owned subsidiary, Ozop Surgical Name Change Subsidiary, Inc., a Nevada corporation (“Merger Sub”). The Merger Sub was formed under the Nevada Revised Statutes for the sole purpose and effect of changing the Company’s name to “Ozop Energy Solutions, Inc.” That same day the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with the Merger Sub and filed Articles of Merger (the “Articles of Merger”) with the Nevada Secretary of State, merging the Merger Sub into the Company, which were stamped effective as of November 3, 2020. As permitted by the Section 92.A.180 of the Nevada Revised Statutes, the sole purpose and effect of the filing of Articles of Merger was to change the name of the Company from Ozop Surgical Corp. to “Ozop Energy Solutions, Inc.”

 

On August 19, 2021, the Company formed Ozop Capital Partners, Inc. (“Ozop Capital”), a Delaware corporation and a wholly owned subsidiary of the Company, and was formed as a holding company. On October 29, 2021, EV Insurance Company, Inc. (“EVCO”) was formed as a captive insurer that reinsures in the State of Delaware. EVCO (DBA “OZOP Plus”) is a wholly owned subsidiary of Ozop Capital.

 

OES is actively engaged in the renewable, electric vehicle (“EV”), energy storage and energy resiliency sectors. We are engaged in multiple business lines that include project development as well as equipment distribution. Our solar and energy storage projects involve large-scale battery and solar photovoltaics (PV) installations. Our utility-scale storage business model is based on an arbitrage business model in which we install multiple 1+ megawatt batteries, charge them with off-peak grid electricity under contract with the utility, then sell the power back during peak load hours at a premium, as dictated by prevailing electricity tariffs.

 

Equipment Distributor: OES has entered the component supply/distribution side of the renewable, resiliency and energy storage industries distributing the core components associated with residential and commercial solar PV systems as well as onsite battery storage and power generation. In April 2021, the Company signed a five- year lease (beginning June 1, 2021) of approximately 8,100 SF in California, for office and warehouse space to support the sales and distribution of our west coast operations. The components we are distributing include PV panels, solar inverters, solar mounting systems, stationary batteries, onsite generators and other associated electrical equipment and components that are all manufactured by multiple companies, both domestic and international. These core products are sourced from management-developed relationships and are distributed through our existing network and our in-house sales team.

 

 3 
 

 

Solar PV: Our PV business model involves the design and construction of electrical generating PV systems that can sell power to the utilities or be used for off grid use as part of our developing Neo-Grids solution. The Neo-GridTM System, patent pending, was developed for the off-grid distribution of electricity to remove or reduce the dependency on utilities that currently burdens the EV Charging sectors. It will also reduce or eliminate the lengthy permitting processes and streamline the installations of those EV chargers.

 

Modular Energy Distribution System: The Neo-GridTM System patent pending, consists of the design, engineering, installation, and operational methodologies as well as the financial arbitrage of how we produce, capture and distribute electrical energy for the EV markets. OES has acquired through a license the rights to a proprietary system, the Neo-GridsTM System (patent pending), for the capture and distribution of electrical energy for the EV market. The Neo-GridsTM System will serve both the private auto and the commercial sectors. The exponential growth of the EV industry has been accelerated by the recent major commitments of most of the major car manufacturers. Our Neo-GridsTM System leverages this accelerated growth by offering (1) charging locations that can be rapidly installed in restricted areas or load limits and (2) EV charger electricity that is produced from renewable sources having little to no carbon footprint.

 

OES has developed a business plan for the Neo GridTM distribution system, a solution to alleviate the stress on the existing grid-tied infrastructure. The Company has completed its’ Neo GridTM research and development as well as the first stage that includes the specifications and engineered technical drawings. This completion of the first stage of allows us to move forward with stage two, as well as to begin to construct the first prototype or proof of concept, (“PoC”). Our PoC design is partially reliant on auto manufacturers establishing standardizations of the actual charging/discharging protocols of the batteries such as on-board inverters as well as bi-directional capabilities in electric vehicles, which have only recently been established. As the market growth rate of EV’s continues to rise, the stress on the existing grid-tied infrastructure shows the need for the continued development of our Neo-GridTM System as a viable solution.

 

OES management has decades of experience in the renewable, storage and resilient energy businesses and associated markets, which include but are not limited to project finance, project development, equipment finance, construction, utility protocol, regulatory policy and technology assessment.

 

Ozop Plus markets vehicle service contracts (“VSC’s”) for electric vehicles (EV’s) that offer consumers to be able to purchase additional months and miles above the manufacturer’s warranty and to also bring added value to EV owners by utilizing our partnerships and strengths in the energy market to offer unique and innovative services. Among EV owners’ concerns are the EV battery repair and replacement costs, range anxiety, environmental responsibilities, roadside assistance, and the accelerated wear on additional components that EV vehicles experience. Management believes that the Ozop Plus marketed VSC’s will give “peace of mind” to the EV buyer.

 

  In May 2022, the Company entered into an agreement with GS Administrators, Inc., a member of Houston-based GSFSGroup. Under the agreement, the Company will market GSFSGroup’s EV VSC’s in all states (except, California, Florida, Massachusetts and Washington) to Ozop’s network of new and used franchised dealerships and other eligible entities. In addition to acting as an agent for the marketing, Ozop also has the right to white label the product under its’ Ozop Plus brand. Ozop’s role won’t be limited to marketing the product. GSFSGroup plans to tap into Ozop’s experience relative to battery collection and disposal and has agreed to insurance risk sharing in connection with the insurance policies that back the VSC’s. GSFSGroup is working on getting the approvals needed for the above four (4) states.

 

  On June 22, 2022, the Company entered into an Agent Agreement with Royal Administration Services, Inc. (“Royal”). Under the agreement, the Company will market Royal’s EV VSC’s and has the right to white label it under Ozop Plus. Royal has agreed to allow Ozop Plus on all VSC’s, marketed by Royal and the Company, to assume all the risk related to the electric battery at an agreed upon premium. The battery premium is dependent on the consumer’s selection of the duration of the VSC, the miles selected for coverage and the type of vehicle that the consumer has purchased, with a key component being the kWh size of the battery. These VSC’s have a maximum of 10 years and 150,000 miles and cover new and used cars from model year 2017 and newer. Royal’s VSCs are now effective in 46 states and the others have various waiting times or approvals needed.

 

  On October 13, 2022, EVCO entered a Reinsurance Contract (the “Contract”) with American Bankers Insurance Company of Florida (“ABIC” or the “Ceding Company”). Royal is the Administrator of the Contract. Pursuant to the terms of the Contract, ABIC will cede 100% of the battery coverage portion of all electric vehicle service contracts to EVCO. On the same date ABIC and EVCO also entered into a Trust Agreement, whereas EVCO as the reinsurer agrees to deposit an amount equal to unearned premium reserves, plus losses reported but unpaid, plus the estimated amount of losses incurred but not reported to the trust account. Permissible investments (with a maturity of no more than five (5) years) of the assets of the Trust account include:

 

 4 
 

 

  U.S. Treasury Securities
  Cash or cash instruments
  U.S agency issues
  Other investments as Ceding Company approves

 

On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners can offer the resources needed for lighting, solar and electrical design projects. OED will provide its’ customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs by working with architects, engineers, facility managers, electrical contractors and engineers.

 

Discontinued Operations

 

On September 1, 2022, the BOD of the Company authorized the filing of a Chapter 7 proceeding which meets the definition of a discontinued operation. Accordingly, the operating results of PCTI are reported as income (loss) from discontinued operations in the accompanying consolidated financial statements for the three months ended March 31, 2023, and 2022.

 

Results of Operations for the three months ended March 31, 2023, and 2022:

 

Revenue

 

For the three months ended March 31, 2023, the Company generated revenue of $2,791,198 compared to $2,919,322 for the three months ended March 31, 2022. Revenues from Ozop Energy Systems, Inc. (“OES”) are classified as sourced and distributed products. Ozop Engineering and Design (“OED”) operations began in the quarter ended June 30, 2022, and are classified as design and installation. Sales are summarized as follows:

 

   Three months ended
March 31,
 
   2023   2022 
Sourced and distributed products  $2,758,798   $2,919,322 
Design and installation   32,400    - 
Total  $2,791,198   $2,919,322 

 

As it did for most of the solar industry; OES’s importing of solar panels issues that began in the 4th quarter of 2021, continued during 2022. Covid issues continued to be disruptive to a continual source of product from foreign manufacturers as well as ocean freight backlogs and covid issues that plagued the port of arrivals related to the unloading of containers and the eventual customs clearance of the imported goods. An announcement by the U.S. Department in March 2022 stated it would investigate allegations that solar panel manufacturers in Southeast Asia are using Chinese-made parts and evading U.S. tariffs has raised alarms concerning both trade and environmental policy The department announced March 28, 2022, that it would investigate claims by a California-based solar panel manufacturer that solar energy equipment manufacturers in Cambodia, Malaysia, Thailand and Vietnam have close business ties to companies in China that produce the raw materials and some components of solar panel assemblies. On June 6, 2022, President Biden waived tariffs on solar panels from four Southeast Asian nations for two years and invoked the Defense Production Act to spur domestic solar panel manufacturing at home. The tariff exemption will serve as a “bridge” while U.S. manufacturing ramps up.

 

As of March 31, 2023, the Company had inventory of approximately $1,648,000. As of the date of this report the Company also has outstanding purchase orders with its panel supplier of $12,626,000 and has paid deposits of approximately $3,172,000 towards these open purchase orders. In order to meet our current customers anticipated needs for 2023, the Company would need to purchase approximately an additional $3,000,000 to be received in Q4/2023. Based on the above, management anticipates revenues may approach $20 million for 2023 for solar products.

 

 5 
 

 

Cost of sales

 

For the three months ended March 31, 2023, and 2022, the Company recognized $2,394,700 and $2,749,349, respectively, of cost of sales.

 

   Three months ended
March 31,
 
   2023   2022 
Sourced and distributed products  $2,394,700   $2,749,349 
           

 

Based on the above cost of sales, gross margin was 13.2% and 5.8% for the three months ended March 31, 2023, and 2022, respectively. Gross margin for OES was higher in the current due to the mix of product sales. The Company anticipates lower margins for the remainder of 2023 compared to the quarter ending March 31, 2023.

 

Operating expenses

 

Total operating expenses for the three months ended March 31, 2023, and 2022, were $1,069,762 and $1,765,567, respectively. The operating expenses were comprised of:

 

   Three months ended March 31, 
   2023   2022 
Management fees, related parties  $240,000   $390,000 
Stock-based compensation, other   -    136,249 
Salaries, taxes, and benefits   266,804    251,399 
Professional and consulting fees   281,008    628,947 
Advertising and marketing   17,772    2,478 
Rent and office expenses   55,116    65,975 
Insurance   48,391    80,834 
General and administrative. Other   160,671    209,685 
Total  $1,069,762   $1,765,567 

 

Management fees- related parties, are amounts paid to our CEO. On July 10, 2020, pursuant to the PCTI transaction, the Company assumed an employment contract entered into on February 28, 2020, between the Company and Mr. Conway (the “Employment Agreement”). Mr. Conway’s compensation as adjusted was $20,000 per month. Effective January 1, 2022, the Company entered into a new employment agreement with Mr. Conway. Pursuant to the agreement, Mr. Conway received a $250,000 contract renewal bonus and receives an annual compensation of $240,000 from the Company and will also be eligible to receive bonuses and equity grants at the discretion of the BOD. The Company also agreed to compensate Mr. Conway for services provided directly to any of the Company’s subsidiaries. Ozop Capital increased Mr. Conway’s compensation to $20,000 per month in January 2022, OES began compensating Mr. Conway $20,000 in March 2022, and OED began compensating Mr. Conway $20,000 per month beginning in April 2022.

 

There was no stock-based compensation for the three months ended March 31, 2023. Stock based compensation for the three months ended March 31, 2022, of $136,249 is comprised of the following:

 

  5,000,000 shares of common stock issued in the aggregate to two employees pursuant to their offers of employment dated March 31, 2021. The shares were valued at $0.027 per share. During the three months ended March 31, 2022, the Company included $135,000 in stock compensation expense.
  $1,249 of amortization of stock compensation for shares issued in April 2021.

 

Salaries, taxes, and benefits increased for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The increase was a result of in the quarter ending March 31, 2023 for Ozop Engineering and Design (“OED”) and EV Insurance Company (“Ozop Plus”) having employees for the entire period, compared to OED beginning in April 2022, and Ozop Plus beginning in October 2022, respectively. These increases were significantly reduced by the termination for cause of all of the employees in the west coast location.

 

   Three months ended March 31, 
   2023   2022 
Ozop Energy Systems  $79,701   $251,399 
Ozop Engineering and Design   152,852    - 
EV Insurance Company   34,251    - 
Total  $266,804   $251,399 

 

Ozop Energy Systems currently has 3 employees with an aggregate annual salary of $276,000 and focused on the battery storage system, information technology and general and administrative functions. The solar distribution of this vertical is being managed by our financial consultant and the Company’s CEO. OED currently has six employees with an aggregate annual compensation of $588,000. EV Insurance Company has one employee with annual compensation of $125,000.

 

Professional and consulting fees decreased for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The decrease is due to the expiration of certain consulting contracts and accounting fees. These decreases were partially offset increases in legal expenses and auditing fees.

 

 6 
 

 

Advertising and marketing expenses increased for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The increases were related to website development, and lead generation costs.

 

Rent and office expense (including supplies, utilities, and internet costs) decreased for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The decrease is the result that on March 1, 2023, OES has subleased the Carlsbad office and warehouse to a third party.

 

Insurance expense decreased for the three months ended March 31, 2023, compared to the three months ended March 31, 2022. The decrease was the result of the termination of the west coast employees in November 2022, resulting in no health insurance and workers compensation expenses related thereto. The Company estimates that the monthly insurance expense to be approximately $20,000 per month.

 

Other (Income) Expenses

 

Other expense, net, for the three months ended March 31, 2023, was $1,859,651 compared to other income, net, for the three months ended March 31, 2022, of $398,305 and were as follows.

 

  

Three months ended

March 31,

 
   2023   2022 
Interest expense  $1,221,533   $3,966,898 
(Gain) loss on change in fair value of derivatives   638,118    (4,365,203)
Total other (income) expense, net  $1,859,651   $(398,305)

 

The decrease in interest expense for the three months ended March 31, 2023, is primarily a result of the amortization period of certain note discounts were completed in 2022, resulting in $500,568 of interest related to the amortization of note discounts in the current period, compared to $3,379,121 for the three months ended March 31, 2022. Interest expense on the face value of the principal balances of the notes payable increased due to the increased rate due to mote defaults and extended maturity dates. For the three months ended March 31, 2023, the Company recognized a loss of $638,118 on the change in the fair value of derivatives compared to a gain of $4,365,203 for the three months ended March 31, 2022.

 

Net loss

 

Net loss attributable to the Company for the three months ended March 31, 2023, was $2,527,552 compared to a net loss of $1,193,761 for the three months ended March 31, 2022. The change was primarily a result of the loss on the change in fair value of derivatives of $638,118 for the three months ended March 31, 2023, compared to the gain of $4,365,203 for the three months ended March 31, 2022. This increase in the loss from the changes in the fair value of derivatives was partially offset by the increase in gross profit, the decrease in operating expenses and interest expense for the three months ended March 31, 2023, compared to the three months ended March 31, 2022.

 

Liquidity and Capital Resources

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2023, the Company had an accumulated deficit of $213,828,351 and a working capital deficit of $9,216,661 (including derivative liabilities of $4,952,388). As of March 31, 2023, the Company was in default of $3,690,000 plus accrued interest on debt instruments due to non-payment upon maturity dates. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date of the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

Currently, our current capital and our other existing resources will be sufficient to provide the working capital needed for our current business, however, additional capital will be required to meet our debt obligations, and to further expand our business. We may be unable to obtain the additional capital required. If we are unable to generate capital or raise additional funds when required, it will have a negative impact on our business development and financial results. These conditions raise substantial doubt about our ability to continue as a going concern as well as our recurring losses from operations, deficit in equity, and the need to raise additional capital to fund operations. This “going concern” could impair our ability to finance our operations through the sale of debt or equity securities. Management’s plans in regard to these factors are discussed below and also in Note 2 to the consolidated financial statements filed herein.

 

 7 
 

 

For the year ended December 31, 2023, we primarily funded our business operations with the existing cash on hand as of January 1, 2023, cash received from sales of inventory, and $526,393 received from sales of common stock.

 

As of March 31, 2023, we had cash of $1,954,814 as compared to $1,369,210 as of December 31, 2022. As of March 31, 2023, we had current liabilities of $16,785,663 (including $4,952,388 of non-cash derivative liabilities), compared to current assets of $7,569,002, which resulted in a working capital deficit of $9,216,661. The current liabilities are comprised of accounts payable, accrued expenses, convertible debt, derivative liabilities, customer deposits, deferred liability, lease obligations, notes payable and liabilities of discontinued operations.

 

In December 2019, a novel strain of coronavirus (COVID-19) emerged. Because COVID-19 infections have been reported throughout the United States, certain federal, state and local governmental authorities have issued stay-at-home orders, proclamations and/or directives aimed at minimizing the spread of COVID-19. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but it may have a material adverse impact on our business, financial condition and results of operations. Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.

 

Operating Activities

 

For the three months ended March 31, 2023, net cash provided by operating activities was $611,373 compared to net cash used in operating activities of $3,060,456 for the three months ended March 31, 2022. For the three months ended March 31, 2023, our net cash provided by operating activities was primarily attributable to the net loss of $2,527,552, adjusted by non- cash items of the loss on the fair value change of derivatives of $638,118, interest expense of $500,568, and amortization and depreciation of $55,912. Net changes of $1,949,690 in operating assets and liabilities added to the cash provided by operating activities.

 

For the three months ended March 31, 2022, our net cash used in operating activities was primarily attributable to the net loss of $1,381,469, adjusted by non- cash interest expense of $3,379,121, stock-based compensation of $136,249 and the non-cash expenses of amortization and depreciation of $41,421. This was offset by the gain on the fair value changes in derivatives related to warrants and convertible notes of $4,365,203. Net changes of $812,666 in operating assets and liabilities increased the cash used in operating activities.

 

Investing Activities

 

For the three months ended March 31, 2023, the net cash used in investing activities was $2,162, compared to $40,000 for the three months ended March 31, 2022.

 

Financing Activities

 

For the three months ended March 31, 2023, the net cash used in financing activities was $23,607. During the three months ended March 31, 2023, we received $526,393, net of issuance costs, from the sales of common stock to GHS. During the three months ended March 31, 2023, we made payments of $550,000 for notes payable. There was no financing activity for the three months ended March 31, 2022.

 

Critical Accounting Policies

 

Our significant accounting policies are described in more details in the notes to our financial statements appearing elsewhere in this Quarterly Report on Form 10-Q. We believe the following accounting policies to be most critical to the judgement and estimates used in the preparation of our financial statements:

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.

 

Inventory

 

Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs consist of finished goods. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues.

 

 8 
 

 

Convertible Instruments

 

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

 

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

 

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

 

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

 

Revenue Recognition

 

Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

 

Earnings (Loss) Per Share

 

The Company computes net income (loss) per share in accordance with FASB ASC 260, “Earnings per Share.” ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the statement of operations. Basic EPS is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period including stock options, using the treasury stock method, and convertible notes and stock warrants, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options, warrants and conversion of convertible notes. Diluted EPS excludes all dilutive potential common shares if their effect is anti-dilutive.

 

OFF BALANCE SHEET ARRANGEMENTS

 

We have no off-balance sheet arrangements, including arrangements that would affect our liquidity, capital resources, market risk support and credit risk support or other benefits.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

Not Applicable.

 

 9 
 

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

 

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of March 31, 2023. Based on the evaluation of these disclosure controls and procedures, and in light of the material weaknesses found in our internal controls over financial reporting, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective for the reasons discussed below.

 

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. In its assessment of the effectiveness of internal control over financial reporting as of March 31, 2023, the Company determined that there were control deficiencies that constituted material weaknesses, as described below.

 

  1. We do not have an Audit Committee – While not being legally obligated to have an audit committee, it is the management’s view that such a committee, including a financial expert member, is an utmost important entity level control over the Company’s financial statement. Currently the Board of Directors acts in the capacity of the Audit Committee, and does not include a member that is considered to be independent of management to provide the necessary oversight over management’s activities.
     
  2. We did not maintain appropriate cash controls – As of March 31, 2023, the Company has not maintained sufficient internal controls over financial reporting for cash, including failure to segregate cash handling and accounting functions, and did not require dual signatures on the Company’s bank accounts.

 

Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls.

 

Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

 

Changes in Internal Controls over Financial Reporting

 

There has been no change in our internal control over financial reporting occurred during the three months ended March 31, 2023, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

PART II. OTHER INFORMATION

 

Item 1. LEGAL PROCEEDINGS

 

We know of no material, existing or pending legal proceedings against our Company. We are involved as a plaintiff in a Complaint filed in the SUPERIOR COURT OF THE STATE OF CALIFORNIA FOR THE COUNTY OF SAN DIEGO NORTH COUNTY (the “Complaint”) on November 14, 2022. The Complaint alleges that former employees would place an order from a customer for purchase of product from OZOP with funds the exact source of which is presently unknown. OZOP alleges that next, the customer would sell that product to OZOP’s customers at a price marked up from the price for which the customer purchased from OZOP – to the benefit of Defendants and to the detriment of OZOP, their employer at the time. The Complaint further alleges that the former employees falsely represented that the price the customer was obtaining from other suppliers and therefore was willing to pay for OZOP product decreased, which allowed them to use the customer to then sell additional product to OZOP’s customers at increasingly larger margins, thus further wrongfully enriching themselves to the detriment of their employer, OZOP. The lawsuit also alleges that the employees were also making false statements to Ozop’s customers regarding the financial condition of Ozop and the lack of module inventory.

 

 10 
 

 

There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

 

Item 1A. RISK FACTORS

 

Not applicable for smaller reporting companies.

 

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

The following table are all shares issued during the quarter ended March 31, 2023:

 

On January 10, 2023, the Company sold 17,357,355 shares to GHS at $0.003825 and received net proceeds of $64,039, after deducting transaction and broker fees of $2,353.

 

On January 17, 2023, the Company sold 20,962,997 shares to GHS at $0.003825 and received net proceeds of $77,555, after deducting transaction and broker fees of $2,629.

 

On January 23, 2023, the Company sold 12,767,276 shares to GHS at $0.005185 and received net proceeds of $63,849, after deducting transaction and broker fees of $2,349.

 

On February 3, 2023, the Company sold 18,247,307 shares to GHS at $0.00629 and received net proceeds of $111,455, after deducting transaction and broker fees of $3,321.

 

On February 14, 2023, the Company sold 14,136,995 shares to GHS at $0.00654 and received net proceeds of $89,651, after deducting transaction and broker fees of $2,876.

 

On March 6, 2023, the Company sold 8,246,054 shares to GHS at $0.00519 and received net proceeds of $40,876, after deducting transaction and broker fees of $1,880.

 

On March 22, 2023, the Company sold 9,459,484 shares to GHS at $0.00501 and received net proceeds of $45,466, after deducting transaction and broker fees of $1,974.

 

On March 30, 2023, the Company sold 6,579,315 shares to GHS at $0.005355 and received net proceeds of $33,503, after deducting transaction and broker fees of $1,730.

 

The Company issued the foregoing securities in reliance on an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506(b) promulgated thereunder, as there was no general solicitation to the investors and the transactions did not involve a public offering.

 

Item 3. DEFAULTS UPON SENIOR SECURITIES

 

None

 

Item 4. MINE SAFETY DISCLOSURE

 

Not applicable.

 

Item 5. OTHER INFORMATION

 

  (a) None.
  (b) During the quarter ended March 31, 2023, there have not been any material changes to the procedures by which security holders may recommend nominees to the Board of Directors.

 

Item 6. EXHIBITS

 

The following documents are filed as part of this report:

 

Exhibit No.   Description
     
2.1   Share Exchange Agreement dated April 5, 2018 by and among Newmarkt Corp., the shareholders of Ozop Surgical, Inc., Ozop Surgical, Inc. and Denis Razvodovskij (Incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed on April 19, 2018).
     
2.2   Stock Purchase Agreement dated June 26, 2020, by and among Ozop Surgical Corp., Power Conversion Technologies, Inc. and Catherine Chis (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on June 29, 2020).
     
2.3   Merger Agreement and Plan of Merger between Ozop Surgical Corp. and Ozop Surgical Name Change Subsidiary, Inc. (Incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed on November 13, 2020).
     
3.1   Articles of Incorporation (Incorporated by reference to our General Form for Registration of Securities on Form S-1 filed on August 1, 2016)
     
3.2   Bylaws (Incorporated by reference to our General Form for Registration of Securities on Form S-1 filed on August 1, 2016)
     
3.3   Certificate of Amendment of Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on May 8, 2018 (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on May 14, 2018).
     
3.4   Certificate of Designations for Series B Preferred Stock. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on April 2, 2019).
     
3.5   Amended and Restated Bylaws of Ozop Surgical Corp. adopted on May 22, 2019. (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on May 22, 2019).
     
3.6   Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on July 25, 2019. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on July 30, 2019).
     
3.7   Certificate of Designation of Series C Preferred Stock. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on September 24, 2019).
     
3.8   Certificate of Withdrawal of Series B Preferred Stock. (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on September 24, 2019).
     
3.9   Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on October 29, 2019. (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on October 31, 2019).
     
3.10   Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on December 30, 2020, (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on December 31, 2019).
     
3.11   Amended and Restated Articles of Incorporation as filed with the Nevada Secretary of State on January 21, 2020. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on February 7, 2020).

  

3.12   Amended and Restated Certificate of Designation of Series C Preferred Stock. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on February 5, 2020).

 

 11 
 

 

3.13   Amendment to Certificate of Designation of Series C Preferred Stock dated July 7, 2020 (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on July 10, 2020).
     
3.14   Certificate of Designation of Series D Preferred Stock dated July 7, 2020 (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on July 10, 2020).
     
3.15   Certificate of Designation of Series E Preferred Stock dated July 7, 2020 (Incorporated by reference to Exhibit 3.3 of the Current Report on Form 8-K filed on July 10, 2020).
     
3.16   Articles of Incorporation of Ozop Surgical Name Change Subsidiary, Inc. (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on November 13, 2020).
     
3.17   Articles of Merger between Ozop Surgical Corp. and Ozop Surgical Name Change Subsidiary, Inc. (Incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on November 13, 2020).
     
3.18   Amended and Restated Certificate of Designation Series D Preferred Stock dated July 27, 2021 (Incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on August 2, 2021).
     
3.19   Advisory agreement between Ozop Capital and RMA dated September 1, 2021 (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on September 2, 2021)
     
10.1   Binding Letter of Intent dated February 28, 2020, by and between Ozop Surgical Corp. and Power Conversion Technologies, Inc, and Catherine Chis, (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on February 28, 2020).
     
10.2+   Employment Agreement dated February 28, 2020, by and between Ozop Surgical Corp. and Brian Conway, (Incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed on February 28, 2020).
     
31.1*   Certification of Chief Executive Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Chief Financial Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1*   Certification of Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63

 

101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

+ Management contract or compensatory plan or arrangement.

 

 12 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: May 15, 2023

 

/s/ Brian P Conway  
Brian P. Conway  
Chief Executive Officer  
(principal executive officer)  
(principal financial and accounting officer)  

 

 

 

EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION

 

I, Brian P. Conway, Chief Executive Officer of OZOP ENERGY SOLUTIONS, INC. (the “registrant”), certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended March 31, 2023;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 15, 2023

 

/s/ Brian P. Conway  
Brian P Conway  
Chief Executive Officer  
(principal executive officer)  

 

 

EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION

 

I, Brian P. Conway, Interim Chief Financial Officer of OZOP ENERGY SOLUTIONS, INC. (the “registrant”), certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended March 31, 2023;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 15, 2023

 

/s/ Brian P Conway  
Brian P Conway  
Interim Chief Financial Officer  
(principal financial and accounting officer)  

 

 

EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Each of the undersigned hereby certifies, in his capacity as an officer of OZOP ENERGY SOLUTIONS, INC. (the “Company”), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

 

(1) The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: May 15, 2023

 

/s/ Brian P Conway  
Brian P. Conway  
Chief Executive Officer  
(principal executive officer)  
(principal financial and accounting officer)  

 

 

EX-101.SCH 5 ozsc-20230331.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statement of Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statement of Stockholders' Deficit (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - GOING CONCERN AND MANAGEMENT’S PLANS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - DEFERRED LIABILITY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - NONCONTROLLING INTEREST link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - DERIVATIVE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - DISAGGREGATION OF REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - DEFERRED LIABILITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - SCHEDULE OF EXPENSES TO OFFICERS (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - NONCONTROLLING INTEREST (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 ozsc-20230331_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 ozsc-20230331_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 ozsc-20230331_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Series D Preferred Stock [Member] Series E Preferred Stock [Member] Series C Preferred Stock [Member] Equity Components [Axis] Common Stock To Be Issued [Member] Preferred Stock [Member] Common Stock [Member] Treasury Stock, Common [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] 1st GHS Purchase Agreement [Member] Award Type [Axis] GHS Investments LLC [Member] 2nd GHS Purchase Agreement [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Customer [Axis] Suppliers One [Member] Concentration Risk Benchmark [Axis] Accounts Payable [Member] Concentration Risk Type [Axis] Supplier Concentration Risk [Member] Suppliers Two [Member] Suppliers Three [Member] Suppliers Four [Member] Two Vendor [Member] Customer A [Member] Accounts Receivable [Member] Customer Concentration Risk [Member] Customer B [Member] Customer C [Member] Customer D [Member] Customer E [Member] Statistical Measurement [Axis] Minimum [Member] Long-Lived Tangible Asset [Axis] Building and Building Improvements [Member] Maximum [Member] Office Furniture And Equipment [Member] Warehouse Equipment [Member] Product and Service [Axis] Sourced And Distributed Products [Member] OED Installations [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Antidilutive Securities [Axis] Convertible Preferred Stock [Member] Unexercised Common Stock Purchase Warrants [Member] Convertible Notes Payable [Member] Promissory Note Payable [Member] Office Equipment [Member] Debt Instrument [Axis] 15% Promissory Note [Member] Measurement Input Type [Axis] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input, Exercise Price [Member] Measurement Input Price Volatility One [Member] Financial Instrument [Axis] Derivative Liabilities Associated With Warrants [Member] Derivative Liabilities Associated With Convertible Notes [Member] Short-Term Debt, Type [Axis] Note Payable [Member] Other [Member] Note Payable One [Member] Note Payable Two [Member] Note Payable Three [Member] Note Payable Four [Member] Note Payable Five [Member] Note Payable Six [Member] Note Payable Seven [Member] Promissory Note [Member] Title of Individual [Axis] Lender [Member] December 7, 2022 [Member] March 31 2023 [Member] March 17 2022 [Member] Promissory Note One [Member] Promissory Note Two [Member] February 9 2021 [Member] Holder [Member] Legal Entity [Axis] PCTI [Member] Exchange Agreement [Member] Award Date [Axis] Per Month [Member] Related Party, Type [Axis] Mr Conway [Member] Employment Agreement [Member] Chief Executive Officer [Member] Chief Executive Officer Bonus [Member] RMA Agreement [Member] PJN Strategies [Member] Co-Directors of Sales [Member] Restricted Stock [Member] Mr Steven Martello [Member] Consulting Agreement [Member] Aurora Enterprises [Member] Ezra Green [Member] Mr Allen Sosis [Member] Related and Nonrelated Party Status [Axis] Related Party [Member] Salman J. Chaudhry [Member] Seperation Agreement [Member] Lease Agreement [Member] Certificates of Designation [Member] Series D Amendment [Member] Investor [Member] Series DSPA [Member] Warrant [Member] Remaining Warrant Shares [Member] Ownership [Axis] Brian Conway [Member] Geographical [Axis] CALIFORNIA Thereafter [Member] Accounting Standards Update [Axis] Accounting Standards Update 2016-02 [Member] Catherine Chis [Member] Extinguishment of Debt [Axis] Line of Credit [Member] Short-Term Debt [Member] Power Conversion Technologies Inc [Member] Financing And Registration Rights Agreement [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS Current Assets Cash Prepaid expenses Accounts receivable Inventory Vendor deposits Total Current Assets Operating lease right-of-use asset, net Property and equipment, net Other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities Current Liabilities Accounts payable and accrued expenses Convertible notes payable, net of discounts Current portion of notes payable, net of discounts Customer deposits Deferred liability Derivative liabilities Operating lease liability, current portion Liabilities of discontinued operations Total Current Liabilities Long Term Liabilities Note payable, net of discount Operating lease liability, net of current portion TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES Stockholders’ Deficit Preferred Stock Common stock (4,990,000,000 shares authorized par value $0.001; 4,879,032,132 and 4,771,275,349 shares issued and outstanding as of March 31, 2023, and December 31, 2022, respectively) Treasury stock, at cost, 47,500 shares of Sereis C Preferred Stock and 18,667 shares of Series D Preferred Stock Common stock to be issued; 637,755 shares as of March 31, 2023 and December 31, 2022 Additional paid in capital Accumulated deficit Total Ozop Energy Solutions, Inc. stockholders’ deficit Noncontrolling interest TOTAL STOCKHOLDERS’ DEFICIT TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares authorized Common stock, par value Common stock, shares issued Common stock, shares outstanding Treasury stock, shares Common stock to be issued Income Statement [Abstract] Revenue Cost of goods sold Gross profit Operating expenses: General and administrative, related parties General and administrative, other Total operating expenses Loss from continuing operations Other (income) expenses: Interest expense (Gain) loss on change in fair value of derivatives Total Other (Income) Expenses Loss from continuing operations before income taxes Income tax provision Net loss from continuing operations Discontinued Operations: Income (loss) from discontinued operations, net of tax Net loss Less: net loss attributable to noncontrolling interest Net loss attributable to Ozop Energy Solutions, Inc. Loss from contuining operations per share of common stockbasic and fully diluted Income (loss) from discontinued operations per share of common stockbasic and fully diluted Loss per share basic and fully diluted Weighted average shares outstanding Basic and diluted Beginning balance, value Beginning balance, shares Issuance of shares of common stock sold, net of issuance costs of $19,110 Issuance of shares of common stock sold, shares Net loss Issuance of common stock for services Common stock issued for services, shares Balances Beginning balance, shares Statement of Stockholders' Equity [Abstract] Issuance cost Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss from continuing operations Net income (loss) from discontinued operations Adjustments to reconcile net loss to net cash provided by (used in) operating activities Non-cash interest expense Amortization and depreciation (Gain) loss on fair value change of derivatives Stock compensation expense Changes in operating assets and liabilities: Accounts receivable Inventory Prepaid expenses Vendor deposits Accounts payable and accrued expenses Operating lease liabilities Customer deposits Net cash provided by (used in) continuing operations Net cash used in discontinued operations Net cash provided by (used in) operating activities Cash flows from investing activities: Purchase of office and computer equipment Net cash used in investing activities Cash flows from financing activities: Proceeds from sale of common stock, net of costs Payments of principal of convertible note payable and notes payable Net cash used in financing activities Net increase (decrease) in cash Cash, Beginning of period Cash, End of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for income taxes Schedule of non-cash Investing or Financing Activity: Issuance of common stock and preferred stockfor consulting fees and compensation Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION GOING CONCERN AND MANAGEMENT’S PLANS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Debt Disclosure [Abstract] CONVERTIBLE NOTES PAYABLE Derivative Liabilities DERIVATIVE LIABILITIES Notes Payable NOTES PAYABLE Deferred Liability DEFERRED LIABILITY Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Equity [Abstract] STOCKHOLDERS’ EQUITY NONCONTROLLING INTEREST Operating Lease Right-of-use Assets And Operating Lease Liabilities OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES Discontinued Operations and Disposal Groups [Abstract] DISCONTINUED OPERATIONS Income Tax Disclosure [Abstract] INCOME TAXES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Use of Estimates Cash and Cash Equivalents Sales Concentration and credit risk Accounts Receivable Inventory Purchase concentration Property, plant, and equipment Revenue Recognition Advertising and Marketing Expenses Convertible Instruments Discontinued Operations Distinguishing Liabilities from Equity Fair Value of Financial Instruments Income Taxes Segment Policy Earnings (Loss) Per Share Recent Accounting Pronouncements SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS DISAGGREGATION OF REVENUE SCHEDULE OF DERIVATIVE INSTRUMENTS SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE SCHEDULE OF PROPERTY AND EQUIPMENT SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE SCHEDULE OF NOTES PAYABLE SCHEDULE OF EXPENSES TO OFFICERS SCHEDULE OF RIGHT-OF-USE ASSETS SCHEDULE OF OPERATING LEASE LIABILITIES SCHEDULE OF MATURITY OF LEASE LIABILITIES SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Retained earnings accumulated deficit Working capital deficit Derivative liabilities current Debt instrument default amount Stock issued during the period Common stock maturity period Agreement description Sale of common stock Proceeds from sale of common stock Lease term Schedule of Product Information [Table] Product Information [Line Items] Sales concentration and credit risk Accounts receivable balance Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, plant and equipment, useful life Total Platform Operator, Crypto-Asset [Table] Platform Operator, Crypto-Asset [Line Items] Derivative Liabilities Total Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] TOTAL  Outstanding shares, percentage Cash equivalents Inventory finished goods Deposits Deposits Concentration of credit risk Advertising and marketing expenses Incremental borrowing percentage Income tax examination, likelihood of unfavorable settlement Dilutive securities common stock, shares Property and equipment, gross Less: Accumulated Depreciation Property and Equipment, Net Depreciation expenses Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Long term debt, gross Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table] Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items] Derivative liability, beginning balance Change in fair value Derivative liability, ending balance Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Derivative liability, measurement input Warrants in conjunction with notes payable Notes payable discount Risk free interest exercise prices Debt Instrument, interest rate, stated percentage Debt Instrument, maturity date Debt Instrument, face amount Debt Instrument, unamortized discount Sub- total notes payable, net of discount Less long-term portion, net of discount Current portion of notes payable, net of discount Debt instrument face amount Debt instrument, maturity date Debt instrument, unamortized discount Accounts and accrued expenses Proceeds from notes payable Original issue discount, amortized Repayments of debt Long-term debt, gross Debt instrument, interest rate, stated percentage Number of warrants to purchase Warrant exercise price Interest expense, amortized Amortization of discount Lender costs Warrant expiry date Warrant issuance, value Debt instrument, description Legal fees Adjustments to additional paid in capital warrant issued Interest payable Notes payable Debt instrument, increase, accrued interest Common stock, shares, issued Product liability contingency, third-Party recovery, percentage Exchange of common stock Royalty percentage Reduce deferred liability Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Total Compensation value Officers compensation received Amount of initial annual compensation Payments of stock issuance costs Number of restricted stock issued, value Payments of stock issuance costs Number of restricted shares issued Cash payments Issuance of common stock Consulting expense Salary and Wage, Officer, Excluding Cost of Good and Service Sold Accrued Bonuses, Current Shares issued, price per share Share price Share-Based Payment Arrangement, Expense Professional fees Deferred compensation equity Due to officers or stockholders Due to officers or stockholders, current Collaborative arrangement, rights and obligations Number of common stock exchanged Accounts payable and accrued expenses Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Issuance of common stock Stock issuance cost Common stock shares authorized Common stock par value Common stock shares outstanding Preferred stock, voting rights Preferred stock shares issued Preferred stock shares outstanding Preferred stock, convertible, conversion price Proceeds from issuance of preferred stock and preference stock Purchase of warrants Warrant exercise Warrant exercise, description Preferred stock, redemption amount Noncontrolling interest percentage Number of share returned Accumulative noncontrolling interest Schedule Of Right-of-use Assets Office and warehouse lease Less: Accumulated amortization Right-of-use assets, net Schedule Of Operating Lease Liabilities Lease liability Less current portion Long term portion For the year ending December 31, 2023 For the year ending December 31, 2024 For the year ending December 31, 2025 For the year ending December 31, 2026 Total Less: present value discount Operating lease term Area of land Lease expiration date Operating lease payments Lease payments increase percentage Operating lease liability Revenues Cost of goods sold Gross profit Operating expenses Interest expense Income (loss) from discontinued operations Accounts payable and accrued liabilities Current portion of notes payable Operating lease liability Deferred revenues Total current liabilities of discontinued operations Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Total assets of discontinued operations Line of credit Interest payable Term loan Line of credit Interest payable Inventory Fixed assets Accrued interest and fees Subsequent Event [Table] Subsequent Event [Line Items] Stock issued during the period Equity financing agreement description Capital stock shares, authorized Common stock shares, authorized Preferrd stock shares, authorized Convertible notes payable net. Customer deposits. Notes Payable [Text Block] Common stock to be issued. Note Payable [Member] Other [Member] Note Payable One [Member] Note Payable Two [Member] Note Payable Three [Member] Note Payable Four [Member] Note Payable Five [Member] Note Payable Six [Member] Note Payable Seven [Member] Common stock yet to be issued. Promissory Note [Member] Lender [Member] December Seven Two Thousand Twenty Two [Member] March Thirty One Two Thousand Twenty Three [Member] Amortization of interest expense. Amortization of discount. General and administrative related parties Lender costs. March Seventeen Two Thousand Twenty Two [Member] Common Stock To Be Issued [Member] Promissory Note One [Member] Promissory Note Two [Member] February Nine Two Thousand Twenty Two [Member] Noncash interest expense. Holder [Member] Issuance of common stock and preferred stock for consulting fees and compensation Working capital deficit. 1st GHS Purchase Agreement [Member] GHS Investments LLC [Member] 2nd GHS Purchase Agreement [Member] Deferred Liability [Text Block] Deferred liability current. PCTI [Member] Exchange Agreement [Member] Royalty percentage Per Month [Member] Mr Conway [Member] Officers compensation received. Employment Agreement [Member] Customer A [Member] Customer B [Member] Customer C [Member] Chief Executive Officer Bonus [Member] Customer D [Member] Customer E [Member] RMA Agreement [Member] Consulting Expense. PJN Strategies [Member] Co-Directors of Sales [Member] Purchase Concentration [Policy Text Block] Suppliers One [Member] Suppliers Two [Member] Suppliers Three [Member] Suppliers Four [Member] Two Vendor [Member] Mr Steven Martello [Member] Consulting Agreement [Member] Aurora Enterprises [Member] Schedule Of Useful Life Of Property And Equipment Assets [Table Text Block] Office Furniture And Equipment [Member] Ezra Green [Member] Warehouse Equipment [Member] Convertible Instruments [Policy Text Block] Distinguishing Liabilities from Equity [Policy Text Block] Mr Allen Sosis [Member] Salman J. Chaudhry [Member] Seperation Agreement [Member] Incremental borrowing percentage. Lease Agreement [Member] 15% Promissory Note [Member] Warrants In Conjunction With Notes Payable Notes payable discount Certificates of Designation [Member] Measurement Input Price Volatility One [Member] Derivative Liabilities Associated With Warrants [Member] Derivative Liabilities Associated With Convertible Notes [Member] Loss on fair value change of derivatives. Series D Amendment [Member] Series DSPA [Member] Remaining Warrant Shares [Member] Brian Conway [Member] Accumulative noncontrolling interest. Operating lease payements increase percentage. Thereafter [Member] Schedule of Right of Use Assets [Table Text Block] Office and warehouse lease. Accumulated amortization. Schedule Of Operating Lease Liabilities Table Text Block. Loss from discontinued operations. Total assets of discontinued operations. Disposal group including discontinued operation current portion of notes payable. Disposal group including discontinued operation pperating lease liability. Total current liabilities of discontinued operations. Catherine Chis [Member] Power Conversion Technologies Inc [Member] Line of credit one. Interest payable current one. Fixed assets write down. Accrued interest and fees. Gain loss on fair value change of derivatives. Deferred compensation liability non current. Financing And Registration Rights Agreement [Member] Net income loss from discontinued operations. Deferred liability noncurrent. OED Installations [Member] Equity financing agreement description. Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. Assets, Current Assets Liabilities, Current Liabilities [Default Label] Treasury Stock, Value Equity, Attributable to Parent Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Derivative, Gain (Loss) on Derivative, Net Nonoperating Income (Expense) Net Income (Loss) Attributable to Parent Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Increase (Decrease) in Deposits Outstanding Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Contract with Customer, Liability Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Commitments and Contingencies Disclosure [Text Block] Inventory, Policy [Policy Text Block] Derivative Assets (Liabilities), at Fair Value, Net Deposits Assets, Noncurrent Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Salary and Wage, Excluding Cost of Good and Service Sold Accounts Payable and Accrued Liabilities Less: Accumulated amortization Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Disposal Group, Including Discontinued Operation, Costs of Goods Sold Disposal Group, Including Discontinued Operation, Interest Expense Interest Payable, Current LineOfCreditOne InterestPayableCurrentOne Inventory Write-down EX-101.PRE 9 ozsc-20230331_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
3 Months Ended
Mar. 31, 2023
May 15, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2023  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 000-55976  
Entity Registrant Name OZOP ENERGY SOLUTIONS, INC.  
Entity Central Index Key 0001679817  
Entity Tax Identification Number 35-2540672  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 55 Ronald Reagan Blvd  
Entity Address, City or Town Warwick  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10990  
City Area Code (877)  
Local Phone Number 785-6967  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   4,894,080,751
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Current Assets    
Cash $ 1,954,814 $ 1,369,210
Prepaid expenses 69,319 59,405
Accounts receivable 209,421 173,151
Inventory 1,648,182 3,601,026
Vendor deposits 3,687,266 3,053,821
Total Current Assets 7,569,002 8,256,613
Operating lease right-of-use asset, net 474,817 507,706
Property and equipment, net 690,755 711,615
Other assets 13,408 13,408
TOTAL ASSETS 8,747,982 9,489,342
Current Liabilities    
Accounts payable and accrued expenses 5,797,368 5,089,009
Convertible notes payable, net of discounts 25,000 25,000
Current portion of notes payable, net of discounts 4,079,423 4,447,605
Customer deposits 250,000 250,000
Deferred liability 490,000 490,000
Derivative liabilities 4,952,388 4,314,270
Operating lease liability, current portion 137,011 133,508
Liabilities of discontinued operations 1,054,473 1,059,837
Total Current Liabilities 16,785,663 15,809,229
Long Term Liabilities    
Note payable, net of discount 14,591,250 14,272,500
Operating lease liability, net of current portion 348,997 384,382
TOTAL LIABILITIES 31,725,910 30,466,111
COMMITMENTS AND CONTINGENCIES
Stockholders’ Deficit    
Preferred Stock 3 3
Common stock (4,990,000,000 shares authorized par value $0.001; 4,879,032,132 and 4,771,275,349 shares issued and outstanding as of March 31, 2023, and December 31, 2022, respectively) 4,879,032 4,771,275
Treasury stock, at cost, 47,500 shares of Sereis C Preferred Stock and 18,667 shares of Series D Preferred Stock (11,249,934) (11,249,934)
Common stock to be issued; 637,755 shares as of March 31, 2023 and December 31, 2022 638 638
Additional paid in capital 198,005,460 197,586,824
Accumulated deficit (213,828,351) (211,300,799)
Total Ozop Energy Solutions, Inc. stockholders’ deficit (22,193,151) (20,191,992)
Noncontrolling interest (784,777) (784,777)
TOTAL STOCKHOLDERS’ DEFICIT (22,977,928) (20,976,769)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT 8,747,982 9,489,342
Series D Preferred Stock [Member]    
Stockholders’ Deficit    
Preferred Stock 1 1
Series E Preferred Stock [Member]    
Stockholders’ Deficit    
Preferred Stock
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 4,990,000,000 4,990,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares issued 4,879,032,132 4,771,275,349
Common stock, shares outstanding 4,879,032,132 4,771,275,349
Common stock to be issued 637,755 637,755
Series C Preferred Stock [Member]    
Preferred stock, shares authorized 50,000 50,000
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares issued 2,500 2,500
Preferred stock, shares outstanding 2,500 2,500
Treasury stock, shares 47,500 47,500
Series D Preferred Stock [Member]    
Preferred stock, shares authorized 4,570 4,570
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares issued 1,334 1,334
Preferred stock, shares outstanding 1,334 1,334
Treasury stock, shares 18,667 18,667
Series E Preferred Stock [Member]    
Preferred stock, shares authorized 3,000 3,000
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenue $ 2,791,198 $ 2,919,322
Cost of goods sold 2,394,700 2,749,349
Gross profit 396,498 169,973
Operating expenses:    
General and administrative, related parties 240,000 390,000
General and administrative, other 829,762 1,375,567
Total operating expenses 1,069,762 1,765,567
Loss from continuing operations (673,264) (1,595,594)
Other (income) expenses:    
Interest expense 1,221,533 3,966,898
(Gain) loss on change in fair value of derivatives 638,118 (4,365,203)
Total Other (Income) Expenses 1,859,651 (398,305)
Loss from continuing operations before income taxes (2,532,915) (1,197,289)
Income tax provision
Net loss from continuing operations (2,532,915) (1,197,289)
Discontinued Operations:    
Income (loss) from discontinued operations, net of tax 5,363 (184,180)
Net loss (2,527,552) (1,381,469)
Less: net loss attributable to noncontrolling interest (187,708)
Net loss attributable to Ozop Energy Solutions, Inc. $ (2,527,552) $ (1,193,761)
Loss from contuining operations per share of common stockbasic and fully diluted $ (0.00) $ (0.00)
Income (loss) from discontinued operations per share of common stockbasic and fully diluted 0.00 (0.00)
Loss per share basic and fully diluted $ (0.00) $ (0.00)
Weighted average shares outstanding    
Basic and diluted 4,834,943,957 4,619,807,422
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statement of Stockholders' Deficit (Unaudited) - USD ($)
Common Stock To Be Issued [Member]
Preferred Stock [Member]
Series C Preferred Stock [Member]
Preferred Stock [Member]
Series D Preferred Stock [Member]
Common Stock [Member]
Treasury Stock, Common [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Dec. 31, 2021 $ 638 $ 3 $ 1 $ 4,617,363 $ (11,249,934) $ 196,464,222 $ (217,326,611) $ (255,105) $ (27,749,423)
Beginning balance, shares at Dec. 31, 2021 637,755 2,500 1,334 4,617,362,977          
Net loss (1,193,761) (187,708) (1,381,469)
Issuance of common stock for services $ 5,000 130,000 135,000
Common stock issued for services, shares       5,000,000          
Balances at Mar. 31, 2022 $ 638 $ 3 $ 1 $ 4,622,363 (11,249,934) 196,594,222 (218,520,372) (442,813) (28,995,892)
Beginning balance, shares at Mar. 31, 2022 637,755 2,500 1,334 4,622,362,977          
Beginning balance, value at Dec. 31, 2022 $ 638 $ 3 $ 1 $ 4,771,275 (11,249,934) 197,586,824 (211,300,799) (784,777) (20,976,769)
Beginning balance, shares at Dec. 31, 2022 637,755 2,500 1,334 4,771,275,349          
Issuance of shares of common stock sold, net of issuance costs of $19,110 $ 107,757 418,636 526,393
Issuance of shares of common stock sold, shares       107,756,783          
Net loss (2,527,552) (2,527,552)
Balances at Mar. 31, 2023 $ 638 $ 3 $ 1 $ 4,879,032 $ (11,249,934) $ 198,005,460 $ (213,828,351) $ (784,777) $ (22,977,928)
Beginning balance, shares at Mar. 31, 2023       4,879,032,132          
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statement of Stockholders' Deficit (Unaudited) (Parenthetical)
3 Months Ended
Mar. 31, 2023
USD ($)
Statement of Stockholders' Equity [Abstract]  
Issuance cost $ 19,110
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Cash flows from operating activities:      
Net loss from continuing operations $ (2,532,915) $ (1,197,289)  
Net income (loss) from discontinued operations 5,363 (184,180)  
Net loss (2,527,552) (1,381,469)  
Adjustments to reconcile net loss to net cash provided by (used in) operating activities      
Non-cash interest expense 500,568 3,379,121  
Amortization and depreciation 55,912 41,421  
(Gain) loss on fair value change of derivatives 638,118 (4,365,203)  
Stock compensation expense 136,249  
Changes in operating assets and liabilities:      
Accounts receivable (36,270) 166,822  
Inventory 1,952,844 (1,253,333)  
Prepaid expenses (9,915) (19,400)  
Vendor deposits (633,445) (621,373)  
Accounts payable and accrued expenses 708,358 542,507  
Operating lease liabilities (31,882) (28,658)  
Customer deposits 400,769  
Net cash provided by (used in) continuing operations 616,736 (3,002,547)  
Net cash used in discontinued operations (5,363) (57,909)  
Net cash provided by (used in) operating activities 611,373 (3,060,456)  
Cash flows from investing activities:      
Purchase of office and computer equipment (2,162) (40,000)  
Net cash used in investing activities (2,162) (40,000)  
Cash flows from financing activities:      
Proceeds from sale of common stock, net of costs 526,393  
Payments of principal of convertible note payable and notes payable (550,000)  
Net cash used in financing activities (23,607)  
Net increase (decrease) in cash 585,604 (3,100,456)  
Cash, Beginning of period 1,369,210 6,632,194 $ 6,632,194
Cash, End of period 1,954,814 3,531,738 $ 1,369,210
Supplemental disclosure of cash flow information:      
Cash paid for interest 10,075  
Cash paid for income taxes  
Schedule of non-cash Investing or Financing Activity:      
Issuance of common stock and preferred stockfor consulting fees and compensation $ 136,249  
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION

NOTE 1 - ORGANIZATION

 

Business

 

Ozop Energy Solutions, Inc. (the” Company,” “we,” “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada.

 

On October 29, 2020, the Company formed a new wholly owned subsidiary, Ozop Surgical Name Change Subsidiary, Inc., a Nevada corporation (“Merger Sub”). The Merger Sub was formed under the Nevada Revised Statutes for the sole purpose and effect of changing the Company’s name to “Ozop Energy Solutions, Inc.” That same day the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with the Merger Sub and filed Articles of Merger (the “Articles of Merger”) with the Nevada Secretary of State, merging the Merger Sub into the Company, which were stamped effective as of November 3, 2020. As permitted by the Section 92.A.180 of the Nevada Revised Statutes, the sole purpose and effect of the filing of Articles of Merger was to change the name of the Company from Ozop Surgical Corp to “Ozop Energy Solutions, Inc.”

 

On December 11, 2020, the Company formed Ozop Energy Systems, Inc. (“OES”), a Nevada corporation and a wholly owned subsidiary of the Company. OES was formed to be a manufacturer and distributor of renewable energy products.

 

On August 19, 2021, the Company formed Ozop Capital Partners, Inc. (“Ozop Capital”), a Delaware corporation and a wholly owned subsidiary of the Company. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital.

 

On October 29, 2021, EV Insurance Company, Inc. (“EVCO”) was formed as a captive insurance company in the State of Delaware. EVCO is a wholly owned subsidiary of Ozop Capital. On January 7, 2022, EVCO filed with New Castle County, Delaware DBA OZOP Plus.

 

On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners offer the resources needed for lighting, solar and electrical design projects. OED provides its customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs. We work with architects, engineers, facility managers, electrical contractors, and engineers.

 

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.1
GOING CONCERN AND MANAGEMENT’S PLANS
3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN AND MANAGEMENT’S PLANS

NOTE 2 – GOING CONCERN AND MANAGEMENT’S PLANS

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2023, the Company had an accumulated deficit of $213,828,351 and a working capital deficit of $9,216,661 (including derivative liabilities of $4,952,388). As of March 31, 2023, the Company was in default of $3,690,000 plus accrued interest on debt instruments due to non-payment upon maturity dates. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date of the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

In December 2019, a novel strain of coronavirus (COVID-19) emerged. Because COVID-19 infections have been reported throughout the United States, certain federal, state and local governmental authorities have issued stay-at-home orders, proclamations and/or directives aimed at minimizing the spread of COVID-19. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but it may have a material adverse impact on our business, financial condition and results of operations. Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.

 

 

Management’s Plans

 

As a public company, Management believes it will be able to access the public equities market for fund raising for product development, sales and marketing and inventory requirements as we expand our distribution in the U.S. market.

 

On April 4, 2022, the Company, and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “1st GHS Purchase Agreement”) for the sale of up to Two Hundred Million (200,000,000) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending October 4, 2022, at our sole discretion, to GHS under the GHS Purchase Agreement. On October 17, 2022, the Company and GHS extended the Maturity Date to April 4, 2023. The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement. During the three months ended March 31, 2023, the Company sold GHS 51,087,628 shares of common stock and received $205,443, net of offering costs. During the year ended December 31, 2022, the Company sold to GHS 148,912,372 shares of common stock and received $1,141,514, net of offering costs. As of January 23, 2023, the Company sold GHS 200,000,000 shares of common stock.

 

On January 18, 2023, the Company and GHS signed a Securities Purchase Agreement (the “2nd GHS Purchase Agreement”) for the sale of up to One Hundred Fifty Million (150,000,000) shares of the Company’s common stock to GHS. The terms and conditions of the 2nd GHS Purchase Agreement are similar to the terms and conditions of the 1st GHS Purchase Agreement. During the quarter ended March 31, 2023, the Company sold to GHS 56,669,155 shares of common stock and received $320,950, net of offering costs. Subsequent to March 31, 2023, the Company has sold GHS 15,048,619 shares of common stock for proceeds of $71,827, net of offering costs.

 

OES is actively engaged in the renewable, electric vehicle (“EV”), energy storage and energy resiliency sectors. We are engaged in multiple business lines that include project development as well as equipment distribution. Our solar and energy storage projects involve large-scale battery and solar photovoltaics (PV) installations. Our utility-scale storage business model is based on an arbitrage business model in which we install multiple 1+ megawatt batteries, charge them with off-peak grid electricity under contract with the utility, then sell the power back during peak load hours at a premium, as dictated by prevailing electricity tariffs.

 

Equipment Distributor: OES has entered the component supply/distribution side of the renewable, resiliency and energy storage industries distributing the core components associated with residential and commercial solar PV systems as well as onsite battery storage and power generation. In April 2021, the Company signed a five- year lease (beginning June 1, 2021) of approximately 8,100 SF in California, for office and warehouse space to support the sales and distribution of our west coast operations. On February 22, 2023, with an effective date of March 1, 2023, the Company entered into a Sublease for a Single Subleasee Agreement (the “Sublease”) with the landlord and a third party for the office and warehouse in Carlsbad California. Pursuant to the Sublease agreement, the third party will be responsible for all of the Company’s lease obligations through May 31, 2026, the lease termination date. The Company and the subleasee have agreed to work together regarding any existing Company inventory in the facility. OES currently is focused on solar panel sales to other distributors and large installation companies.

 

Solar PV: Our PV business model involves the design and construction of electrical generating PV systems that can sell power to the utilities or be used for off grid use as part of our developing Neo-Grids solution. The Neo-Grids proprietary program, patent pending, was developed for the off-grid distribution of electricity to remove or reduce the dependency on utilities that currently burdens the EV Charging sectors. It will also reduce or eliminate the lengthy permitting processes and streamline the installations of those EV chargers.

 

Modular Energy Distribution System: The Neo-Grids, patent pending, is comprised of the design engineering, installation, and operational methodologies as well as the financial arbitrage of how we produce, capture and distribute electrical energy for the EV markets. OES has acquired the license rights to a proprietary system, the Neo-GridsTM System (patent pending), for the capture and distribution of electrical energy for the EV market. The Neo-GridsTM System will serve both the private auto and the commercial sectors. The exponential growth of the EV industry has been accelerated by the recent major commitments of most of the major car manufacturers. Our Neo-GridsTM System leverages this accelerated growth by offering (1) charging locations that can be installed with reduced delays, restricted areas or load limits and (2) EV charger electricity that is produced from renewable sources claiming little to no carbon footprint.

 

OES has developed a business plan for the Neo Grids distribution, a solution to the stress forthcoming to the existing grid infrastructure. The Company has completed its’ Neo Grid research and development as well as the first set of engineered technical drawings. This first stage of engineered technical drawings allows us to move forward with stage two, as well as to begin to construct the first prototype or proof of concept, (“PoC”). Our PoC design is partially reliant on auto manufacturers establishing standardizations of the actual charging/discharging protocols of the batteries such as on-board inverters as well as bi-directional capabilities in electric vehicles, which have only recently been established. As the market growth rate of EV’s continues to rise, the stress on the existing grid-tied infrastructure shows the need for the continued development of our Neo-Grid solution.

 

 

Ozop Plus markets vehicle service contracts (“VSC’s”) for electric vehicles (EV’s) that offer consumers to be able to purchase additional months and miles above the manufacturer’s warranty and to also bring added value to EV owners by utilizing our partnerships and strengths in the energy market to offer unique and innovative services. Among EV owners’ concerns are the EV battery repair and replacement costs, range anxiety, environmental responsibilities, roadside assistance, and the accelerated wear on additional components that EV vehicles experience. Management believes that the Ozop Plus marketed VSC’s will give “peace of mind” to the EV buyer.

 

  In May 2022, the Company entered into an agreement with GS Administrators, Inc., a member of Houston-based GSFSGroup. Under the agreement, the Company will market GSFSGroup’s EV VSC’s in all states (except, California, Florida, Massachusetts and Washington) to Ozop’s network of new and used franchised dealerships and other eligible entities. In addition to acting as an agent for the marketing, Ozop also has the right to white label the product under its’ Ozop Plus brand. Ozop’s role won’t be limited to marketing the product. GSFSGroup plans to tap into Ozop’s experience relative to battery collection and disposal and has agreed to insurance risk sharing in connection with the insurance policies that back the VSC’s. GSFSGroup is working on getting the approvals needed for the above four (4) states.
     
  On June 22, 2022, the Company entered into an Agent Agreement with Royal Administration Services, Inc. (“Royal”). Under the agreement, the Company will market Royal’s EV VSC’s and has the right to white label it under Ozop Plus. Royal has agreed to allow Ozop Plus on all VSC’s, marketed by Royal and the Company, to assume all the risk related to the electric battery at an agreed upon premium. The battery premium is dependent on the consumer’s selection of the duration of the VSC, the miles selected for coverage and the type of vehicle that the consumer has purchased, with a key component being the kWh size of the battery. These VSC’s have a maximum of 10 years and 150,000 miles and cover new and used cars from model year 2017 and newer. Royal’s VSCs are now effective in 46 states and the others have various waiting times or approvals needed.
     
  On October 13, 2022, EVCO entered into a Reinsurance Contract (the “Contract”) with American Bankers Insurance Company of Florida (“ABIC” or the “Ceding Company”). Royal is the Administrator of the Contract. Pursuant to the terms of the Contract, ABIC will cede 100% of the battery coverage portion of all electric vehicle service contracts to EVCO. On the same date ABIC and EVCO also entered into a Trust Agreement, whereas EVCO as the reinsurer agrees to deposit an amount equal to unearned premium reserves, plus losses reported but unpaid, plus the estimated amount of losses incurred but not reported to the trust account. Permissible investments (with a maturity of no more than five (5) years) of the assets of the Trust account include:

 

  U.S. Treasury Securities
  Cash or cash instruments
  U.S agency issues
  Other investments as Ceding Company approves

 

On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners offer the resources needed for lighting, solar and electrical design projects. OED will provide its’ customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs by working with architects, engineers, facility managers, electrical contractors and engineers.

 

XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS
3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS

 

Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2023, and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2023, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Current Report on Form 10-K filed on April 17, 2023.

 

The unaudited consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries Ozop Capital Partners, Inc., Ozop Engineering and Design, Inc., Power Conversion Technologies, Inc. (“PCTI”), Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”). All intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”).

 

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. The Company has no cash equivalents at March 31, 2023 and December 31, 2022.

 

Sales Concentration and credit risk

 

Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the three months ended March 31, 2023, and 2022, and their accounts receivable balance as of March 31, 2023:

 

   Sales % Three Months Ended March 31, 2023   Sales % Three Months Ended March 31, 2022   Accounts receivable balance March 31, 2023 
Customer A   97%   -   $149,040 
Customer B   -    19%  $- 
Customer C   -    15%  $- 
Customer D   -    15%  $- 
Customer E   -    14%  $- 

 

Accounts Receivable

 

The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.

 

Inventory

 

Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs consist of finished goods. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues. Finished goods inventories as of March 31, 2023, and December 31, 2022, were $1,648,182 and $3,601,026, respectively. As of March 31, 2023, the Company has on deposit with vendor(s) approximately $3,687,000 and has a balance due of approximately $10,264,000 for open purchase orders. The remaining balance is partially due when the vendor ships the product, with the final balance due prior to delivery.

 

Purchase concentration

 

OES purchases finished renewable energy products from its’ suppliers. For the three months ended March 31, 2023, there was one supplier that accounted for 100%. For the three months ended March 31, 2022, there were four suppliers that accounted for approximately 36%, 24%,13%, and 10%, respectively. There are only a handful of major suppliers, and we currently have supply arrangements with some of those vendors. One of these vendors requires a 20% down payment with the balances due on shipment and delivery, while other vendors’ terms are due immediately prior to delivery. We may also buy product from other distributors if we are not able to purchase direct from the manufacturer. While management believes its relationships with its vendors are good, if we are unable to continue to use and/or find alternative suppliers, when we cannot buy direct, it may have a material negative effect on our business.

 

 

Property, plant, and equipment

 

Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.

 

The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows:

 

  Building 10-25 years
  Office furniture and equipment 3-5 years
  Warehouse equipment 7 years

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. The Company has no outstanding contracts with any of its’ customers. The Company recognizes revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms.

 

For contracts with customers, ownership of the goods and associated revenue are transferred to customers at a point in time, generally upon shipment of a product to the customer or receipt of the product by the customer and without significant judgments. Any advance payments are recorded as current liability until revenue is recognized.

 

For the periods covered herein, we did not have post shipment obligations such as training or installation, customer acceptance provisions, credits and discounts, rebates and price protection, or other similar privileges.

 

The following table disaggregates our revenue by major source for the three months ended March 31, 2023, and 2022:

 

    2023     2022  
    Three months ended March 31,  
    2023     2022  
Sourced and distributed products   $ 2,758,798     $ 2,919,322  
OED Installations     32,400       -  
Total   $ 2,791,198     $ 2,919,322  

 

Revenues from sourced and distributed products are purchased from suppliers as finished goods and the Company currently brings the finished goods into a third-party warehouse to fill orders as well as to build inventory for future sales orders.

 

Advertising and Marketing Expenses

 

The Company expenses advertising and marketing costs as incurred. For the three months ended March 31, 2023, and 2022, the Company recorded advertising and marketing expenses of $17,772 and $2,478, respectively.

 

Convertible Instruments

 

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

 

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

 

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

 

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

 

 

Discontinued Operations

 

In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meet the criteria in paragraph 205-20-45-10. In the period in which the component meets held-for-sale or discontinued operations criteria the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations.

 

On September 1, 2022, the BOD of the Company authorized the filing of a Chapter 7 proceeding which meets the definition of a discontinued operation. Accordingly, the operating results of PCTI are reported as income (loss) from discontinued operations in the accompanying consolidated financial statements for the three months ended March 31, 2023, and 2022. For additional information, see Note 14- Discontinued Operations.

 

Distinguishing Liabilities from Equity

 

The Company relies on the guidance provided by ASC Topic 480, Distinguishing Liabilities from Equity, to classify certain redeemable and/or convertible instruments. The Company first determines whether a financial instrument should be classified as a liability. The Company will determine the liability classification if the financial instrument is mandatorily redeemable, or if the financial instrument, other than outstanding shares, embodies a conditional obligation that the Company must or may settle by issuing a variable number of its equity shares.

 

Once the Company determines that a financial instrument should not be classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet (“temporary equity”). The Company will determine temporary equity classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity.

 

Our CEO and Chairman holds sufficient shares of the Company’s voting preferred stock that give sufficient voting rights under the articles of incorporation and bylaws of the Company such that the CEO and Chairman can at any time unilaterally vote to increase the number of authorized shares of common stock of the Company, without the need to call a general meeting of common shareholders of the Company.

 

Initial Measurement

 

The Company records its financial instruments classified as liability, temporary equity, or permanent equity at issuance at the fair value, or cash received.

 

Subsequent Measurement – Financial Instruments Classified as Liabilities

 

The Company records the fair value of its financial instruments classified as liabilities at each subsequent measurement date. The changes in the fair value of its financial instruments classified as liabilities are recorded as other income (expenses).

 

Fair Value of Financial Instruments

 

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

  Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
  Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
  Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

 

From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.

 

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of March 31, 2023, and December 31, 2022, for each fair value hierarchy level:

 

March 31, 2023  Derivative Liabilities   Total 
Level I  $-   $- 
Level II  $-   $- 
Level III  $4,952,388   $4,952,388 

 

December 31, 2022  Derivative Liabilities   Total 
Level I  $-   $- 
Level II  $-   $- 
Level III  $4,314,270   $4,314,270 

 

Leases

 

The Company accounts for leases under ASU 2016-02 (see Note 13), applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

 

Operating lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company used an incremental borrowing rate of 7.5%, for the existing lease, based on the information available at the adoption date in determining the present value of future payments. Operating lease expense is recognized pursuant to on a straight-line basis over the lease term and is included in rent in the consolidated statements of operations.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.

 

Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.

 

 

Segment Policy

 

The Company has no reportable segments as it operates in one segment: renewable energy.

 

Earnings (Loss) Per Share

 

The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of March 31, 2023, and 2022, the Company’s dilutive securities are convertible into approximately 8,471,310,904 and 7,689,322,026, respectively, shares of common stock. The following table represents the classes of dilutive securities as of March 31, 2023, and 2022:

 

    March 31, 2023     March 31, 2022  
Convertible preferred stock (1)     7,318,548,198       6,933,544,496  
Unexercised common stock purchase warrants (1)     1,047,024,518       672,024,518  
Convertible notes payable (1)     11,025,635       2,461,916  
Promissory notes payable (1)     94,712,553       81,291,096  
TOTAL      8,471,310,904       7,689,322,026  

 

(1) The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than 4.99% of the then outstanding shares of common stock subsequent to any conversion or exercise. These shares were excluded from the diluted per share calculation because the effect of including these potential shares was anti-dilutive due to the Company’s net loss position.

 

Recent Accounting Pronouncements

 

In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging —Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company does not believe the adoption of the ASU will have a material impact on the Company’s financial position, results of operations or cash flows.

 

Other than the above, there have been no recent accounting pronouncements or changes in accounting pronouncements during the period ended March 31, 2023, that are of significance or potential significance to the Company.

 

XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY AND EQUIPMENT
3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

NOTE 4 – PROPERTY AND EQUIPMENT

 

The following table summarizes the Company’s property and equipment:

 

    March 31, 2023     December 31, 2022  
Office equipment   $ 224,733     $ 222,571  
Building and building improvements     600,000       600,000  
Less: Accumulated Depreciation     (133,978 )     (110,956 )
Property and Equipment, Net   $ 690,755     $ 711,615  

 

Depreciation expenses were $23,022 and $10,805 for the three months ended March 31, 2023, and 2022, respectively.

 

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE NOTES PAYABLE
3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
CONVERTIBLE NOTES PAYABLE

NOTE 5 - CONVERTIBLE NOTES PAYABLE

 

On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a past-due 15% convertible note issued by the Company on September 13, 2017. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $25,000.

 

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.1
DERIVATIVE LIABILITIES
3 Months Ended
Mar. 31, 2023
Derivative Liabilities  
DERIVATIVE LIABILITIES

NOTE 6 – DERIVATIVE LIABILITIES

 

The Company determined the conversion feature of the convertible notes, which all contain variable conversion rates, represented an embedded derivative since the notes were convertible into a variable number of shares upon conversion. Accordingly, the notes are not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability.

 

 

At any given time, certain of the Company’s embedded conversion features on debt and outstanding warrants may be treated as derivative liabilities for accounting purposes under ASC 815-40 due to insufficient authorized shares to settle these outstanding contracts. Pursuant to SEC staff guidance that permits a sequencing approach based on the use of ASC 815-15-25 which provides guidance for contracts that permit partial net share settlement. The sequencing approach may be applied in one of two ways: contracts may be evaluated based on (1) earliest issuance date or (2) latest maturity date. Pursuant to the sequencing approach, the Company evaluates its contracts based upon the latest maturity date.

 

The Company valued the derivative liabilities as of March 31, 2023, and December 31, 2022, at $4,952,388 and $4,314,270 respectively. For the derivative liability associated with convertible notes, the Company used the Monte Carlo simulation valuation model with the following assumptions as of March 31, 2023, and December 31, 2022, risk free interest rates at 4.85% and 4.76%, respectively, and volatility of 86% and 71%, respectively. During the year ended December 31, 2022, the Company issued 375,000,000 warrants in conjunction with the extension of certain notes payable. The Company recorded a discount to notes payable of $2,550,000 with the offset to derivative liabilities for the initial fair value of the warrants based on the Black-Scholes option pricing model. The following assumptions were utilized in the initial Black-Scholes valuation of issued warrants during the year ended December 31, 2022, risk free interest rate of 4.45%, volatility of 509%, and an exercise price of $0.0067.

 

The following assumptions were utilized in the Black-Scholes valuation of outstanding warrants as of March 31, 2023, and December 31, 2022, risk free interest rate of 3.94% to 4.64%, and 4.39% to 4.73%, respectively, volatility of 112% to 168%, and 109% to 272%, respectively, and exercise prices of $0.0061 to $0.15.

 

A summary of the activity related to derivative liabilities for the three months ended March 31, 2023, is as follows:

 

   Derivative liabilities associated with warrants   Derivative liabilities associated with convertible notes   Total derivative liabilities 
             
Balance January 1, 2023  $4,285,400   $28,870   $4,314,270 
Change in fair value   636,213    1,905    638,118 
Balance March 31, 2023  $4,921,613   $30,775   $4,952,388 

 

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.1
NOTES PAYABLE
3 Months Ended
Mar. 31, 2023
Notes Payable  
NOTES PAYABLE

NOTE 7 – NOTES PAYABLE

 

The Company has the following notes payable outstanding:

 

   March 31, 2023   December 31, 2022 
         
Note payable, interest at 8%, matured January 5, 2020, in default  $45,000   $45,000 
Other, due on demand, interest at 6%, currently in default   50,000    50,000 
Note payable $750,000 face value, interest at 12%, matured August 24, 2021, in default   375,000    375,000 
Note payable $389,423 face value, interest at 12%, matures November 6, 2023   389,423    389,423 
Note payable $1,000,000 face value, interest at 12%, matured November 13, 2021, in default   1,000,000    1,000,000 
Note payable $2,200,000 face value, interest at 15%, matures October 31, 2024, net of discount of $269,167 (2023) and $311,667 (2022)   1,930,833    1,888,333 
Note payable $11,110,000 face value, interest at 15%, matures October 31, 2024, net of discount of $1,345,833 (2023) and $1,558,333 (2022)   9,764,167    9,551,667 
Note payable $3,300,000 face value, interest at 15%, matures October 31, 2024, net of discount of $403,750 (2023) and $467,500 (2022)   2,896,250    2,832,500 
Note payable $3,020,000 face value, matured March 31, 2023, net of discount of $0 (2023) and $181,818 (2022), in default   2,220,000    2,588,182 
Sub- total notes payable, net of discount   18,670,673    18,720,105 
Less long-term portion, net of discount   14,591,250    14,272,500 
Current portion of notes payable, net of discount  $4,079,423   $4,447,605 

 

 

On November 11, 2022, the Company entered into a non-interest bearing, $3,020,000 face value promissory note with a third-party lender with scheduled weekly payments and a maturity date of March 31, 2023. In exchange for the issuance of the $3,020,000 note, inclusive of an original issue discount of $250,000, and the reclass of $260,000 from accounts payable and accrued expenses the Company received proceeds of $2,510,000 on November 11, 2022, from the lender. For the three months ended March 31, 2023, amortization of the original issue discount of $181,818 was charged to interest expense. During the three months ended March 31, 2023, the Company also repaid $550,000 of the principal of the note. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $2,220,000 and $2,770,000, respectively, with a carrying value as of March 31, 2023, and December 31, 2022, of $2,220,000 and $2,588,182, respectively, net of unamortized discounts of $181,818 as of December 31, 2022. The Company is in default on the weekly payments. The Company is currently in discussions with the lender regarding an extension of the maturity date.

 

On December 7, 2021, the Company entered into a 12%, $3,300,000 face value promissory note with a third- party lender with a maturity date of December 7, 2022. In exchange for the issuance of the $3,300,000 note, inclusive of an original issue discount of $300,000, the Company received proceeds of $3,000,000 on December 13, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 75,000,000 shares of common stock at $0.039 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. On October 31, 2022, the maturity date of the note was extended to October 31, 2024, and the interest rate was increased to 15% per annum. The Company issued 75,000,000 warrants at an exercise price of $0.0067 and with an expiration of October 31, 2025, in exchange for the extension. The warrants were valued at $510,000 by the Black-Scholes option pricing method and will be amortized through the new maturity date of the note. The Company determined that this transaction was a modification of the existing note. For the three months ended March 31, 2023, $63,750 was charged to interest expense. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $3,300,000 with carrying values of $2,896,250 and $2,832,500, respectively, net of unamortized discounts of $403,750 and $467,500 as of March 31, 2023 and December 31, 2022, respectively.

 

On March 17, 2021, the Company entered into a 12%, $11,110,000 face value promissory note with a third- party lender with a maturity date of March 17, 2022. In exchange for the issuance of the $11,110,000 note, inclusive of an original issue discount of $1,000,000 and lender costs of $110,000 the Company received proceeds of $10,000,000 on March 23, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 250,000,000 shares of common stock at $0.13 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. On October 31, 2022, the maturity date of the note was extended to October 31, 2024, and the interest rate was increased to 15% per annum. The Company issued 250,000,000 warrants at an exercise price of $0.0067 and with an expiration of October 31, 2025, in exchange for the extension. The warrants were valued at $1,700,000 by the Black-Scholes option pricing method and will be amortized through the new maturity date of the note. The Company determined that this transaction was a modification of the existing note. For the three months ended March 31, 2023, $212,500 was charged to interest expense. As of March 31, 2023 and December 31, 2022, the outstanding principal balance of this note was $11,110,000 with a carrying value of $9,764,167 and $9,551,667, respectively, net of unamortized discounts of $1,345,833 and $1,558,333, respectively.

 

On February 9, 2021, the Company entered into a 12%, $2,200,000 face value promissory note with a third- party lender with a maturity date of February 9, 2022. In exchange for the issuance of the $2,200,000 note, inclusive of an original issue discount of $200,000 the Company received proceeds of $2,000,000 on February 16, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase 50,000,000 shares of common stock at $0.15 per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. On October 31, 2022, the maturity date of the note was extended to October 31, 2024, and the interest rate was increased to 15% per annum. The Company issued 50,000,000 warrants at an exercise price of $0.0067 and with an expiration of October 31, 2025, in exchange for the extension. The warrants were valued at $340,000 by the Black-Scholes option pricing method and will be amortized through the new maturity date of the note. The Company determined that this transaction was a modification of the existing note. For the three months ended March 31, 2023, $42,500 was charged to interest expense. As of March 31, 2023 and December 31, 2022, the outstanding principal balance of this note was $2,200,000 with a carrying value of $1,930,833 and $1,888,333, respectively, net of unamortized discounts of $269,167 and $311,667, respectively.

 

On November 13, 2020, the Company entered into a 12%, $1,000,000 face value promissory note with a third-party due November 13, 2021. Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date. The Company received proceeds of $890,000 on November 20, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $110,000. In conjunction with this note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase 125,000,000 shares of common stock at an exercise price of $0.008, subject to adjustments and expires on the five-year anniversary of the issue date. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $1,000,000. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of March 31, 2023, and December 31, 2022, the accrued interest is $435,452 and $375,452, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

 

On November 6, 2020, the Company entered into a Settlement Agreement with the holder of $120,000 of convertible notes with accrued and unpaid interest of $8,716 and a $210,000 Promissory Noted dated June 23, 2020, with accrued and unpaid interest of $15,707. The Company issued a new 12% Promissory Note with a face value of $389,423 and a maturity date of November 6, 2023. In conjunction with this settlement, the Company issued a warrant to purchase 60,000,000 shares of common stock at an exercise price of $0.0075, subject to adjustments and expires on the five-year anniversary of the issue date. The Company analyzed the transaction and concluded that this was a modification to the existing debt. The investor exercised the warrant on January 14, 2021.

 

 

On August 24, 2020 (the “Issue Date”), the Company entered into a 12%, $750,000 face value promissory note with a third-party (the “Holder”) due August 24, 2021 (the “Maturity Date”). Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date. The Company received proceeds of $663,000 on August 25, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $87,000. In conjunction with this Note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase 122,950,819 shares of common stock at an exercise price of $0.0061, subject to adjustments and expires on the five-year anniversary of the Issue Date. During the year ended December 31, 2021, the Company paid $375,000 to the Holder. On May 3, 2021, the Company issued 75,000,000 shares of common stock to the Holder, upon the cashless exercise of a portion of the warrants. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $375,000. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of March 31, 2023, and December 31, 2022, the accrued interest is $202,747 and $180,247, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.

 

XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.1
DEFERRED LIABILITY
3 Months Ended
Mar. 31, 2023
Deferred Liability  
DEFERRED LIABILITY

NOTE 8 – DEFERRED LIABILITY

 

On September 2, 2020, PCTI entered into an agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $750,000, PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement. Payments are due ninety (90) days after each calendar quarter, with the first payment due on or before March 31, 2021, for revenues for the quarter ending December 31, 2020. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the note was amended, whereby in exchange for 175,000,000 shares of common stock, the royalty percentage was amended to 1.8%.

 

No payments have been made and the Company is in default of the agreement. On November 11, 2022, the third-party and the Company agreed to reduce the liability by $260,000 and add $260,000 to the promissory note issued on November 11, 2022. The deferred liability as of March 31, 2023, and December 31, 2022, on the consolidated balance sheet is $490,000.

 

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS
3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 9 – RELATED PARTY TRANSACTIONS

 

Employment Agreement

 

On July 10, 2020, pursuant to the PCTI transaction, the Company assumed an employment contract entered into on February 28, 2020, between the Company and Mr. Conway (the “Employment Agreement”). Mr. Conway’s compensation as adjusted was $20,000 per month, and effective September 1, 2021, Mr. Conway received $10,000 per month from Ozop Capital. Effective January 1, 2022, the Company entered into a new employment agreement with Mr. Conway. Pursuant to the agreement, Mr. Conway received a $250,000 contract renewal bonus and will receive annual compensation of $240,000 from the Company and will also be eligible to receive bonuses and equity grants at the discretion of the BOD. The Company also agreed to compensate Mr. Conway for services provided directly to any of the Company’s subsidiaries. Ozop Capital increased Mr. Conway’s compensation to $20,000 per month in January 2022, OES began compensating Mr. Conway $20,000 in March 2022, and OED began compensation Mr. Conway $20,000 per month beginning in April 2022.

 

Management Fees and related party payables

 

For the three months ended March 31, 2023 and 2022, the Company recorded expenses to its officers in the following amounts:

 

   2023   2022 
   Three months ended March 31, 
   2023   2022 
CEO  $240,000   $140,000 
CEO bonus   -    250,000 
Total  $240,000   $390,000 

 

 

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 10 – COMMITMENTS AND CONTINGENCIES

 

Agreements

 

On September 1, 2021, Ozop Capital entered into an advisory agreement (the “RMA Agreement”) with Risk Management Advisors, Inc. (“RMA”). Pursuant to the terms of the RMA Agreement, RMA will assist Ozop Capital in analyzing, structuring, and coordinating Ozop Capital’s participation in a captive insurance company. RMA will coordinate legal, accounting, tax, actuarial and other services necessary to implement the Company’s participation in a captive insurance company, including, but not limited to, the preparation of an actuarial feasibility study, filing of all required regulatory applications, domicile selection, structural selection, and coordination of the preparation of legal documentation. In connection with the services listed above, Ozop Capital agreed to pay $50,000 and to issue $50,000 of shares of restricted common stock. One-half of the cash and stock were due upon the signing of the RMA Agreement. Accordingly, RMA received $25,000 and 452,080 shares of restricted common stock of the Company in September 2021. The balance of the cash and stock became due on October 29, 2021, upon the issuance of the captive insurance company’s certificate of authority from the state of Delaware. The Company has paid the $25,000 balance and recorded 637,755 shares of common stock to be issued.

 

On April 13, 2021, the Company agreed to engage PJN Strategies, LLC (“PJN”) as a consultant. Pursuant to the agreement, the Company agreed to compensate PJN $20,000 per month. Effective September 1, 2021, a new agreement was entered into between PJN and Ozop Capital. Pursuant to the terms of the one- year agreement Ozop Capital agreed to compensate PJN $84,000 per month. For the three months ended March 31, 2023, and 2022, the Company recorded $-0- and $252,000, respectively, of consulting expenses.

 

On March 30, 2021, OES hired 2 individuals as Co-Directors of Sales. Pursuant to their respective offers of employment, the Company agreed to an annual salary of $130,000 with a signing bonus of $20,000 for each and to issue each 2,500,000 shares of restricted common stock upon the execution of the agreements and every 90 days thereafter for the first year as long as the employee is still employed. The Company valued the initial shares at $0.092 per share (the market price of the common stock on the date of the agreement). On July 1, 2021, the Company issued each of the Co-Directors the 2,500,000 shares due after the first ninety days of employment. The shares were valued at $0.0745 per share (the market price of the common stock on the date of the issuance). On October 1, 2021, the Company issued each of the Co-Directors the 2,500,000 shares due after the first one hundred eighty days of employment. The shares were valued at $0.0445 per share (the market price of the common stock on the date of the issuance). On January 14, 2022, the Company issued each of the Co-Directors their final 2,500,000 shares due. The shares were valued at $0.027 per share (the market price of the common stock on the date of the issuance), and $135,000 is included in stock-based compensation expense for the three months ended March 31, 2022. One of the individuals resigned on January 24, 2022, and the other was terminated for cause on November 3, 2022.

 

On March 15, 2021, the Company entered into a consulting agreement with Aurora Enterprises (“Aurora”). Mr. Steven Martello is a principal of Aurora. Pursuant to the agreement Mr. Martello will provide strategic analysis regarding existing markets and revenue streams as well as the development of new lines of revenue. The Company agreed to a monthly retainer fee of $10,000 and to issue to Aurora or their designee 5,000,000 shares of restricted common stock. For the three months ended March 31, 2023, and 2022, the Company has recorded consulting expenses of $-0- and $30,000, respectively.

 

On January 6, 2021, the Company entered into a consulting agreement with Ezra Green to begin on February 8, 2021. The Company agreed to issue 10,000,000 shares of restricted common stock to Mr. Green and to a monthly fee of $2,500. The Company valued the shares at $0.0076 per share (the market price of the common stock on the date of the agreement), and $76,000 was recorded as deferred stock-based compensation, to be amortized over the one-year term of the agreement. Effective April 1, 2021, the agreement was amended to $10,000 per month. Effective June 30, 2022, Mr. Green was no longer providing consulting services to the Company. For the three months ended March 31, 2023, and 2022, the Company recorded consulting expenses of $-0- and $30,000 of consulting expenses respectively.

 

On March 4, 2019, the Company entered into a Separation Agreement (the “Separation Agreement”) with Salman J. Chaudhry, pursuant to which the Company agreed to pay Mr. Chaudry $227,200 (the “Outstanding Fees”) in certain increments as set forth in the Separation Agreement. As of March 31, 2023, and December 31, 2022, the balance owed Mr. Chaudhry is $162,085.

 

On September 2, 2020, PCTI entered into an Agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $750,000, PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the agreement was amended, whereby in exchange for 175,000,000 shares of common stock, the royalty percentage was amended to 1.8% (see Note 8). As of March 31, 2023, and December 31, 2022, the Company has recorded $243,272, respectively, and is included in accounts payable and accrued expenses on the consolidated balance sheet presented herein.

 

Legal matters

 

We know of no material, existing or pending legal proceedings against our Company.

 

We are involved as a plaintiff in a Complaint filed in the SUPERIOR COURT OF THE STATE OF CALIFORNIA FOR THE COUNTY OF SAN DIEGO NORTH COUNTY (the “Complaint”) on November 14, 2022. The Complaint alleges that former employees would place an order from a customer for purchase of product from OZOP with funds the exact source of which is presently unknown. OZOP alleges that next, the customer would sell that product to OZOP’s customers at a price marked up from the price for which the customer purchased from OZOP – to the benefit of Defendants and to the detriment of OZOP, their employer at the time. The Complaint further alleges that the former employees falsely represented that the price the customer was obtaining from other suppliers and therefore was willing to pay for OZOP product decreased, which allowed them to use the customer to then sell additional product to OZOP’s customers at increasingly larger margins, thus further wrongfully enriching themselves to the detriment of their employer, OZOP. The lawsuit also alleges that the employees were also making false statements to Ozop’s customers regarding the financial condition of Ozop and the lack of module inventory.

 

 

There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

 

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY
3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 11– STOCKHOLDERS’ EQUITY

 

Common stock

 

During the three months ended March 31, 2023, the Company issued 107,756,783 shares of common stock and received net proceeds of $526,393 after issuance costs of $19,110.

 

During the three months ended March 31, 2022, the Company issued 5,000,000 shares of restricted common stock in the aggregate for services.

 

As of March 31, 2023, the Company has 4,990,000,000 shares of $0.001 par value common stock authorized and there are 4,879,032,132 shares of common stock issued and outstanding.

 

Preferred stock

 

As of March 31, 2023, 10,000,000 shares have been authorized as preferred stock, par value $0.001 (the “Preferred Stock”), which such Preferred Stock shall be issuable in such series, and with such designations, rights and preferences as the Board of Directors may determine from time to time.

 

Series C Preferred Stock

 

On July 7, 2020, the Company filed an Amended and Restated Certificate of Designation with the State of Nevada of the Company’s Series C Preferred Stock. Under the terms of the Amendment to Certificate of Designation of Series C Preferred Stock, 50,000 shares of the Company’s preferred remain designated as Series C Preferred Stock. The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote. As of March 31, 2023, and December 31, 2022, there were 2,500 shares of Series C Preferred Stock issued and outstanding and the shares are held by Mr. Conway.

 

Series D Preferred Stock

 

On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series D Preferred Stock.

 

On July 27, 2021, the Company filed with the Secretary of State of the State of Nevada an Amended and Restated Certificate of Designation of Series D Preferred Stock (the “Series D Amendment”). Under the terms of the Series D Amendment, 4,570 shares of the Company’s preferred stock will be designated as Series D Convertible Preferred Stock. The holders of the Series D Convertible Preferred Stock shall not be entitled to receive dividends. Any holder may, at any time convert any number of shares of Series D Convertible Preferred Stock held by such holder into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion, by 1.5 and dividing that number by the number of authorized shares of Series D Convertible Preferred Stock and multiply that result by the number of shares of Series D Convertible Preferred Stock being converted. Except as provided in the Series D Amendment or as otherwise required by law, no holder of the Series D Convertible Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. The Series D Convertible Preferred Stock shall not bear any liquidation rights. On July 28, 2021, the Company closed on a Stock and Warrant Purchase Agreement (the “Series D SPA”). Pursuant to the terms of Series D SPA, an investor in exchange for $13,200,000 purchased one share of Series D Preferred Stock, and a warrant to acquire 3,236 shares of Series D Preferred Stock. As of March 31, 2023, and December 31, 2022, there were 1,334 shares, respectively, of Series D Preferred Stock issued and outstanding and a warrant to purchase 3,236 shares of Series D Preferred Stock are outstanding as of March 31, 2023, and December 31, 2022.

 

 

The warrant has a 15- year term and Partial Warrant Lock Up and Leak-Out Period. The Holder may only exercise the Warrant and purchase Warrant Shares as follows:

 

  i. Up to 162 (one hundred and sixty-two) Warrant Shares, at any time or times on or after five (5) business days from the closing of the Series D SPA (“the Initial Exercise Date”) subject to up to a maximum number of Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company and no later than on or before the 15th year anniversary of the Initial Exercise Date (“the Termination Date”); and
     
  ii. The Remainder of the Warrant representing up to 3,074 (three thousand and seventy-four) Warrant Shares (“Remaining Warrant Shares”) shall be locked up for a period of 36 (thirty-six) months from the Initial Exercise Date (“Lock Up Period”) and shall become exercisable at any time or times from the date that is the 36 (thirty-six) month anniversary of the Initial Exercise Date (“Lock Up Period Termination Date”) and no later than on or before the Termination Date, as follows:

 

  a. During every 1 (one) year period, starting on the day that is the Lock Up Period Termination Date, the Holder shall have the right to exercise the Remainder of the Warrant up to a maximum number of Remaining Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company during such given year (“Leak-Out Period”). The Leak-Out Period shall come into effect on the day that is the Lock Up Period Termination Date and remain effective on a yearly basis, for a period of 10 (ten) years thereafter, after which the Leak-Out Period will automatically terminate and become null and void. For clarity purposes the Remainder of the Warrant shall become freely exercisable at any time or times beginning on June 29, 2034, and until the Termination Date.

 

Series E Preferred Stock

 

On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series E Preferred Stock. Under the terms of the Certificate of Designation of Series E Preferred Stock, 3,000 shares of the Company’s preferred stock have been designated as Series E Preferred Stock. The holders of the Series E Convertible Preferred Stock shall not be entitled to receive dividends. No holder of the Series E Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, except as may be otherwise expressly required by law. At any time, the Corporation may redeem for cash out of funds legally available therefor, any or all of the outstanding Preferred Stock (“Optional Redemption”) at $1,000 (one thousand dollars) per share. The shares of Series E Preferred Stock have not been registered under the Securities Act of 1933 or the laws of any state of the United States and may not be transferred without such registration or an exemption from registration. As of March 31, 2023, and December 31, 2022, there were -0- shares of Series E Preferred Stock issued and outstanding, respectively.

 

XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.1
NONCONTROLLING INTEREST
3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
NONCONTROLLING INTEREST

NOTE 12 – NONCONTROLLING INTEREST

 

On August 19, 2021, the Company formed Ozop Capital. The Company initially owned 51% with PJN Holdings, LLC (“PJN”) owning 49%. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital. The Company presents interest held by noncontrolling interest holders within noncontrolling interest in the consolidated financial statements. On September 13, 2022, there was a change in the ownership percentages, as PJN returned 490,000 shares, representing their 49% ownership. As of that date, Ozop Capital is a wholly owned subsidiary of the Company. As of March 31, 2023, and December 31, 2022, the accumulative noncontrolling interest is $784,777.

 

XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.1
OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES
3 Months Ended
Mar. 31, 2023
Operating Lease Right-of-use Assets And Operating Lease Liabilities  
OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES

NOTE 13 - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES

 

On April 14, 2021, the Company entered into a five-year lease which began on June 1, 2021, for approximately 8,100 square feet of office and warehouse space in Carlsbad, California, expiring May 31, 2026. Initial lease payments of $13,481 begin on June 1, 2021, and increase by approximately 2.4% annually thereafter. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be 7.5%, as the interest rate implicit in most of our leases is not readily determinable. During the year ended December 31, 2021, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $702,888 for this lease. On February 22, 2023, with an effective date of March 1, 2023, the Company entered into a Sublease for a Single Subleasee Agreement (the “Sublease”) with the landlord and a third party for the office and warehouse in Carlsbad California. Pursuant to the Sublease agreement, the third party will be responsible for all of the Company’s lease obligations through May 31, 2026, the lease termination date. The Company and the subleasee have agreed to work together regarding any existing Company inventory in the facility.

 

In adopting Topic 842, the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less.

 

 

Right-of- use assets are summarized below:

 

   March 31, 2023   December 31, 2022 
Office and warehouse lease  $702,888   $702,888 
Less: Accumulated amortization   (228,071)   (195,182)
Right-of-use assets, net  $474,817   $507,706 

 

Operating lease liabilities are summarized as follows:

 

   March 31, 2023   December 31, 2022 
Lease liability  $486,008   $517,890 
Less current portion   (137,011)   (133,508)
Long term portion  $348,997   $384,382 

 

Maturity of lease liabilities are as follows:

 

   Amount 
For the year ending December 31, 2023  $126,464 
For the year ending December 31, 2024   171,840 
For the year ending December 31, 2025   175,942 
For the year ending December 31, 2026   74,030 
Total  $548,276 
Less: present value discount   (62,268)
Lease liability  $486,008 

 

XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.1
DISCONTINUED OPERATIONS
3 Months Ended
Mar. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS

NOTE 14 – DISCONTINUED OPERATIONS

 

On September 1, 2022, the BOD of the Company authorized the filing of a Chapter 7 proceeding which meets the definition of a discontinued operation. Accordingly, the operating results of PCTI are reported as income (loss) from discontinued operations in the accompanying consolidated financial statements for the three months ended March 31, 2023, and 2022. On October 3, 2022, PCTI filed a Voluntary Petition for Non- Individuals Filing for Bankruptcy. On November 30, 2022, the Trustee filed a Notice of Abandonment of Estate Property, as it is over encumbered by the secured creditors. No objections were filed, and as such the inventory and equipment is now considered abandoned to the secured creditors to do with what they wish. In March 2023, the Trustee declared this a no-asset case and closed the bankruptcy.

 

The results of operations of this component, for all periods, are separately reported as “discontinued operations”. A reconciliation of the major classes of line items constituting the income (loss) from discontinued operations, net of income taxes as is presented in the Consolidated Statements of Operations for the three months ended March 31, 2023, and 2022 are summarized below:

 

   2023   2022 
   Three months ended March 31, 
   2023   2022 
Revenues  $5,363   $162,916 
Cost of goods sold   -    126,482 
Gross profit   5,363    36,434 
Operating expenses   -    212,290 
Interest expense   -    8,324 
Income (loss) from discontinued operations  $5,363   $(184,180)

 

There are no assets as of March 31, 2023, and December 31, 2022, as the secured lender has taken possession. Liabilities of discontinued operations are separately reported as “liabilities held for disposal” as of March 31, 2023, and December 31, 2022. All liabilities are classified as current. The following tables present the reconciliation of carrying amounts of the major classes of liabilities of the Company classified as discontinued operations in the consolidated balance sheets at March 31, 2023, and December 31, 2022:

 

 

Current liabilities

 

         
  

March 31,

2023
   December 31,
2022
 
Accounts payable and accrued liabilities  $445,565   $445,565 
Current portion of notes payable   589,246    589,246 
Operating lease liability   -    3,575 
Deferred revenues   19,662    21,451 
Total current liabilities of discontinued operations  $1,054,473   $1,059,837 

 

On May 16, 2022, Huntington National Bank (“Huntington”) filed a Complaint for Confession of Judgment (“COJ”) against Catherine Chis (“Chis”). Chis was the former CEO of PCTI and a Guarantor on Huntington’s Letter of Credit financing (“LOC”) and a Term Loan (“Term Loan”). The Chis COJ for the LOC was for $352,415 and accrues per diem interest of $63.65, and the Chis COJ for the Term Loan was for $141,415 and accrues per diem interest of $28.60. On June 24, 2022, Huntington filed a COJ against Power Conversion Technologies, Inc (“PCTI”). The PCTI COJ for the LOC was for $354,774 and accrues per diem interest of $63.65 and the PCTI COJ for the LOC was for $142,473 and accrues per diem interest of $28.60. On July 20, 2022, Huntington assigned the PCTI judgment against PCTI to Meraki Advisors, LLC. (“Meraki”). The Company’s understanding is Meraki is a Pennsylvania limited liability company, controlled by Chis.

 

The Company wrote off the book value of the inventory of $237,091 and fixed assets of $15,447 during the year ended December 31, 2022, with the offset to Loss on Disposal of Assets of Discontinued Operations. Included in the Current portion of notes payable are the principal balances of Huntington’s LOC of $344,166 and Term Loan of $134,681. Accrued interest and fees on the LOC and Term Loan debt $54,256 is included in accounts payable and accrued liabilities.

 

XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES
3 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 15 - INCOME TAXES

 

The Company provides for income taxes under ASC 740, Accounting for Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely- than not that some or all of the deferred tax assets will not be realized.

 

In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future income, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability.

 

XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 16 – SUBSEQUENT EVENTS

 

From April 1, 2023, through the filing of this report, the Company sold GHS 15,048,619 shares of common stock for proceeds of $71,827 net of offering costs. These sales were under the January 20, 2023, GHS SPA.

 

On May 2, 2023, the Company entered into an Equity Financing Agreement (the “Financing Agreement”) and Registration Rights Agreement (the “Registration Rights Agreement”) with GHS. Under the terms of the Financing Agreement, GHS has agreed to provide the Company with up to $10,000,000 of funding upon effectiveness of a registration statement on Form S-1. Following effectiveness of the registration statement, the Company shall have the right to deliver puts to GHS and GHS will be obligated to purchase shares of our common stock based on the investment amount specified in each put notice. The maximum amount that the Company shall be entitled to put to GHS in each put notice will not exceed two hundred fifty percent (250%) of the average of the daily trading dollar volume of the Company’s common stock during the ten (10) trading days preceding the put, so long as such amount does not exceed 4.99% of the outstanding shares of the Company. Pursuant to the Financing Agreement, GHS and its affiliates will not be permitted to purchase, and the Company may not put shares of the Company’s common stock to GHS that would result in GHS’s beneficial ownership equaling more than 4.99% of the Company’s outstanding common stock. The price of each put share shall be equal to eighty percent (80%) of the lowest daily volume weighted average price of the Company’s common stock for the ten (10) consecutive trading days preceding the date on which the applicable put is delivered to GHS. No put will be made in an amount equaling less than $10,000 or greater than $750,000. Puts may be delivered by the Company to GHS until the earlier of twenty-four (24) months after the effectiveness of the registration statement on Form S-1 or the date on which GHS has purchased an aggregate of $10,000,000 worth of put shares.

 

On May 5, 2023, the Board of Directors of the Company approved to amend the Company’s Articles of Incorporation (the “Amendment”) to increase the authorized capital stock of the Company to 7,000,000,000 shares, of which 6,990,000,000 shall be authorized as common shares and 10,000,000 shall be authorized as preferred shares. The Company is in the process of filing the Amendment with the State of Nevada,

 

The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no other such events that warrant disclosure or recognition in the financial statements, except as stated herein.

XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)
3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2023, and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2023, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Current Report on Form 10-K filed on April 17, 2023.

 

The unaudited consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries Ozop Capital Partners, Inc., Ozop Engineering and Design, Inc., Power Conversion Technologies, Inc. (“PCTI”), Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”). All intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”).

 

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. The Company has no cash equivalents at March 31, 2023 and December 31, 2022.

 

Sales Concentration and credit risk

Sales Concentration and credit risk

 

Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the three months ended March 31, 2023, and 2022, and their accounts receivable balance as of March 31, 2023:

 

   Sales % Three Months Ended March 31, 2023   Sales % Three Months Ended March 31, 2022   Accounts receivable balance March 31, 2023 
Customer A   97%   -   $149,040 
Customer B   -    19%  $- 
Customer C   -    15%  $- 
Customer D   -    15%  $- 
Customer E   -    14%  $- 

 

Accounts Receivable

Accounts Receivable

 

The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.

 

Inventory

Inventory

 

Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs consist of finished goods. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues. Finished goods inventories as of March 31, 2023, and December 31, 2022, were $1,648,182 and $3,601,026, respectively. As of March 31, 2023, the Company has on deposit with vendor(s) approximately $3,687,000 and has a balance due of approximately $10,264,000 for open purchase orders. The remaining balance is partially due when the vendor ships the product, with the final balance due prior to delivery.

 

Purchase concentration

Purchase concentration

 

OES purchases finished renewable energy products from its’ suppliers. For the three months ended March 31, 2023, there was one supplier that accounted for 100%. For the three months ended March 31, 2022, there were four suppliers that accounted for approximately 36%, 24%,13%, and 10%, respectively. There are only a handful of major suppliers, and we currently have supply arrangements with some of those vendors. One of these vendors requires a 20% down payment with the balances due on shipment and delivery, while other vendors’ terms are due immediately prior to delivery. We may also buy product from other distributors if we are not able to purchase direct from the manufacturer. While management believes its relationships with its vendors are good, if we are unable to continue to use and/or find alternative suppliers, when we cannot buy direct, it may have a material negative effect on our business.

 

 

Property, plant, and equipment

Property, plant, and equipment

 

Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.

 

The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows:

 

  Building 10-25 years
  Office furniture and equipment 3-5 years
  Warehouse equipment 7 years

 

Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. The Company has no outstanding contracts with any of its’ customers. The Company recognizes revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms.

 

For contracts with customers, ownership of the goods and associated revenue are transferred to customers at a point in time, generally upon shipment of a product to the customer or receipt of the product by the customer and without significant judgments. Any advance payments are recorded as current liability until revenue is recognized.

 

For the periods covered herein, we did not have post shipment obligations such as training or installation, customer acceptance provisions, credits and discounts, rebates and price protection, or other similar privileges.

 

The following table disaggregates our revenue by major source for the three months ended March 31, 2023, and 2022:

 

    2023     2022  
    Three months ended March 31,  
    2023     2022  
Sourced and distributed products   $ 2,758,798     $ 2,919,322  
OED Installations     32,400       -  
Total   $ 2,791,198     $ 2,919,322  

 

Revenues from sourced and distributed products are purchased from suppliers as finished goods and the Company currently brings the finished goods into a third-party warehouse to fill orders as well as to build inventory for future sales orders.

 

Advertising and Marketing Expenses

Advertising and Marketing Expenses

 

The Company expenses advertising and marketing costs as incurred. For the three months ended March 31, 2023, and 2022, the Company recorded advertising and marketing expenses of $17,772 and $2,478, respectively.

 

Convertible Instruments

Convertible Instruments

 

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

 

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

 

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

 

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

 

 

Discontinued Operations

Discontinued Operations

 

In accordance with ASC 205-20 Presentation of Financial Statements: Discontinued Operations, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meet the criteria in paragraph 205-20-45-10. In the period in which the component meets held-for-sale or discontinued operations criteria the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations.

 

On September 1, 2022, the BOD of the Company authorized the filing of a Chapter 7 proceeding which meets the definition of a discontinued operation. Accordingly, the operating results of PCTI are reported as income (loss) from discontinued operations in the accompanying consolidated financial statements for the three months ended March 31, 2023, and 2022. For additional information, see Note 14- Discontinued Operations.

 

Distinguishing Liabilities from Equity

Distinguishing Liabilities from Equity

 

The Company relies on the guidance provided by ASC Topic 480, Distinguishing Liabilities from Equity, to classify certain redeemable and/or convertible instruments. The Company first determines whether a financial instrument should be classified as a liability. The Company will determine the liability classification if the financial instrument is mandatorily redeemable, or if the financial instrument, other than outstanding shares, embodies a conditional obligation that the Company must or may settle by issuing a variable number of its equity shares.

 

Once the Company determines that a financial instrument should not be classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet (“temporary equity”). The Company will determine temporary equity classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity.

 

Our CEO and Chairman holds sufficient shares of the Company’s voting preferred stock that give sufficient voting rights under the articles of incorporation and bylaws of the Company such that the CEO and Chairman can at any time unilaterally vote to increase the number of authorized shares of common stock of the Company, without the need to call a general meeting of common shareholders of the Company.

 

Initial Measurement

 

The Company records its financial instruments classified as liability, temporary equity, or permanent equity at issuance at the fair value, or cash received.

 

Subsequent Measurement – Financial Instruments Classified as Liabilities

 

The Company records the fair value of its financial instruments classified as liabilities at each subsequent measurement date. The changes in the fair value of its financial instruments classified as liabilities are recorded as other income (expenses).

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

 

The following are the hierarchical levels of inputs to measure fair value:

 

  Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.
  Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
  Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

 

 

From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.

 

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of March 31, 2023, and December 31, 2022, for each fair value hierarchy level:

 

March 31, 2023  Derivative Liabilities   Total 
Level I  $-   $- 
Level II  $-   $- 
Level III  $4,952,388   $4,952,388 

 

December 31, 2022  Derivative Liabilities   Total 
Level I  $-   $- 
Level II  $-   $- 
Level III  $4,314,270   $4,314,270 

 

Leases

 

The Company accounts for leases under ASU 2016-02 (see Note 13), applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

 

Operating lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company used an incremental borrowing rate of 7.5%, for the existing lease, based on the information available at the adoption date in determining the present value of future payments. Operating lease expense is recognized pursuant to on a straight-line basis over the lease term and is included in rent in the consolidated statements of operations.

 

Income Taxes

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.

 

Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.

 

 

Segment Policy

Segment Policy

 

The Company has no reportable segments as it operates in one segment: renewable energy.

 

Earnings (Loss) Per Share

Earnings (Loss) Per Share

 

The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of March 31, 2023, and 2022, the Company’s dilutive securities are convertible into approximately 8,471,310,904 and 7,689,322,026, respectively, shares of common stock. The following table represents the classes of dilutive securities as of March 31, 2023, and 2022:

 

    March 31, 2023     March 31, 2022  
Convertible preferred stock (1)     7,318,548,198       6,933,544,496  
Unexercised common stock purchase warrants (1)     1,047,024,518       672,024,518  
Convertible notes payable (1)     11,025,635       2,461,916  
Promissory notes payable (1)     94,712,553       81,291,096  
TOTAL      8,471,310,904       7,689,322,026  

 

(1) The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than 4.99% of the then outstanding shares of common stock subsequent to any conversion or exercise. These shares were excluded from the diluted per share calculation because the effect of including these potential shares was anti-dilutive due to the Company’s net loss position.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging —Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company does not believe the adoption of the ASU will have a material impact on the Company’s financial position, results of operations or cash flows.

 

Other than the above, there have been no recent accounting pronouncements or changes in accounting pronouncements during the period ended March 31, 2023, that are of significance or potential significance to the Company.

XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)
3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR

Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the three months ended March 31, 2023, and 2022, and their accounts receivable balance as of March 31, 2023:

 

   Sales % Three Months Ended March 31, 2023   Sales % Three Months Ended March 31, 2022   Accounts receivable balance March 31, 2023 
Customer A   97%   -   $149,040 
Customer B   -    19%  $- 
Customer C   -    15%  $- 
Customer D   -    15%  $- 
Customer E   -    14%  $- 
SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS

 

  Building 10-25 years
  Office furniture and equipment 3-5 years
  Warehouse equipment 7 years
DISAGGREGATION OF REVENUE

The following table disaggregates our revenue by major source for the three months ended March 31, 2023, and 2022:

 

    2023     2022  
    Three months ended March 31,  
    2023     2022  
Sourced and distributed products   $ 2,758,798     $ 2,919,322  
OED Installations     32,400       -  
Total   $ 2,791,198     $ 2,919,322  
SCHEDULE OF DERIVATIVE INSTRUMENTS

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of March 31, 2023, and December 31, 2022, for each fair value hierarchy level:

 

March 31, 2023  Derivative Liabilities   Total 
Level I  $-   $- 
Level II  $-   $- 
Level III  $4,952,388   $4,952,388 

 

December 31, 2022  Derivative Liabilities   Total 
Level I  $-   $- 
Level II  $-   $- 
Level III  $4,314,270   $4,314,270 
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

 

    March 31, 2023     March 31, 2022  
Convertible preferred stock (1)     7,318,548,198       6,933,544,496  
Unexercised common stock purchase warrants (1)     1,047,024,518       672,024,518  
Convertible notes payable (1)     11,025,635       2,461,916  
Promissory notes payable (1)     94,712,553       81,291,096  
TOTAL      8,471,310,904       7,689,322,026  

 

(1) The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than 4.99% of the then outstanding shares of common stock subsequent to any conversion or exercise. These shares were excluded from the diluted per share calculation because the effect of including these potential shares was anti-dilutive due to the Company’s net loss position.
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY AND EQUIPMENT (Tables)
3 Months Ended
Mar. 31, 2023
Property, Plant and Equipment [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT

The following table summarizes the Company’s property and equipment:

 

    March 31, 2023     December 31, 2022  
Office equipment   $ 224,733     $ 222,571  
Building and building improvements     600,000       600,000  
Less: Accumulated Depreciation     (133,978 )     (110,956 )
Property and Equipment, Net   $ 690,755     $ 711,615  
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.1
DERIVATIVE LIABILITIES (Tables)
3 Months Ended
Mar. 31, 2023
Derivative Liabilities  
SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE

A summary of the activity related to derivative liabilities for the three months ended March 31, 2023, is as follows:

 

   Derivative liabilities associated with warrants   Derivative liabilities associated with convertible notes   Total derivative liabilities 
             
Balance January 1, 2023  $4,285,400   $28,870   $4,314,270 
Change in fair value   636,213    1,905    638,118 
Balance March 31, 2023  $4,921,613   $30,775   $4,952,388 
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.1
NOTES PAYABLE (Tables)
3 Months Ended
Mar. 31, 2023
Notes Payable  
SCHEDULE OF NOTES PAYABLE

The Company has the following notes payable outstanding:

 

   March 31, 2023   December 31, 2022 
         
Note payable, interest at 8%, matured January 5, 2020, in default  $45,000   $45,000 
Other, due on demand, interest at 6%, currently in default   50,000    50,000 
Note payable $750,000 face value, interest at 12%, matured August 24, 2021, in default   375,000    375,000 
Note payable $389,423 face value, interest at 12%, matures November 6, 2023   389,423    389,423 
Note payable $1,000,000 face value, interest at 12%, matured November 13, 2021, in default   1,000,000    1,000,000 
Note payable $2,200,000 face value, interest at 15%, matures October 31, 2024, net of discount of $269,167 (2023) and $311,667 (2022)   1,930,833    1,888,333 
Note payable $11,110,000 face value, interest at 15%, matures October 31, 2024, net of discount of $1,345,833 (2023) and $1,558,333 (2022)   9,764,167    9,551,667 
Note payable $3,300,000 face value, interest at 15%, matures October 31, 2024, net of discount of $403,750 (2023) and $467,500 (2022)   2,896,250    2,832,500 
Note payable $3,020,000 face value, matured March 31, 2023, net of discount of $0 (2023) and $181,818 (2022), in default   2,220,000    2,588,182 
Sub- total notes payable, net of discount   18,670,673    18,720,105 
Less long-term portion, net of discount   14,591,250    14,272,500 
Current portion of notes payable, net of discount  $4,079,423   $4,447,605 
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Tables)
3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
SCHEDULE OF EXPENSES TO OFFICERS

For the three months ended March 31, 2023 and 2022, the Company recorded expenses to its officers in the following amounts:

 

   2023   2022 
   Three months ended March 31, 
   2023   2022 
CEO  $240,000   $140,000 
CEO bonus   -    250,000 
Total  $240,000   $390,000 
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.1
OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables)
3 Months Ended
Mar. 31, 2023
Operating Lease Right-of-use Assets And Operating Lease Liabilities  
SCHEDULE OF RIGHT-OF-USE ASSETS

Right-of- use assets are summarized below:

 

   March 31, 2023   December 31, 2022 
Office and warehouse lease  $702,888   $702,888 
Less: Accumulated amortization   (228,071)   (195,182)
Right-of-use assets, net  $474,817   $507,706 
SCHEDULE OF OPERATING LEASE LIABILITIES

Operating lease liabilities are summarized as follows:

 

   March 31, 2023   December 31, 2022 
Lease liability  $486,008   $517,890 
Less current portion   (137,011)   (133,508)
Long term portion  $348,997   $384,382 
SCHEDULE OF MATURITY OF LEASE LIABILITIES

Maturity of lease liabilities are as follows:

 

   Amount 
For the year ending December 31, 2023  $126,464 
For the year ending December 31, 2024   171,840 
For the year ending December 31, 2025   175,942 
For the year ending December 31, 2026   74,030 
Total  $548,276 
Less: present value discount   (62,268)
Lease liability  $486,008 
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.1
DISCONTINUED OPERATIONS (Tables)
3 Months Ended
Mar. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]  
SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS

 

   2023   2022 
   Three months ended March 31, 
   2023   2022 
Revenues  $5,363   $162,916 
Cost of goods sold   -    126,482 
Gross profit   5,363    36,434 
Operating expenses   -    212,290 
Interest expense   -    8,324 
Income (loss) from discontinued operations  $5,363   $(184,180)

 

There are no assets as of March 31, 2023, and December 31, 2022, as the secured lender has taken possession. Liabilities of discontinued operations are separately reported as “liabilities held for disposal” as of March 31, 2023, and December 31, 2022. All liabilities are classified as current. The following tables present the reconciliation of carrying amounts of the major classes of liabilities of the Company classified as discontinued operations in the consolidated balance sheets at March 31, 2023, and December 31, 2022:

 

 

Current liabilities

 

         
  

March 31,

2023
   December 31,
2022
 
Accounts payable and accrued liabilities  $445,565   $445,565 
Current portion of notes payable   589,246    589,246 
Operating lease liability   -    3,575 
Deferred revenues   19,662    21,451 
Total current liabilities of discontinued operations  $1,054,473   $1,059,837 
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.1
GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 02, 2023
Apr. 01, 2023
Oct. 17, 2022
Apr. 04, 2022
Jan. 23, 2023
Jan. 18, 2023
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Apr. 30, 2021
Apr. 14, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Retained earnings accumulated deficit             $ 213,828,351   $ 211,300,799    
Working capital deficit             9,216,661        
Derivative liabilities current             4,952,388   $ 4,314,270    
Debt instrument default amount             3,690,000        
Proceeds from sale of common stock             $ 526,393      
Lease term                   5 years 5 years
Common Stock [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Stock issued during the period             107,756,783        
Proceeds from sale of common stock             $ 526,393        
GHS Investments LLC [Member] | Common Stock [Member] | Subsequent Event [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Stock issued during the period   15,048,619                  
1st GHS Purchase Agreement [Member] | GHS Investments LLC [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Common stock maturity period     Apr. 04, 2023                
1st GHS Purchase Agreement [Member] | GHS Investments LLC [Member] | Common Stock [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Stock issued during the period       200,000,000 200,000,000            
Common stock maturity period       Oct. 04, 2022              
Agreement description       The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement              
Sale of common stock             51,087,628   148,912,372    
Proceeds from sale of common stock             $ 205,443   $ 1,141,514    
1st GHS Purchase Agreement [Member] | GHS Investments LLC [Member] | Common Stock [Member] | Subsequent Event [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Sale of common stock 15,048,619                    
Proceeds from sale of common stock $ 71,827                    
2nd GHS Purchase Agreement [Member] | GHS Investments LLC [Member] | Common Stock [Member]                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Stock issued during the period           150,000,000          
Sale of common stock             56,669,155        
Proceeds from sale of common stock             $ 320,950        
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Customer A [Member]    
Product Information [Line Items]    
Accounts receivable balance $ 149,040  
Customer A [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]    
Product Information [Line Items]    
Sales concentration and credit risk 97.00%
Customer B [Member]    
Product Information [Line Items]    
Accounts receivable balance  
Customer B [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]    
Product Information [Line Items]    
Sales concentration and credit risk 19.00%
Customer C [Member]    
Product Information [Line Items]    
Accounts receivable balance  
Customer C [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]    
Product Information [Line Items]    
Sales concentration and credit risk 15.00%
Customer D [Member]    
Product Information [Line Items]    
Accounts receivable balance  
Customer D [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]    
Product Information [Line Items]    
Sales concentration and credit risk 15.00%
Customer E [Member]    
Product Information [Line Items]    
Accounts receivable balance  
Customer E [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]    
Product Information [Line Items]    
Sales concentration and credit risk 14.00%
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details)
Mar. 31, 2023
Warehouse Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 7 years
Minimum [Member] | Building and Building Improvements [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 10 years
Minimum [Member] | Office Furniture And Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 3 years
Maximum [Member] | Building and Building Improvements [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 25 years
Maximum [Member] | Office Furniture And Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 5 years
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.1
DISAGGREGATION OF REVENUE (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Product Information [Line Items]    
Total $ 2,791,198 $ 2,919,322
Sourced And Distributed Products [Member]    
Product Information [Line Items]    
Total 2,758,798 2,919,322
OED Installations [Member]    
Product Information [Line Items]    
Total $ 32,400
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Fair Value, Inputs, Level 1 [Member]    
Platform Operator, Crypto-Asset [Line Items]    
Derivative Liabilities
Total
Fair Value, Inputs, Level 2 [Member]    
Platform Operator, Crypto-Asset [Line Items]    
Derivative Liabilities
Total
Fair Value, Inputs, Level 3 [Member]    
Platform Operator, Crypto-Asset [Line Items]    
Derivative Liabilities 4,952,388 4,314,270
Total $ 4,952,388 $ 4,314,270
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
TOTAL  8,471,310,904 7,689,322,026
Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
TOTAL  [1] 7,318,548,198 6,933,544,496
Unexercised Common Stock Purchase Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
TOTAL  [1] 1,047,024,518 672,024,518
Convertible Notes Payable [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
TOTAL  [1] 11,025,635 2,461,916
Promissory Note Payable [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
TOTAL  [1] 94,712,553 81,291,096
[1] The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than 4.99% of the then outstanding shares of common stock subsequent to any conversion or exercise. These shares were excluded from the diluted per share calculation because the effect of including these potential shares was anti-dilutive due to the Company’s net loss position.
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) (Parenthetical)
3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Outstanding shares, percentage 4.99%
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Product Information [Line Items]      
Cash equivalents $ 0   $ 0
Inventory finished goods 1,648,182   $ 3,601,026
Deposits 3,687,000    
Deposits 10,264,000    
Advertising and marketing expenses $ 17,772 $ 2,478  
Incremental borrowing percentage 7.50%    
Income tax examination, likelihood of unfavorable settlement greater than fifty percent    
Dilutive securities common stock, shares 8,471,310,904 7,689,322,026  
Suppliers One [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]      
Product Information [Line Items]      
Concentration of credit risk 100.00% 36.00%  
Suppliers Two [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]      
Product Information [Line Items]      
Concentration of credit risk   24.00%  
Suppliers Three [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]      
Product Information [Line Items]      
Concentration of credit risk   13.00%  
Suppliers Four [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]      
Product Information [Line Items]      
Concentration of credit risk   10.00%  
Two Vendor [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]      
Product Information [Line Items]      
Concentration of credit risk 20.00%    
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Less: Accumulated Depreciation $ (133,978) $ (110,956)
Property and Equipment, Net 690,755 711,615
Office Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 224,733 222,571
Building and Building Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 600,000 $ 600,000
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.1
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation expenses $ 23,022 $ 10,805
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.1
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
15% Promissory Note [Member]    
Short-Term Debt [Line Items]    
Long term debt, gross $ 25,000 $ 25,000
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details)
3 Months Ended
Mar. 31, 2023
USD ($)
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]  
Derivative liability, beginning balance $ 4,314,270
Change in fair value 638,118
Derivative liability, ending balance 4,952,388
Derivative Liabilities Associated With Warrants [Member]  
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]  
Derivative liability, beginning balance 4,285,400
Change in fair value 636,213
Derivative liability, ending balance 4,921,613
Derivative Liabilities Associated With Convertible Notes [Member]  
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]  
Derivative liability, beginning balance 28,870
Change in fair value 1,905
Derivative liability, ending balance $ 30,775
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.23.1
DERIVATIVE LIABILITIES (Details Narrative)
12 Months Ended
Dec. 31, 2022
USD ($)
$ / shares
shares
Mar. 31, 2023
USD ($)
$ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liabilities | $ $ 4,314,270 $ 4,952,388
Warrants in conjunction with notes payable | shares 375,000,000  
Notes payable discount | $ $ 2,550,000  
Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability, measurement input 4.76 4.85
Risk free interest exercise prices 4.45  
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Risk free interest exercise prices 4.39 3.94
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Risk free interest exercise prices 4.73 4.64
Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Derivative liability, measurement input 71 86
Risk free interest exercise prices 509  
Measurement Input, Exercise Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Risk free interest exercise prices 0.0067  
Measurement Input, Exercise Price [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Risk free interest exercise prices   0.0061
Measurement Input, Exercise Price [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Risk free interest exercise prices   0.15
Measurement Input Price Volatility One [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Risk free interest exercise prices 109 112
Measurement Input Price Volatility One [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Risk free interest exercise prices 272 168
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Note Payable [Member]    
Short-Term Debt [Line Items]    
Debt Instrument, interest rate, stated percentage 8.00% 8.00%
Debt Instrument, maturity date Jan. 05, 2020 Jan. 05, 2020
Other [Member]    
Short-Term Debt [Line Items]    
Debt Instrument, interest rate, stated percentage 6.00% 6.00%
Note Payable One [Member]    
Short-Term Debt [Line Items]    
Debt Instrument, interest rate, stated percentage 12.00% 12.00%
Debt Instrument, maturity date Aug. 24, 2021 Aug. 24, 2021
Debt Instrument, face amount $ 750,000 $ 750,000
Note Payable Two [Member]    
Short-Term Debt [Line Items]    
Debt Instrument, interest rate, stated percentage 12.00% 12.00%
Debt Instrument, maturity date Nov. 06, 2023 Nov. 06, 2023
Debt Instrument, face amount $ 389,423 $ 389,423
Note Payable Three [Member]    
Short-Term Debt [Line Items]    
Debt Instrument, interest rate, stated percentage 12.00% 12.00%
Debt Instrument, maturity date Nov. 13, 2021 Nov. 13, 2021
Debt Instrument, face amount $ 1,000,000 $ 1,000,000
Note Payable Four [Member]    
Short-Term Debt [Line Items]    
Debt Instrument, interest rate, stated percentage 15.00% 15.00%
Debt Instrument, maturity date Oct. 31, 2024 Oct. 31, 2024
Debt Instrument, face amount $ 2,200,000 $ 2,200,000
Debt Instrument, unamortized discount $ 269,167 $ 311,667
Note Payable Five [Member]    
Short-Term Debt [Line Items]    
Debt Instrument, interest rate, stated percentage 15.00% 15.00%
Debt Instrument, maturity date Oct. 31, 2024 Oct. 31, 2024
Debt Instrument, face amount $ 11,110,000 $ 11,110,000
Debt Instrument, unamortized discount $ 1,345,833 $ 1,558,333
Note Payable Six [Member]    
Short-Term Debt [Line Items]    
Debt Instrument, interest rate, stated percentage 15.00% 15.00%
Debt Instrument, maturity date Oct. 31, 2024 Oct. 31, 2024
Debt Instrument, face amount $ 3,300,000 $ 3,300,000
Debt Instrument, unamortized discount $ 403,750 $ 467,500
Note Payable Seven [Member]    
Short-Term Debt [Line Items]    
Debt Instrument, maturity date Mar. 31, 2023 Mar. 31, 2023
Debt Instrument, face amount $ 3,020,000 $ 3,020,000
Debt Instrument, unamortized discount $ 0 $ 181,818
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF NOTES PAYABLE (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Short-Term Debt [Line Items]    
Sub- total notes payable, net of discount $ 18,670,673 $ 18,720,105
Less long-term portion, net of discount 14,591,250 14,272,500
Current portion of notes payable, net of discount 4,079,423 4,447,605
Note Payable [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable, net of discount 45,000 45,000
Other [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable, net of discount 50,000 50,000
Note Payable One [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable, net of discount 375,000 375,000
Note Payable Two [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable, net of discount 389,423 389,423
Note Payable Three [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable, net of discount 1,000,000 1,000,000
Note Payable Four [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable, net of discount 1,930,833 1,888,333
Note Payable Five [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable, net of discount 9,764,167 9,551,667
Note Payable Six [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable, net of discount 2,896,250 2,832,500
Note Payable Seven [Member]    
Short-Term Debt [Line Items]    
Sub- total notes payable, net of discount $ 2,220,000 $ 2,588,182
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.23.1
NOTES PAYABLE (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Nov. 11, 2022
Oct. 31, 2022
Dec. 13, 2021
Dec. 07, 2021
Mar. 23, 2021
Mar. 17, 2021
Feb. 16, 2021
Feb. 09, 2021
Nov. 20, 2020
Nov. 13, 2020
Nov. 06, 2020
Aug. 25, 2020
Aug. 24, 2020
Jul. 23, 2020
Mar. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
May 03, 2021
Short-Term Debt [Line Items]                                    
Accounts and accrued expenses                             $ 5,797,368 $ 5,089,009    
Notes payable                             $ 18,670,673 $ 18,720,105    
Common stock, shares, issued                             4,879,032,132 4,771,275,349    
Holder [Member]                                    
Short-Term Debt [Line Items]                                    
Number of warrants to purchase                             125,000,000      
Warrant exercise price                             $ 0.008      
Promissory Note [Member]                                    
Short-Term Debt [Line Items]                                    
Debt instrument face amount                                 $ 375,000  
Debt instrument, unamortized discount                             $ 375,000 $ 375,000    
Interest payable                             202,747 180,247    
Common stock, shares, issued                                   75,000,000
Promissory Note [Member] | Lender [Member]                                    
Short-Term Debt [Line Items]                                    
Debt instrument face amount           $ 11,110,000                 11,110,000 11,110,000    
Debt instrument, maturity date           Mar. 17, 2022                        
Debt instrument, unamortized discount           $ 1,000,000                 1,345,833 1,558,333    
Proceeds from notes payable         $ 10,000,000                          
Long-term debt, gross                             9,764,167 9,551,667    
Debt instrument, interest rate, stated percentage   15.00%       12.00%                        
Number of warrants to purchase   250,000,000       250,000,000                        
Warrant exercise price   $ 0.0067       $ 0.13                        
Lender costs           $ 110,000                        
Warrant expiry date   Oct. 31, 2025                                
Promissory Note [Member] | Lender [Member] | December 7, 2022 [Member]                                    
Short-Term Debt [Line Items]                                    
Debt instrument face amount $ 3,020,000     $ 3,300,000                     3,300,000 3,300,000    
Debt instrument, maturity date       Dec. 07, 2022                            
Debt instrument, unamortized discount       $ 300,000                     403,750 467,500    
Proceeds from notes payable     $ 3,000,000                              
Long-term debt, gross                             2,896,250 2,832,500    
Debt instrument, interest rate, stated percentage   15.00%   12.00%                            
Number of warrants to purchase   75,000,000   75,000,000                            
Warrant exercise price   $ 0.0067   $ 0.039                            
Interest expense, amortized                             510,000      
Amortization of discount                             63,750      
Promissory Note [Member] | Lender [Member] | March 31 2023 [Member]                                    
Short-Term Debt [Line Items]                                    
Debt instrument face amount $ 3,020,000                           2,220,000 2,770,000    
Debt instrument, maturity date Mar. 31, 2023                                  
Debt instrument, unamortized discount $ 250,000                             181,818    
Accounts and accrued expenses 260,000                                  
Proceeds from notes payable $ 2,510,000                                  
Original issue discount, amortized                             181,818      
Repayments of debt                             550,000      
Long-term debt, gross                             2,220,000 2,588,182    
Promissory Note [Member] | Lender [Member] | March 17 2022 [Member]                                    
Short-Term Debt [Line Items]                                    
Interest expense, amortized                             1,700,000      
Amortization of discount                             212,500      
Promissory Note [Member] | Lender [Member] | February 9 2021 [Member]                                    
Short-Term Debt [Line Items]                                    
Interest expense, amortized                             340,000      
Amortization of discount                             42,500      
Promissory Note [Member] | Holder [Member]                                    
Short-Term Debt [Line Items]                                    
Debt instrument face amount                   $ 1,000,000 $ 389,423   $ 750,000 $ 210,000        
Debt instrument, maturity date                   Nov. 13, 2021 Nov. 06, 2023              
Proceeds from notes payable                 $ 890,000     $ 663,000            
Debt instrument, interest rate, stated percentage                   12.00% 12.00%   12.00%          
Number of warrants to purchase                     60,000,000   122,950,819          
Warrant exercise price                     $ 0.0075   $ 0.0061          
Debt instrument, description                   Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date.     Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date.          
Legal fees                 $ 110,000     $ 87,000            
Interest payable                             435,452 375,452    
Notes payable                     $ 120,000              
Debt instrument, increase, accrued interest                     $ 8,716     $ 15,707        
Promissory Note One [Member] | Lender [Member]                                    
Short-Term Debt [Line Items]                                    
Debt instrument face amount               $ 2,200,000             2,200,000 2,200,000    
Debt instrument, maturity date               Feb. 09, 2022                    
Debt instrument, unamortized discount               $ 200,000             269,167 311,667    
Proceeds from notes payable             $ 2,000,000                      
Long-term debt, gross                             1,930,833 1,888,333    
Debt instrument, interest rate, stated percentage               12.00%                    
Number of warrants to purchase               50,000,000                    
Warrant exercise price               $ 0.15                    
Promissory Note One [Member] | Holder [Member]                                    
Short-Term Debt [Line Items]                                    
Adjustments to additional paid in capital warrant issued                             $ 1,000,000 $ 1,000,000    
Promissory Note Two [Member] | Lender [Member]                                    
Short-Term Debt [Line Items]                                    
Debt instrument, interest rate, stated percentage   15.00%                                
Warrant exercise price   $ 0.0067                                
Warrant issuance, value   50,000,000                                
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.23.1
DEFERRED LIABILITY (Details Narrative) - USD ($)
Nov. 11, 2022
Feb. 26, 2021
Sep. 02, 2020
Mar. 31, 2023
Dec. 31, 2022
Deferred liability       $ 490,000 $ 490,000
Reduce deferred liability $ 260,000        
Promissory Note [Member]          
Reduce deferred liability $ 260,000        
PCTI [Member] | Exchange Agreement [Member]          
Deferred liability     $ 750,000    
Product liability contingency, third-Party recovery, percentage     3.00%    
Exchange of common stock   175,000,000      
Royalty percentage   1.80%      
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF EXPENSES TO OFFICERS (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Related Party Transaction [Line Items]    
Total $ 240,000 $ 390,000
Chief Executive Officer [Member]    
Related Party Transaction [Line Items]    
Total 240,000 140,000
Chief Executive Officer Bonus [Member]    
Related Party Transaction [Line Items]    
Total $ 250,000
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended
Jan. 02, 2022
Jul. 10, 2020
Apr. 30, 2022
Mar. 31, 2022
Jan. 31, 2022
Employment Agreement [Member]          
Related Party Transaction [Line Items]          
Amount of initial annual compensation $ 240,000        
Mr Conway [Member] | Employment Agreement [Member]          
Related Party Transaction [Line Items]          
Amount of initial annual compensation $ 250,000        
Per Month [Member] | Mr Conway [Member]          
Related Party Transaction [Line Items]          
Compensation value   $ 20,000     $ 20,000
Officers compensation received   $ 10,000 $ 20,000 $ 20,000  
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Jan. 14, 2022
Oct. 01, 2021
Sep. 02, 2021
Sep. 01, 2021
Jul. 02, 2021
Apr. 13, 2021
Mar. 30, 2021
Mar. 15, 2021
Feb. 26, 2021
Jan. 06, 2021
Sep. 02, 2020
Sep. 30, 2021
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Jul. 01, 2021
Mar. 04, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Payments of stock issuance costs                         $ 19,110        
Cash payments                         $ 25,000        
Issuance of common stock                         637,755        
Share-Based Payment Arrangement, Expense                         $ 135,000        
Accounts payable and accrued expenses                         243,272   $ 243,272    
PJN Strategies [Member]                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Consulting expense       $ 84,000   $ 20,000             $ 0 $ 252,000      
Co-Directors of Sales [Member]                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Salary and Wage, Officer, Excluding Cost of Good and Service Sold             $ 130,000                    
Accrued Bonuses, Current             $ 20,000                    
Issuance of shares of common stock sold, shares 2,500,000 2,500,000     2,500,000                        
Shares issued, price per share                         $ 0.027        
Share price   $ 0.0445                           $ 0.0745  
Co-Directors of Sales [Member] | Restricted Stock [Member]                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Issuance of shares of common stock sold, shares             2,500,000                    
Shares issued, price per share             $ 0.092                    
Ezra Green [Member] | Restricted Stock [Member]                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Consulting expense                         $ 0 30,000      
Shares issued, price per share                   $ 0.0076              
Professional fees                   $ 2,500              
Ezra Green [Member] | Restricted Stock [Member] | Related Party [Member]                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Due to officers or stockholders                   $ 10,000              
RMA Agreement [Member]                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Payments of stock issuance costs     $ 50,000                            
Number of restricted stock issued, value     $ 50,000                            
Payments of stock issuance costs                       $ 25,000          
Number of restricted shares issued                       452,080          
Consulting Agreement [Member] | Mr Steven Martello [Member] | Aurora Enterprises [Member]                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Number of restricted shares issued               5,000,000                  
Consulting expense                         0 $ 30,000      
Legal fees               $ 10,000                  
Consulting Agreement [Member] | Ezra Green [Member] | Restricted Stock [Member]                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Number of restricted shares issued                   10,000,000              
Consulting Agreement [Member] | Mr Allen Sosis [Member] | Restricted Stock [Member]                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Deferred compensation equity                   $ 76,000              
Seperation Agreement [Member] | Salman J. Chaudhry [Member] | Related Party [Member]                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Due to officers or stockholders, current                         $ 162,085   $ 162,085   $ 227,200
Exchange Agreement [Member] | PCTI [Member]                                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                  
Professional fees                     $ 750,000            
Collaborative arrangement, rights and obligations                     PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement.            
Number of common stock exchanged                 175,000,000                
Royalty percentage                 1.80%                
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Jul. 07, 2020
Jul. 28, 2021
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Jul. 27, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Common stock, shares issued     4,879,032,132   4,771,275,349  
Issuance of common stock     $ 526,393    
Stock issuance cost     $ 19,110      
Common stock shares authorized     4,990,000,000   4,990,000,000  
Common stock par value     $ 0.001   $ 0.001  
Common stock shares outstanding     4,879,032,132   4,771,275,349  
Preferred stock, shares authorized     10,000,000   10,000,000  
Preferred stock, par value     $ 0.001   $ 0.001  
Series C Preferred Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Preferred stock, shares authorized     50,000   50,000  
Preferred stock, par value     $ 0.001   $ 0.001  
Preferred stock shares issued     2,500   2,500  
Preferred stock shares outstanding     2,500   2,500  
Series D Preferred Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Preferred stock, shares authorized     4,570   4,570  
Preferred stock, par value     $ 0.001   $ 0.001  
Preferred stock shares issued     1,334   1,334  
Preferred stock shares outstanding     1,334   1,334  
Purchase of warrants     3,236   3,236  
Series E Preferred Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Preferred stock, shares authorized     3,000   3,000  
Preferred stock, par value     $ 0.001   $ 0.001  
Preferred stock shares issued     0   0  
Preferred stock shares outstanding     0   0  
Certificates of Designation [Member] | Series C Preferred Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Preferred stock, shares authorized 50,000          
Preferred stock, voting rights The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote.          
Certificates of Designation [Member] | Series E Preferred Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Preferred stock, shares authorized 3,000          
Preferred stock, redemption amount $ 1,000          
Series D Amendment [Member] | Series D Preferred Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Preferred stock, shares authorized           4,570
Preferred stock, convertible, conversion price           $ 1.5
Series DSPA [Member] | Series D Preferred Stock [Member] | Investor [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Proceeds from issuance of preferred stock and preference stock   $ 13,200,000        
Purchase of warrants   3,236        
Restricted Stock [Member] | Lease Agreement [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Issuance of shares of common stock sold, shares       5,000,000    
Warrant [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Warrant exercise     162      
Warrant exercise, description     During every 1 (one) year period, starting on the day that is the Lock Up Period Termination Date, the Holder shall have the right to exercise the Remainder of the Warrant up to a maximum number of Remaining Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company during such given year (“Leak-Out Period”). The Leak-Out Period shall come into effect on the day that is the Lock Up Period Termination Date and remain effective on a yearly basis, for a period of 10 (ten) years thereafter, after which the Leak-Out Period will automatically terminate and become null and void. For clarity purposes the Remainder of the Warrant shall become freely exercisable at any time or times beginning on June 29, 2034, and until the Termination Date.      
Remaining Warrant Shares [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Warrant exercise     3,074      
Common Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Common stock, shares issued     107,756,783      
Issuance of common stock     $ 526,393      
Stock issuance cost     $ 19,110      
Issuance of shares of common stock sold, shares     107,756,783      
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.23.1
NONCONTROLLING INTEREST (Details Narrative) - USD ($)
Sep. 13, 2022
Mar. 31, 2023
Dec. 31, 2022
Aug. 19, 2021
Accumulative noncontrolling interest   $ 784,777 $ 784,777  
Brian Conway [Member]        
Noncontrolling interest percentage       51.00%
PJN Strategies [Member]        
Noncontrolling interest percentage 49.00%     49.00%
Number of share returned 490,000      
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF RIGHT-OF-USE ASSETS (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Operating Lease Right-of-use Assets And Operating Lease Liabilities    
Office and warehouse lease $ 702,888 $ 702,888
Less: Accumulated amortization (228,071) (195,182)
Right-of-use assets, net $ 474,817 $ 507,706
XML 64 R55.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF OPERATING LEASE LIABILITIES (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Operating Lease Right-of-use Assets And Operating Lease Liabilities    
Lease liability $ 486,008 $ 517,890
Less current portion (137,011) (133,508)
Long term portion $ 348,997 $ 384,382
XML 65 R56.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Operating Lease Right-of-use Assets And Operating Lease Liabilities    
For the year ending December 31, 2023 $ 126,464  
For the year ending December 31, 2024 171,840  
For the year ending December 31, 2025 175,942  
For the year ending December 31, 2026 74,030  
Total 548,276  
Less: present value discount (62,268)  
Lease liability $ 486,008 $ 517,890
XML 66 R57.htm IDEA: XBRL DOCUMENT v3.23.1
OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative)
Apr. 14, 2021
USD ($)
ft²
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Apr. 30, 2021
Operating lease term 5 years       5 years
Area of land | ft² 8,100        
Operating lease liability   $ 486,008 $ 517,890    
Accounting Standards Update 2016-02 [Member]          
Operating lease liability       $ 702,888  
Thereafter [Member]          
Lease payments increase percentage 2.40%        
CALIFORNIA          
Lease expiration date May 31, 2026        
Operating lease payments $ 13,481        
Lease payments increase percentage 7.50%        
XML 67 R58.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]      
Revenues $ 5,363 $ 162,916  
Cost of goods sold 126,482  
Gross profit 5,363 36,434  
Operating expenses 212,290  
Interest expense 8,324  
Income (loss) from discontinued operations 5,363 $ (184,180)  
Accounts payable and accrued liabilities 445,565   $ 445,565
Current portion of notes payable 589,246   589,246
Operating lease liability   3,575
Deferred revenues 19,662   21,451
Total current liabilities of discontinued operations $ 1,054,473   $ 1,059,837
XML 68 R59.htm IDEA: XBRL DOCUMENT v3.23.1
DISCONTINUED OPERATIONS (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2022
Mar. 31, 2023
Jun. 24, 2022
May 16, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Total assets of discontinued operations $ 0 $ 0    
Line of credit 344,166      
Term loan 134,681      
Inventory 237,091      
Fixed assets 15,447      
Accrued interest and fees $ 54,256      
Catherine Chis [Member] | Line of Credit [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Line of credit       $ 352,415
Catherine Chis [Member] | Line of Credit [Member] | Line of Credit [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Interest payable       63.65
Catherine Chis [Member] | Short-Term Debt [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Interest payable       28.60
Term loan       $ 141,415
Power Conversion Technologies Inc [Member] | Line of Credit [Member]        
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]        
Line of credit     $ 354,774  
Interest payable     63.65  
Line of credit     142,473  
Interest payable     $ 28.60  
XML 69 R60.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
3 Months Ended
May 02, 2023
Apr. 01, 2023
Mar. 31, 2023
May 05, 2023
Dec. 31, 2022
Subsequent Event [Line Items]          
Stock issued during the period     $ 526,393    
Common stock shares, authorized     4,990,000,000   4,990,000,000
Preferrd stock shares, authorized     10,000,000   10,000,000
Common Stock [Member]          
Subsequent Event [Line Items]          
Issuance of shares of common stock sold, shares     107,756,783    
Stock issued during the period     $ 107,757    
Subsequent Event [Member]          
Subsequent Event [Line Items]          
Capital stock shares, authorized       7,000,000,000  
Common stock shares, authorized       6,990,000,000  
Preferrd stock shares, authorized       10,000,000  
Subsequent Event [Member] | Financing And Registration Rights Agreement [Member]          
Subsequent Event [Line Items]          
Equity financing agreement description Under the terms of the Financing Agreement, GHS has agreed to provide the Company with up to $10,000,000 of funding upon effectiveness of a registration statement on Form S-1. Following effectiveness of the registration statement, the Company shall have the right to deliver puts to GHS and GHS will be obligated to purchase shares of our common stock based on the investment amount specified in each put notice. The maximum amount that the Company shall be entitled to put to GHS in each put notice will not exceed two hundred fifty percent (250%) of the average of the daily trading dollar volume of the Company’s common stock during the ten (10) trading days preceding the put, so long as such amount does not exceed 4.99% of the outstanding shares of the Company. Pursuant to the Financing Agreement, GHS and its affiliates will not be permitted to purchase, and the Company may not put shares of the Company’s common stock to GHS that would result in GHS’s beneficial ownership equaling more than 4.99% of the Company’s outstanding common stock. The price of each put share shall be equal to eighty percent (80%) of the lowest daily volume weighted average price of the Company’s common stock for the ten (10) consecutive trading days preceding the date on which the applicable put is delivered to GHS. No put will be made in an amount equaling less than $10,000 or greater than $750,000. Puts may be delivered by the Company to GHS until the earlier of twenty-four (24) months after the effectiveness of the registration statement on Form S-1 or the date on which GHS has purchased an aggregate of $10,000,000 worth of put shares.        
GHS Investments LLC [Member] | Subsequent Event [Member] | Common Stock [Member]          
Subsequent Event [Line Items]          
Issuance of shares of common stock sold, shares   15,048,619      
Stock issued during the period   $ 71,827      
XML 70 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001679817 2023-01-01 2023-03-31 0001679817 2023-05-15 0001679817 2023-03-31 0001679817 2022-12-31 0001679817 us-gaap:SeriesDPreferredStockMember 2023-03-31 0001679817 us-gaap:SeriesDPreferredStockMember 2022-12-31 0001679817 us-gaap:SeriesEPreferredStockMember 2023-03-31 0001679817 us-gaap:SeriesEPreferredStockMember 2022-12-31 0001679817 us-gaap:SeriesCPreferredStockMember 2022-12-31 0001679817 us-gaap:SeriesCPreferredStockMember 2023-03-31 0001679817 2022-01-01 2022-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2022-12-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001679817 us-gaap:CommonStockMember 2022-12-31 0001679817 us-gaap:TreasuryStockCommonMember 2022-12-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001679817 us-gaap:RetainedEarningsMember 2022-12-31 0001679817 us-gaap:NoncontrollingInterestMember 2022-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2021-12-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001679817 us-gaap:CommonStockMember 2021-12-31 0001679817 us-gaap:TreasuryStockCommonMember 2021-12-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001679817 us-gaap:RetainedEarningsMember 2021-12-31 0001679817 us-gaap:NoncontrollingInterestMember 2021-12-31 0001679817 2021-12-31 0001679817 OZSC:CommonStockToBeIssuedMember 2023-01-01 2023-03-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001679817 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001679817 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001679817 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001679817 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2022-01-01 2022-03-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001679817 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001679817 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001679817 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2023-03-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001679817 us-gaap:CommonStockMember 2023-03-31 0001679817 us-gaap:TreasuryStockCommonMember 2023-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001679817 us-gaap:RetainedEarningsMember 2023-03-31 0001679817 us-gaap:NoncontrollingInterestMember 2023-03-31 0001679817 OZSC:CommonStockToBeIssuedMember 2022-03-31 0001679817 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001679817 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001679817 us-gaap:CommonStockMember 2022-03-31 0001679817 us-gaap:TreasuryStockCommonMember 2022-03-31 0001679817 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001679817 us-gaap:RetainedEarningsMember 2022-03-31 0001679817 us-gaap:NoncontrollingInterestMember 2022-03-31 0001679817 2022-03-31 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember OZSC:FirstSecuritiesPurchaseAgreementMember 2022-04-01 2022-04-04 0001679817 OZSC:GHSInvestmentsLLCMember OZSC:FirstSecuritiesPurchaseAgreementMember 2022-10-16 2022-10-17 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember OZSC:FirstSecuritiesPurchaseAgreementMember 2023-01-01 2023-03-31 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember OZSC:FirstSecuritiesPurchaseAgreementMember 2022-01-01 2022-12-31 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember OZSC:FirstSecuritiesPurchaseAgreementMember 2023-01-01 2023-01-23 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember OZSC:SecondSecuritiesPurchaseAgreementMember 2023-01-01 2023-01-18 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember OZSC:SecondSecuritiesPurchaseAgreementMember 2023-01-01 2023-03-31 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember OZSC:FirstSecuritiesPurchaseAgreementMember 2023-04-01 2023-04-02 0001679817 2021-04-30 0001679817 OZSC:SuppliersOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:SuppliersOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:SuppliersTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:SuppliersThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:SuppliersFourMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:TwoVendorMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:CustomerAMember 2023-03-31 0001679817 OZSC:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:CustomerBMember 2023-03-31 0001679817 OZSC:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:CustomerCMember 2023-03-31 0001679817 OZSC:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:CustomerDMember 2023-03-31 0001679817 OZSC:CustomerEMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001679817 OZSC:CustomerEMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001679817 OZSC:CustomerEMember 2023-03-31 0001679817 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2023-03-31 0001679817 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2023-03-31 0001679817 srt:MinimumMember OZSC:OfficeFurnitureAndEquipmentMember 2023-03-31 0001679817 srt:MaximumMember OZSC:OfficeFurnitureAndEquipmentMember 2023-03-31 0001679817 OZSC:WarehouseEquipmentMember 2023-03-31 0001679817 OZSC:SourcedAndDistributedProductsMember 2023-01-01 2023-03-31 0001679817 OZSC:SourcedAndDistributedProductsMember 2022-01-01 2022-03-31 0001679817 OZSC:OEDInstallationsMember 2023-01-01 2023-03-31 0001679817 OZSC:OEDInstallationsMember 2022-01-01 2022-03-31 0001679817 us-gaap:FairValueInputsLevel1Member 2023-03-31 0001679817 us-gaap:FairValueInputsLevel2Member 2023-03-31 0001679817 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001679817 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001679817 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001679817 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001679817 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001679817 us-gaap:ConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001679817 OZSC:UnexercisedCommonStockPurchaseWarrantsMember 2023-01-01 2023-03-31 0001679817 OZSC:UnexercisedCommonStockPurchaseWarrantsMember 2022-01-01 2022-03-31 0001679817 us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-03-31 0001679817 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-03-31 0001679817 OZSC:PromissoryNotePayableMember 2023-01-01 2023-03-31 0001679817 OZSC:PromissoryNotePayableMember 2022-01-01 2022-03-31 0001679817 us-gaap:OfficeEquipmentMember 2023-03-31 0001679817 us-gaap:OfficeEquipmentMember 2022-12-31 0001679817 us-gaap:BuildingAndBuildingImprovementsMember 2023-03-31 0001679817 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0001679817 OZSC:FifteenPercentPromissoryNoteMember 2023-03-31 0001679817 OZSC:FifteenPercentPromissoryNoteMember 2022-12-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001679817 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001679817 us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001679817 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001679817 2022-01-01 2022-12-31 0001679817 us-gaap:MeasurementInputExercisePriceMember 2022-12-31 0001679817 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001679817 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001679817 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001679817 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001679817 srt:MinimumMember OZSC:MeasurementInputPriceVolatilityOneMember 2023-03-31 0001679817 srt:MaximumMember OZSC:MeasurementInputPriceVolatilityOneMember 2023-03-31 0001679817 srt:MinimumMember OZSC:MeasurementInputPriceVolatilityOneMember 2022-12-31 0001679817 srt:MaximumMember OZSC:MeasurementInputPriceVolatilityOneMember 2022-12-31 0001679817 srt:MinimumMember us-gaap:MeasurementInputExercisePriceMember 2023-03-31 0001679817 srt:MaximumMember us-gaap:MeasurementInputExercisePriceMember 2023-03-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2022-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2022-12-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2023-01-01 2023-03-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2023-01-01 2023-03-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithWarrantsMember 2023-03-31 0001679817 OZSC:DerivativeLiabilitiesAssociatedWithConvertibleNotesMember 2023-03-31 0001679817 OZSC:NotePayableMember 2023-03-31 0001679817 OZSC:NotePayableMember 2022-12-31 0001679817 OZSC:NotePayableMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableMember 2022-01-01 2022-12-31 0001679817 OZSC:OtherMember 2023-03-31 0001679817 OZSC:OtherMember 2022-12-31 0001679817 OZSC:NotePayableOneMember 2023-03-31 0001679817 OZSC:NotePayableOneMember 2022-12-31 0001679817 OZSC:NotePayableOneMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableOneMember 2022-01-01 2022-12-31 0001679817 OZSC:NotePayableTwoMember 2023-03-31 0001679817 OZSC:NotePayableTwoMember 2022-12-31 0001679817 OZSC:NotePayableTwoMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableTwoMember 2022-01-01 2022-12-31 0001679817 OZSC:NotePayableThreeMember 2023-03-31 0001679817 OZSC:NotePayableThreeMember 2022-12-31 0001679817 OZSC:NotePayableThreeMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableThreeMember 2022-01-01 2022-12-31 0001679817 OZSC:NotePayableFourMember 2023-03-31 0001679817 OZSC:NotePayableFourMember 2022-12-31 0001679817 OZSC:NotePayableFourMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableFourMember 2022-01-01 2022-12-31 0001679817 OZSC:NotePayableFiveMember 2023-03-31 0001679817 OZSC:NotePayableFiveMember 2022-12-31 0001679817 OZSC:NotePayableFiveMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableFiveMember 2022-01-01 2022-12-31 0001679817 OZSC:NotePayableSixMember 2023-03-31 0001679817 OZSC:NotePayableSixMember 2022-12-31 0001679817 OZSC:NotePayableSixMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableSixMember 2022-01-01 2022-12-31 0001679817 OZSC:NotePayableSevenMember 2023-03-31 0001679817 OZSC:NotePayableSevenMember 2022-12-31 0001679817 OZSC:NotePayableSevenMember 2023-01-01 2023-03-31 0001679817 OZSC:NotePayableSevenMember 2022-01-01 2022-12-31 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2022-11-11 0001679817 OZSC:LenderMember OZSC:MarchThirtyOneTwoThousandTwentyThreeMember OZSC:PromissoryNoteMember 2022-11-11 2022-11-11 0001679817 OZSC:LenderMember OZSC:MarchThirtyOneTwoThousandTwentyThreeMember OZSC:PromissoryNoteMember 2022-11-11 0001679817 OZSC:LenderMember OZSC:MarchThirtyOneTwoThousandTwentyThreeMember OZSC:PromissoryNoteMember 2023-01-01 2023-03-31 0001679817 OZSC:LenderMember OZSC:MarchThirtyOneTwoThousandTwentyThreeMember OZSC:PromissoryNoteMember 2023-03-31 0001679817 OZSC:LenderMember OZSC:MarchThirtyOneTwoThousandTwentyThreeMember OZSC:PromissoryNoteMember 2022-12-31 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2021-12-07 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2021-12-05 2021-12-07 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2021-12-12 2021-12-13 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2022-10-31 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2023-01-01 2023-03-31 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2023-03-31 0001679817 OZSC:LenderMember OZSC:DecemberSevenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2022-12-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2021-03-17 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2021-03-16 2021-03-17 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2021-03-22 2021-03-23 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2022-10-31 0001679817 OZSC:LenderMember OZSC:MarchSeventeenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2023-01-01 2023-03-31 0001679817 OZSC:LenderMember OZSC:MarchSeventeenTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2023-03-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2023-03-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteMember 2022-12-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2021-02-09 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2021-02-08 2021-02-09 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2021-02-15 2021-02-16 0001679817 OZSC:LenderMember OZSC:PromissoryNoteTwoMember 2022-10-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteTwoMember 2022-10-28 2022-10-31 0001679817 OZSC:LenderMember OZSC:FebruaryNineTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2023-01-01 2023-03-31 0001679817 OZSC:LenderMember OZSC:FebruaryNineTwoThousandTwentyTwoMember OZSC:PromissoryNoteMember 2023-03-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2023-03-31 0001679817 OZSC:LenderMember OZSC:PromissoryNoteOneMember 2022-12-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-13 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-12 2020-11-13 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-17 2020-11-20 0001679817 OZSC:HolderMember 2023-03-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteOneMember 2023-01-01 2023-03-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteOneMember 2022-01-01 2022-12-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2023-03-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2022-12-31 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-06 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-11-05 2020-11-06 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-07-23 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-07-20 2020-07-23 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-08-24 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-08-23 2020-08-24 0001679817 OZSC:HolderMember OZSC:PromissoryNoteMember 2020-08-22 2020-08-25 0001679817 OZSC:PromissoryNoteMember 2021-12-31 0001679817 OZSC:PromissoryNoteMember 2021-05-03 0001679817 OZSC:PromissoryNoteMember 2023-03-31 0001679817 OZSC:PromissoryNoteMember 2022-12-31 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2020-09-02 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2020-08-30 2020-09-02 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2021-02-25 2021-02-26 0001679817 2022-11-10 2022-11-11 0001679817 OZSC:PromissoryNoteMember 2022-11-10 2022-11-11 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2020-07-01 2020-07-10 0001679817 OZSC:MrConwayMember OZSC:EmploymentAgreementMember 2021-12-29 2022-01-02 0001679817 OZSC:EmploymentAgreementMember 2021-12-29 2022-01-02 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2022-01-01 2022-01-31 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2022-03-01 2022-03-31 0001679817 OZSC:PerMonthMember OZSC:MrConwayMember 2022-04-01 2022-04-30 0001679817 srt:ChiefExecutiveOfficerMember 2023-01-01 2023-03-31 0001679817 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-03-31 0001679817 OZSC:ChiefExecutiveOfficerBonusMember 2023-01-01 2023-03-31 0001679817 OZSC:ChiefExecutiveOfficerBonusMember 2022-01-01 2022-03-31 0001679817 OZSC:RMAAgreementMember 2021-08-28 2021-09-02 0001679817 OZSC:RMAAgreementMember 2021-09-03 2021-09-30 0001679817 OZSC:PJNStrategiesMember 2021-04-12 2021-04-13 0001679817 OZSC:PJNStrategiesMember 2021-08-30 2021-09-01 0001679817 OZSC:PJNStrategiesMember 2023-01-01 2023-03-31 0001679817 OZSC:PJNStrategiesMember 2022-01-01 2022-03-31 0001679817 OZSC:CoDirectorsOfSalesMember 2021-03-29 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember us-gaap:RestrictedStockMember 2021-03-29 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember us-gaap:RestrictedStockMember 2021-03-30 0001679817 OZSC:CoDirectorsOfSalesMember 2021-06-29 2021-07-02 0001679817 OZSC:CoDirectorsOfSalesMember 2021-07-01 0001679817 OZSC:CoDirectorsOfSalesMember 2021-09-28 2021-10-01 0001679817 OZSC:CoDirectorsOfSalesMember 2021-10-01 0001679817 OZSC:CoDirectorsOfSalesMember 2022-01-01 2022-01-14 0001679817 OZSC:CoDirectorsOfSalesMember 2023-03-31 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2021-03-14 2021-03-15 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2023-01-01 2023-03-31 0001679817 OZSC:MrStevenMartelloMember OZSC:ConsultingAgreementMember OZSC:AuroraEnterprisesMember 2022-01-01 2022-03-31 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-05 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2021-01-05 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2021-01-06 0001679817 OZSC:MrAllenSosisMember us-gaap:RestrictedStockMember OZSC:ConsultingAgreementMember 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember us-gaap:RelatedPartyMember 2021-01-06 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001679817 OZSC:EzraGreenMember us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001679817 OZSC:SalmanJChaudhryMember us-gaap:RelatedPartyMember OZSC:SeparationAgreementMember 2019-03-04 0001679817 OZSC:SalmanJChaudhryMember us-gaap:RelatedPartyMember OZSC:SeparationAgreementMember 2023-03-31 0001679817 OZSC:SalmanJChaudhryMember us-gaap:RelatedPartyMember OZSC:SeparationAgreementMember 2022-12-31 0001679817 OZSC:ExchangeAgreementMember OZSC:PCTIMember 2020-09-01 2020-09-02 0001679817 us-gaap:RestrictedStockMember OZSC:LeaseAgreementMember 2022-01-01 2022-03-31 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-07 0001679817 us-gaap:SeriesCPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-06 2020-07-07 0001679817 us-gaap:SeriesDPreferredStockMember OZSC:SeriesDAmendmentMember 2021-07-27 0001679817 us-gaap:InvestorMember us-gaap:SeriesDPreferredStockMember OZSC:SeriesDSPAMember 2021-06-28 2021-07-28 0001679817 us-gaap:InvestorMember us-gaap:SeriesDPreferredStockMember OZSC:SeriesDSPAMember 2021-07-28 0001679817 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001679817 OZSC:RemainingWarrantSharesMember 2023-01-01 2023-03-31 0001679817 us-gaap:SeriesEPreferredStockMember OZSC:CertificatesOfDesignationMember 2020-07-07 0001679817 OZSC:BrianConwayMember 2021-08-19 0001679817 OZSC:PJNStrategiesMember 2021-08-19 0001679817 OZSC:PJNStrategiesMember 2022-09-12 2022-09-13 0001679817 OZSC:PJNStrategiesMember 2022-09-13 0001679817 2021-04-14 0001679817 stpr:CA 2021-04-11 2021-04-14 0001679817 OZSC:ThereafterMember 2021-04-14 0001679817 stpr:CA 2021-04-14 0001679817 us-gaap:AccountingStandardsUpdate201602Member 2021-12-31 0001679817 OZSC:CatherineChisMember us-gaap:LineOfCreditMember 2022-05-16 0001679817 OZSC:CatherineChisMember us-gaap:LineOfCreditMember us-gaap:LineOfCreditMember 2022-05-16 0001679817 OZSC:CatherineChisMember us-gaap:ShortTermDebtMember 2022-05-16 0001679817 OZSC:PowerConversionTechnologiesIncMember us-gaap:LineOfCreditMember 2022-06-24 0001679817 OZSC:GHSInvestmentsLLCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2023-04-01 2023-04-01 0001679817 us-gaap:SubsequentEventMember OZSC:FinancingAndRegistrationRightsAgreementMember 2023-05-02 2023-05-02 0001679817 us-gaap:SubsequentEventMember 2023-05-05 iso4217:USD shares iso4217:USD shares utr:sqft pure 0001679817 false --12-31 Q1 P5Y P5Y 10-Q true 2023-03-31 2023 false 000-55976 OZOP ENERGY SOLUTIONS, INC. NV 35-2540672 55 Ronald Reagan Blvd Warwick NY 10990 (877) 785-6967 Yes Yes Non-accelerated Filer true false false 4894080751 1954814 1369210 69319 59405 209421 173151 1648182 3601026 3687266 3053821 7569002 8256613 474817 507706 690755 711615 13408 13408 8747982 9489342 5797368 5089009 25000 25000 4079423 4447605 250000 250000 490000 490000 4952388 4314270 137011 133508 1054473 1059837 16785663 15809229 14591250 14272500 348997 384382 31725910 30466111 10000000 10000000 0.001 0.001 50000 50000 2500 2500 2500 2500 0.001 0.001 3 3 4570 4570 1334 1334 1334 1334 0.001 0.001 1 1 3000 3000 0 0 0 0 0.001 0.001 4990000000 4990000000 0.001 0.001 4879032132 4879032132 4771275349 4771275349 4879032 4771275 47500 47500 18667 18667 11249934 11249934 637755 637755 638 638 198005460 197586824 -213828351 -211300799 -22193151 -20191992 -784777 -784777 -22977928 -20976769 8747982 9489342 2791198 2919322 2394700 2749349 396498 169973 240000 390000 829762 1375567 1069762 1765567 -673264 -1595594 1221533 3966898 -638118 4365203 -1859651 398305 -2532915 -1197289 -2532915 -1197289 5363 -184180 -2527552 -1381469 -187708 -2527552 -1193761 -0.00 -0.00 -0.00 -0.00 0.00 -0.00 0.00 -0.00 -0.00 -0.00 4834943957 4619807422 637755 638 2500 3 1334 1 4771275349 4771275 -11249934 197586824 -211300799 -784777 -20976769 19110 107756783 107757 418636 526393 -2527552 -2527552 637755 638 2500 3 1334 1 4879032132 4879032 -11249934 198005460 -213828351 -784777 -22977928 637755 638 2500 3 1334 1 4879032132 4879032 -11249934 198005460 -213828351 -784777 -22977928 637755 638 2500 3 1334 1 4617362977 4617363 -11249934 196464222 -217326611 -255105 -27749423 5000000 5000 130000 135000 -1193761 -187708 -1381469 637755 638 2500 3 1334 1 4622362977 4622363 -11249934 196594222 -218520372 -442813 -28995892 637755 638 2500 3 1334 1 4622362977 4622363 -11249934 196594222 -218520372 -442813 -28995892 -2532915 -1197289 5363 -184180 -2527552 -1381469 500568 3379121 55912 41421 638118 -4365203 136249 36270 -166822 -1952844 1253333 9915 19400 633445 621373 708358 542507 -31882 -28658 400769 616736 -3002547 -5363 -57909 611373 -3060456 2162 40000 -2162 -40000 526393 550000 -23607 585604 -3100456 1369210 6632194 1954814 3531738 10075 136249 <p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zxvoYu7yKnMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_82B_zGpcHqpLmUa3">ORGANIZATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ozop Energy Solutions, Inc. (the” Company,” “we,” “us” or “our”) was originally incorporated as Newmarkt Corp. on July 17, 2015, under the laws of the State of Nevada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 29, 2020, the Company formed a new wholly owned subsidiary, Ozop Surgical Name Change Subsidiary, Inc., a Nevada corporation (“Merger Sub”). The Merger Sub was formed under the Nevada Revised Statutes for the sole purpose and effect of changing the Company’s name to “Ozop Energy Solutions, Inc.” That same day the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with the Merger Sub and filed Articles of Merger (the “Articles of Merger”) with the Nevada Secretary of State, merging the Merger Sub into the Company, which were stamped effective as of November 3, 2020. As permitted by the Section 92.A.180 of the Nevada Revised Statutes, the sole purpose and effect of the filing of Articles of Merger was to change the name of the Company from Ozop Surgical Corp to “Ozop Energy Solutions, Inc.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 11, 2020, the Company formed Ozop Energy Systems, Inc. (“OES”), a Nevada corporation and a wholly owned subsidiary of the Company. OES was formed to be a manufacturer and distributor of renewable energy products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 19, 2021, the Company formed Ozop Capital Partners, Inc. (“Ozop Capital”), a Delaware corporation and a wholly owned subsidiary of the Company. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 29, 2021, EV Insurance Company, Inc. (“EVCO”) was formed as a captive insurance company in the State of Delaware. EVCO is a wholly owned subsidiary of Ozop Capital. On January 7, 2022, EVCO filed with New Castle County, Delaware DBA OZOP Plus.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners offer the resources needed for lighting, solar and electrical design projects. OED provides its customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs. We work with architects, engineers, facility managers, electrical contractors, and engineers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_809_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zgcfBSOlRZf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_829_znUzDe8nqbs3">GOING CONCERN AND MANAGEMENT’S PLANS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2023, the Company had an accumulated deficit of $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20230331_zILJ6xRTG9Z6" title="Retained earnings accumulated deficit">213,828,351</span> and a working capital deficit of $<span id="xdx_901_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20230331_zqNlnxBM0K99" title="Working capital deficit">9,216,661</span> (including derivative liabilities of $<span id="xdx_906_eus-gaap--DerivativeLiabilitiesCurrent_iI_pp0p0_c20230331_zt29gqkGo2Ea" title="Derivative liabilities current">4,952,388</span>). As of March 31, 2023, the Company was in default of $<span id="xdx_901_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20230331_zHqhgud0Jht4" title="Debt instrument default amount">3,690,000</span> plus accrued interest on debt instruments due to non-payment upon maturity dates. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date of the issuance of these financial statements. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, a novel strain of coronavirus (COVID-19) emerged. Because COVID-19 infections have been reported throughout the United States, certain federal, state and local governmental authorities have issued stay-at-home orders, proclamations and/or directives aimed at minimizing the spread of COVID-19. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but it may have a material adverse impact on our business, financial condition and results of operations. Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management’s Plans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a public company, Management believes it will be able to access the public equities market for fund raising for product development, sales and marketing and inventory requirements as we expand our distribution in the U.S. market.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 4, 2022, the Company, and GHS Investments LLC (“GHS”). signed a Securities Purchase Agreement (the “1<sup>st </sup>GHS Purchase Agreement”) for the sale of up to Two Hundred Million (<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220401__20220404__us-gaap--TypeOfArrangementAxis__custom--FirstSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAA6lmohAxVl" title="Stock issued during the period">200,000,000</span>) shares of the Company’s common stock to GHS. We may sell shares of our common stock from time to time over a six (6)- month period ending <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20220401__20220404__us-gaap--TypeOfArrangementAxis__custom--FirstSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxMS9zBMGJBb" title="Common stock maturity period">October 4, 2022</span>, at our sole discretion, to GHS under the GHS Purchase Agreement. On October 17, 2022, the Company and GHS extended the Maturity Date to <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20221016__20221017__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--TypeOfArrangementAxis__custom--FirstSecuritiesPurchaseAgreementMember_zwQKyiipoala" title="Common stock maturity period">April 4, 2023</span>. <span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20220401__20220404__us-gaap--TypeOfArrangementAxis__custom--FirstSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYRDXn6sMYGl" title="Agreement description">The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement</span>. During the three months ended March 31, 2023, the Company sold GHS <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--FirstSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrZuCmwFlqX7" title="Sale of common stock">51,087,628</span> shares of common stock and received $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pid_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--FirstSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zINPP2kJHnJ3" title="Proceeds from sale of common stock">205,443</span>, net of offering costs. During the year ended December 31, 2022, the Company sold to GHS <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--FirstSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbmDiTrxwVua" title="Sale of common stock">148,912,372</span> shares of common stock and received $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--FirstSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zicry18FQx8" title="Proceeds from sale of common stock">1,141,514</span>, net of offering costs. As of January 23, 2023, the Company sold GHS <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230123__us-gaap--TypeOfArrangementAxis__custom--FirstSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zthXGkKk654j" title="Stock issued during the period">200,000,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 18, 2023, the Company and GHS signed a Securities Purchase Agreement (the “2<sup>nd</sup> GHS Purchase Agreement”) for the sale of up to One Hundred Fifty Million (<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230118__us-gaap--TypeOfArrangementAxis__custom--SecondSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcgc9aDsyo19" title="Stock issued during the period">150,000,000</span>) shares of the Company’s common stock to GHS. The terms and conditions of the 2<sup>nd</sup> GHS Purchase Agreement are similar to the terms and conditions of the 1<sup>st</sup> GHS Purchase Agreement. During the quarter ended March 31, 2023, the Company sold to GHS <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SecondSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlhLWJoFHutl" title="Sale of common stock">56,669,155</span> shares of common stock and received $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pid_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--SecondSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAr0hLu907o4" title="Proceeds from sale of common stock">320,950</span>, net of offering costs. Subsequent to March 31, 2023, the Company has sold GHS <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230401__20230402__us-gaap--TypeOfArrangementAxis__custom--FirstSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWIuSZnYDxq6" title="Sale of common stock">15,048,619</span> shares of common stock for proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pid_c20230401__20230402__us-gaap--TypeOfArrangementAxis__custom--FirstSecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9wwWx2mOJ1l" title="Proceeds from sale of common stock">71,827</span>, net of offering costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OES is actively engaged in the renewable, electric vehicle (“EV”), energy storage and energy resiliency sectors. We are engaged in multiple business lines that include project development as well as equipment distribution. Our solar and energy storage projects involve large-scale battery and solar photovoltaics (PV) installations. Our utility-scale storage business model is based on an arbitrage business model in which we install multiple 1+ megawatt batteries, charge them with off-peak grid electricity under contract with the utility, then sell the power back during peak load hours at a premium, as dictated by prevailing electricity tariffs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Equipment Distributor:</span></i> OES has entered the component supply/distribution side of the renewable, resiliency and energy storage industries distributing the core components associated with residential and commercial solar PV systems as well as onsite battery storage and power generation. In April 2021, the Company signed a <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20210430_zVibQZRIJ5F8" title="Lease term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0630">five</span></span>- year lease (beginning June 1, 2021) of approximately 8,100 SF in California, for office and warehouse space to support the sales and distribution of our west coast operations. On February 22, 2023, with an effective date of March 1, 2023, the Company entered into a Sublease for a Single Subleasee Agreement (the “Sublease”) with the landlord and a third party for the office and warehouse in Carlsbad California. Pursuant to the Sublease agreement, the third party will be responsible for all of the Company’s lease obligations through May 31, 2026, the lease termination date. The Company and the subleasee have agreed to work together regarding any existing Company inventory in the facility. OES currently is focused on solar panel sales to other distributors and large installation companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Solar PV:</span></i> Our PV business model involves the design and construction of electrical generating PV systems that can sell power to the utilities or be used for off grid use as part of our developing Neo-Grids solution. The Neo-Grids proprietary program, patent pending, was developed for the off-grid distribution of electricity to remove or reduce the dependency on utilities that currently burdens the EV Charging sectors. It will also reduce or eliminate the lengthy permitting processes and streamline the installations of those EV chargers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Modular Energy Distribution System:</span></i> The Neo-Grids, patent pending, is comprised of the design engineering, installation, and operational methodologies as well as the financial arbitrage of how we produce, capture and distribute electrical energy for the EV markets. <span style="background-color: white"> OES has acquired the license rights to a proprietary system, the <b>Neo-Grids<sup>TM</sup> System</b> (patent pending), for the capture and distribution of electrical energy for the EV market. The <b>Neo-Grids<sup>TM</sup> System</b></span> will serve both the private auto and the commercial sectors. The exponential growth of the EV industry has been accelerated by the recent major commitments of most of the major car manufacturers. Our <span style="background-color: white"><b>Neo-Grids<sup>TM</sup> System </b></span>leverages this accelerated growth by offering (1) charging locations that can be installed with reduced delays, restricted areas or load limits and (2) EV charger electricity that is produced from renewable sources claiming little to no carbon footprint.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OES has developed a business plan for the Neo Grids distribution, a solution to the stress forthcoming to the existing grid infrastructure. The Company has completed its’ Neo Grid research and development as well as the first set of engineered technical drawings. This first stage of engineered technical drawings allows us to move forward with stage two, as well as to begin to construct the first prototype or proof of concept, (“PoC”). Our PoC design is partially reliant on auto manufacturers establishing standardizations of the actual charging/discharging protocols of the batteries such as on-board inverters as well as bi-directional capabilities in electric vehicles, which have only recently been established. As the market growth rate of EV’s continues to rise, the stress on the existing grid-tied infrastructure shows the need for the continued development of our Neo-Grid solution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ozop Plus markets vehicle service contracts (“VSC’s”) for electric vehicles (EV’s) that offer consumers to be able to purchase additional months and miles above the manufacturer’s warranty and to also bring added value to EV owners by utilizing our partnerships and strengths in the energy market to offer unique and innovative services. Among EV owners’ concerns are the EV battery repair and replacement costs, range anxiety, environmental responsibilities, roadside assistance, and the accelerated wear on additional components that EV vehicles experience. Management believes that the Ozop Plus marketed VSC’s will give “peace of mind” to the EV buyer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2022, the Company entered into an agreement with GS Administrators, Inc., a member of Houston-based GSFSGroup. Under the agreement, the Company will market GSFSGroup’s EV VSC’s in all states (except, California, Florida, Massachusetts and Washington) to Ozop’s network of new and used franchised dealerships and other eligible entities. In addition to acting as an agent for the marketing, Ozop also has the right to white label the product under its’ Ozop Plus brand. Ozop’s role won’t be limited to marketing the product. GSFSGroup plans to tap into Ozop’s experience relative to battery collection and disposal and has agreed to insurance risk sharing in connection with the insurance policies that back the VSC’s. GSFSGroup is working on getting the approvals needed for the above four (4) states.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 22, 2022, the Company entered into an Agent Agreement with Royal Administration Services, Inc. (“Royal”). Under the agreement, the Company will market Royal’s EV VSC’s and has the right to white label it under Ozop Plus. Royal has agreed to allow Ozop Plus on all VSC’s, marketed by Royal and the Company, to assume all the risk related to the electric battery at an agreed upon premium. The battery premium is dependent on the consumer’s selection of the duration of the VSC, the miles selected for coverage and the type of vehicle that the consumer has purchased, with a key component being the kWh size of the battery. These VSC’s have a maximum of 10 years and 150,000 miles and cover new and used cars from model year 2017 and newer. Royal’s VSCs are now effective in 46 states and the others have various waiting times or approvals needed.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 13, 2022, EVCO entered into a Reinsurance Contract (the “Contract”) with American Bankers Insurance Company of Florida (“ABIC” or the “Ceding Company”). Royal is the Administrator of the Contract. Pursuant to the terms of the Contract, ABIC will cede 100% of the battery coverage portion of all electric vehicle service contracts to EVCO. On the same date ABIC and EVCO also entered into a Trust Agreement, whereas EVCO as the reinsurer agrees to deposit an amount equal to unearned premium reserves, plus losses reported but unpaid, plus the estimated amount of losses incurred but not reported to the trust account. Permissible investments (with a maturity of no more than five (5) years) of the assets of the Trust account include:</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">○</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Treasury Securities</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">○</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash or cash instruments</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">○</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S agency issues</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">○</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other investments as Ceding Company approves</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 25, 2022, the Company formed Ozop Engineering and Design, Inc. (“OED”) a Nevada corporation, as a wholly owned subsidiary of the Company. OED was formed to become a premier engineering and lighting control design firm. OED offers product and design support for lighting and solar projects with a focus on fast lead times and technical support. OED and our partners offer the resources needed for lighting, solar and electrical design projects. OED will provide its’ customers systems to coordinate the understanding of electrical usage with the relationship between lighting design and lighting controls, by developing more efficient ecofriendly designs by working with architects, engineers, facility managers, electrical contractors and engineers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> -213828351 9216661 4952388 3690000 200000000 2022-10-04 2023-04-04 The purchase price shall be 85% of lowest VWAP for the ten (10) days preceding the Company’s notice to GHS for the sale of the Company’s common stock. On April 8, 2022, the Company filed a Prospectus Supplement to the Registration Statement dated October 14, 2021, regarding the GHS Purchase Agreement 51087628 205443 148912372 1141514 200000000 150000000 56669155 320950 15048619 71827 <p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zRS9jygM6sEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 – <span id="xdx_829_zefak7HaRlp1">SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRVTiGOksWSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z2q9wIU6VZ8">Basis of Presentation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2023, and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2023, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Current Report on Form 10-K filed on April 17, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries Ozop Capital Partners, Inc., Ozop Engineering and Design, Inc., Power Conversion Technologies, Inc. (“PCTI”), Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”). All intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84C_eus-gaap--UseOfEstimates_z8DrKR4eCiwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zN1cZlYUj8Bl">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zyNC0rZBohQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zXRQX7lXu6L3">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. The Company has <span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_zAs2mg2rQIjc" title="Cash equivalents"><span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20230331_zZESlWV85ac6" title="Cash equivalents">no</span></span> cash equivalents at March 31, 2023 and December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zZYNoApp2V4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zRxYbIMS1fbc">Sales Concentration and credit risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zG0yQ3ssGLDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the three months ended March 31, 2023, and 2022, and their accounts receivable balance as of March 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B2_zDBsHDbkLDZg" style="display: none">SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Three Months Ended March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Three Months Ended March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accounts receivable balance March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify">Customer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSR9tw4zcqK3" style="width: 14%; text-align: right" title="Sales concentration and credit risk">97</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z53ztSy0Olcl" style="width: 14%; text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerAMember_zgCAvQkgTxIk" style="width: 14%; text-align: right" title="Accounts receivable balance">149,040</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer B</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z49ZKu4ut0Ce" style="text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuawIp5nSoI9" style="text-align: right" title="Sales concentration and credit risk">19</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerBMember_zQyYNe6o7eA4" style="text-align: right" title="Accounts receivable balance"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer C</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCT6OZQi6q88" style="text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0660">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7umk3x9CGf5" style="text-align: right" title="Sales concentration and credit risk">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerCMember_zvkyJrfT9Tn7" style="text-align: right" title="Accounts receivable balance"><span style="-sec-ix-hidden: xdx2ixbrl0664">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9eIJOBJI685" style="text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zJyJhvjeW8Y5" style="text-align: right" title="Sales concentration and credit risk">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerDMember_zWFRqaQcEHSj" style="text-align: right" title="Accounts receivable balance"><span style="-sec-ix-hidden: xdx2ixbrl0670">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer E</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zU8TSg4ubJH" style="text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0672">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzEYtPdD4Ncl" style="text-align: right" title="Sales concentration and credit risk">14</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerEMember_zsncoLQSyrld" style="text-align: right" title="Accounts receivable balance"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_zZYkScBKOvAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z83boIAse3I8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zEhThfwJbPeg">Accounts Receivable</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zRATc74yfMR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zJLSOyIHESYj">Inventory</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs consist of finished goods. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues. Finished goods inventories as of March 31, 2023, and December 31, 2022, were $<span id="xdx_903_eus-gaap--InventoryFinishedGoods_iI_c20230331_zBAL9PyMTCdg" title="Inventory finished goods">1,648,182</span> and $<span id="xdx_906_eus-gaap--InventoryFinishedGoods_iI_c20221231_zgJxrr4ITsI9" title="Inventory finished goods">3,601,026</span>, respectively. As of March 31, 2023, the Company has on deposit with vendor(s) approximately $<span id="xdx_90D_eus-gaap--DepositsAssetsCurrent_iI_c20230331_z64BsK9opgj2" title="Deposits">3,687,000</span> and has a balance due of approximately $<span id="xdx_902_eus-gaap--DepositsAssetsNoncurrent_iI_c20230331_zeYi8ItRweBk" title="Deposits">10,264,000</span> for open purchase orders. The remaining balance is partially due when the vendor ships the product, with the final balance due prior to delivery.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_ecustom--PurchaseConcentrationPolicyTextBlock_zBm62tm5rfU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zTK8VueTfGb5">Purchase concentration</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OES purchases finished renewable energy products from its’ suppliers. For the three months ended March 31, 2023, there was one supplier that accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zLohGave8ga3" title="Concentration of credit risk">100</span>%. For the three months ended March 31, 2022, there were four suppliers that accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z2qgon5zTow4" title="Concentration of credit risk">36</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--SuppliersTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z75XetQ9cZQa" title="Concentration of credit risk">24</span>%,<span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--SuppliersThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zxeWafE7T7K6" title="Concentration of credit risk">13</span>%, and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--SuppliersFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zfh50eP5Mz3i" title="Concentration of credit risk">10</span>%, respectively. There are only a handful of major suppliers, and we currently have supply arrangements with some of those vendors. One of these vendors requires a <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--TwoVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zde3kLhVmk84" title="Concentration of credit risk">20</span>% down payment with the balances due on shipment and delivery, while other vendors’ terms are due immediately prior to delivery. We may also buy product from other distributors if we are not able to purchase direct from the manufacturer. While management believes its relationships with its vendors are good, if we are unable to continue to use and/or find alternative suppliers, when we cannot buy direct, it may have a material negative effect on our business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z4LnVyfmSrVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_ziJRcQni8VB2">Property, plant, and equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows:</span></p> <p id="xdx_89D_ecustom--ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock_zP4EL5rCrJy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B9_zHVDKKPYlcE7" style="display: none">SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zSZlMOVzLJq5" title="Property, plant and equipment, useful life">10</span>-<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zH3DsqLPbrJ4" title="Property, plant and equipment, useful life">25</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture and equipment </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zeznQXYgAVh8" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zGf5Cao2sld9" title="Property, plant and equipment, useful life">5</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warehouse equipment </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WarehouseEquipmentMember_zewk9sTesBP9" title="Property, plant and equipment, useful life">7</span> years</span></td></tr> </table> <p id="xdx_8AD_zAU3S2H6mDN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_ziVmx5FkZyqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zzq1SWNqku61">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in accordance with ASC 606, from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. The Company has no outstanding contracts with any of its’ customers. The Company recognizes revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For contracts with customers, ownership of the goods and associated revenue are transferred to customers at a point in time, generally upon shipment of a product to the customer or receipt of the product by the customer and without significant judgments. Any advance payments are recorded as current liability until revenue is recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the periods covered herein, we did not have post shipment obligations such as training or installation, customer acceptance provisions, credits and discounts, rebates and price protection, or other similar privileges.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--DisaggregationOfRevenueTableTextBlock_zPTXlxyFUvzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates our revenue by major source for the three months ended March 31, 2023, and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_z28TvA6bEffi" style="display: none">DISAGGREGATION OF REVENUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20230101__20230331_zsV2IIZ9Uvd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_496_20220101__20220331_zFMvpzhQdyWi" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three months ended March 31,</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SourcedAndDistributedProductsMember_zBZ875COr2Nc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sourced and distributed products</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,758,798</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,919,322</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OEDInstallationsMember_ziwQjK1Ke4Y2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OED Installations</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,400</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0726">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zHcGgCLmrlbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,791,198</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,919,322</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A7_zqLZ2VYXjnO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues from sourced and distributed products are purchased from suppliers as finished goods and the Company currently brings the finished goods into a third-party warehouse to fill orders as well as to build inventory for future sales orders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_842_eus-gaap--AdvertisingCostsPolicyTextBlock_zTVtpKEQ3Hs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zgPxvFZ104Q8">Advertising and Marketing Expenses</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses advertising and marketing costs as incurred. For the three months ended March 31, 2023, and 2022, the Company recorded advertising and marketing expenses of $<span id="xdx_907_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20230331_zz0c3YIceuSa" title="Advertising and marketing expenses">17,772</span> and $<span id="xdx_909_eus-gaap--MarketingAndAdvertisingExpense_c20220101__20220331_ziRbv9U8mYrl" title="Advertising and marketing expenses">2,478</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_ecustom--ConvertibleInstrumentsPolicyTextBlock_zR8LLb72hNJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z1wXlq7LQpQg">Convertible Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_840_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zEjavsB2NQG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zOol5ffKZ7m3">Discontinued Operations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 205-20 <i>Presentation of Financial Statements: Discontinued Operations</i>, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meet the criteria in paragraph 205-20-45-10. In the period in which the component meets held-for-sale or discontinued operations criteria the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 1, 2022, the BOD of the Company authorized the filing of a Chapter 7 proceeding which meets the definition of a discontinued operation. Accordingly, the operating results of PCTI are reported as income (loss) from discontinued operations in the accompanying consolidated financial statements for the three months ended March 31, 2023, and 2022. For additional information, see Note 14- Discontinued Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84D_ecustom--DistinguishingLiabilitiesFromEquityPolicyTextBlock_zUH0jv4eS3Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zbXSUeyGA1gi">Distinguishing Liabilities from Equity</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company relies on the guidance provided by ASC Topic 480, <i>Distinguishing Liabilities from Equity</i>, to classify certain redeemable and/or convertible instruments. The Company first determines whether a financial instrument should be classified as a liability. The Company will determine the liability classification if the financial instrument is mandatorily redeemable, or if the financial instrument, other than outstanding shares, embodies a conditional obligation that the Company must or may settle by issuing a variable number of its equity shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once the Company determines that a financial instrument should not be classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet (“temporary equity”). The Company will determine temporary equity classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our CEO and Chairman holds sufficient shares of the Company’s voting preferred stock that give sufficient voting rights under the articles of incorporation and bylaws of the Company such that the CEO and Chairman can at any time unilaterally vote to increase the number of authorized shares of common stock of the Company, without the need to call a general meeting of common shareholders of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Initial Measurement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records its financial instruments classified as liability, temporary equity, or permanent equity at issuance at the fair value, or cash received.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subsequent Measurement – Financial Instruments Classified as Liabilities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records the fair value of its financial instruments classified as liabilities at each subsequent measurement date. The changes in the fair value of its financial instruments classified as liabilities are recorded as other income (expenses).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zd9xw5ygBhnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zC5FDD9BQSXb">Fair Value of Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following are the hierarchical levels of inputs to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_ziupHju4pIz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of March 31, 2023, and December 31, 2022, for each fair value hierarchy level:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zuwqJegGFuc6" style="display: none">SCHEDULE OF DERIVATIVE INSTRUMENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpjxn3VemUEl" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbJ6aPaA7iIl" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLxqho0xm8h1" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgan7UnGzJy1" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0753">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKPQOp0mY8bh" style="width: 16%; text-align: right" title="Derivative Liabilities">4,952,388</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zK3nMS5KWLPi" style="width: 16%; text-align: right" title="Total">4,952,388</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJaF1Mm7BJI5" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0759">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3aXnqJwIjX9" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0761">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zElpE8Gbq4J2" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0763">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zc9Qf3CIGJv1" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0765">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0tYHymGy422" style="width: 16%; text-align: right" title="Derivative Liabilities">4,314,270</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7oX34jESYB9" style="width: 16%; text-align: right" title="Total">4,314,270</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zYRnOBEyj5th" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for leases under ASU 2016-02 (see Note 13), applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company used an incremental borrowing rate of <span id="xdx_90D_ecustom--IncrementalBorrowingPercentage_pid_dp_uPure_c20230101__20230331_zRLClaDnpOH1" title="Incremental borrowing percentage">7.5</span>%, for the existing lease, based on the information available at the adoption date in determining the present value of future payments. Operating lease expense is recognized pursuant to on a straight-line basis over the lease term and is included in rent in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_zCCi9gU2mRB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zYNOXl1xXgS3">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a <span id="xdx_90D_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20230101__20230331_zZdVhtNWN7X6" title="Income tax examination, likelihood of unfavorable settlement">greater than fifty percent</span> likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zhfET8EPm26b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zdTMhsqakxte">Segment Policy</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has no reportable segments as it operates in one segment: renewable energy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_z36P3bGSpIUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_z4q7ZZgDt4g1">Earnings (Loss) Per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of March 31, 2023, and 2022, the Company’s dilutive securities are convertible into approximately <span id="xdx_90E_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_c20230101__20230331_ze6eApYTMaWa" title="Dilutive securities common stock, shares">8,471,310,904</span> and <span id="xdx_90D_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_c20220101__20220331_zi2XeATM2yPa" title="Dilutive securities common stock, shares">7,689,322,026</span>, respectively, shares of common stock. The following table represents the classes of dilutive securities as of March 31, 2023, and 2022:</span></p> <p id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zUWUbF4V0Jr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BA_zgrslgJp5aa1" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_497_20230101__20230331_zmBgUKfzk33i" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_497_20220101__20220331_zr6GaHSKwHy1" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zXxH7H3JJMId" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible preferred stock <span id="xdx_F4F_zZ3vC61jo4tg">(1)</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,318,548,198</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,933,544,496</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnexercisedCommonStockPurchaseWarrantsMember_z75LAKqlQpz" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unexercised common stock purchase warrants <span id="xdx_F4F_zRR9AESati5l">(1)</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,047,024,518</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">672,024,518</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zhmeJO35Gwof" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes payable <span id="xdx_F47_z8SiuN3MtTF7">(1)</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,025,635</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,461,916</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PromissoryNotePayableMember_zQuxRE8q5LX1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory notes payable <span id="xdx_F4F_z55e6GHs5LSf">(1)</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94,712,553</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81,291,096</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zyhT5TfwlxEi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,471,310,904</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,689,322,026</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F04_zVEYPsErWRyd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_z9WrFHHn99wa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVElESUxVVElWRSBTRUNVUklUSUVTIEVYQ0xVREVEIEZST00gQ09NUFVUQVRJT04gT0YgRUFSTklOR1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_dp_c20230101__20230331_zDDy1mHalsSc" title="Outstanding shares, percentage">4.99</span>% of the then outstanding shares of common stock subsequent to any conversion or exercise. <span style="color: #222222; background-color: white">These shares </span><span style="background-color: white">were excluded from the diluted per share calculation because the effect of including these potential shares was anti-dilutive due to the Company’s net loss position.</span></span></td></tr> </table> <p id="xdx_8AB_zudBnxShxou6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQrbrUfiEnL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zm4ud2ZUmIvb">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging —Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company does not believe the adoption of the ASU will have a material impact on the Company’s financial position, results of operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other than the above, there have been no recent accounting pronouncements or changes in accounting pronouncements during the period ended March 31, 2023, that are of significance or potential significance to the Company.</span></p> <p id="xdx_85A_zggNdV18mmdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRVTiGOksWSg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z2q9wIU6VZ8">Basis of Presentation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2023, and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2023, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Current Report on Form 10-K filed on April 17, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited consolidated financial statements include the accounts of the Company and Ozop Energy Systems, Inc. and the Company’s other wholly owned subsidiaries Ozop Capital Partners, Inc., Ozop Engineering and Design, Inc., Power Conversion Technologies, Inc. (“PCTI”), Ozop LLC, Ozop HK and Spinus, LLC (“Spinus”). All intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“US GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84C_eus-gaap--UseOfEstimates_z8DrKR4eCiwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zN1cZlYUj8Bl">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zyNC0rZBohQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zXRQX7lXu6L3">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. The Company has <span id="xdx_904_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_zAs2mg2rQIjc" title="Cash equivalents"><span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20230331_zZESlWV85ac6" title="Cash equivalents">no</span></span> cash equivalents at March 31, 2023 and December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zZYNoApp2V4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zRxYbIMS1fbc">Sales Concentration and credit risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zG0yQ3ssGLDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the three months ended March 31, 2023, and 2022, and their accounts receivable balance as of March 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B2_zDBsHDbkLDZg" style="display: none">SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Three Months Ended March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Three Months Ended March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accounts receivable balance March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify">Customer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSR9tw4zcqK3" style="width: 14%; text-align: right" title="Sales concentration and credit risk">97</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z53ztSy0Olcl" style="width: 14%; text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerAMember_zgCAvQkgTxIk" style="width: 14%; text-align: right" title="Accounts receivable balance">149,040</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer B</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z49ZKu4ut0Ce" style="text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuawIp5nSoI9" style="text-align: right" title="Sales concentration and credit risk">19</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerBMember_zQyYNe6o7eA4" style="text-align: right" title="Accounts receivable balance"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer C</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCT6OZQi6q88" style="text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0660">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7umk3x9CGf5" style="text-align: right" title="Sales concentration and credit risk">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerCMember_zvkyJrfT9Tn7" style="text-align: right" title="Accounts receivable balance"><span style="-sec-ix-hidden: xdx2ixbrl0664">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9eIJOBJI685" style="text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zJyJhvjeW8Y5" style="text-align: right" title="Sales concentration and credit risk">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerDMember_zWFRqaQcEHSj" style="text-align: right" title="Accounts receivable balance"><span style="-sec-ix-hidden: xdx2ixbrl0670">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer E</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zU8TSg4ubJH" style="text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0672">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzEYtPdD4Ncl" style="text-align: right" title="Sales concentration and credit risk">14</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerEMember_zsncoLQSyrld" style="text-align: right" title="Accounts receivable balance"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_zZYkScBKOvAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zG0yQ3ssGLDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the three months ended March 31, 2023, and 2022, and their accounts receivable balance as of March 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B2_zDBsHDbkLDZg" style="display: none">SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Three Months Ended March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Sales % Three Months Ended March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accounts receivable balance March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify">Customer A</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSR9tw4zcqK3" style="width: 14%; text-align: right" title="Sales concentration and credit risk">97</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z53ztSy0Olcl" style="width: 14%; text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerAMember_zgCAvQkgTxIk" style="width: 14%; text-align: right" title="Accounts receivable balance">149,040</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer B</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z49ZKu4ut0Ce" style="text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuawIp5nSoI9" style="text-align: right" title="Sales concentration and credit risk">19</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerBMember_zQyYNe6o7eA4" style="text-align: right" title="Accounts receivable balance"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer C</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCT6OZQi6q88" style="text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0660">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7umk3x9CGf5" style="text-align: right" title="Sales concentration and credit risk">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerCMember_zvkyJrfT9Tn7" style="text-align: right" title="Accounts receivable balance"><span style="-sec-ix-hidden: xdx2ixbrl0664">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Customer D</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9eIJOBJI685" style="text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zJyJhvjeW8Y5" style="text-align: right" title="Sales concentration and credit risk">15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerDMember_zWFRqaQcEHSj" style="text-align: right" title="Accounts receivable balance"><span style="-sec-ix-hidden: xdx2ixbrl0670">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Customer E</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zU8TSg4ubJH" style="text-align: right" title="Sales concentration and credit risk"><span style="-sec-ix-hidden: xdx2ixbrl0672">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzEYtPdD4Ncl" style="text-align: right" title="Sales concentration and credit risk">14</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AccountsReceivableNet_iI_c20230331__srt--MajorCustomersAxis__custom--CustomerEMember_zsncoLQSyrld" style="text-align: right" title="Accounts receivable balance"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="text-align: left"> </td></tr> </table> 0.97 149040 0.19 0.15 0.15 0.14 <p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_z83boIAse3I8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zEhThfwJbPeg">Accounts Receivable</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zRATc74yfMR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zJLSOyIHESYj">Inventory</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are valued at the lower of cost or net realizable value, with cost determined on the first-in, first-out basis. Inventory costs consist of finished goods. In evaluating the net realizable value of inventory, management also considers, if applicable, other factors, including known trends, market conditions, currency exchange rates and other such issues. Finished goods inventories as of March 31, 2023, and December 31, 2022, were $<span id="xdx_903_eus-gaap--InventoryFinishedGoods_iI_c20230331_zBAL9PyMTCdg" title="Inventory finished goods">1,648,182</span> and $<span id="xdx_906_eus-gaap--InventoryFinishedGoods_iI_c20221231_zgJxrr4ITsI9" title="Inventory finished goods">3,601,026</span>, respectively. As of March 31, 2023, the Company has on deposit with vendor(s) approximately $<span id="xdx_90D_eus-gaap--DepositsAssetsCurrent_iI_c20230331_z64BsK9opgj2" title="Deposits">3,687,000</span> and has a balance due of approximately $<span id="xdx_902_eus-gaap--DepositsAssetsNoncurrent_iI_c20230331_zeYi8ItRweBk" title="Deposits">10,264,000</span> for open purchase orders. The remaining balance is partially due when the vendor ships the product, with the final balance due prior to delivery.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1648182 3601026 3687000 10264000 <p id="xdx_842_ecustom--PurchaseConcentrationPolicyTextBlock_zBm62tm5rfU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zTK8VueTfGb5">Purchase concentration</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OES purchases finished renewable energy products from its’ suppliers. For the three months ended March 31, 2023, there was one supplier that accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zLohGave8ga3" title="Concentration of credit risk">100</span>%. For the three months ended March 31, 2022, there were four suppliers that accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--SuppliersOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z2qgon5zTow4" title="Concentration of credit risk">36</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--SuppliersTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z75XetQ9cZQa" title="Concentration of credit risk">24</span>%,<span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--SuppliersThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zxeWafE7T7K6" title="Concentration of credit risk">13</span>%, and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--SuppliersFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zfh50eP5Mz3i" title="Concentration of credit risk">10</span>%, respectively. There are only a handful of major suppliers, and we currently have supply arrangements with some of those vendors. One of these vendors requires a <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--TwoVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zde3kLhVmk84" title="Concentration of credit risk">20</span>% down payment with the balances due on shipment and delivery, while other vendors’ terms are due immediately prior to delivery. We may also buy product from other distributors if we are not able to purchase direct from the manufacturer. While management believes its relationships with its vendors are good, if we are unable to continue to use and/or find alternative suppliers, when we cannot buy direct, it may have a material negative effect on our business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 0.36 0.24 0.13 0.10 0.20 <p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z4LnVyfmSrVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_ziJRcQni8VB2">Property, plant, and equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment is as follows:</span></p> <p id="xdx_89D_ecustom--ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock_zP4EL5rCrJy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B9_zHVDKKPYlcE7" style="display: none">SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zSZlMOVzLJq5" title="Property, plant and equipment, useful life">10</span>-<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zH3DsqLPbrJ4" title="Property, plant and equipment, useful life">25</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture and equipment </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zeznQXYgAVh8" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zGf5Cao2sld9" title="Property, plant and equipment, useful life">5</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warehouse equipment </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WarehouseEquipmentMember_zewk9sTesBP9" title="Property, plant and equipment, useful life">7</span> years</span></td></tr> </table> <p id="xdx_8AD_zAU3S2H6mDN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_ecustom--ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock_zP4EL5rCrJy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B9_zHVDKKPYlcE7" style="display: none">SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zSZlMOVzLJq5" title="Property, plant and equipment, useful life">10</span>-<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zH3DsqLPbrJ4" title="Property, plant and equipment, useful life">25</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture and equipment </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zeznQXYgAVh8" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zGf5Cao2sld9" title="Property, plant and equipment, useful life">5</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warehouse equipment </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WarehouseEquipmentMember_zewk9sTesBP9" title="Property, plant and equipment, useful life">7</span> years</span></td></tr> </table> P10Y P25Y P3Y P5Y P7Y <p id="xdx_843_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_ziVmx5FkZyqb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zzq1SWNqku61">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in accordance with ASC 606, from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. The Company has no outstanding contracts with any of its’ customers. The Company recognizes revenue when title, ownership, and risk of loss pass to the customer, all of which occurs upon shipment or delivery of the product and is based on the applicable shipping terms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For contracts with customers, ownership of the goods and associated revenue are transferred to customers at a point in time, generally upon shipment of a product to the customer or receipt of the product by the customer and without significant judgments. Any advance payments are recorded as current liability until revenue is recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the periods covered herein, we did not have post shipment obligations such as training or installation, customer acceptance provisions, credits and discounts, rebates and price protection, or other similar privileges.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--DisaggregationOfRevenueTableTextBlock_zPTXlxyFUvzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates our revenue by major source for the three months ended March 31, 2023, and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_z28TvA6bEffi" style="display: none">DISAGGREGATION OF REVENUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20230101__20230331_zsV2IIZ9Uvd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_496_20220101__20220331_zFMvpzhQdyWi" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three months ended March 31,</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SourcedAndDistributedProductsMember_zBZ875COr2Nc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sourced and distributed products</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,758,798</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,919,322</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OEDInstallationsMember_ziwQjK1Ke4Y2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OED Installations</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,400</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0726">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zHcGgCLmrlbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,791,198</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,919,322</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A7_zqLZ2VYXjnO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues from sourced and distributed products are purchased from suppliers as finished goods and the Company currently brings the finished goods into a third-party warehouse to fill orders as well as to build inventory for future sales orders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_891_eus-gaap--DisaggregationOfRevenueTableTextBlock_zPTXlxyFUvzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table disaggregates our revenue by major source for the three months ended March 31, 2023, and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_z28TvA6bEffi" style="display: none">DISAGGREGATION OF REVENUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20230101__20230331_zsV2IIZ9Uvd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_496_20220101__20220331_zFMvpzhQdyWi" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three months ended March 31,</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--SourcedAndDistributedProductsMember_zBZ875COr2Nc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sourced and distributed products</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,758,798</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,919,322</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--OEDInstallationsMember_ziwQjK1Ke4Y2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OED Installations</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,400</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0726">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zHcGgCLmrlbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,791,198</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,919,322</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2758798 2919322 32400 2791198 2919322 <p id="xdx_842_eus-gaap--AdvertisingCostsPolicyTextBlock_zTVtpKEQ3Hs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zgPxvFZ104Q8">Advertising and Marketing Expenses</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expenses advertising and marketing costs as incurred. For the three months ended March 31, 2023, and 2022, the Company recorded advertising and marketing expenses of $<span id="xdx_907_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20230331_zz0c3YIceuSa" title="Advertising and marketing expenses">17,772</span> and $<span id="xdx_909_eus-gaap--MarketingAndAdvertisingExpense_c20220101__20220331_ziRbv9U8mYrl" title="Advertising and marketing expenses">2,478</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 17772 2478 <p id="xdx_84B_ecustom--ConvertibleInstrumentsPolicyTextBlock_zR8LLb72hNJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z1wXlq7LQpQg">Convertible Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_840_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zEjavsB2NQG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zOol5ffKZ7m3">Discontinued Operations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 205-20 <i>Presentation of Financial Statements: Discontinued Operations</i>, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meet the criteria in paragraph 205-20-45-10. In the period in which the component meets held-for-sale or discontinued operations criteria the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations, less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 1, 2022, the BOD of the Company authorized the filing of a Chapter 7 proceeding which meets the definition of a discontinued operation. Accordingly, the operating results of PCTI are reported as income (loss) from discontinued operations in the accompanying consolidated financial statements for the three months ended March 31, 2023, and 2022. For additional information, see Note 14- Discontinued Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84D_ecustom--DistinguishingLiabilitiesFromEquityPolicyTextBlock_zUH0jv4eS3Ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zbXSUeyGA1gi">Distinguishing Liabilities from Equity</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company relies on the guidance provided by ASC Topic 480, <i>Distinguishing Liabilities from Equity</i>, to classify certain redeemable and/or convertible instruments. The Company first determines whether a financial instrument should be classified as a liability. The Company will determine the liability classification if the financial instrument is mandatorily redeemable, or if the financial instrument, other than outstanding shares, embodies a conditional obligation that the Company must or may settle by issuing a variable number of its equity shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once the Company determines that a financial instrument should not be classified as a liability, the Company determines whether the financial instrument should be presented between the liability section and the equity section of the balance sheet (“temporary equity”). The Company will determine temporary equity classification if the redemption of the financial instrument is outside the control of the Company (i.e. at the option of the holder). Otherwise, the Company accounts for the financial instrument as permanent equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our CEO and Chairman holds sufficient shares of the Company’s voting preferred stock that give sufficient voting rights under the articles of incorporation and bylaws of the Company such that the CEO and Chairman can at any time unilaterally vote to increase the number of authorized shares of common stock of the Company, without the need to call a general meeting of common shareholders of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Initial Measurement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records its financial instruments classified as liability, temporary equity, or permanent equity at issuance at the fair value, or cash received.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subsequent Measurement – Financial Instruments Classified as Liabilities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records the fair value of its financial instruments classified as liabilities at each subsequent measurement date. The changes in the fair value of its financial instruments classified as liabilities are recorded as other income (expenses).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zd9xw5ygBhnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zC5FDD9BQSXb">Fair Value of Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following are the hierarchical levels of inputs to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, certain of the Company’s embedded conversion features on debt and outstanding warrants have been treated as derivative liabilities for accounting purposes under ASC 815 due to insufficient authorized shares to fully settle conversion features of the instruments if exercised. In this case, the Company utilized the latest inception date sequencing method to reclassify outstanding instruments as derivative instruments. These contracts were recognized at fair value with changes in fair value recognized in earnings until such time as the conditions giving rise to such derivative liability classification were settled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_ziupHju4pIz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of March 31, 2023, and December 31, 2022, for each fair value hierarchy level:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zuwqJegGFuc6" style="display: none">SCHEDULE OF DERIVATIVE INSTRUMENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpjxn3VemUEl" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbJ6aPaA7iIl" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLxqho0xm8h1" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgan7UnGzJy1" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0753">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKPQOp0mY8bh" style="width: 16%; text-align: right" title="Derivative Liabilities">4,952,388</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zK3nMS5KWLPi" style="width: 16%; text-align: right" title="Total">4,952,388</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJaF1Mm7BJI5" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0759">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3aXnqJwIjX9" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0761">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zElpE8Gbq4J2" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0763">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zc9Qf3CIGJv1" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0765">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0tYHymGy422" style="width: 16%; text-align: right" title="Derivative Liabilities">4,314,270</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7oX34jESYB9" style="width: 16%; text-align: right" title="Total">4,314,270</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zYRnOBEyj5th" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for leases under ASU 2016-02 (see Note 13), applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether we have the right to direct the use of the asset. We allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease ROU assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company used an incremental borrowing rate of <span id="xdx_90D_ecustom--IncrementalBorrowingPercentage_pid_dp_uPure_c20230101__20230331_zRLClaDnpOH1" title="Incremental borrowing percentage">7.5</span>%, for the existing lease, based on the information available at the adoption date in determining the present value of future payments. Operating lease expense is recognized pursuant to on a straight-line basis over the lease term and is included in rent in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfDerivativeInstrumentsTextBlock_ziupHju4pIz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of March 31, 2023, and December 31, 2022, for each fair value hierarchy level:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zuwqJegGFuc6" style="display: none">SCHEDULE OF DERIVATIVE INSTRUMENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpjxn3VemUEl" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbJ6aPaA7iIl" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLxqho0xm8h1" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgan7UnGzJy1" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0753">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKPQOp0mY8bh" style="width: 16%; text-align: right" title="Derivative Liabilities">4,952,388</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zK3nMS5KWLPi" style="width: 16%; text-align: right" title="Total">4,952,388</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Derivative Liabilities</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJaF1Mm7BJI5" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0759">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3aXnqJwIjX9" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0761">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zElpE8Gbq4J2" style="text-align: right" title="Derivative Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0763">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zc9Qf3CIGJv1" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0765">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Level III</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0tYHymGy422" style="width: 16%; text-align: right" title="Derivative Liabilities">4,314,270</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7oX34jESYB9" style="width: 16%; text-align: right" title="Total">4,314,270</td><td style="width: 1%; text-align: left"> </td></tr> </table> 4952388 4952388 4314270 4314270 0.075 <p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_zCCi9gU2mRB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zYNOXl1xXgS3">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance on deferred tax assets is established when management considers it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax benefits from an uncertain tax position are only recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a <span id="xdx_90D_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20230101__20230331_zZdVhtNWN7X6" title="Income tax examination, likelihood of unfavorable settlement">greater than fifty percent</span> likelihood of being realized upon ultimate resolution. Interest and penalties related to unrecognized tax benefits are recorded as incurred as a component of income tax expense. The Company has not recognized any tax benefits from uncertain tax positions for any of the reporting periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> greater than fifty percent <p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zhfET8EPm26b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zdTMhsqakxte">Segment Policy</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has no reportable segments as it operates in one segment: renewable energy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_z36P3bGSpIUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_z4q7ZZgDt4g1">Earnings (Loss) Per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of March 31, 2023, and 2022, the Company’s dilutive securities are convertible into approximately <span id="xdx_90E_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_c20230101__20230331_ze6eApYTMaWa" title="Dilutive securities common stock, shares">8,471,310,904</span> and <span id="xdx_90D_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_c20220101__20220331_zi2XeATM2yPa" title="Dilutive securities common stock, shares">7,689,322,026</span>, respectively, shares of common stock. The following table represents the classes of dilutive securities as of March 31, 2023, and 2022:</span></p> <p id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zUWUbF4V0Jr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BA_zgrslgJp5aa1" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_497_20230101__20230331_zmBgUKfzk33i" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_497_20220101__20220331_zr6GaHSKwHy1" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zXxH7H3JJMId" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible preferred stock <span id="xdx_F4F_zZ3vC61jo4tg">(1)</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,318,548,198</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,933,544,496</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnexercisedCommonStockPurchaseWarrantsMember_z75LAKqlQpz" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unexercised common stock purchase warrants <span id="xdx_F4F_zRR9AESati5l">(1)</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,047,024,518</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">672,024,518</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zhmeJO35Gwof" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes payable <span id="xdx_F47_z8SiuN3MtTF7">(1)</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,025,635</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,461,916</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PromissoryNotePayableMember_zQuxRE8q5LX1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory notes payable <span id="xdx_F4F_z55e6GHs5LSf">(1)</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94,712,553</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81,291,096</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zyhT5TfwlxEi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,471,310,904</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,689,322,026</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F04_zVEYPsErWRyd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_z9WrFHHn99wa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVElESUxVVElWRSBTRUNVUklUSUVTIEVYQ0xVREVEIEZST00gQ09NUFVUQVRJT04gT0YgRUFSTklOR1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_dp_c20230101__20230331_zDDy1mHalsSc" title="Outstanding shares, percentage">4.99</span>% of the then outstanding shares of common stock subsequent to any conversion or exercise. <span style="color: #222222; background-color: white">These shares </span><span style="background-color: white">were excluded from the diluted per share calculation because the effect of including these potential shares was anti-dilutive due to the Company’s net loss position.</span></span></td></tr> </table> <p id="xdx_8AB_zudBnxShxou6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 8471310904 7689322026 <p id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zUWUbF4V0Jr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BA_zgrslgJp5aa1" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_497_20230101__20230331_zmBgUKfzk33i" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_497_20220101__20220331_zr6GaHSKwHy1" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zXxH7H3JJMId" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible preferred stock <span id="xdx_F4F_zZ3vC61jo4tg">(1)</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,318,548,198</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,933,544,496</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnexercisedCommonStockPurchaseWarrantsMember_z75LAKqlQpz" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unexercised common stock purchase warrants <span id="xdx_F4F_zRR9AESati5l">(1)</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,047,024,518</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">672,024,518</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zhmeJO35Gwof" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes payable <span id="xdx_F47_z8SiuN3MtTF7">(1)</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,025,635</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,461,916</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PromissoryNotePayableMember_zQuxRE8q5LX1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory notes payable <span id="xdx_F4F_z55e6GHs5LSf">(1)</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94,712,553</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81,291,096</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zyhT5TfwlxEi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,471,310,904</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,689,322,026</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F04_zVEYPsErWRyd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_z9WrFHHn99wa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFOVElESUxVVElWRSBTRUNVUklUSUVTIEVYQ0xVREVEIEZST00gQ09NUFVUQVRJT04gT0YgRUFSTklOR1MgUEVSIFNIQVJFIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_dp_c20230101__20230331_zDDy1mHalsSc" title="Outstanding shares, percentage">4.99</span>% of the then outstanding shares of common stock subsequent to any conversion or exercise. <span style="color: #222222; background-color: white">These shares </span><span style="background-color: white">were excluded from the diluted per share calculation because the effect of including these potential shares was anti-dilutive due to the Company’s net loss position.</span></span></td></tr> </table> 7318548198 6933544496 1047024518 672024518 11025635 2461916 94712553 81291096 8471310904 7689322026 0.0499 <p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQrbrUfiEnL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zm4ud2ZUmIvb">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging —Contracts in Entity’ Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company does not believe the adoption of the ASU will have a material impact on the Company’s financial position, results of operations or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other than the above, there have been no recent accounting pronouncements or changes in accounting pronouncements during the period ended March 31, 2023, that are of significance or potential significance to the Company.</span></p> <p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zYP9kIG21Oh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 – <span id="xdx_826_zGE3QiazWulg">PROPERTY AND EQUIPMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zQkPEkhN0Fzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s property and equipment:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B3_zdnyGTv6s59k" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_495_20230331_z0ymWYNhTjq9" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_49E_20221231_zYW2mb12rYmg" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zjS4pMHQWEpi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">224,733</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">222,571</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zO8mH8W5bH5g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building and building improvements</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zRfIj9Ziu48d" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zTFWokYu5oeg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Accumulated Depreciation</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(133,978</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(110,956</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iI_zNCBqoHZDujb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and Equipment, Net</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">690,755</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">711,615</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A7_zddPpfFq1lZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expenses were $<span id="xdx_90F_eus-gaap--Depreciation_pp0p0_c20230101__20230331_ze4GMp0To1z3" title="Depreciation expenses">23,022</span> and $<span id="xdx_905_eus-gaap--Depreciation_pp0p0_c20220101__20220331_zzn5qCXmYbEi" title="Depreciation expenses">10,805</span> for the three months ended March 31, 2023, and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zQkPEkhN0Fzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s property and equipment:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B3_zdnyGTv6s59k" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_495_20230331_z0ymWYNhTjq9" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, 2023</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="2" id="xdx_49E_20221231_zYW2mb12rYmg" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2022</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zjS4pMHQWEpi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">224,733</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">222,571</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zO8mH8W5bH5g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building and building improvements</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zRfIj9Ziu48d" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, gross</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,000</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_406_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zTFWokYu5oeg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Accumulated Depreciation</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(133,978</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(110,956</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iI_zNCBqoHZDujb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and Equipment, Net</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">690,755</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">711,615</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 224733 222571 600000 600000 600000 600000 133978 110956 690755 711615 23022 10805 <p id="xdx_80B_eus-gaap--DebtDisclosureTextBlock_zgYAcyTFrR7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 - <span id="xdx_829_z2L8vvZB89Hg">CONVERTIBLE NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 10, 2020, PCTI (the accounting acquirer) assumed the balance of a past-due 15% convertible note issued by the Company on September 13, 2017. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $<span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--FifteenPercentPromissoryNoteMember_z3jttqxkY0Vg" title="Long term debt, gross"><span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--FifteenPercentPromissoryNoteMember_zdXRTuSEoRL8" title="Long term debt, gross">25,000</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 25000 25000 <p id="xdx_80E_eus-gaap--DerivativesAndFairValueTextBlock_zilEESmdYuHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_82A_zIAWqWujTCse">DERIVATIVE LIABILITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined the conversion feature of the convertible notes, which all contain variable conversion rates, represented an embedded derivative since the notes were convertible into a variable number of shares upon conversion. Accordingly, the notes are not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At any given time, certain of the Company’s embedded conversion features on debt and outstanding warrants may be treated as derivative liabilities for accounting purposes under ASC 815-40 due to insufficient authorized shares to settle these outstanding contracts. Pursuant to SEC staff guidance that permits a sequencing approach based on the use of ASC 815-15-25 which provides guidance for contracts that permit partial net share settlement. The sequencing approach may be applied in one of two ways: contracts may be evaluated based on (1) earliest issuance date or (2) latest maturity date. Pursuant to the sequencing approach, the Company evaluates its contracts based upon the latest maturity date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company valued the derivative liabilities as of March 31, 2023, and December 31, 2022, at $<span id="xdx_907_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20230331_zCWgxHg45yZ1" title="Derivative liabilities">4,952,388</span> and $<span id="xdx_904_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231_zwJB376QuoRk" title="Derivative liabilities">4,314,270</span> respectively. For the derivative liability associated with convertible notes, the Company used the Monte Carlo simulation valuation model with the following assumptions as of March 31, 2023, and December 31, 2022, risk free interest rates at <span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zXX1H5hJzFK" title="Derivative liability measurement input">4.85</span>% and <span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zKyW8vEBavTh" title="Derivative liability measurement input">4.76</span>%, respectively, and volatility of <span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z8GyyoXHbqmh" title="Derivative liability, measurement input">86</span>% and <span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zkudBpKNmrAf" title="Derivative liability, measurement input">71</span>%, respectively. During the year ended December 31, 2022, the Company issued <span id="xdx_902_ecustom--WarrantsInConjunctionWithNotesPayable_pid_c20220101__20221231_zhSCcUumg0E9" title="Warrants in conjunction with notes payable">375,000,000</span> warrants in conjunction with the extension of certain notes payable. The Company recorded a discount to notes payable of $<span id="xdx_907_ecustom--NotesPayableDiscount_pp0p0_c20220101__20221231_zR5AajKveJMf" title="Notes payable discount">2,550,000</span> with the offset to derivative liabilities for the initial fair value of the warrants based on the Black-Scholes option pricing model. The following assumptions were utilized in the initial Black-Scholes valuation of issued warrants during the year ended December 31, 2022, risk free interest rate of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztgIsp1w4Dvl" title="Warrant measurement input">4.45</span>%, volatility of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zqBHU3Z6Aupa" title="Warrant measurement input">509</span>%, and an exercise price of $<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zXuXkTROs5he" title="Warrant measurement input">0.0067</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following assumptions were utilized in the Black-Scholes valuation of outstanding warrants as of March 31, 2023, and December 31, 2022, risk free interest rate of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zgH3UxC4uvI" title="Risk free interest rate">3.94</span>% to <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zYtZbWNVuYFi" title="Risk free interest rate">4.64</span>%, and <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z4UALyq2HGeb" title="Risk free interest rate">4.39</span>% to <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zg0Ys4Dtfir8" title="Risk free interest rate">4.73</span>%, respectively, volatility of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputPriceVolatilityOneMember__srt--RangeAxis__srt--MinimumMember_zvYluXWwELAg" title="Risk free interest volatility">112</span>% to <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230331__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputPriceVolatilityOneMember__srt--RangeAxis__srt--MaximumMember_zbZlmVVOtBZ3" title="Risk free interest volatility">168</span>%, and <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputPriceVolatilityOneMember__srt--RangeAxis__srt--MinimumMember_zqiePapLwkm2" title="Risk free interest volatility">109</span>% to <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputPriceVolatilityOneMember__srt--RangeAxis__srt--MaximumMember_zQDJ6OTCC6Zk" title="Risk free interest volatility">272</span>%, respectively, and exercise prices of $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_z55wLHxp4996" title="Risk free interest exercise prices">0.0061</span> to $<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20230331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_zP9Sr4H8FCJl" title="Risk free interest exercise prices">0.15</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zKanuHt525ya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the activity related to derivative liabilities for the three months ended March 31, 2023, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zlkWVrVb0Ojl" style="display: none">SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities associated with warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities associated with convertible notes</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total derivative liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iS_pp0p0_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zon8UcMKUCFa" style="width: 14%; text-align: right" title="Derivative liability, beginning balance">4,285,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilitiesCurrent_iS_pp0p0_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zRd9wI7QSwi4" style="width: 14%; text-align: right" title="Derivative liability, beginning balance">28,870</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iS_pp0p0_c20230101__20230331_zqYICQ43TNIf" style="width: 14%; text-align: right" title="Derivative liability, beginning balance">4,314,270</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--LossOnFairValueChangeOfDerivatives_pp0p0_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zINeOKcCjGtd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">636,213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--LossOnFairValueChangeOfDerivatives_pp0p0_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zG6RylvaaAzl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">1,905</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--LossOnFairValueChangeOfDerivatives_pp0p0_c20230101__20230331_zIOcwmXvEkl2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">638,118</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iE_pp0p0_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zIW3YSwRpbMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">4,921,613</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesCurrent_iE_pp0p0_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_z70CEHx53rPl" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">30,775</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iE_pp0p0_c20230101__20230331_zIjuzj48A8Wd" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">4,952,388</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zEVhFGCxeWue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 4952388 4314270 4.85 4.76 86 71 375000000 2550000 4.45 509 0.0067 3.94 4.64 4.39 4.73 112 168 109 272 0.0061 0.15 <p id="xdx_89F_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zKanuHt525ya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the activity related to derivative liabilities for the three months ended March 31, 2023, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zlkWVrVb0Ojl" style="display: none">SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities associated with warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liabilities associated with convertible notes</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total derivative liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iS_pp0p0_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zon8UcMKUCFa" style="width: 14%; text-align: right" title="Derivative liability, beginning balance">4,285,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilitiesCurrent_iS_pp0p0_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zRd9wI7QSwi4" style="width: 14%; text-align: right" title="Derivative liability, beginning balance">28,870</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iS_pp0p0_c20230101__20230331_zqYICQ43TNIf" style="width: 14%; text-align: right" title="Derivative liability, beginning balance">4,314,270</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--LossOnFairValueChangeOfDerivatives_pp0p0_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zINeOKcCjGtd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">636,213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--LossOnFairValueChangeOfDerivatives_pp0p0_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_zG6RylvaaAzl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">1,905</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--LossOnFairValueChangeOfDerivatives_pp0p0_c20230101__20230331_zIOcwmXvEkl2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">638,118</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iE_pp0p0_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithWarrantsMember_zIW3YSwRpbMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">4,921,613</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilitiesCurrent_iE_pp0p0_c20230101__20230331__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilitiesAssociatedWithConvertibleNotesMember_z70CEHx53rPl" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">30,775</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilitiesCurrent_iE_pp0p0_c20230101__20230331_zIjuzj48A8Wd" style="border-bottom: Black 2.5pt double; text-align: right" title="Derivative liability, ending balance">4,952,388</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4285400 28870 4314270 636213 1905 638118 4921613 30775 4952388 <p id="xdx_800_ecustom--NotesPayableTextBlock_zCVOIJSplloc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 – <span id="xdx_822_ztlAmEfDVHD2">NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfDebtTableTextBlock_zroODdYIiSJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has the following notes payable outstanding:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B2_z4Ic86aLvZf5" style="display: none">SCHEDULE OF NOTES PAYABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230331_zqHB3jOOipO6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20221231_zIWhWADhg4w7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Note payable, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_z5XIJhnv5MT" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zI1R5WtYO0Tj" title="Debt Instrument, interest rate, stated percentage">8%</span></span>, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zJzpqx6WlNo8" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zQ2vooPrM4w1" title="Debt Instrument, maturity date">January 5, 2020</span></span>, in default</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zofEIuW9KfP9" style="width: 16%; text-align: right" title="Sub- total notes payable">45,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zor9vJhjv9Bc" style="width: 16%; text-align: right" title="Sub- total notes payable">45,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other, due on demand, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zfGLymDd3OCc" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zow6qLQjqsj6" title="Debt Instrument, interest rate, stated percentage">6%</span></span>, currently in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zZTRfPNWsB4h" style="text-align: right" title="Sub- total notes payable">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_z12mvWQ6Sn34" style="text-align: right" title="Sub- total notes payable">50,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_z3G0ZQW7Yxnd" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zyu3glOkNjVj" title="Debt Instrument, face amount">750,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zVN76vhgp7K8" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_z4tICxMCXWa5" title="Debt Instrument, interest rate, stated percentage">12%</span></span>, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zPEMufV36YOi" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zoX4Z8X7zlCj" title="Debt Instrument, maturity date">August 24, 2021</span></span>, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zczMtwPEoPx8" style="text-align: right" title="Sub- total notes payable">375,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zy29KfNJRdQh" style="text-align: right" title="Sub- total notes payable">375,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zeW7Wo8uOKS9" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zn4gsFhxOhGd" title="Debt Instrument, face amount">389,423</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_z68FWrMeRoB7" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zQYjjbZHOp1l" title="Debt Instrument, interest rate, stated percentage">12%</span></span>, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_z5jPIQRU3eNb" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zTKrpxukFBv6" title="Debt Instrument, maturity date">November 6, 2023</span></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zQNQHw4SVjO3" style="text-align: right" title="Sub- total notes payable">389,423</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zbbLsQ9jKas" style="text-align: right" title="Sub- total notes payable">389,423</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zohG4BUPqvj" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_z3m83qecdmr8" title="Debt Instrument, face amount">1,000,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zvxHSwGyPTJ1" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_z4j9e4rYjkR8" title="Debt Instrument, interest rate, stated percentage">12%</span></span>, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zMNU8LBfRCkf" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zFMmMuzzZq8c" title="Debt Instrument, maturity date">November 13, 2021</span></span>, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zt8d9Rg3dDVi" style="text-align: right" title="Sub- total notes payable">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zcotRveWGi6h" style="text-align: right" title="Sub- total notes payable">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zJAK6nZHIQR6" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zCDz5ERyH7Nl" title="Debt Instrument, face amount">2,200,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zUuvWLWisDJ9" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zxBX2it3zBej" title="Debt Instrument, interest rate, stated percentage">15%</span></span>, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_z1bhGRo9LCC7" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zR0Em34Jq6a9" title="Debt Instrument, maturity date">October 31, 2024</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zvH8b4mokwqk" title="Debt Instrument, unamortized discount">269,167</span> (2023) and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zi83K7EMQtS2" title="Debt Instrument, unamortized discount">311,667</span> (2022)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zvWXealkYCF6" style="text-align: right" title="Sub- total notes payable">1,930,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zRjzoHkmPiDl" style="text-align: right" title="Sub- total notes payable">1,888,333</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z62gB8amW4ig" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zHxkdzzbJny9" title="Debt Instrument, face amount">11,110,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z713WaoBp31g" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z5QTLRVNqn5d" title="Debt Instrument, interest rate, stated percentage">15%</span></span>, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zZ2nzOUc4T74" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zOTUQgyWUVx6" title="Debt Instrument, maturity date">October 31, 2024</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zppCwdwLFEA7" title="Debt Instrument, unamortized discount">1,345,833</span> (2023) and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z90av4m8Try8" title="Debt Instrument, unamortized discount">1,558,333</span> (2022)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zpIUb0a4Xw4g" style="text-align: right" title="Sub- total notes payable">9,764,167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zfsGRi0dqanl" style="text-align: right" title="Sub- total notes payable">9,551,667</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zcBm9F7Qck66" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zxNwrmgzOkbg" title="Debt Instrument, face amount">3,300,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zo0t9Zm0wBid" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z81RKVLcPMg6" title="Debt Instrument, interest rate, stated percentage">15%</span></span>, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z4UzfFxfTnD2" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z3Owsbx2wPel" title="Debt Instrument, maturity date">October 31, 2024</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zS7h1hkY3Ip6" title="Debt Instrument, unamortized discount">403,750</span> (2023) and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z66vHEmqK1V1" title="Debt Instrument, unamortized discount">467,500</span> (2022)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zwp8KnL8eQe1" style="text-align: right" title="Sub- total notes payable">2,896,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zM4GPNVBMvgc" style="text-align: right" title="Sub- total notes payable">2,832,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_z3PKFCLffeHa" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_z9HhLhqpqyf" title="Debt Instrument, face amount">3,020,000</span></span> face value, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zmepGqwHm9A1" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_znsh8DdibFd5" title="Debt Instrument, maturity date">March 31, 2023</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zeGQNDdbvTCa" title="Debt Instrument, unamortized discount">0</span> (2023) and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zPq44b010o5f" title="Debt Instrument, unamortized discount">181,818</span> (2022), in default</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zOUgXSwGwp63" style="border-bottom: Black 1.5pt solid; text-align: right" title="Sub- total notes payable">2,220,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zlisPbwMkuv7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Sub- total notes payable">2,588,182</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Sub- total notes payable, net of discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,670,673</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,720,105</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermNotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less long-term portion, net of discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,591,250</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,272,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of notes payable, net of discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,079,423</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,447,605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zoy645gdRVE9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 11, 2022, the Company entered into a non-interest bearing, $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221111__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zSPwL1oYJUx4" title="Debt instrument, face amount">3,020,000</span> face value promissory note with a third-party lender with scheduled weekly payments and a maturity date of <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_pp0p0_dd_c20221111__20221111__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchThirtyOneTwoThousandTwentyThreeMember_zbvwhrP2sVti" title="Debt Instrument, maturity date">March 31, 2023</span>. In exchange for the issuance of the $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20221111__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchThirtyOneTwoThousandTwentyThreeMember_zQJYujgohlqa" title="Debt instrument face amount">3,020,000</span> note, inclusive of an original issue discount of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221111__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchThirtyOneTwoThousandTwentyThreeMember_zpOLFbgMGUt2" title="Original issue discount">250,000</span>, and the reclass of $<span id="xdx_90D_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20221111__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchThirtyOneTwoThousandTwentyThreeMember_zYjD436XHRU9" title="Accounts and accrued expenses">260,000</span> from accounts payable and accrued expenses the Company received proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromNotesPayable_c20221111__20221111__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchThirtyOneTwoThousandTwentyThreeMember_zxxCoUjwn7sg" title="Proceeds received">2,510,000</span> on November 11, 2022, from the lender. For the three months ended March 31, 2023, amortization of the original issue discount of $<span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchThirtyOneTwoThousandTwentyThreeMember_z1PJn9Mkwka" title="Original issue discount, amortized">181,818</span> was charged to interest expense. During the three months ended March 31, 2023, the Company also repaid $<span id="xdx_90E_eus-gaap--RepaymentsOfDebt_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchThirtyOneTwoThousandTwentyThreeMember_zok09Q0KDrGd" title="Repayments of debt">550,000</span> of the principal of the note. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchThirtyOneTwoThousandTwentyThreeMember_zQNv9duxvxpb" title="Debt Instrument, face amount">2,220,000</span> and $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchThirtyOneTwoThousandTwentyThreeMember_zSEH2hI0o91l" title="Debt Instrument, face amount">2,770,000</span>, respectively, with a carrying value as of March 31, 2023, and December 31, 2022, of $<span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchThirtyOneTwoThousandTwentyThreeMember_zlcAbLDB16Pj" title="Debt instrument, carrying amount">2,220,000</span> and $<span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchThirtyOneTwoThousandTwentyThreeMember_ztNdkVQWQOUa" title="Debt instrument, carrying amount">2,588,182</span>, respectively, net of unamortized discounts of $<span id="xdx_901_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchThirtyOneTwoThousandTwentyThreeMember_zHtxbKyRO6r5" title="Debt Instrument, unamortized discount">181,818</span> as of December 31, 2022. The Company is in default on the weekly payments. The Company is currently in discussions with the lender regarding an extension of the maturity date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 7, 2021, the Company entered into a <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zpiRdNiEP2d5" title="Debt instrument, interest rate, stated percentage">12%</span>, $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zfxIScegrXp2" title="Debt instrument, face amount">3,300,000</span> face value promissory note with a third- party lender with a maturity date of <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20211205__20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_z6XJSNxDQEMc" title="Debt instrument, maturity date">December 7, 2022</span>. In exchange for the issuance of the $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zwpL5XJNNEpc" title="Debt instrument face amount">3,300,000</span> note, inclusive of an original issue discount of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zlimyM1MclB5" title="Original issue discount">300,000</span>, the Company received proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromNotesPayable_c20211212__20211213__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zg1RBHt5Egph" title="Proceeds from notes payable">3,000,000</span> on December 13, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zhvkdPpPZyz1" title="Warrant to purchase shares">75,000,000</span> shares of common stock at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211207__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zQKAVX5Ycrdi" title="Warrant exercise price">0.039</span> per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. On October 31, 2022, the maturity date of the note was extended to October 31, 2024, and the interest rate was increased to <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221031__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_z2rLnQ07H7J2" title="Debt instrument, interest rate, stated percentage">15%</span> per annum. The Company issued <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221031__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zUQk2PbqTHEf" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">75,000,000</span> warrants at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221031__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zTGxmEKZNQKi" title="Warrant exercise price">0.0067</span> and with an expiration of October 31, 2025, in exchange for the extension. The warrants were valued at $<span id="xdx_90F_ecustom--AmortizationOfInterestExpense_pp0p0_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zaEIopuY1Gih" title="Interest expense, amortized">510,000</span> by the Black-Scholes option pricing method and will be amortized through the new maturity date of the note. The Company determined that this transaction was a modification of the existing note. For the three months ended March 31, 2023, $<span id="xdx_907_ecustom--AmortizationOfDiscount_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zzcu9SdAfRk7" title="Amortization of discount">63,750</span> was charged to interest expense. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zIxuG62SdoD8" title="Debt Instrument, face amount"><span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zAMaImOcIkla" title="Debt Instrument, face amount">3,300,000</span></span> with carrying values of $<span id="xdx_90C_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zePwtuj9u7t6" title="Debt Instrument, carrying amount">2,896,250</span> and $<span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zBjpg1zVyVWj" title="Debt Instrument, carrying amount">2,832,500</span>, respectively, net of unamortized discounts of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_z8wxhZafVuI2" title="Debt Instrument, unamortized discount">403,750</span> and $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--DecemberSevenTwoThousandTwentyTwoMember_zb1HIwpeDGme" title="Debt Instrument, unamortized discount">467,500</span> as of March 31, 2023 and December 31, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 17, 2021, the Company entered into a <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zY2MbpXN4Ut1" title="Debt instrument, interest rate, stated percentage">12%</span>, $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zEZXCKGD9Ugj" title="Debt Instrument, Face Amount">11,110,000</span> face value promissory note with a third- party lender with a maturity date of <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210316__20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_z3eqwoT6rtv8" title="Debt Instrument, Maturity Date">March 17, 2022</span>. In exchange for the issuance of the $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zc6OP10gWAwd" title="Debt instrument face amount">11,110,000</span> note, inclusive of an original issue discount of $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zCDzmGGqUq41" title="Original issue discount">1,000,000</span> and lender costs of $<span id="xdx_90D_ecustom--LenderCosts_c20210316__20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zwTm9zCxra85" title="Lender costs">110,000</span> the Company received proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromNotesPayable_c20210322__20210323__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zLwTvA3YW42e" title="Proceeds from notes payable">10,000,000</span> on March 23, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zhqrxrDdQPd6" title="Warrant purchase">250,000,000</span> shares of common stock at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210317__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_z03rpe3hzkZa" title="Warrant per share value">0.13</span> per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. On October 31, 2022, the maturity date of the note was extended to October 31, 2024, and the interest rate was increased to <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221031__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zlyGGVdQuBe2" title="Debt instrument, interest rate, stated percentage">15%</span> per annum. The Company issued <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221031__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zIOyms7SK6Nl" title="Class of warrant or right, number of securities called by warrants or rights">250,000,000</span> warrants at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221031__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_z8wGTkDIuIwj" title="Class of warrant or right, exercise price of warrants or rights">0.0067</span> and with an expiration of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221031__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_z5XlJpQytpo3" title="Warrant expiry date">October 31, 2025</span>, in exchange for the extension. The warrants were valued at $<span id="xdx_90A_ecustom--AmortizationOfInterestExpense_pp0p0_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchSeventeenTwoThousandTwentyTwoMember_zooUtKkLNSx8" title="Interest expense, amortized">1,700,000</span> by the Black-Scholes option pricing method and will be amortized through the new maturity date of the note. The Company determined that this transaction was a modification of the existing note. For the three months ended March 31, 2023, $<span id="xdx_909_ecustom--AmortizationOfDiscount_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--MarchSeventeenTwoThousandTwentyTwoMember_zThU1KWx4dm7" title="Amortization of discount">212,500</span> was charged to interest expense. As of March 31, 2023 and December 31, 2022, the outstanding principal balance of this note was $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zDSyUjx4R57" title="Debt Instrument, Face Amount"><span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_z3qMo6D6JeC6" title="Debt Instrument, Face Amount">11,110,000</span></span> with a carrying value of $<span id="xdx_903_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zaZrJz0aqqn" title="Debt Instrument, carrying amount">9,764,167</span> and $<span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zo2NGS71z2D7" title="Debt Instrument, carrying amount">9,551,667</span>, respectively, net of unamortized discounts of $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_zOxRMHwA6qY9" title="Debt instrument unamortized discount">1,345,833</span> and $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember_z9TNoh0PhP7c" title="Debt instrument unamortized discount">1,558,333</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 9, 2021, the Company entered into a <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zpzbvTmIppQk" title="Debt instrument, interest rate, stated percentage">12%</span>, $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zJ0GHi2yN06e" title="Debt Instrument, Face Amount">2,200,000</span> face value promissory note with a third- party lender with a maturity date of <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20210208__20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zdDdoVPqVlka" title="Debt instrument, maturity date">February 9, 2022</span>. In exchange for the issuance of the $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zHuxDoB6Z4X1" title="Debt instrument face amount">2,200,000</span> note, inclusive of an original issue discount of $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_ziBnEvkgMph" title="Original issue discount">200,000</span> the Company received proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromNotesPayable_c20210215__20210216__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zhQmLxdXyYBd" title="Proceeds from notes payable">2,000,000</span> on February 16, 2021, from the lender. In conjunction with the note, the Company issued a warrant to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zGneM5ZzQzCg" title="Warrant to purchase">50,000,000</span> shares of common stock at $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210209__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_z36Tv6JKXAJ8" title="Warrant per share value">0.15</span> per share (subject to adjustments) with an expiry date on the three- year anniversary of the note. On October 31, 2022, the maturity date of the note was extended to October 31, 2024, and the interest rate was increased to <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221031__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember__srt--TitleOfIndividualAxis__custom--LenderMember_ztAQ9TOX3j5l" title="Debt Instrument, Interest Rate, Stated Percentage">15%</span> per annum. The Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221028__20221031__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember__srt--TitleOfIndividualAxis__custom--LenderMember_zgbYfRP3DYX8" title="Warrant issuance, value">50,000,000</span> warrants at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221031__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteTwoMember__srt--TitleOfIndividualAxis__custom--LenderMember_zpe4OtyhhKz4" title="Class of warrant or right, exercise price of warrants or rights">0.0067</span> and with an expiration of October 31, 2025, in exchange for the extension. The warrants were valued at $<span id="xdx_902_ecustom--AmortizationOfInterestExpense_pp0p0_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--FebruaryNineTwoThousandTwentyTwoMember_zkHUUzIFiDlc" title="Interest expense, amortized">340,000</span> by the Black-Scholes option pricing method and will be amortized through the new maturity date of the note. The Company determined that this transaction was a modification of the existing note. For the three months ended March 31, 2023, $<span id="xdx_904_ecustom--AmortizationOfDiscount_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--LenderMember__us-gaap--AwardTypeAxis__custom--FebruaryNineTwoThousandTwentyTwoMember_zyr73TEQ0Tel" title="Amortization of discount">42,500</span> was charged to interest expense. As of March 31, 2023 and December 31, 2022, the outstanding principal balance of this note was $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zoDseYRQHeo4" title="Debt Instrument, Face Amount"><span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zk42LXqJy55e" title="Debt Instrument, Face Amount">2,200,000</span></span> with a carrying value of $<span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_z6GxczCzwTOk" title="Long-Term Debt, Gross">1,930,833</span> and $<span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zCCaaHU1v3V5" title="Long-term debt, gross">1,888,333</span>, respectively, net of unamortized discounts of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_zKRQwOPQsbf9" title="Debt Instrument, Unamortized Discount">269,167</span> and $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--LenderMember_z8hvMSKYRIT6" title="Debt Instrument, Unamortized Discount">311,667</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 13, 2020, the Company entered into a <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201113__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zt1tfaXgvnCi" title="Debt instrument, interest rate, stated percentage">12%</span>, $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20201113__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zUxG7g94Ba1e" title="Debt Instrument, Face Amount">1,000,000</span> face value promissory note with a third-party due <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20201112__20201113__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zCc4yGF11e1f" title="Debt instrument, maturity date">November 13, 2021</span>. <span id="xdx_901_eus-gaap--DebtInstrumentDescription_c20201112__20201113__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zjSp0dhXsZ8k" title="Debt instrument description">Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date.</span> The Company received proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20201117__20201120__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zi5f7hWotqag" title="Proceeds from Notes Payable">890,000</span> on November 20, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $<span id="xdx_903_eus-gaap--LegalFees_pp0p0_c20201117__20201120__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zsDC4FsBiLw5" title="Legal fees">110,000</span>. In conjunction with this note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230331__srt--TitleOfIndividualAxis__custom--HolderMember_zo2jSMmRePbf" title="Class of warrant or right, number of securities called by warrants or rights">125,000,000</span> shares of common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230331__srt--TitleOfIndividualAxis__custom--HolderMember_zUCjaH41c942" title="Class of warrant or right, exercise price of warrants or rights">0.008</span>, subject to adjustments and expires on the five-year anniversary of the issue date. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $<span id="xdx_902_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_pp0p0_c20230101__20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--HolderMember_zuur7vDUs1p9" title="Adjustments to additional paid in capital warrant issued"><span id="xdx_906_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_pp0p0_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteOneMember__srt--TitleOfIndividualAxis__custom--HolderMember_zFTUQBvkP6h2" title="Adjustments to additional paid in capital warrant issued">1,000,000</span></span>. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of March 31, 2023, and December 31, 2022, the accrued interest is $<span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zY4I2KApsEg2" title="Interest Payable">435,452</span> and $<span id="xdx_907_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zjODWFUeRkB9" title="Interest payable">375,452</span>, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 6, 2020, the Company entered into a Settlement Agreement with the holder of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_pp0p0_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_z1d9sGCuNsjc" title="Notes payable">120,000</span> of convertible notes with accrued and unpaid interest of $<span id="xdx_904_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pp0p0_c20201105__20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zqG42yMUWyyf" title="Debt instrument, increase, accrued interest">8,716</span> and a $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200723__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zIH83FzOrAK2" title="Debt instrument, face amount">210,000 </span>Promissory Noted dated June 23, 2020, with accrued and unpaid interest of $<span id="xdx_90A_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pp0p0_c20200720__20200723__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zWNcSkM6DvZd" title="Debt instrument, increase, accrued interest">15,707</span>. The Company issued a new <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zmcoYUnxXHIk" title="Debt instrument, interest rate, stated percentage">12%</span> Promissory Note with a face value of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zB8TaGBwI7kd" title="Debt instrument, face amount">389,423</span> and a maturity date of <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20201105__20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_z5CXiN3vpeGc" title="Debt instrument, maturity date">November 6, 2023</span>. In conjunction with this settlement, the Company issued a warrant to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zIokD0t6cIO3" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights">60,000,000</span> shares of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20201106__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zruePAquSJH6" title="Warrant exercise price">0.0075</span>, subject to adjustments and expires on the five-year anniversary of the issue date. The Company analyzed the transaction and concluded that this was a modification to the existing debt. The investor exercised the warrant on January 14, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 24, 2020 (the “Issue Date”), the Company entered into a <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zFmax8K73i" title="Debt instrument, interest rate, stated percentage">12%</span>, $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zYBR686i8IE6" title="Debt instrument, face amount">750,000</span> face value promissory note with a third-party (the “Holder”) due August 24, 2021 (the “Maturity Date”). <span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20200823__20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zS37L2mvbFsb" title="Debt instrument, description">Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date.</span> The Company received proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20200822__20200825__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zatiRHZawxy" title="Proceeds from notes payable">663,000</span> on August 25, 2020, and the Company reimbursed the investor for expenses for legal fees and due diligence of $<span id="xdx_907_eus-gaap--LegalFees_pp0p0_c20200822__20200825__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_zuiYjLc464Zg" title="Legal fees">87,000</span>. In conjunction with this Note, the Company issued 2 common stock purchase warrants; each warrant entitles the Holder to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_z4BH4L0oTWN8" title="Number of warrants to purchase">122,950,819</span> shares of common stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200824__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__srt--TitleOfIndividualAxis__custom--HolderMember_z1xPmLZGbrgl" title="Warrant exercise price">0.0061</span>, subject to adjustments and expires on the five-year anniversary of the Issue Date. During the year ended December 31, 2021, the Company paid $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zgM4p4GlgHq" title="Debt instrument face amount">375,000</span> to the Holder. On May 3, 2021, the Company issued <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_c20210503__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zBkQsn3JbBJ7" title="Common stock, shares, issued">75,000,000</span> shares of common stock to the Holder, upon the cashless exercise of a portion of the warrants. As of March 31, 2023, and December 31, 2022, the outstanding principal balance of this note was $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zhPH274BXz06" title="Debt instrument, unamortized discount"><span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z3jKQjizZVTd" title="Debt instrument, unamortized discount">375,000</span></span>. This note is in default and the interest rate from the date of default is the lesser of 24% or the highest amount permitted by law. As of March 31, 2023, and December 31, 2022, the accrued interest is $<span id="xdx_908_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20230331__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z528xDVkDrs" title="Interest Payable">202,747</span> and $<span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zk7VTGNvHase" title="Interest payable">180,247</span>, respectively. The Company is in discussions with the lender regarding the extension of the maturity date of this note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfDebtTableTextBlock_zroODdYIiSJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has the following notes payable outstanding:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B2_z4Ic86aLvZf5" style="display: none">SCHEDULE OF NOTES PAYABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230331_zqHB3jOOipO6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20221231_zIWhWADhg4w7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Note payable, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_z5XIJhnv5MT" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zI1R5WtYO0Tj" title="Debt Instrument, interest rate, stated percentage">8%</span></span>, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zJzpqx6WlNo8" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zQ2vooPrM4w1" title="Debt Instrument, maturity date">January 5, 2020</span></span>, in default</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zofEIuW9KfP9" style="width: 16%; text-align: right" title="Sub- total notes payable">45,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableMember_zor9vJhjv9Bc" style="width: 16%; text-align: right" title="Sub- total notes payable">45,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other, due on demand, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zfGLymDd3OCc" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zow6qLQjqsj6" title="Debt Instrument, interest rate, stated percentage">6%</span></span>, currently in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zZTRfPNWsB4h" style="text-align: right" title="Sub- total notes payable">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_z12mvWQ6Sn34" style="text-align: right" title="Sub- total notes payable">50,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_z3G0ZQW7Yxnd" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zyu3glOkNjVj" title="Debt Instrument, face amount">750,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zVN76vhgp7K8" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_z4tICxMCXWa5" title="Debt Instrument, interest rate, stated percentage">12%</span></span>, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zPEMufV36YOi" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zoX4Z8X7zlCj" title="Debt Instrument, maturity date">August 24, 2021</span></span>, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zczMtwPEoPx8" style="text-align: right" title="Sub- total notes payable">375,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zy29KfNJRdQh" style="text-align: right" title="Sub- total notes payable">375,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zeW7Wo8uOKS9" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zn4gsFhxOhGd" title="Debt Instrument, face amount">389,423</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_z68FWrMeRoB7" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zQYjjbZHOp1l" title="Debt Instrument, interest rate, stated percentage">12%</span></span>, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_z5jPIQRU3eNb" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zTKrpxukFBv6" title="Debt Instrument, maturity date">November 6, 2023</span></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zQNQHw4SVjO3" style="text-align: right" title="Sub- total notes payable">389,423</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zbbLsQ9jKas" style="text-align: right" title="Sub- total notes payable">389,423</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zohG4BUPqvj" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_z3m83qecdmr8" title="Debt Instrument, face amount">1,000,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zvxHSwGyPTJ1" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_z4j9e4rYjkR8" title="Debt Instrument, interest rate, stated percentage">12%</span></span>, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zMNU8LBfRCkf" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zFMmMuzzZq8c" title="Debt Instrument, maturity date">November 13, 2021</span></span>, in default</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zt8d9Rg3dDVi" style="text-align: right" title="Sub- total notes payable">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zcotRveWGi6h" style="text-align: right" title="Sub- total notes payable">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zJAK6nZHIQR6" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zCDz5ERyH7Nl" title="Debt Instrument, face amount">2,200,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zUuvWLWisDJ9" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zxBX2it3zBej" title="Debt Instrument, interest rate, stated percentage">15%</span></span>, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_z1bhGRo9LCC7" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zR0Em34Jq6a9" title="Debt Instrument, maturity date">October 31, 2024</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zvH8b4mokwqk" title="Debt Instrument, unamortized discount">269,167</span> (2023) and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zi83K7EMQtS2" title="Debt Instrument, unamortized discount">311,667</span> (2022)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zvWXealkYCF6" style="text-align: right" title="Sub- total notes payable">1,930,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zRjzoHkmPiDl" style="text-align: right" title="Sub- total notes payable">1,888,333</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z62gB8amW4ig" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zHxkdzzbJny9" title="Debt Instrument, face amount">11,110,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z713WaoBp31g" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z5QTLRVNqn5d" title="Debt Instrument, interest rate, stated percentage">15%</span></span>, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zZ2nzOUc4T74" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zOTUQgyWUVx6" title="Debt Instrument, maturity date">October 31, 2024</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zppCwdwLFEA7" title="Debt Instrument, unamortized discount">1,345,833</span> (2023) and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z90av4m8Try8" title="Debt Instrument, unamortized discount">1,558,333</span> (2022)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zpIUb0a4Xw4g" style="text-align: right" title="Sub- total notes payable">9,764,167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zfsGRi0dqanl" style="text-align: right" title="Sub- total notes payable">9,551,667</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zcBm9F7Qck66" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zxNwrmgzOkbg" title="Debt Instrument, face amount">3,300,000</span></span> face value, interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zo0t9Zm0wBid" title="Debt Instrument, interest rate, stated percentage"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z81RKVLcPMg6" title="Debt Instrument, interest rate, stated percentage">15%</span></span>, matures <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z4UzfFxfTnD2" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z3Owsbx2wPel" title="Debt Instrument, maturity date">October 31, 2024</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zS7h1hkY3Ip6" title="Debt Instrument, unamortized discount">403,750</span> (2023) and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_z66vHEmqK1V1" title="Debt Instrument, unamortized discount">467,500</span> (2022)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zwp8KnL8eQe1" style="text-align: right" title="Sub- total notes payable">2,896,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zM4GPNVBMvgc" style="text-align: right" title="Sub- total notes payable">2,832,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Note payable $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_z3PKFCLffeHa" title="Debt Instrument, face amount"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_z9HhLhqpqyf" title="Debt Instrument, face amount">3,020,000</span></span> face value, matured <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zmepGqwHm9A1" title="Debt Instrument, maturity date"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_znsh8DdibFd5" title="Debt Instrument, maturity date">March 31, 2023</span></span>, net of discount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zeGQNDdbvTCa" title="Debt Instrument, unamortized discount">0</span> (2023) and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zPq44b010o5f" title="Debt Instrument, unamortized discount">181,818</span> (2022), in default</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20230331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zOUgXSwGwp63" style="border-bottom: Black 1.5pt solid; text-align: right" title="Sub- total notes payable">2,220,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zlisPbwMkuv7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Sub- total notes payable">2,588,182</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Sub- total notes payable, net of discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,670,673</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,720,105</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LongTermNotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less long-term portion, net of discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,591,250</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,272,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of notes payable, net of discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,079,423</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,447,605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.08 0.08 2020-01-05 2020-01-05 45000 45000 0.06 0.06 50000 50000 750000 750000 0.12 0.12 2021-08-24 2021-08-24 375000 375000 389423 389423 0.12 0.12 2023-11-06 2023-11-06 389423 389423 1000000 1000000 0.12 0.12 2021-11-13 2021-11-13 1000000 1000000 2200000 2200000 0.15 0.15 2024-10-31 2024-10-31 269167 311667 1930833 1888333 11110000 11110000 0.15 0.15 2024-10-31 2024-10-31 1345833 1558333 9764167 9551667 3300000 3300000 0.15 0.15 2024-10-31 2024-10-31 403750 467500 2896250 2832500 3020000 3020000 2023-03-31 2023-03-31 0 181818 2220000 2588182 18670673 18720105 14591250 14272500 4079423 4447605 3020000 2023-03-31 3020000 250000 260000 2510000 181818 550000 2220000 2770000 2220000 2588182 181818 0.12 3300000 2022-12-07 3300000 300000 3000000 75000000 0.039 0.15 75000000 0.0067 510000 63750 3300000 3300000 2896250 2832500 403750 467500 0.12 11110000 2022-03-17 11110000 1000000 110000 10000000 250000000 0.13 0.15 250000000 0.0067 2025-10-31 1700000 212500 11110000 11110000 9764167 9551667 1345833 1558333 0.12 2200000 2022-02-09 2200000 200000 2000000 50000000 0.15 0.15 50000000 0.0067 340000 42500 2200000 2200000 1930833 1888333 269167 311667 0.12 1000000 2021-11-13 Principal payments shall be made in six instalments of $166,667 commencing 180 days from the issue date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the maturity date. 890000 110000 125000000 0.008 1000000 1000000 435452 375452 120000 8716 210000 15707 0.12 389423 2023-11-06 60000000 0.0075 0.12 750000 Principal payments shall be made in six instalments of $125,000 commencing 180 days from the Issue Date and continuing each 30 days thereafter for 5 months and the final payment of principal and interest due on the Maturity Date. The Holder shall have the right from time to time, and at any time following an event of default, as defined on the agreement, to convert all or any part of the outstanding and unpaid principal, interest and any other amounts due into fully paid and non-assessable shares of common stock of the Company, at the lower of i) the Trading Price (as defined in the agreement) during the previous five trading days prior to the Issuance Date or ii) the volume weighted average price during the five trading days ending on the day preceding the conversion date. 663000 87000 122950819 0.0061 375000 75000000 375000 375000 202747 180247 <p id="xdx_803_ecustom--DeferredLiabilityTextBlock_z9REKWjcTLD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_822_zzCU5YKZ5r9b">DEFERRED LIABILITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 2, 2020, PCTI entered into an agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $<span id="xdx_907_ecustom--DeferredLiabilityCurrent_iI_c20200902__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zcEUtovAVkei" title="Deferred liability current">750,000</span>, PCTI agreed to pay the third-party a perpetual three percent (<span id="xdx_902_eus-gaap--ProductLiabilityContingencyThirdPartyRecoveryPercentage_pid_dp_uPure_c20200830__20200902__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zRHy2plk9zQ8" title="Product liability contingency, third-Party recovery, percentage">3%</span>) payment of revenues, as defined in the agreement. Payments are due ninety (90) days after each calendar quarter, with the first payment due on or before March 31, 2021, for revenues for the quarter ending December 31, 2020. On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the note was amended, whereby in exchange for <span id="xdx_905_eus-gaap--DeferredCompensationArrangementWithIndividualSharesIssued_pid_c20210225__20210226__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zOQBYWvmwP51" title="Exchange of common stock">175,000,000</span> shares of common stock, the royalty percentage was amended to <span id="xdx_90F_ecustom--RoyaltyPercentage_pid_dp_uPure_c20210225__20210226__dei--LegalEntityAxis__custom--PCTIMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_z2IbVF0Pffbc" title="Royalty percentage">1.8%</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No payments have been made and the Company is in default of the agreement. On November 11, 2022, the third-party and the Company agreed to reduce the liability by $<span id="xdx_907_eus-gaap--IncreaseDecreaseInDeferredLiabilities_c20221110__20221111_zN2ar9ZLJqck" title="Reduce deferred liability">260,000</span> and add $<span id="xdx_906_eus-gaap--IncreaseDecreaseInDeferredLiabilities_c20221110__20221111__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zYS5TMrrqj0a" title="Reduce deferred liability">260,000</span> to the promissory note issued on November 11, 2022. The deferred liability as of March 31, 2023, and December 31, 2022, on the consolidated balance sheet is $<span id="xdx_90F_ecustom--DeferredLiabilityCurrent_iI_c20230331_z6rNsdmGIy6j" title="Deferred liability"><span id="xdx_90D_ecustom--DeferredLiabilityCurrent_iI_c20221231_zPmdcPVBoMD3" title="Deferred liability">490,000</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 750000 0.03 175000000 0.018 260000 260000 490000 490000 <p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zf40q4eZhJRd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_824_zLeiVYHBfGWe">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 10, 2020, pursuant to the PCTI transaction, the Company assumed an employment contract entered into on February 28, 2020, between the Company and Mr. Conway (the “Employment Agreement”). Mr. Conway’s compensation as adjusted was $<span id="xdx_90E_eus-gaap--OfficersCompensation_pp0p0_c20200701__20200710__us-gaap--AwardDateAxis__custom--PerMonthMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zh1QtHvv73C1" title="Compensation value">20,000</span> per month, and effective September 1, 2021, Mr. Conway received $<span id="xdx_905_ecustom--OfficersCompensationReceived_pp0p0_c20200701__20200710__us-gaap--AwardDateAxis__custom--PerMonthMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zZQPdVpPWcNl" title="Officers compensation received">10,000</span> per month from Ozop Capital. Effective January 1, 2022, the Company entered into a new employment agreement with Mr. Conway. Pursuant to the agreement, Mr. Conway received a $<span id="xdx_90F_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0p0_c20211229__20220102__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zWz8PtcHWbOg" title="Amount of initial annual compensation">250,000</span> contract renewal bonus and will receive annual compensation of $<span id="xdx_906_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0p0_c20211229__20220102__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zdvVA81cgBt8" title="Amount of initial annual compensation">240,000</span> from the Company and will also be eligible to receive bonuses and equity grants at the discretion of the BOD. The Company also agreed to compensate Mr. Conway for services provided directly to any of the Company’s subsidiaries. Ozop Capital increased Mr. Conway’s compensation to $<span id="xdx_901_eus-gaap--OfficersCompensation_pp0p0_c20220101__20220131__us-gaap--AwardDateAxis__custom--PerMonthMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zOHVVjxBL5l2" title="Compensation value">20,000</span> per month in January 2022, OES began compensating Mr. Conway $<span id="xdx_902_ecustom--OfficersCompensationReceived_pp0p0_c20220301__20220331__us-gaap--AwardDateAxis__custom--PerMonthMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zipMOGL8lL77" title="Officers compensation received">20,000</span> in March 2022, and OED began compensation Mr. Conway $<span id="xdx_901_ecustom--OfficersCompensationReceived_pp0p0_c20220401__20220430__us-gaap--AwardDateAxis__custom--PerMonthMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrConwayMember_zTDKgDRmGwr" title="Officers compensation received">20,000</span> per month beginning in April 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management Fees and related party payables</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_ztOfa0N6Mq1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2023 and 2022, the Company recorded expenses to its officers in the following amounts:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BF_zaPQI7kuCjr6" style="display: none">SCHEDULE OF EXPENSES TO OFFICERS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230101__20230331_zOnGxYQ48yLj" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20220331_zkcmRPOCa9ma" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zBH3AlqU0j2l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">CEO</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">240,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">140,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerBonusMember_z37MBuk3ksbg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">CEO bonus</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1308">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SalariesWagesAndOfficersCompensation_z2GmdwFOHicl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">240,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">390,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zd1ha7RFOr8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 20000 10000 250000 240000 20000 20000 20000 <p id="xdx_894_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_ztOfa0N6Mq1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended March 31, 2023 and 2022, the Company recorded expenses to its officers in the following amounts:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BF_zaPQI7kuCjr6" style="display: none">SCHEDULE OF EXPENSES TO OFFICERS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230101__20230331_zOnGxYQ48yLj" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20220331_zkcmRPOCa9ma" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zBH3AlqU0j2l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">CEO</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">240,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">140,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--SalariesWagesAndOfficersCompensation_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChiefExecutiveOfficerBonusMember_z37MBuk3ksbg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">CEO bonus</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1308">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SalariesWagesAndOfficersCompensation_z2GmdwFOHicl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">240,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">390,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 240000 140000 250000 240000 390000 <p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zHFv7Ep1lQT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 – <span id="xdx_82F_z3v0hEeMpn48">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Agreements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 1, 2021, Ozop Capital entered into an advisory agreement (the “RMA Agreement”) with Risk Management Advisors, Inc. (“RMA”). Pursuant to the terms of the RMA Agreement, RMA will assist Ozop Capital in analyzing, structuring, and coordinating Ozop Capital’s participation in a captive insurance company. RMA will coordinate legal, accounting, tax, actuarial and other services necessary to implement the Company’s participation in a captive insurance company, including, but not limited to, the preparation of an actuarial feasibility study, filing of all required regulatory applications, domicile selection, structural selection, and coordination of the preparation of legal documentation. In connection with the services listed above, Ozop Capital agreed to pay $<span id="xdx_908_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20210828__20210902__us-gaap--TypeOfArrangementAxis__custom--RMAAgreementMember_zgdOmtasVjqk" title="Payments of stock issuance costs">50,000</span> and to issue $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pp0p0_c20210828__20210902__us-gaap--TypeOfArrangementAxis__custom--RMAAgreementMember_zjeqMUASDn12" title="Number of restricted stock issued, value">50,000</span> of shares of restricted common stock. One-half of the cash and stock were due upon the signing of the RMA Agreement. Accordingly, RMA received $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20210903__20210930__us-gaap--TypeOfArrangementAxis__custom--RMAAgreementMember_z89qHztfk3P7" title="Payments of stock issuance costs">25,000</span> and <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210903__20210930__us-gaap--TypeOfArrangementAxis__custom--RMAAgreementMember_zyILQiM1vuY4" title="Number of restricted stock issued, shares">452,080</span> shares of restricted common stock of the Company in September 2021. The balance of the cash and stock became due on October 29, 2021, upon the issuance of the captive insurance company’s certificate of authority from the state of Delaware. The Company has paid the $<span id="xdx_90E_eus-gaap--PaymentsForParticipationLiabilities_pp0p0_c20230101__20230331_z7pbQfdiD0gg" title="Cash payments">25,000</span> balance and recorded <span id="xdx_90F_eus-gaap--SharesIssued_iI_pid_c20230331_zL9nC6f0wx75" title="Issuance of common stock">637,755</span> shares of common stock to be issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2021, the Company agreed to engage PJN Strategies, LLC (“PJN”) as a consultant. Pursuant to the agreement, the Company agreed to compensate PJN $<span id="xdx_90D_ecustom--ConsultingExpense_pp0p0_c20210412__20210413__srt--TitleOfIndividualAxis__custom--PJNStrategiesMember_zRWh71RtBXsh" title="Consulting expense">20,000</span> per month. Effective September 1, 2021, a new agreement was entered into between PJN and Ozop Capital. Pursuant to the terms of the one- year agreement Ozop Capital agreed to compensate PJN $<span id="xdx_90D_ecustom--ConsultingExpense_pp0p0_c20210830__20210901__srt--TitleOfIndividualAxis__custom--PJNStrategiesMember_z6nZgGH1Tkwa" title="Consulting expense">84,000</span> per month. For the three months ended March 31, 2023, and 2022, the Company recorded $-<span id="xdx_904_ecustom--ConsultingExpense_pp0p0_c20230101__20230331__srt--TitleOfIndividualAxis__custom--PJNStrategiesMember_zBQtRkpsGz11" title="Consulting expense">0</span>- and $<span id="xdx_907_ecustom--ConsultingExpense_pp0p0_c20220101__20220331__srt--TitleOfIndividualAxis__custom--PJNStrategiesMember_zzEAdwWXsVj3" title="Consulting expense">252,000</span>, respectively, of consulting expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 30, 2021, OES hired 2 individuals as Co-Directors of Sales. Pursuant to their respective offers of employment, the Company agreed to an annual salary of $<span id="xdx_905_eus-gaap--OfficersCompensation_pp0p0_c20210329__20210330__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember_ztnhRBEH7gWj">130,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a signing bonus of $<span id="xdx_902_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_c20210330__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember_zowAeZgKc3hf">20,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for each and to issue each <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210329__20210330__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMdGXj7DyBxc">2,500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of restricted common stock upon the execution of the agreements and every 90 days thereafter for the first year as long as the employee is still employed. The Company valued the initial shares at $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210330__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEhR5B7g1HXj">0.092 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (the market price of the common stock on the date of the agreement). On July 1, 2021, the Company issued each of the Co-Directors the <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210629__20210702__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember_zUhG3OKE8Z6j">2,500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares due after the first ninety days of employment. The shares were valued at $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20210701__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember_zk54BK9KBV21" title="Share price">0.0745</span> per share (the market price of the common stock on the date of the issuance). On October 1, 2021, the Company issued each of the Co-Directors the <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210928__20211001__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember_zmu0FKZM50uj">2,500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares due after the first one hundred eighty days of employment. The shares were valued at $<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20211001__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember_z7FifyNyRzj9" title="Share price">0.0445</span> per share (the market price of the common stock on the date of the issuance). On January 14, 2022, the Company issued each of the Co-Directors their final <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220114__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember_zKaFbLvkwwZ1">2,500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares due. The shares were valued at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230331__srt--TitleOfIndividualAxis__custom--CoDirectorsOfSalesMember_zR7inIt8CTU8">0.027 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (the market price of the common stock on the date of the issuance), and $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230331_zAV5dR10kPe6">135,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is included in stock-based compensation expense for the three months ended March 31, 2022. One of the individuals resigned on January 24, 2022, and the other was terminated for cause on November 3, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 15, 2021, the Company entered into a consulting agreement with Aurora Enterprises (“Aurora”). Mr. Steven Martello is a principal of Aurora. Pursuant to the agreement Mr. Martello will provide strategic analysis regarding existing markets and revenue streams as well as the development of new lines of revenue. The Company agreed to a monthly retainer fee of $<span id="xdx_904_eus-gaap--LegalFees_pp0p0_c20210314__20210315__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_z5nX635bu9tc" title="Legal fees">10,000</span> and to issue to Aurora or their designee <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210314__20210315__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_zMjHSp2zlxcc" title="Number of restricted shares issued">5,000,000</span> shares of restricted common stock. For the three months ended March 31, 2023, and 2022, the Company has recorded consulting expenses of $-<span id="xdx_906_ecustom--ConsultingExpense_pp0p0_c20230101__20230331__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_zNM3H6mVI1Ie" title="Consulting expense">0</span>- and $<span id="xdx_904_ecustom--ConsultingExpense_pp0p0_c20220101__20220331__srt--TitleOfIndividualAxis__custom--MrStevenMartelloMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AuroraEnterprisesMember_zNgoaaCLFBua" title="Consulting expense">30,000</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 6, 2021, the Company entered into a consulting agreement with Ezra Green to begin on February 8, 2021. The Company agreed to issue <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20210105__20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zdYIPDogWmUj" title="Number of restricted shares issued">10,000,000</span> shares of restricted common stock to Mr. Green and to a monthly fee of $<span id="xdx_90E_eus-gaap--ProfessionalFees_pp0p0_c20210105__20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zS6nca6Xmfc1" title="Professional fees">2,500</span>. The Company valued the shares at $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEGj5k8uIGg" title="Shares issued, price per share">0.0076</span> per share (the market price of the common stock on the date of the agreement), and $<span id="xdx_90F_eus-gaap--DeferredCompensationEquity_iI_pp0p0_c20210106__srt--TitleOfIndividualAxis__custom--MrAllenSosisMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zouXOazBQor6" title="Deferred compensation equity">76,000</span> was recorded as deferred stock-based compensation, to be amortized over the one-year term of the agreement. Effective April 1, 2021, the agreement was amended to $<span id="xdx_90D_eus-gaap--OtherLiabilities_iI_pp0p0_c20210106__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_zyAwPcfDj7Z8" title="Due to officers or stockholders">10,000</span> per month. Effective June 30, 2022, Mr. Green was no longer providing consulting services to the Company. For the three months ended March 31, 2023, and 2022, the Company recorded consulting expenses of $-<span id="xdx_90A_ecustom--ConsultingExpense_pp0p0_c20230101__20230331__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztxi1ovW8gh4" title="Consulting expense">0</span>- and $<span id="xdx_906_ecustom--ConsultingExpense_pp0p0_c20220101__20220331__srt--TitleOfIndividualAxis__custom--EzraGreenMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOmRCa357MH6" title="Consulting expense">30,000</span> of consulting expenses respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 4, 2019, the Company entered into a Separation Agreement (the “Separation Agreement”) with Salman J. Chaudhry, pursuant to which the Company agreed to pay Mr. Chaudry $<span id="xdx_909_eus-gaap--OtherLiabilitiesCurrent_iI_pp0p0_c20190304__srt--TitleOfIndividualAxis__custom--SalmanJChaudhryMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_zT9PEOPfsNYe" title="Due to officers or stockholders, current">227,200</span> (the “Outstanding Fees”) in certain increments as set forth in the Separation Agreement. As of March 31, 2023, and December 31, 2022, the balance owed Mr. Chaudhry is $<span id="xdx_90A_eus-gaap--OtherLiabilitiesCurrent_iI_pp0p0_c20230331__srt--TitleOfIndividualAxis__custom--SalmanJChaudhryMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_zXIFP6F1AlUb" title="Due to officers or stockholders, current"><span id="xdx_907_eus-gaap--OtherLiabilitiesCurrent_iI_pp0p0_c20221231__srt--TitleOfIndividualAxis__custom--SalmanJChaudhryMember__us-gaap--TypeOfArrangementAxis__custom--SeparationAgreementMember__us-gaap--RelatedAndNonrelatedPartyStatusAxis__us-gaap--RelatedPartyMember_zxmGAIXxhUF3" title="Due to officers or stockholders, current">162,085</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 2, 2020, PCTI entered into an Agreement with a third- party. Pursuant to the terms of the agreement, in exchange for $<span id="xdx_904_eus-gaap--ProfessionalFees_pp0p0_c20200901__20200902__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_z2tjMfbAOfjb" title="Professional fees">750,000</span>, <span id="xdx_901_eus-gaap--CollaborativeArrangementRightsAndObligations_c20200901__20200902__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zzSsw6YvFqYa" title="Collaborative arrangement, rights and obligations">PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement.</span> On February 26, 2021, the agreement was assigned to Ozop and on March 4, 2021, the agreement was amended, whereby in exchange for <span id="xdx_904_eus-gaap--DeferredCompensationArrangementWithIndividualSharesIssued_pid_c20210225__20210226__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zIPMzQUjssK5" title="Number of common stock exchanged">175,000,000</span> shares of common stock, the royalty percentage was amended to <span id="xdx_90F_ecustom--RoyaltyPercentage_pid_dp_uPure_c20210225__20210226__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__dei--LegalEntityAxis__custom--PCTIMember_zeFlHt04c3Gi" title="Royalty percentage">1.8%</span> (see Note 8). As of March 31, 2023, and December 31, 2022, the Company has recorded $<span id="xdx_909_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20230331_zpqVNVqID3Yg" title="Accounts payable and accrued expenses"><span id="xdx_90E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20221231_zNiZLKHWdqSj" title="Accounts payable and accrued expenses">243,272</span></span>, respectively, and is included in accounts payable and accrued expenses on the consolidated balance sheet presented herein.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal matters</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We know of no material, existing or pending legal proceedings against our Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are involved as a plaintiff in a Complaint filed in the <b>SUPERIOR COURT OF THE STATE OF CALIFORNIA FOR THE COUNTY OF SAN DIEGO NORTH COUNTY (the “Complaint”) </b>on November 14, 2022<b>.</b> The Complaint alleges that former employees would place an order from a customer for purchase of product from OZOP with funds the exact source of which is presently unknown. OZOP alleges that next, the customer would sell that product to OZOP’s customers at a price marked up from the price for which the customer purchased from OZOP – to the benefit of Defendants and to the detriment of OZOP, their employer at the time. The Complaint further alleges that the former employees falsely represented that the price the customer was obtaining from other suppliers and therefore was willing to pay for OZOP product decreased, which allowed them to use the customer to then sell additional product to OZOP’s customers at increasingly larger margins, thus further wrongfully enriching themselves to the detriment of their employer, OZOP. The lawsuit also alleges that the employees were also making false statements to Ozop’s customers regarding the financial condition of Ozop and the lack of module inventory.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 50000 50000 25000 452080 25000 637755 20000 84000 0 252000 130000 20000 2500000 0.092 2500000 0.0745 2500000 0.0445 2500000 0.027 135000 10000 5000000 0 30000 10000000 2500 0.0076 76000 10000 0 30000 227200 162085 162085 750000 PCTI agreed to pay the third-party a perpetual three percent (3%) payment of revenues, as defined in the agreement. 175000000 0.018 243272 243272 <p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ztvxbjsFuZ77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11– <span id="xdx_82A_zK6IjIYtiW04">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2023, the Company issued <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pid_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQIxgyK04fA3" title="Common stock, shares issued">107,756,783</span> shares of common stock and received net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPjGV3u6Rfrc" title="Issuance of common stock">526,393</span> after issuance costs of $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWYYjmnMTbS" title="Stock issuance cost">19,110</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2022, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zttvUBouZQde" title="Number of shares issued shares">5,000,000</span> shares of restricted common stock in the aggregate for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023, the Company has <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20230331_zoOljVtnPQj5" title="Common stock shares authorized">4,990,000,000</span> shares of $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230331_znrlOVzh4Eml" title="Common stock par value">0.001</span> par value common stock authorized and there are <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20230331_zkxZaZ8j5js5" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230331_zk4ATrcB1dIi" title="Common stock shares outstanding">4,879,032,132</span></span> shares of common stock issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2023, <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230331_znXBxQm4QPeb" title="Preferred stock, shares authorized">10,000,000</span> shares have been authorized as preferred stock, par value $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230331_zJZcdwbaGaT1" title="Preferred stock, par value">0.001</span> (the “Preferred Stock”), which such Preferred Stock shall be issuable in such series, and with such designations, rights and preferences as the Board of Directors may determine from time to time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series C Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2020, the Company filed an Amended and Restated Certificate of Designation with the State of Nevada of the Company’s Series C Preferred Stock. Under the terms of the Amendment to Certificate of Designation of Series C Preferred Stock, <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20200707__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificatesOfDesignationMember_zWzMOMrJslO4" title="Preferred stock, shares authorized">50,000</span> shares of the Company’s preferred remain designated as Series C Preferred Stock. <span id="xdx_902_eus-gaap--PreferredStockVotingRights_c20200706__20200707__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificatesOfDesignationMember_zjMQXEGUio57" title="Preferred stock, voting rights">The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote.</span> As of March 31, 2023, and December 31, 2022, there were <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z58WjwHMYmA5" title="Preferred stock shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zpcB6CwbtrD4" title="Preferred stock shares outstanding"><span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zvvcaLSfRUD6" title="Preferred stock shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zr278y9VMDU" title="Preferred stock shares outstanding">2,500</span></span></span></span> shares of Series C Preferred Stock issued and outstanding and the shares are held by Mr. Conway.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series D Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series D Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 27, 2021, the Company filed with the Secretary of State of the State of Nevada an Amended and Restated Certificate of Designation of Series D Preferred Stock (the “Series D Amendment”). Under the terms of the Series D Amendment, <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210727__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesDAmendmentMember_zqrBI162sLH8" title="Preferred stock, shares authorized">4,570</span> shares of the Company’s preferred stock will be designated as Series D Convertible Preferred Stock. The holders of the Series D Convertible Preferred Stock shall not be entitled to receive dividends. Any holder may, at any time convert any number of shares of Series D Convertible Preferred Stock held by such holder into a number of fully paid and nonassessable shares of common stock determined by multiplying the number of issued and outstanding shares of common stock of the Company on the date of conversion, by <span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20210727__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesDAmendmentMember_ziDt24BkDrzb" title="Preferred stock, convertible, conversion price">1.5</span> and dividing that number by the number of authorized shares of Series D Convertible Preferred Stock and multiply that result by the number of shares of Series D Convertible Preferred Stock being converted. Except as provided in the Series D Amendment or as otherwise required by law, no holder of the Series D Convertible Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Company for their vote, waiver, release or other action. The Series D Convertible Preferred Stock shall not bear any liquidation rights. On July 28, 2021, the Company closed on a Stock and Warrant Purchase Agreement (the “Series D SPA”). Pursuant to the terms of Series D SPA, an investor in exchange for $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pp0p0_c20210628__20210728__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesDSPAMember_ztRFPHPCC9Jg" title="Proceeds from issuance of preferred stock and preference stock">13,200,000</span> purchased one share of Series D Preferred Stock, and a warrant to acquire <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210728__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesDSPAMember_z5TlBlIHJzO7" title="Purchase of warrants">3,236</span> shares of Series D Preferred Stock. As of March 31, 2023, and December 31, 2022, there were <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zEnJwZjDdzvc" title="Preferred stock shares issued"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z6KXwaBhtMgc" title="Preferred stock shares outstanding"><span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zlbuKyyyOob3" title="Preferred stock shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zn0lvO7r0Ski" title="Preferred stock shares outstanding">1,334</span></span></span></span> shares, respectively, of Series D Preferred Stock issued and outstanding and a warrant to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zCmO34NSCdyk" title="Purchase of warrants"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zYEyHlX4Uqmh" title="Purchase of warrants">3,236</span></span> shares of Series D Preferred Stock are outstanding as of March 31, 2023, and December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrant has a 15- year term and Partial Warrant Lock Up and Leak-Out Period. The Holder may only exercise the Warrant and purchase Warrant Shares as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zywEWq34hPYe" title="Warrant exercise">162</span> (one hundred and sixty-two) Warrant Shares, at any time or times on or after five (5) business days from the closing of the Series D SPA (“the Initial Exercise Date”) subject to up to a maximum number of Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company and no later than on or before the 15<sup>th</sup> year anniversary of the Initial Exercise Date (“the Termination Date”); and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Remainder of the Warrant representing up to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20230331__us-gaap--AwardTypeAxis__custom--RemainingWarrantSharesMember_zkdlkkWFkQp" title="Warrant exercise">3,074</span> (three thousand and seventy-four) Warrant Shares (“Remaining Warrant Shares”) shall be locked up for a period of 36 (thirty-six) months from the Initial Exercise Date (“Lock Up Period”) and shall become exercisable at any time or times from the date that is the 36 (thirty-six) month anniversary of the Initial Exercise Date (“Lock Up Period Termination Date”) and no later than on or before the Termination Date, as follows:</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5SBwpjCE0rk" title="Warrant exercise, description">During every 1 (one) year period, starting on the day that is the Lock Up Period Termination Date, the Holder shall have the right to exercise the Remainder of the Warrant up to a maximum number of Remaining Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company during such given year (“Leak-Out Period”). The Leak-Out Period shall come into effect on the day that is the Lock Up Period Termination Date and remain effective on a yearly basis, for a period of 10 (ten) years thereafter, after which the Leak-Out Period will automatically terminate and become null and void. For clarity purposes the Remainder of the Warrant shall become freely exercisable at any time or times beginning on June 29, 2034, and until the Termination Date.</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series E Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2020, the Company filed a Certificate of Designation with the State of Nevada of the Company’s Series E Preferred Stock. Under the terms of the Certificate of Designation of Series E Preferred Stock, <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20200707__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificatesOfDesignationMember_zlTwOpW9Y36f" title="Preferred stock, shares authorized">3,000</span> shares of the Company’s preferred stock have been designated as Series E Preferred Stock. The holders of the Series E Convertible Preferred Stock shall not be entitled to receive dividends. No holder of the Series E Preferred Stock shall be entitled to vote on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, except as may be otherwise expressly required by law. At any time, the Corporation may redeem for cash out of funds legally available therefor, any or all of the outstanding Preferred Stock (“Optional Redemption”) at $<span id="xdx_90B_eus-gaap--PreferredStockRedemptionAmount_iI_pp0p0_c20200707__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--CertificatesOfDesignationMember_z6e2lyvOAnK6" title="Preferred stock, redemption amount">1,000</span> (one thousand dollars) per share. The shares of Series E Preferred Stock have not been registered under the Securities Act of 1933 or the laws of any state of the United States and may not be transferred without such registration or an exemption from registration. As of March 31, 2023, and December 31, 2022, there were -<span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pid_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zeUkSLjusRw7" title="Preferred stock shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zN103oBdWjOh" title="Preferred stock shares outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z1bEsUCGh12k" title="Preferred stock shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zBtDljV9q8lb" title="Preferred stock shares outstanding">0</span></span></span></span>- shares of Series E Preferred Stock issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 107756783 526393 19110 5000000 4990000000 0.001 4879032132 4879032132 10000000 0.001 50000 The holders of Series C Preferred Stock have no conversion rights and no dividend rights. For so long as any shares of the Series C Preferred Stock remain issued and outstanding, the Holder thereof, voting separately as a class, shall have the right to vote on all shareholder matters equal to sixty-seven (67%) percent of the total vote. 2500 2500 2500 2500 4570 1.5 13200000 3236 1334 1334 1334 1334 3236 3236 162 3074 During every 1 (one) year period, starting on the day that is the Lock Up Period Termination Date, the Holder shall have the right to exercise the Remainder of the Warrant up to a maximum number of Remaining Warrant Shares that, if converted, would be equal to no more than a maximum of 4.99% of the total number of outstanding shares of Common Stock of the Company during such given year (“Leak-Out Period”). The Leak-Out Period shall come into effect on the day that is the Lock Up Period Termination Date and remain effective on a yearly basis, for a period of 10 (ten) years thereafter, after which the Leak-Out Period will automatically terminate and become null and void. For clarity purposes the Remainder of the Warrant shall become freely exercisable at any time or times beginning on June 29, 2034, and until the Termination Date. 3000 1000 0 0 0 0 <p id="xdx_80C_eus-gaap--OtherComprehensiveIncomeNoncontrollingInterestTextBlock_zPF1KzB5zPQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12 – <span id="xdx_82D_z5z36SO9vcN9">NONCONTROLLING INTEREST</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 19, 2021, the Company formed Ozop Capital. The Company initially owned <span id="xdx_902_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20210819__srt--OwnershipAxis__custom--BrianConwayMember_zFFcl8aZi0Ha" title="Noncontrolling interest percentage">51%</span> with PJN Holdings, LLC (“PJN”) owning <span id="xdx_908_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20210819__srt--OwnershipAxis__custom--PJNStrategiesMember_z9zrIEAQaOAl" title="Noncontrolling interest percentage">49%</span>. Brian Conway was appointed as the sole officer and director of Ozop Capital and has voting control of Ozop Capital. The Company presents interest held by noncontrolling interest holders within noncontrolling interest in the consolidated financial statements. On September 13, 2022, there was a change in the ownership percentages, as PJN returned <span id="xdx_90E_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_pid_c20220912__20220913__srt--OwnershipAxis__custom--PJNStrategiesMember_zQZkmVcFzR9g" title="Number of share returned">490,000</span> shares, representing their <span id="xdx_90E_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20220913__srt--OwnershipAxis__custom--PJNStrategiesMember_zuSXaYUEofU4" title="Noncontrolling interest percentage">49%</span> ownership. As of that date, Ozop Capital is a wholly owned subsidiary of the Company. As of March 31, 2023, and December 31, 2022, the accumulative noncontrolling interest is $<span id="xdx_90C_ecustom--AccumulativeNoncontrollingInterest_iI_c20230331_z2rWZUexk4sk" title="Accumulative noncontrolling interest"><span id="xdx_90F_ecustom--AccumulativeNoncontrollingInterest_iI_c20221231_z7qxDatEQbVf" title="Accumulative noncontrolling interest">784,777</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.51 0.49 490000 0.49 784777 784777 <p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zQLHCp4ijWvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13 - <span id="xdx_82F_zh6gqCT8ZIyf">OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 14, 2021, the Company entered into a <span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtYxL_c20210414_zDy7ws8A6XTh" title="Operating lease term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1477">five</span></span>-year lease which began on June 1, 2021, for approximately <span id="xdx_900_eus-gaap--AreaOfLand_iI_usqft_c20210414_zfRg2VqXMsGj" title="Area of land">8,100</span> square feet of office and warehouse space in Carlsbad, California, expiring <span id="xdx_907_eus-gaap--LeaseExpirationDate1_dd_c20210411__20210414__srt--StatementGeographicalAxis__stpr--CA_zG2EiHV86ZCa" title="Lease expiration date">May 31, 2026</span>. Initial lease payments of $<span id="xdx_90F_eus-gaap--OperatingLeasePayments_pp0p0_c20210411__20210414__srt--StatementGeographicalAxis__stpr--CA_zxserslnUdD6" title="Operating lease payments">13,481</span> begin on June 1, 2021, and increase by approximately <span id="xdx_90E_ecustom--OperatingLeasePayementsIncreasePercentage_iI_pid_dp_uPure_c20210414__us-gaap--AwardTypeAxis__custom--ThereafterMember_zDgiJkMxqlq" title="Lease payments increase percentage">2.4%</span> annually thereafter. The interest rate used to determine the present value is our incremental borrowing rate, estimated to be <span id="xdx_902_ecustom--OperatingLeasePayementsIncreasePercentage_iI_pid_dp_uPure_c20210414__srt--StatementGeographicalAxis__stpr--CA_zzA0ZHMAEeZ8" title="Lease payments increase percentage">7.5%</span>, as the interest rate implicit in most of our leases is not readily determinable. During the year ended December 31, 2021, upon adoption of ASC Topic 842, the Company recorded right-of-use assets and lease liabilities of $<span id="xdx_90E_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20211231__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member_zNK4ZV1N9vq6" title="Operating lease liability">702,888</span> for this lease. On February 22, 2023, with an effective date of March 1, 2023, the Company entered into a Sublease for a Single Subleasee Agreement (the “Sublease”) with the landlord and a third party for the office and warehouse in Carlsbad California. Pursuant to the Sublease agreement, the third party will be responsible for all of the Company’s lease obligations through May 31, 2026, the lease termination date. The Company and the subleasee have agreed to work together regarding any existing Company inventory in the facility.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In adopting Topic 842, the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfRightofUseAssetsTableTextBlock_zoBC8MWpCS56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of- use assets are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zSrXoZUOMn47" style="display: none">SCHEDULE OF RIGHT-OF-USE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230331_znkRWDW7DNh9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zj63to9rUNp" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_ecustom--OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_pp0p0_maOLROUzSPd_zS7cDBQBzBnf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Office and warehouse lease</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">702,888</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">702,888</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iNI_pp0p0_di_msOLROUzSPd_zfXCNhfTQKb2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(228,071</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(195,182</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_pp0p0_mtOLROUzSPd_zootJ574FwY6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">474,817</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">507,706</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zLVwZOZF64ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_ecustom--ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_zL53NeumyLs" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease liabilities are summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zx7Ypvn4pkx7" style="display: none">SCHEDULE OF OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230331_zOi1QLasRdz9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zkQkts79YFMd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iI_pp0p0_z8WSkTAx3CNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Lease liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">486,008</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">517,890</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zDYHqQjtWodb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(137,011</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(133,508</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zKPD7uemMPMj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Long term portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">348,997</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">384,382</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zgmCB8wgHdt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zyD2n7wV1uB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity of lease liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zLcgc6CfIfpd" style="display: none">SCHEDULE OF MATURITY OF LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230331_z3e6hN7SLI86" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzvSK_zYs49tzE0yQh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: justify">For the year ending December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">126,464</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzvSK_zicP3A6lXHx8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">For the year ending December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,840</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzvSK_zdO8Zg7OX6oe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">For the year ending December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,942</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzvSK_z3weWmwgmXud" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">For the year ending December 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,030</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzvSK_zzjMpft8FKN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">548,276</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zJdpCrbncf9l" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62,268</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">486,008</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zkmnx5x3okv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 8100 2026-05-31 13481 0.024 0.075 702888 <p id="xdx_89B_ecustom--ScheduleOfRightofUseAssetsTableTextBlock_zoBC8MWpCS56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of- use assets are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zSrXoZUOMn47" style="display: none">SCHEDULE OF RIGHT-OF-USE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230331_znkRWDW7DNh9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zj63to9rUNp" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_ecustom--OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_pp0p0_maOLROUzSPd_zS7cDBQBzBnf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Office and warehouse lease</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">702,888</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">702,888</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iNI_pp0p0_di_msOLROUzSPd_zfXCNhfTQKb2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(228,071</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(195,182</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_iTI_pp0p0_mtOLROUzSPd_zootJ574FwY6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">474,817</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">507,706</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 702888 702888 228071 195182 474817 507706 <p id="xdx_892_ecustom--ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_zL53NeumyLs" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease liabilities are summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zx7Ypvn4pkx7" style="display: none">SCHEDULE OF OPERATING LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230331_zOi1QLasRdz9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zkQkts79YFMd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iI_pp0p0_z8WSkTAx3CNa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Lease liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">486,008</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">517,890</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_zDYHqQjtWodb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(137,011</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(133,508</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zKPD7uemMPMj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Long term portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">348,997</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">384,382</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 486008 517890 137011 133508 348997 384382 <p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zyD2n7wV1uB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity of lease liabilities are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zLcgc6CfIfpd" style="display: none">SCHEDULE OF MATURITY OF LEASE LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230331_z3e6hN7SLI86" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzvSK_zYs49tzE0yQh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: justify">For the year ending December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">126,464</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzvSK_zicP3A6lXHx8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">For the year ending December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,840</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzvSK_zdO8Zg7OX6oe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">For the year ending December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,942</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzvSK_z3weWmwgmXud" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">For the year ending December 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">74,030</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzvSK_zzjMpft8FKN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">548,276</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zJdpCrbncf9l" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62,268</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">486,008</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 126464 171840 175942 74030 548276 62268 486008 <p id="xdx_80E_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zTkS7saaB5I8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14 – <span id="xdx_829_zeSqnvQyO1x6">DISCONTINUED OPERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 1, 2022, the BOD of the Company authorized the filing of a Chapter 7 proceeding which meets the definition of a discontinued operation. Accordingly, the operating results of PCTI are reported as income (loss) from discontinued operations in the accompanying consolidated financial statements for the three months ended March 31, 2023, and 2022. On October 3, 2022, PCTI filed a Voluntary Petition for Non- Individuals Filing for Bankruptcy. On November 30, 2022, the Trustee filed a Notice of Abandonment of Estate Property, as it is over encumbered by the secured creditors. No objections were filed, and as such the inventory and equipment is now considered abandoned to the secured creditors to do with what they wish. In March 2023, the Trustee declared this a no-asset case and closed the bankruptcy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The results of operations of this component, for all periods, are separately reported as “discontinued operations”. A reconciliation of the major classes of line items constituting the income (loss) from discontinued operations, net of income taxes as is presented in the Consolidated Statements of Operations for the three months ended March 31, 2023, and 2022 are summarized below:</span></p> <p id="xdx_89C_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zrHYUsR8XDKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zMkHivi1XaG1" style="display: none">SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20230101__20230331_zAARpgKPEava" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20220331_zwpy72oitMg9" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_maDGIDOza4t_zAhGq18qyMAj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,363</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">162,916</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_msDGIDOza4t_zGxShtfRDlJ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1536">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">126,482</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_mtDGIDOza4t_maLFDOzIrx_zCJGaJnADVY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,434</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_msLFDOzIrx_zeWtlHTtsRr5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1542">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">212,290</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInterestExpense_msLFDOzIrx_zyiqA2wDCi14" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Interest expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1545">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,324</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--LossFromDiscontinuedOperations_mtLFDOzIrx_z4y2B2Id1sD6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income (loss) from discontinued operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,363</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(184,180</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are <span id="xdx_900_ecustom--TotalAssetsOfDiscontinuedOperations_iI_do_c20230331_zzx3xTkr4Cme" title="Total assets of discontinued operations"><span id="xdx_904_ecustom--TotalAssetsOfDiscontinuedOperations_iI_do_c20221231_z3hEzJ0bffC2" title="Total assets of discontinued operations">no</span></span> assets as of March 31, 2023, and December 31, 2022, as the secured lender has taken possession. Liabilities of discontinued operations are separately reported as “liabilities held for disposal” as of March 31, 2023, and December 31, 2022. All liabilities are classified as current. The following tables present the reconciliation of carrying amounts of the major classes of liabilities of the Company classified as discontinued operations in the consolidated balance sheets at March 31, 2023, and December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Current liabilities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20230331_zQMXiyz6O9G8" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_zDrvMFpNYQTd" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">March 31,</p>2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_iI_maTCLODz750_zl7oGW2CBn4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable and accrued liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">445,565</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">445,565</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfNotesPayable_iI_maTCLODz750_zl4mxXOykOHe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current portion of notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">589,246</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">589,246</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiability_iI_maTCLODz750_zE1SMi0zcX89" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1561">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,575</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_iI_maTCLODz750_zKjHpuhkf1Q2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Deferred revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,662</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,451</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--TotalCurrentLiabilitiesOfDiscontinuedOperations_iI_mtTCLODz750_z6JXygmOIeD5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total current liabilities of discontinued operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,054,473</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,059,837</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zOBhFyTJvdt8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 16, 2022, Huntington National Bank (“Huntington”) filed a Complaint for Confession of Judgment (“COJ”) against Catherine Chis (“Chis”). Chis was the former CEO of PCTI and a Guarantor on Huntington’s Letter of Credit financing (“LOC”) and a Term Loan (“Term Loan”). The Chis COJ for the LOC was for $<span id="xdx_900_eus-gaap--LineOfCredit_iI_c20220516__srt--TitleOfIndividualAxis__custom--CatherineChisMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--LineOfCreditMember_zQpMX4tjFdp1" title="Line of credit">352,415</span> and accrues per diem interest of $<span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_pp2d_c20220516__srt--TitleOfIndividualAxis__custom--CatherineChisMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LineOfCreditMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--LineOfCreditMember_zX3lg0TOXTfg" title="Interest payable">63.65</span>, and the Chis COJ for the Term Loan was for $<span id="xdx_904_eus-gaap--ShortTermBorrowings_iI_c20220516__srt--TitleOfIndividualAxis__custom--CatherineChisMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_z9JkyR8kfHMg" title="Term loan">141,415</span> and accrues per diem interest of $<span id="xdx_905_eus-gaap--InterestPayableCurrent_iI_pp2d_c20220516__srt--TitleOfIndividualAxis__custom--CatherineChisMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ShortTermDebtMember_zmlXy1mG5zok" title="Interest payable">28.60</span>. On June 24, 2022, Huntington filed a COJ against Power Conversion Technologies, Inc (“PCTI”). The PCTI COJ for the LOC was for $<span id="xdx_90F_eus-gaap--LineOfCredit_iI_c20220624__srt--TitleOfIndividualAxis__custom--PowerConversionTechnologiesIncMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--LineOfCreditMember_zT4OvM5wNbUd" title="Line of credit">354,774</span> and accrues per diem interest of $<span id="xdx_907_eus-gaap--InterestPayableCurrent_iI_pp2d_c20220624__srt--TitleOfIndividualAxis__custom--PowerConversionTechnologiesIncMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--LineOfCreditMember_z8aiYZjQVRJ8" title="Interest payable">63.65</span> and the PCTI COJ for the LOC was for $<span id="xdx_90A_ecustom--LineOfCreditOne_iI_c20220624__srt--TitleOfIndividualAxis__custom--PowerConversionTechnologiesIncMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--LineOfCreditMember_zDBeqbz2z1ee" title="Line of credit">142,473</span> and accrues per diem interest of $<span id="xdx_909_ecustom--InterestPayableCurrentOne_iI_pp2d_c20220624__srt--TitleOfIndividualAxis__custom--PowerConversionTechnologiesIncMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--LineOfCreditMember_zGtgLMPu5zPh" title="Interest payable">28.60</span>. On July 20, 2022, Huntington assigned the PCTI judgment against PCTI to Meraki Advisors, LLC. (“Meraki”). The Company’s understanding is Meraki is a Pennsylvania limited liability company, controlled by Chis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company wrote off the book value of the inventory of $<span id="xdx_905_eus-gaap--InventoryWriteDown_c20220101__20221231_zlzXCTcMrgM8" title="Inventory">237,091</span> and fixed assets of $<span id="xdx_907_ecustom--FixedAssetsWriteDown_c20220101__20221231_zu0mKQDO2bt5" title="Fixed assets">15,447</span> during the year ended December 31, 2022, with the offset to Loss on Disposal of Assets of Discontinued Operations. Included in the Current portion of notes payable are the principal balances of Huntington’s LOC of $<span id="xdx_908_eus-gaap--LineOfCredit_iI_c20221231_zQ1Dw1khQERg" title="Line of credit">344,166</span> and Term Loan of $<span id="xdx_904_eus-gaap--ShortTermBorrowings_iI_c20221231_zI0juRD16Ix2" title="Term loan">134,681</span>. Accrued interest and fees on the LOC and Term Loan debt $<span id="xdx_902_ecustom--AccruedInterestAndFees_c20220101__20221231_zsELrh3tkjA2" title="Accrued interest and fees">54,256</span> is included in accounts payable and accrued liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zrHYUsR8XDKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zMkHivi1XaG1" style="display: none">SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20230101__20230331_zAARpgKPEava" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20220331_zwpy72oitMg9" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three months ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_maDGIDOza4t_zAhGq18qyMAj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,363</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">162,916</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_msDGIDOza4t_zGxShtfRDlJ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1536">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">126,482</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_mtDGIDOza4t_maLFDOzIrx_zCJGaJnADVY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,434</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_msLFDOzIrx_zeWtlHTtsRr5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1542">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">212,290</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInterestExpense_msLFDOzIrx_zyiqA2wDCi14" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Interest expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1545">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,324</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--LossFromDiscontinuedOperations_mtLFDOzIrx_z4y2B2Id1sD6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income (loss) from discontinued operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,363</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(184,180</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are <span id="xdx_900_ecustom--TotalAssetsOfDiscontinuedOperations_iI_do_c20230331_zzx3xTkr4Cme" title="Total assets of discontinued operations"><span id="xdx_904_ecustom--TotalAssetsOfDiscontinuedOperations_iI_do_c20221231_z3hEzJ0bffC2" title="Total assets of discontinued operations">no</span></span> assets as of March 31, 2023, and December 31, 2022, as the secured lender has taken possession. Liabilities of discontinued operations are separately reported as “liabilities held for disposal” as of March 31, 2023, and December 31, 2022. All liabilities are classified as current. The following tables present the reconciliation of carrying amounts of the major classes of liabilities of the Company classified as discontinued operations in the consolidated balance sheets at March 31, 2023, and December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Current liabilities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20230331_zQMXiyz6O9G8" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_zDrvMFpNYQTd" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">March 31,</p>2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_iI_maTCLODz750_zl7oGW2CBn4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable and accrued liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">445,565</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">445,565</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfNotesPayable_iI_maTCLODz750_zl4mxXOykOHe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current portion of notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">589,246</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">589,246</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiability_iI_maTCLODz750_zE1SMi0zcX89" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1561">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,575</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_iI_maTCLODz750_zKjHpuhkf1Q2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Deferred revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,662</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,451</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--TotalCurrentLiabilitiesOfDiscontinuedOperations_iI_mtTCLODz750_z6JXygmOIeD5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total current liabilities of discontinued operations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,054,473</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,059,837</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5363 162916 126482 5363 36434 212290 8324 5363 -184180 0 0 445565 445565 589246 589246 3575 19662 21451 1054473 1059837 352415 63.65 141415 28.60 354774 63.65 142473 28.60 237091 15447 344166 134681 54256 <p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_zzgx93U0kHN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15 - <span id="xdx_825_zfEQKBM6SZcl">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company provides for income taxes under ASC 740, Accounting for Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. ASC 740 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely- than not that some or all of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future income, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zBvUSwVb6r4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 16 – <span id="xdx_825_zl6x8R8VjBDf">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From April 1, 2023, through the filing of this report, the Company sold GHS <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230401__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXXAPQFFPQO4" title="Stock issued during the period, shares">15,048,619</span> shares of common stock for proceeds of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230401__20230401__us-gaap--AwardTypeAxis__custom--GHSInvestmentsLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsXoQSbpS5q2" title="Stock issued during the period">71,827</span> net of offering costs. These sales were under the January 20, 2023, GHS SPA.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On May 2, 2023, the Company entered into an Equity Financing Agreement (the “Financing Agreement”) and Registration Rights Agreement (the “Registration Rights Agreement”) with GHS. <span id="xdx_907_ecustom--EquityFinancingAgreementDescription_c20230502__20230502__us-gaap--TypeOfArrangementAxis__custom--FinancingAndRegistrationRightsAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEWf2QA3dwG" title="Equity financing agreement description">Under the terms of the Financing Agreement, GHS has agreed to provide the Company with up to $10,000,000 of funding upon effectiveness of a registration statement on Form S-1. Following effectiveness of the registration statement, the Company shall have the right to deliver puts to GHS and GHS will be obligated to purchase shares of our common stock based on the investment amount specified in each put notice. The maximum amount that the Company shall be entitled to put to GHS in each put notice will not exceed two hundred fifty percent (250%) of the average of the daily trading dollar volume of the Company’s common stock during the ten (10) trading days preceding the put, so long as such amount does not exceed 4.99% of the outstanding shares of the Company. Pursuant to the Financing Agreement, GHS and its affiliates will not be permitted to purchase, and the Company may not put shares of the Company’s common stock to GHS that would result in GHS’s beneficial ownership equaling more than 4.99% of the Company’s outstanding common stock. The price of each put share shall be equal to eighty percent (80%) of the lowest daily volume weighted average price of the Company’s common stock for the ten (10) consecutive trading days preceding the date on which the applicable put is delivered to GHS. No put will be made in an amount equaling less than $10,000 or greater than $750,000. Puts may be delivered by the Company to GHS until the earlier of twenty-four (24) months after the effectiveness of the registration statement on Form S-1 or the date on which GHS has purchased an aggregate of $10,000,000 worth of put shares.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 5, 2023, the Board of Directors of the Company approved to amend the Company’s Articles of Incorporation (the “Amendment”) to increase the authorized capital stock of the Company to <span id="xdx_905_eus-gaap--CapitalUnitsAuthorized_iI_c20230505__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zT4e5Uj8wgn7" title="Capital stock shares, authorized">7,000,000,000</span> shares, of which <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230505__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVLufM1ZTuy4" title="Common stock shares, authorized">6,990,000,000</span> shall be authorized as common shares and <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230505__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zskMVhZTz0H1" title="Preferrd stock shares, authorized">10,000,000</span> shall be authorized as preferred shares. The Company is in the process of filing the Amendment with the State of Nevada,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated subsequent events through the date the financial statements were issued. The Company has determined that there are no other such events that warrant disclosure or recognition in the financial statements, except as stated herein.</span></p> 15048619 71827 Under the terms of the Financing Agreement, GHS has agreed to provide the Company with up to $10,000,000 of funding upon effectiveness of a registration statement on Form S-1. Following effectiveness of the registration statement, the Company shall have the right to deliver puts to GHS and GHS will be obligated to purchase shares of our common stock based on the investment amount specified in each put notice. The maximum amount that the Company shall be entitled to put to GHS in each put notice will not exceed two hundred fifty percent (250%) of the average of the daily trading dollar volume of the Company’s common stock during the ten (10) trading days preceding the put, so long as such amount does not exceed 4.99% of the outstanding shares of the Company. Pursuant to the Financing Agreement, GHS and its affiliates will not be permitted to purchase, and the Company may not put shares of the Company’s common stock to GHS that would result in GHS’s beneficial ownership equaling more than 4.99% of the Company’s outstanding common stock. The price of each put share shall be equal to eighty percent (80%) of the lowest daily volume weighted average price of the Company’s common stock for the ten (10) consecutive trading days preceding the date on which the applicable put is delivered to GHS. No put will be made in an amount equaling less than $10,000 or greater than $750,000. Puts may be delivered by the Company to GHS until the earlier of twenty-four (24) months after the effectiveness of the registration statement on Form S-1 or the date on which GHS has purchased an aggregate of $10,000,000 worth of put shares. 7000000000 6990000000 10000000 The potentially dilutive shares included in the above table are limited whereby the conversion or exercise cannot result in the beneficial owner holding more than 4.99% of the then outstanding shares of common stock subsequent to any conversion or exercise. These shares were excluded from the diluted per share calculation because the effect of including these potential shares was anti-dilutive due to the Company’s net loss position. EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 295 283 1 true 105 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://ir.ozopsurgical.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://ir.ozopsurgical.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://ir.ozopsurgical.com/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statement of Stockholders' Deficit (Unaudited) Sheet http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit Consolidated Statement of Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statement of Stockholders' Deficit (Unaudited) (Parenthetical) Sheet http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficitParenthetical Consolidated Statement of Stockholders' Deficit (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://ir.ozopsurgical.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - ORGANIZATION Sheet http://ir.ozopsurgical.com/role/Organization ORGANIZATION Notes 8 false false R9.htm 00000009 - Disclosure - GOING CONCERN AND MANAGEMENT???S PLANS Sheet http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlans GOING CONCERN AND MANAGEMENT???S PLANS Notes 9 false false R10.htm 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS Sheet http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncements SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS Notes 10 false false R11.htm 00000011 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://ir.ozopsurgical.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 11 false false R12.htm 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://ir.ozopsurgical.com/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE Notes 12 false false R13.htm 00000013 - Disclosure - DERIVATIVE LIABILITIES Sheet http://ir.ozopsurgical.com/role/DerivativeLiabilities DERIVATIVE LIABILITIES Notes 13 false false R14.htm 00000014 - Disclosure - NOTES PAYABLE Notes http://ir.ozopsurgical.com/role/NotesPayable NOTES PAYABLE Notes 14 false false R15.htm 00000015 - Disclosure - DEFERRED LIABILITY Sheet http://ir.ozopsurgical.com/role/DeferredLiability DEFERRED LIABILITY Notes 15 false false R16.htm 00000016 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://ir.ozopsurgical.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://ir.ozopsurgical.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 17 false false R18.htm 00000018 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://ir.ozopsurgical.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 18 false false R19.htm 00000019 - Disclosure - NONCONTROLLING INTEREST Sheet http://ir.ozopsurgical.com/role/NoncontrollingInterest NONCONTROLLING INTEREST Notes 19 false false R20.htm 00000020 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES Sheet http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilities OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES Notes 20 false false R21.htm 00000021 - Disclosure - DISCONTINUED OPERATIONS Sheet http://ir.ozopsurgical.com/role/DiscontinuedOperations DISCONTINUED OPERATIONS Notes 21 false false R22.htm 00000022 - Disclosure - INCOME TAXES Sheet http://ir.ozopsurgical.com/role/IncomeTaxes INCOME TAXES Notes 22 false false R23.htm 00000023 - Disclosure - SUBSEQUENT EVENTS Sheet http://ir.ozopsurgical.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 23 false false R24.htm 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies) Sheet http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies) Policies 24 false false R25.htm 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables) Sheet http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables) Tables http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncements 25 false false R26.htm 00000026 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://ir.ozopsurgical.com/role/PropertyAndEquipment 26 false false R27.htm 00000027 - Disclosure - DERIVATIVE LIABILITIES (Tables) Sheet http://ir.ozopsurgical.com/role/DerivativeLiabilitiesTables DERIVATIVE LIABILITIES (Tables) Tables http://ir.ozopsurgical.com/role/DerivativeLiabilities 27 false false R28.htm 00000028 - Disclosure - NOTES PAYABLE (Tables) Notes http://ir.ozopsurgical.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://ir.ozopsurgical.com/role/NotesPayable 28 false false R29.htm 00000029 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Sheet http://ir.ozopsurgical.com/role/RelatedPartyTransactionsTables RELATED PARTY TRANSACTIONS (Tables) Tables http://ir.ozopsurgical.com/role/RelatedPartyTransactions 29 false false R30.htm 00000030 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables) Sheet http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables) Tables http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilities 30 false false R31.htm 00000031 - Disclosure - DISCONTINUED OPERATIONS (Tables) Sheet http://ir.ozopsurgical.com/role/DiscontinuedOperationsTables DISCONTINUED OPERATIONS (Tables) Tables http://ir.ozopsurgical.com/role/DiscontinuedOperations 31 false false R32.htm 00000032 - Disclosure - GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Sheet http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Details http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlans 32 false false R33.htm 00000033 - Disclosure - SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details) Sheet http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details) Details 33 false false R34.htm 00000034 - Disclosure - SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details) Details 34 false false R35.htm 00000035 - Disclosure - DISAGGREGATION OF REVENUE (Details) Sheet http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails DISAGGREGATION OF REVENUE (Details) Details 35 false false R36.htm 00000036 - Disclosure - SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) Details 36 false false R37.htm 00000037 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) Details 37 false false R38.htm 00000038 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) (Parenthetical) Sheet http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) (Parenthetical) Details 38 false false R39.htm 00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) Sheet http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative) Details http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables 39 false false R40.htm 00000040 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfPropertyAndEquipmentDetails SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Details 40 false false R41.htm 00000041 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables 41 false false R42.htm 00000042 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://ir.ozopsurgical.com/role/ConvertibleNotesPayable 42 false false R43.htm 00000043 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) Details 43 false false R44.htm 00000044 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) Sheet http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative DERIVATIVE LIABILITIES (Details Narrative) Details http://ir.ozopsurgical.com/role/DerivativeLiabilitiesTables 44 false false R45.htm 00000045 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) Notes http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) Details 45 false false R46.htm 00000046 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) Notes http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails SCHEDULE OF NOTES PAYABLE (Details) Details 46 false false R47.htm 00000047 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://ir.ozopsurgical.com/role/NotesPayableTables 47 false false R48.htm 00000048 - Disclosure - DEFERRED LIABILITY (Details Narrative) Sheet http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative DEFERRED LIABILITY (Details Narrative) Details http://ir.ozopsurgical.com/role/DeferredLiability 48 false false R49.htm 00000049 - Disclosure - SCHEDULE OF EXPENSES TO OFFICERS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails SCHEDULE OF EXPENSES TO OFFICERS (Details) Details 49 false false R50.htm 00000050 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://ir.ozopsurgical.com/role/RelatedPartyTransactionsTables 50 false false R51.htm 00000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://ir.ozopsurgical.com/role/CommitmentsAndContingencies 51 false false R52.htm 00000052 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://ir.ozopsurgical.com/role/StockholdersEquity 52 false false R53.htm 00000053 - Disclosure - NONCONTROLLING INTEREST (Details Narrative) Sheet http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative NONCONTROLLING INTEREST (Details Narrative) Details http://ir.ozopsurgical.com/role/NoncontrollingInterest 53 false false R54.htm 00000054 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails SCHEDULE OF RIGHT-OF-USE ASSETS (Details) Details 54 false false R55.htm 00000055 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITIES (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails SCHEDULE OF OPERATING LEASE LIABILITIES (Details) Details 55 false false R56.htm 00000056 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) Details 56 false false R57.htm 00000057 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative) Sheet http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative) Details http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables 57 false false R58.htm 00000058 - Disclosure - SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS (Details) Sheet http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS (Details) Details 58 false false R59.htm 00000059 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative) Sheet http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative DISCONTINUED OPERATIONS (Details Narrative) Details http://ir.ozopsurgical.com/role/DiscontinuedOperationsTables 59 false false R60.htm 00000060 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://ir.ozopsurgical.com/role/SubsequentEvents 60 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LesseeOperatingLeaseTermOfContract - form10-q.htm 71, 91 form10-q.htm ex31-1.htm ex31-2.htm ex32-1.htm ozsc-20230331.xsd ozsc-20230331_cal.xml ozsc-20230331_def.xml ozsc-20230331_lab.xml ozsc-20230331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 77 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 26, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 785, "http://xbrl.sec.gov/dei/2023": 26 }, "contextCount": 295, "dts": { "calculationLink": { "local": [ "ozsc-20230331_cal.xml" ] }, "definitionLink": { "local": [ "ozsc-20230331_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "ozsc-20230331_lab.xml" ] }, "presentationLink": { "local": [ "ozsc-20230331_pre.xml" ] }, "schema": { "local": [ "ozsc-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 533, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 66, "http://ir.ozopsurgical.com/20230331": 2, "http://xbrl.sec.gov/dei/2023": 4, "total": 72 }, "keyCustom": 43, "keyStandard": 240, "memberCustom": 68, "memberStandard": 35, "nsprefix": "OZSC", "nsuri": "http://ir.ozopsurgical.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://ir.ozopsurgical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS", "menuCat": "Notes", "order": "10", "role": "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncements", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - PROPERTY AND EQUIPMENT", "menuCat": "Notes", "order": "11", "role": "http://ir.ozopsurgical.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE", "menuCat": "Notes", "order": "12", "role": "http://ir.ozopsurgical.com/role/ConvertibleNotesPayable", "shortName": "CONVERTIBLE NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - DERIVATIVE LIABILITIES", "menuCat": "Notes", "order": "13", "role": "http://ir.ozopsurgical.com/role/DerivativeLiabilities", "shortName": "DERIVATIVE LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:NotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - NOTES PAYABLE", "menuCat": "Notes", "order": "14", "role": "http://ir.ozopsurgical.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:NotesPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:DeferredLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - DEFERRED LIABILITY", "menuCat": "Notes", "order": "15", "role": "http://ir.ozopsurgical.com/role/DeferredLiability", "shortName": "DEFERRED LIABILITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:DeferredLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "16", "role": "http://ir.ozopsurgical.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "17", "role": "http://ir.ozopsurgical.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "menuCat": "Notes", "order": "18", "role": "http://ir.ozopsurgical.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - NONCONTROLLING INTEREST", "menuCat": "Notes", "order": "19", "role": "http://ir.ozopsurgical.com/role/NoncontrollingInterest", "shortName": "NONCONTROLLING INTEREST", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://ir.ozopsurgical.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES", "menuCat": "Notes", "order": "20", "role": "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilities", "shortName": "OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - DISCONTINUED OPERATIONS", "menuCat": "Notes", "order": "21", "role": "http://ir.ozopsurgical.com/role/DiscontinuedOperations", "shortName": "DISCONTINUED OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "22", "role": "http://ir.ozopsurgical.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "23", "role": "http://ir.ozopsurgical.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)", "menuCat": "Policies", "order": "24", "role": "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)", "menuCat": "Tables", "order": "25", "role": "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "menuCat": "Tables", "order": "26", "role": "http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - DERIVATIVE LIABILITIES (Tables)", "menuCat": "Tables", "order": "27", "role": "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesTables", "shortName": "DERIVATIVE LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - NOTES PAYABLE (Tables)", "menuCat": "Tables", "order": "28", "role": "http://ir.ozopsurgical.com/role/NotesPayableTables", "shortName": "NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)", "menuCat": "Tables", "order": "29", "role": "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsTables", "shortName": "RELATED PARTY TRANSACTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "OZSC:CommonStockYetToBeIssued", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "lang": null, "name": "OZSC:CommonStockYetToBeIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:ScheduleOfRightofUseAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables)", "menuCat": "Tables", "order": "30", "role": "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables", "shortName": "OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "OZSC:ScheduleOfRightofUseAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - DISCONTINUED OPERATIONS (Tables)", "menuCat": "Tables", "order": "31", "role": "http://ir.ozopsurgical.com/role/DiscontinuedOperationsTables", "shortName": "DISCONTINUED OPERATIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "shortName": "GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "lang": null, "name": "OZSC:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_custom_CustomerAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details)", "menuCat": "Details", "order": "33", "role": "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "shortName": "SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_custom_CustomerAMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "OZSC:ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_custom_WarehouseEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details)", "menuCat": "Details", "order": "34", "role": "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails", "shortName": "SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "OZSC:ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_custom_WarehouseEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - DISAGGREGATION OF REVENUE (Details)", "menuCat": "Details", "order": "35", "role": "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails", "shortName": "DISAGGREGATION OF REVENUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-012023-03-31_custom_SourcedAndDistributedProductsMember", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - SCHEDULE OF DERIVATIVE INSTRUMENTS (Details)", "menuCat": "Details", "order": "36", "role": "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails", "shortName": "SCHEDULE OF DERIVATIVE INSTRUMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)", "menuCat": "Details", "order": "37", "role": "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) (Parenthetical)", "menuCat": "Details", "order": "38", "role": "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical", "shortName": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:CashEquivalentsAtCarryingValue", "span", "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:CashEquivalentsAtCarryingValue", "span", "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://ir.ozopsurgical.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "menuCat": "Details", "order": "40", "role": "http://ir.ozopsurgical.com/role/ScheduleOfPropertyAndEquipmentDetails", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "menuCat": "Details", "order": "41", "role": "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_custom_FifteenPercentPromissoryNoteMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)", "menuCat": "Details", "order": "42", "role": "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "shortName": "CONVERTIBLE NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_custom_FifteenPercentPromissoryNoteMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilitiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details)", "menuCat": "Details", "order": "43", "role": "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails", "shortName": "SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "OZSC:LossOnFairValueChangeOfDerivatives", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilitiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative)", "menuCat": "Details", "order": "44", "role": "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "shortName": "DERIVATIVE LIABILITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-12-31", "decimals": "INF", "lang": null, "name": "OZSC:WarrantsInConjunctionWithNotesPayable", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_custom_NotePayableMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical)", "menuCat": "Details", "order": "45", "role": "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical", "shortName": "SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_custom_NotePayableMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details)", "menuCat": "Details", "order": "46", "role": "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "shortName": "SCHEDULE OF NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_custom_NotePayableMember", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - NOTES PAYABLE (Details Narrative)", "menuCat": "Details", "order": "47", "role": "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "OZSC:NotesPayableTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_custom_HolderMember", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "OZSC:DeferredLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - DEFERRED LIABILITY (Details Narrative)", "menuCat": "Details", "order": "48", "role": "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "shortName": "DEFERRED LIABILITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "OZSC:DeferredLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-11-102022-11-11", "decimals": "0", "lang": null, "name": "us-gaap:IncreaseDecreaseInDeferredLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesWagesAndOfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - SCHEDULE OF EXPENSES TO OFFICERS (Details)", "menuCat": "Details", "order": "49", "role": "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails", "shortName": "SCHEDULE OF EXPENSES TO OFFICERS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesWagesAndOfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_custom_CommonStockToBeIssuedMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statement of Stockholders' Deficit (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit", "shortName": "Consolidated Statement of Stockholders' Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_custom_CommonStockToBeIssuedMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-12-292022-01-02_custom_EmploymentAgreementMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "50", "role": "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-12-292022-01-02_custom_EmploymentAgreementMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "51", "role": "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:PaymentsForParticipationLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "menuCat": "Details", "order": "52", "role": "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31_us-gaap_SeriesDPreferredStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "OZSC:AccumulativeNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - NONCONTROLLING INTEREST (Details Narrative)", "menuCat": "Details", "order": "53", "role": "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative", "shortName": "NONCONTROLLING INTEREST (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "OZSC:AccumulativeNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "OZSC:ScheduleOfRightofUseAssetsTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "OZSC:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - SCHEDULE OF RIGHT-OF-USE ASSETS (Details)", "menuCat": "Details", "order": "54", "role": "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails", "shortName": "SCHEDULE OF RIGHT-OF-USE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "OZSC:ScheduleOfRightofUseAssetsTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "OZSC:OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "OZSC:ScheduleOfOperatingLeaseLiabilitiesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - SCHEDULE OF OPERATING LEASE LIABILITIES (Details)", "menuCat": "Details", "order": "55", "role": "http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails", "shortName": "SCHEDULE OF OPERATING LEASE LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)", "menuCat": "Details", "order": "56", "role": "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails", "shortName": "SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-04-14", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AreaOfLand", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative)", "menuCat": "Details", "order": "57", "role": "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "shortName": "OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-04-14", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AreaOfLand", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS (Details)", "menuCat": "Details", "order": "58", "role": "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails", "shortName": "SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "OZSC:TotalAssetsOfDiscontinuedOperations", "span", "span", "span", "p", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "OZSC:TotalAssetsOfDiscontinuedOperations", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative)", "menuCat": "Details", "order": "59", "role": "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative", "shortName": "DISCONTINUED OPERATIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "OZSC:TotalAssetsOfDiscontinuedOperations", "span", "span", "span", "p", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "OZSC:TotalAssetsOfDiscontinuedOperations", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statement of Stockholders' Deficit (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficitParenthetical", "shortName": "Consolidated Statement of Stockholders' Deficit (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "menuCat": "Details", "order": "60", "role": "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-05-05_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:CapitalUnitsAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://ir.ozopsurgical.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "OZSC:IncomeLossFromDiscontinuedOperationNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - ORGANIZATION", "menuCat": "Notes", "order": "8", "role": "http://ir.ozopsurgical.com/role/Organization", "shortName": "ORGANIZATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - GOING CONCERN AND MANAGEMENT\u2019S PLANS", "menuCat": "Notes", "order": "9", "role": "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlans", "shortName": "GOING CONCERN AND MANAGEMENT\u2019S PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 105, "tag": { "OZSC_AccruedInterestAndFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued interest and fees.", "label": "Accrued interest and fees" } } }, "localname": "AccruedInterestAndFees", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_AccumulativeNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulative noncontrolling interest.", "label": "Accumulative noncontrolling interest" } } }, "localname": "AccumulativeNoncontrollingInterest", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_AmortizationOfDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amortization of discount.", "label": "Amortization of discount" } } }, "localname": "AmortizationOfDiscount", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_AmortizationOfInterestExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of interest expense.", "label": "Interest expense, amortized" } } }, "localname": "AmortizationOfInterestExpense", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_AuroraEnterprisesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurora Enterprises [Member]", "label": "Aurora Enterprises [Member]" } } }, "localname": "AuroraEnterprisesMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_BrianConwayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brian Conway [Member]", "label": "Brian Conway [Member]" } } }, "localname": "BrianConwayMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_CatherineChisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Catherine Chis [Member]", "label": "Catherine Chis [Member]" } } }, "localname": "CatherineChisMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_CertificatesOfDesignationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Certificates of Designation [Member]", "label": "Certificates of Designation [Member]" } } }, "localname": "CertificatesOfDesignationMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ChiefExecutiveOfficerBonusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chief Executive Officer Bonus [Member]", "label": "Chief Executive Officer Bonus [Member]" } } }, "localname": "ChiefExecutiveOfficerBonusMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "domainItemType" }, "OZSC_CoDirectorsOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Co-Directors of Sales [Member]", "label": "Co-Directors of Sales [Member]" } } }, "localname": "CoDirectorsOfSalesMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_CommonStockToBeIssued": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock to be issued.", "label": "Common stock to be issued; 637,755 shares as of March 31, 2023 and December 31, 2022" } } }, "localname": "CommonStockToBeIssued", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "OZSC_CommonStockToBeIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock To Be Issued [Member]", "label": "Common Stock To Be Issued [Member]" } } }, "localname": "CommonStockToBeIssuedMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "OZSC_CommonStockYetToBeIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock yet to be issued.", "label": "Common stock to be issued" } } }, "localname": "CommonStockYetToBeIssued", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "OZSC_ConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting Agreement [Member]", "label": "Consulting Agreement [Member]" } } }, "localname": "ConsultingAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ConsultingExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consulting Expense.", "label": "Consulting expense" } } }, "localname": "ConsultingExpense", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_ConvertibleInstrumentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Instruments [Policy Text Block]", "label": "Convertible Instruments" } } }, "localname": "ConvertibleInstrumentsPolicyTextBlock", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "OZSC_ConvertibleNotesPayableNet": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible notes payable net.", "label": "Convertible notes payable, net of discounts" } } }, "localname": "ConvertibleNotesPayableNet", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "OZSC_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]" } } }, "localname": "CustomerAMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer B [Member]", "label": "Customer B [Member]" } } }, "localname": "CustomerBMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer C [Member]", "label": "Customer C [Member]" } } }, "localname": "CustomerCMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer D [Member]", "label": "Customer D [Member]" } } }, "localname": "CustomerDMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_CustomerDeposits": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Customer deposits.", "label": "Customer deposits" } } }, "localname": "CustomerDeposits", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "OZSC_CustomerEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer E [Member]", "label": "Customer E [Member]" } } }, "localname": "CustomerEMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "OZSC_DecemberSevenTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December Seven Two Thousand Twenty Two [Member]", "label": "December 7, 2022 [Member]" } } }, "localname": "DecemberSevenTwoThousandTwentyTwoMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_DeferredLiabilityCurrent": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred liability current.", "label": "Deferred liability" } } }, "localname": "DeferredLiabilityCurrent", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_DeferredLiabilityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Liability [Text Block]", "label": "DEFERRED LIABILITY" } } }, "localname": "DeferredLiabilityTextBlock", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredLiability" ], "xbrltype": "textBlockItemType" }, "OZSC_DerivativeLiabilitiesAssociatedWithConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Liabilities Associated With Convertible Notes [Member]", "label": "Derivative Liabilities Associated With Convertible Notes [Member]" } } }, "localname": "DerivativeLiabilitiesAssociatedWithConvertibleNotesMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "OZSC_DerivativeLiabilitiesAssociatedWithWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Liabilities Associated With Warrants [Member]", "label": "Derivative Liabilities Associated With Warrants [Member]" } } }, "localname": "DerivativeLiabilitiesAssociatedWithWarrantsMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "OZSC_DisclosureDeferredLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Liability" } } }, "localname": "DisclosureDeferredLiabilityAbstract", "nsuri": "http://ir.ozopsurgical.com/20230331", "xbrltype": "stringItemType" }, "OZSC_DisclosureDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities" } } }, "localname": "DisclosureDerivativeLiabilitiesAbstract", "nsuri": "http://ir.ozopsurgical.com/20230331", "xbrltype": "stringItemType" }, "OZSC_DisclosureNotesPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable" } } }, "localname": "DisclosureNotesPayableAbstract", "nsuri": "http://ir.ozopsurgical.com/20230331", "xbrltype": "stringItemType" }, "OZSC_DisclosureOperatingLeaseRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Right-of-use Assets And Operating Lease Liabilities", "terseLabel": "Schedule Of Operating Lease Liabilities", "verboseLabel": "Schedule Of Right-of-use Assets" } } }, "localname": "DisclosureOperatingLeaseRightofuseAssetsAndOperatingLeaseLiabilitiesAbstract", "nsuri": "http://ir.ozopsurgical.com/20230331", "xbrltype": "stringItemType" }, "OZSC_DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfNotesPayable": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "OZSC_TotalCurrentLiabilitiesOfDiscontinuedOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation current portion of notes payable.", "label": "Current portion of notes payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCurrentPortionOfNotesPayable", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails": { "order": 3.0, "parentTag": "OZSC_TotalCurrentLiabilitiesOfDiscontinuedOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation pperating lease liability.", "label": "Operating lease liability" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiability", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_DistinguishingLiabilitiesFromEquityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distinguishing Liabilities from Equity [Policy Text Block]", "label": "Distinguishing Liabilities from Equity" } } }, "localname": "DistinguishingLiabilitiesFromEquityPolicyTextBlock", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "OZSC_EmploymentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employment Agreement [Member]", "label": "Employment Agreement [Member]" } } }, "localname": "EmploymentAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_EquityFinancingAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity financing agreement description.", "label": "Equity financing agreement description" } } }, "localname": "EquityFinancingAgreementDescription", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "OZSC_ExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange Agreement [Member]", "label": "Exchange Agreement [Member]" } } }, "localname": "ExchangeAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_EzraGreenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ezra Green [Member]", "label": "Ezra Green [Member]" } } }, "localname": "EzraGreenMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_FebruaryNineTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "February Nine Two Thousand Twenty Two [Member]", "label": "February 9 2021 [Member]" } } }, "localname": "FebruaryNineTwoThousandTwentyTwoMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_FifteenPercentPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "15% Promissory Note [Member]", "label": "15% Promissory Note [Member]" } } }, "localname": "FifteenPercentPromissoryNoteMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_FinancingAndRegistrationRightsAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financing And Registration Rights Agreement [Member]", "label": "Financing And Registration Rights Agreement [Member]" } } }, "localname": "FinancingAndRegistrationRightsAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_FirstSecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1st GHS Purchase Agreement [Member]", "label": "1st GHS Purchase Agreement [Member]" } } }, "localname": "FirstSecuritiesPurchaseAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_FixedAssetsWriteDown": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fixed assets write down.", "label": "Fixed assets" } } }, "localname": "FixedAssetsWriteDown", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_GHSInvestmentsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GHS Investments LLC [Member]", "label": "GHS Investments LLC [Member]" } } }, "localname": "GHSInvestmentsLLCMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_GainLossOnFairValueChangeOfDerivatives": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gain loss on fair value change of derivatives.", "label": "(Gain) loss on fair value change of derivatives" } } }, "localname": "GainLossOnFairValueChangeOfDerivatives", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_GeneralAndAdministrativeRelatedParties": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "General and administrative related parties", "label": "General and administrative, related parties" } } }, "localname": "GeneralAndAdministrativeRelatedParties", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "OZSC_HolderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Holder [Member]", "label": "Holder [Member]" } } }, "localname": "HolderMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_IncomeLossFromDiscontinuedOperationNetOfTax": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Net income (loss) from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationNetOfTax", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_IncrementalBorrowingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental borrowing percentage.", "label": "Incremental borrowing percentage" } } }, "localname": "IncrementalBorrowingPercentage", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "OZSC_InterestPayableCurrentOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest payable current one.", "label": "InterestPayableCurrentOne", "verboseLabel": "Interest payable" } } }, "localname": "InterestPayableCurrentOne", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_IssuanceOfCommonStockAndPreferredStockForConsultingFeesAndCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock and preferred stock for consulting fees and compensation", "label": "Issuance of common stock and preferred stockfor consulting fees and compensation" } } }, "localname": "IssuanceOfCommonStockAndPreferredStockForConsultingFeesAndCompensation", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_LeaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Agreement [Member]", "label": "Lease Agreement [Member]" } } }, "localname": "LeaseAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_LenderCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lender costs.", "label": "Lender costs" } } }, "localname": "LenderCosts", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_LenderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lender [Member]", "label": "Lender [Member]" } } }, "localname": "LenderMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_LineOfCreditOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line of credit one.", "label": "LineOfCreditOne", "verboseLabel": "Line of credit" } } }, "localname": "LineOfCreditOne", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_LossFromDiscontinuedOperations": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss from discontinued operations.", "label": "Income (loss) from discontinued operations" } } }, "localname": "LossFromDiscontinuedOperations", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_LossOnFairValueChangeOfDerivatives": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss on fair value change of derivatives.", "label": "Change in fair value" } } }, "localname": "LossOnFairValueChangeOfDerivatives", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_MarchSeventeenTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March Seventeen Two Thousand Twenty Two [Member]", "label": "March 17 2022 [Member]" } } }, "localname": "MarchSeventeenTwoThousandTwentyTwoMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_MarchThirtyOneTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March Thirty One Two Thousand Twenty Three [Member]", "label": "March 31 2023 [Member]" } } }, "localname": "MarchThirtyOneTwoThousandTwentyThreeMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_MeasurementInputPriceVolatilityOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Price Volatility One [Member]", "label": "Measurement Input Price Volatility One [Member]" } } }, "localname": "MeasurementInputPriceVolatilityOneMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_MrAllenSosisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr Allen Sosis [Member]", "label": "Mr Allen Sosis [Member]" } } }, "localname": "MrAllenSosisMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_MrConwayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr Conway [Member]", "label": "Mr Conway [Member]" } } }, "localname": "MrConwayMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_MrStevenMartelloMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr Steven Martello [Member]", "label": "Mr Steven Martello [Member]" } } }, "localname": "MrStevenMartelloMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_NoncashInterestExpense": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash interest expense.", "label": "Non-cash interest expense" } } }, "localname": "NoncashInterestExpense", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "OZSC_NotePayableFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Five [Member]", "label": "Note Payable Five [Member]" } } }, "localname": "NotePayableFiveMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Four [Member]", "label": "Note Payable Four [Member]" } } }, "localname": "NotePayableFourMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable [Member]", "label": "Note Payable [Member]" } } }, "localname": "NotePayableMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable One [Member]", "label": "Note Payable One [Member]" } } }, "localname": "NotePayableOneMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Seven [Member]", "label": "Note Payable Seven [Member]" } } }, "localname": "NotePayableSevenMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Six [Member]", "label": "Note Payable Six [Member]" } } }, "localname": "NotePayableSixMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Three [Member]", "label": "Note Payable Three [Member]" } } }, "localname": "NotePayableThreeMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotePayableTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Payable Two [Member]", "label": "Note Payable Two [Member]" } } }, "localname": "NotePayableTwoMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_NotesPayableDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes payable discount", "label": "Notes payable discount" } } }, "localname": "NotesPayableDiscount", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_NotesPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable [Text Block]", "label": "NOTES PAYABLE" } } }, "localname": "NotesPayableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "OZSC_OEDInstallationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OED Installations [Member]", "label": "OED Installations [Member]" } } }, "localname": "OEDInstallationsMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "OZSC_OfficeFurnitureAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office Furniture And Equipment [Member]", "label": "Office Furniture And Equipment [Member]" } } }, "localname": "OfficeFurnitureAndEquipmentMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "OZSC_OfficersCompensationReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Officers compensation received.", "label": "Officers compensation received" } } }, "localname": "OfficersCompensationReceived", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_OperatingLeasePayementsIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease payements increase percentage.", "label": "Lease payments increase percentage" } } }, "localname": "OperatingLeasePayementsIncreasePercentage", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "OZSC_OperatingLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amortization.", "label": "Less: Accumulated amortization", "negatedLabel": "Less: Accumulated amortization" } } }, "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Office and warehouse lease.", "label": "Office and warehouse lease" } } }, "localname": "OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other [Member]", "label": "Other [Member]" } } }, "localname": "OtherMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "OZSC_PCTIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PCTI [Member]", "label": "PCTI [Member]" } } }, "localname": "PCTIMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PJNStrategiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PJN Strategies [Member]", "label": "PJN Strategies [Member]" } } }, "localname": "PJNStrategiesMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PerMonthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per Month [Member]", "label": "Per Month [Member]" } } }, "localname": "PerMonthMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PowerConversionTechnologiesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Power Conversion Technologies Inc [Member]", "label": "Power Conversion Technologies Inc [Member]" } } }, "localname": "PowerConversionTechnologiesIncMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note [Member]", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PromissoryNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note One [Member]", "label": "Promissory Note One [Member]" } } }, "localname": "PromissoryNoteOneMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PromissoryNotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note Payable [Member]" } } }, "localname": "PromissoryNotePayableMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "OZSC_PromissoryNoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note Two [Member]", "label": "Promissory Note Two [Member]" } } }, "localname": "PromissoryNoteTwoMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_PurchaseConcentrationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Concentration [Policy Text Block]", "label": "Purchase concentration" } } }, "localname": "PurchaseConcentrationPolicyTextBlock", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "OZSC_RMAAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RMA Agreement [Member]", "label": "RMA Agreement [Member]" } } }, "localname": "RMAAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_RemainingWarrantSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining Warrant Shares [Member]", "label": "Remaining Warrant Shares [Member]" } } }, "localname": "RemainingWarrantSharesMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_RoyaltyPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty percentage", "label": "Royalty percentage" } } }, "localname": "RoyaltyPercentage", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "percentItemType" }, "OZSC_SalmanJChaudhryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Salman J. Chaudhry [Member]", "label": "Salman J. Chaudhry [Member]" } } }, "localname": "SalmanJChaudhryMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Operating Lease Liabilities Table Text Block.", "label": "SCHEDULE OF OPERATING LEASE LIABILITIES" } } }, "localname": "ScheduleOfOperatingLeaseLiabilitiesTableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "OZSC_ScheduleOfRightofUseAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Right of Use Assets [Table Text Block]", "label": "SCHEDULE OF RIGHT-OF-USE ASSETS" } } }, "localname": "ScheduleOfRightofUseAssetsTableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "OZSC_ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Useful Life Of Property And Equipment Assets [Table Text Block]", "label": "SCHEDULE OF USEFUL LIFE OF PROPERTY AND EQUIPMENT ASSETS" } } }, "localname": "ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsTableTextBlock", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "OZSC_SecondSecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2nd GHS Purchase Agreement [Member]", "label": "2nd GHS Purchase Agreement [Member]" } } }, "localname": "SecondSecuritiesPurchaseAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SeparationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seperation Agreement [Member]", "label": "Seperation Agreement [Member]" } } }, "localname": "SeparationAgreementMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SeriesDAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Amendment [Member]", "label": "Series D Amendment [Member]" } } }, "localname": "SeriesDAmendmentMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SeriesDSPAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series DSPA [Member]", "label": "Series DSPA [Member]" } } }, "localname": "SeriesDSPAMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SourcedAndDistributedProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sourced And Distributed Products [Member]" } } }, "localname": "SourcedAndDistributedProductsMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "OZSC_SuppliersFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suppliers Four [Member]", "label": "Suppliers Four [Member]" } } }, "localname": "SuppliersFourMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SuppliersOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suppliers One [Member]", "label": "Suppliers One [Member]" } } }, "localname": "SuppliersOneMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SuppliersThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suppliers Three [Member]", "label": "Suppliers Three [Member]" } } }, "localname": "SuppliersThreeMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_SuppliersTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Suppliers Two [Member]", "label": "Suppliers Two [Member]" } } }, "localname": "SuppliersTwoMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_ThereafterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thereafter [Member]", "label": "Thereafter [Member]" } } }, "localname": "ThereafterMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_TotalAssetsOfDiscontinuedOperations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total assets of discontinued operations.", "label": "Total assets of discontinued operations" } } }, "localname": "TotalAssetsOfDiscontinuedOperations", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "OZSC_TotalCurrentLiabilitiesOfDiscontinuedOperations": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total current liabilities of discontinued operations.", "label": "Total current liabilities of discontinued operations" } } }, "localname": "TotalCurrentLiabilitiesOfDiscontinuedOperations", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "OZSC_TwoVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Vendor [Member]", "label": "Two Vendor [Member]" } } }, "localname": "TwoVendorMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "OZSC_UnexercisedCommonStockPurchaseWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unexercised Common Stock Purchase Warrants [Member]" } } }, "localname": "UnexercisedCommonStockPurchaseWarrantsMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "OZSC_WarehouseEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warehouse Equipment [Member]", "label": "Warehouse Equipment [Member]" } } }, "localname": "WarehouseEquipmentMember", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "OZSC_WarrantsInConjunctionWithNotesPayable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants In Conjunction With Notes Payable", "label": "Warrants in conjunction with notes payable" } } }, "localname": "WarrantsInConjunctionWithNotesPayable", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "OZSC_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital deficit.", "label": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://ir.ozopsurgical.com/20230331", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r830" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r830" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r829" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r827", "r829", "r830" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r828" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r816" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r829" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r829" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r831" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r822" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r835" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r830" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r833" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r829" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r817" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r821" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r820" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r825" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r826" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r834" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r864" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r279", "r795", "r880", "r932", "r933" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r343", "r344", "r345", "r346", "r423", "r590", "r637", "r681", "r682", "r744", "r746", "r748", "r749", "r751", "r773", "r774", "r785", "r792", "r799", "r804", "r877", "r920", "r921", "r922", "r923", "r924", "r925" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r343", "r344", "r345", "r346", "r423", "r590", "r637", "r681", "r682", "r744", "r746", "r748", "r749", "r751", "r773", "r774", "r785", "r792", "r799", "r804", "r877", "r920", "r921", "r922", "r923", "r924", "r925" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r279", "r795", "r880", "r932", "r933" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_PlatformOperatorCryptoAssetLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto-Asset [Line Items]" } } }, "localname": "PlatformOperatorCryptoAssetLineItems", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "srt_PlatformOperatorCryptoAssetTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto-Asset [Table]" } } }, "localname": "PlatformOperatorCryptoAssetTable", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r276", "r593", "r631", "r632", "r633", "r634", "r635", "r636", "r776", "r793", "r803", "r839", "r873", "r874", "r880", "r932" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r276", "r593", "r631", "r632", "r633", "r634", "r635", "r636", "r776", "r793", "r803", "r839", "r873", "r874", "r880", "r932" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r343", "r344", "r345", "r346", "r415", "r423", "r446", "r447", "r448", "r566", "r590", "r637", "r681", "r682", "r744", "r746", "r748", "r749", "r751", "r773", "r774", "r785", "r792", "r799", "r804", "r807", "r871", "r877", "r921", "r922", "r923", "r924", "r925" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r343", "r344", "r345", "r346", "r415", "r423", "r446", "r447", "r448", "r566", "r590", "r637", "r681", "r682", "r744", "r746", "r748", "r749", "r751", "r773", "r774", "r785", "r792", "r799", "r804", "r807", "r871", "r877", "r921", "r922", "r923", "r924", "r925" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r277", "r278", "r678", "r679", "r680", "r745", "r747", "r750", "r752", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r777", "r794", "r807", "r880", "r932" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r277", "r278", "r678", "r679", "r680", "r745", "r747", "r750", "r752", "r760", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r777", "r794", "r807", "r880", "r932" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r864", "r916" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CALIFORNIA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2023", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses", "verboseLabel": "Accounts and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r762" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r699", "r761", "r808", "r930" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts receivable balance" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r280", "r281" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r53", "r195", "r621" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [ "r208", "r209", "r522", "r523", "r524", "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r208", "r209", "r522", "r523", "r524", "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r118", "r802", "r936" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r451", "r452", "r453", "r666", "r860", "r861", "r862", "r908", "r940" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r183", "r184", "r185", "r186", "r187", "r230", "r231", "r232", "r233", "r242", "r285", "r286", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r340", "r451", "r452", "r453", "r465", "r466", "r467", "r468", "r475", "r476", "r477", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r514", "r515", "r518", "r519", "r520", "r521", "r529", "r530", "r534", "r535", "r536", "r537", "r544", "r545", "r546", "r547", "r548", "r594", "r595", "r596", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r10", "r54", "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to additional paid in capital warrant issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising and Marketing Expenses" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r450", "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r5", "r79", "r131", "r378" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Original issue discount, amortized" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "TOTAL" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r155", "r197", "r222", "r257", "r270", "r274", "r317", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r480", "r484", "r517", "r613", "r704", "r802", "r815", "r875", "r876", "r918" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r190", "r203", "r222", "r317", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r480", "r484", "r517", "r802", "r875", "r876", "r918" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalUnitsAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Capital stock shares, authorized" } } }, "localname": "CapitalUnitsAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r39", "r193", "r778" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r39", "r133", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, End of period", "periodStartLabel": "Cash, Beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r133" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r847", "r929" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of non-cash Investing or Financing Activity:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r106", "r133" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net cash used in discontinued operations" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r182", "r198", "r199", "r200", "r222", "r244", "r245", "r249", "r251", "r255", "r256", "r317", "r347", "r349", "r350", "r351", "r354", "r355", "r385", "r386", "r389", "r392", "r399", "r517", "r655", "r656", "r657", "r658", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r691", "r713", "r736", "r753", "r754", "r755", "r756", "r757", "r836", "r857", "r863" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrant exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Number of warrants to purchase", "verboseLabel": "Purchase of warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of reason for issuing warrant or right.", "label": "Warrant exercise, description" } } }, "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementRightsAndObligations": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Description of rights and obligations under the collaborative arrangements.", "label": "Collaborative arrangement, rights and obligations" } } }, "localname": "CollaborativeArrangementRightsAndObligations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r30", "r89", "r614", "r690" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r143", "r341", "r342", "r763", "r872" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r805", "r806", "r807", "r809", "r810", "r811", "r812", "r860", "r861", "r908", "r934", "r940" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r117", "r691" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "terseLabel": "Common stock shares, authorized", "verboseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued", "verboseLabel": "Common stock, shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r117", "r691", "r710", "r940", "r941" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "verboseLabel": "Common stock shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r117", "r616", "r802" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock (4,990,000,000 shares authorized par value $0.001; 4,879,032,132 and 4,771,275,349 shares issued and outstanding as of March 31, 2023, and December 31, 2022, respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r45", "r47", "r77", "r78", "r279", "r762" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r45", "r47", "r77", "r78", "r279", "r650", "r762" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r45", "r47", "r77", "r78", "r279", "r762", "r837" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r91", "r173" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Sales Concentration and credit risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r45", "r47", "r77", "r78", "r279" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Sales concentration and credit risk", "verboseLabel": "Concentration of credit risk" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r45", "r47", "r77", "r78", "r279", "r762" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r402", "r403", "r414" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Vendor deposits" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r114", "r156" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r385", "r386", "r389", "r809", "r810", "r811", "r812" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r127", "r593" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r46", "r279" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDefaultLongtermDebtAmount": { "auth_ref": [ "r220" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.", "label": "Debt instrument default amount" } } }, "localname": "DebtDefaultLongtermDebtAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r144", "r220", "r356", "r362", "r363", "r364", "r365", "r366", "r367", "r372", "r379", "r380", "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "CONVERTIBLE NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r114", "r115", "r156", "r157", "r226", "r357", "r358", "r359", "r360", "r361", "r363", "r368", "r369", "r370", "r371", "r373", "r374", "r375", "r376", "r377", "r378", "r532", "r787", "r788", "r789", "r790", "r791", "r858" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r17", "r157", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long term debt, gross", "verboseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r17", "r57", "r90", "r114", "r156", "r157" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Agreement description", "verboseLabel": "Debt instrument, description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r80", "r82", "r357", "r532", "r788", "r789" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, face amount", "verboseLabel": "Debt instrument face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r858" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt instrument, increase, accrued interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r28", "r358" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, interest rate, stated percentage", "verboseLabel": "Debt instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r180", "r787", "r910" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Common stock maturity period", "terseLabel": "Debt instrument, maturity date", "verboseLabel": "Debt Instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r29", "r226", "r357", "r358", "r359", "r360", "r361", "r363", "r368", "r369", "r370", "r371", "r373", "r374", "r375", "r376", "r377", "r378", "r532", "r787", "r788", "r789", "r790", "r791", "r858" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r79", "r82", "r878" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, unamortized discount", "verboseLabel": "Debt instrument, unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable": { "auth_ref": [ "r870" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]" } } }, "localname": "DebtSecuritiesHeldToMaturityAllowanceForCreditLossTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems": { "auth_ref": [ "r870" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]" } } }, "localname": "DebtSecuritiesHeldtomaturityAllowanceForCreditLossLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement.", "label": "Exchange of common stock", "verboseLabel": "Number of common stock exchanged" } } }, "localname": "DeferredCompensationArrangementWithIndividualSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredCompensationEquity": { "auth_ref": [ "r34", "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.", "label": "Deferred compensation equity" } } }, "localname": "DeferredCompensationEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r852" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r848" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "verboseLabel": "Deposits" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r5", "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expenses" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "auth_ref": [ "r5" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization and depreciation" } } }, "localname": "DepreciationAmortizationAndAccretionNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r6" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "verboseLabel": "Derivative Liabilities" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Total" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r907" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedLabel": "(Gain) loss on change in fair value of derivatives" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r204" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liabilities", "periodEndLabel": "Derivative liability, ending balance", "periodStartLabel": "Derivative liability, beginning balance", "verboseLabel": "Derivative liabilities current" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative liability, measurement input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativesAndFairValueTextBlock": { "auth_ref": [ "r152", "r153" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.", "label": "DERIVATIVE LIABILITIES" } } }, "localname": "DerivativesAndFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r880" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "DISAGGREGATION OF REVENUE" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Income (loss) from discontinued operations per share of common stockbasic and fully diluted" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "auth_ref": [ "r9", "r21" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.", "label": "Discontinued Operations" } } }, "localname": "DiscontinuedOperationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r2", "r94", "r107", "r139", "r141" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "OZSC_TotalCurrentLiabilitiesOfDiscontinuedOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r105", "r189" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "verboseLabel": "Cost of goods sold" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent": { "auth_ref": [ "r2", "r94", "r107", "r139", "r141" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails": { "order": 4.0, "parentTag": "OZSC_TotalCurrentLiabilitiesOfDiscontinuedOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Deferred revenues" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "auth_ref": [ "r105", "r189" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "OZSC_LossFromDiscontinuedOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Gross profit" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": { "auth_ref": [ "r18", "r19", "r21", "r105" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails": { "order": 3.0, "parentTag": "OZSC_LossFromDiscontinuedOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Interest Expense", "verboseLabel": "Interest expense" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "auth_ref": [ "r105" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails": { "order": 2.0, "parentTag": "OZSC_LossFromDiscontinuedOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Operating expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r105", "r189" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Revenues" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfLossFromDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r93", "r138" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "DISCONTINUED OPERATIONS" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r212", "r234", "r235", "r236", "r237", "r238", "r243", "r244", "r249", "r250", "r251", "r253", "r508", "r509", "r609", "r629", "r781" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Loss per share basic and fully diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r42", "r43" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Amount of initial annual compensation" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r10", "r185", "r208", "r209", "r210", "r227", "r228", "r229", "r231", "r239", "r241", "r254", "r321", "r327", "r401", "r451", "r452", "r453", "r467", "r468", "r489", "r491", "r492", "r493", "r494", "r496", "r507", "r522", "r523", "r524", "r525", "r526", "r527", "r548", "r640", "r641", "r642", "r666", "r736" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished." } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r370", "r416", "r417", "r418", "r419", "r420", "r421", "r511", "r563", "r564", "r565", "r788", "r789", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r370", "r416", "r421", "r511", "r563", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r370", "r416", "r421", "r511", "r564", "r788", "r789", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r370", "r416", "r417", "r418", "r419", "r420", "r421", "r511", "r565", "r788", "r789", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r370", "r416", "r417", "r418", "r419", "r420", "r421", "r563", "r564", "r565", "r788", "r789", "r796", "r797", "r798" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r8", "r15" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r381", "r397", "r497", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r628", "r786", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r865", "r866", "r867", "r868" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r126", "r222", "r257", "r269", "r273", "r275", "r317", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r517", "r783", "r875" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r124", "r161", "r257", "r269", "r273", "r275", "r610", "r623", "r783" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Loss from continuing operations before income taxes", "verboseLabel": "Net loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows", "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r150", "r222", "r230", "r257", "r269", "r273", "r275", "r317", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r509", "r517", "r623", "r783", "r875" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Net loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r123", "r160", "r162", "r212", "r230", "r234", "r235", "r236", "r237", "r244", "r249", "r250", "r509", "r609", "r931" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Loss from contuining operations per share of common stockbasic and fully diluted" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r95", "r96", "r97", "r98", "r99", "r109", "r189", "r472", "r624" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (loss) from discontinued operations, net of tax" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations:" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r223", "r455", "r459", "r460", "r463", "r469", "r471", "r473", "r474", "r660" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": { "auth_ref": [ "r63", "r148" ], "lang": { "en-us": { "role": { "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.", "label": "Income tax examination, likelihood of unfavorable settlement" } } }, "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r168", "r179", "r240", "r241", "r261", "r458", "r470", "r630" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r207", "r456", "r457", "r460", "r461", "r462", "r464", "r654" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r4" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r4" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r591", "r856" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Customer deposits" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredLiabilities": { "auth_ref": [ "r4" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.", "label": "Reduce deferred liability" } } }, "localname": "IncreaseDecreaseInDeferredLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDepositsOutstanding": { "auth_ref": [ "r4" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in monies given as security or collateral for items acquired or borrowed on a temporary basis. Deposits may also be paid as initial payment of the cost of acquisition or for the right to enter into a contract or agreement.", "label": "Increase (Decrease) in Deposits Outstanding", "negatedLabel": "Vendor deposits" } } }, "localname": "IncreaseDecreaseInDepositsOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r4" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r838", "r856" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r4" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r246", "r247", "r251" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Dilutive securities common stock, shares" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r81", "r164", "r211", "r260", "r531", "r721", "r813", "r937" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r213", "r216", "r217" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "verboseLabel": "Interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r87", "r926" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r851" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r202", "r779", "r802" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r169", "r192", "r201", "r336", "r337", "r339", "r592", "r780" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "verboseLabel": "Inventory" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r914", "r915" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r128" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r913" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF MATURITY OF LEASE LIABILITIES" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r543" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r543" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "For the year ending December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r543" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "For the year ending December 31, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r543" ], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "For the year ending December 31, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r543" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r912" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lease term", "verboseLabel": "Operating lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "OPERATING LEASE RIGHT-OF-USE ASSETS AND OPERATING LEASE LIABILITIES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25", "r222", "r317", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r481", "r484", "r485", "r517", "r689", "r782", "r815", "r875", "r918", "r919" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities [Default Label]", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r122", "r159", "r619", "r802", "r859", "r869", "r911" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r27", "r191", "r222", "r317", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r481", "r484", "r485", "r517", "r802", "r875", "r918", "r919" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r2", "r94", "r107", "r139", "r141", "r188", "r189" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Liabilities of discontinued operations" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r17", "r157", "r928" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r29" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Note payable, net of discount", "verboseLabel": "Less long-term portion, net of discount" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketingAndAdvertisingExpense": { "auth_ref": [ "r129" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Advertising and marketing expenses" } } }, "localname": "MarketingAndAdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r909" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r909" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r909" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r35", "r158", "r222", "r317", "r347", "r349", "r350", "r351", "r354", "r355", "r517", "r618", "r693" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.", "label": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling interest percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r215" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r215" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r133", "r134", "r135" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r133", "r134", "r135" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash provided by (used in) continuing operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r125", "r135", "r163", "r189", "r205", "r206", "r210", "r222", "r230", "r234", "r235", "r236", "r237", "r240", "r241", "r248", "r257", "r269", "r273", "r275", "r317", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r509", "r517", "r627", "r712", "r734", "r735", "r783", "r813", "r875" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss attributable to Ozop Energy Solutions, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r68", "r151", "r205", "r206", "r240", "r241", "r626", "r853" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Less: net loss attributable to noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r65", "r401", "r860", "r861", "r862", "r940" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r130" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total Other (Income) Expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (income) expenses:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r17", "r157", "r928" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Sub- total notes payable, net of discount", "verboseLabel": "Notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Current portion of notes payable, net of discounts", "verboseLabel": "Current portion of notes payable, net of discount" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r854" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Compensation value", "verboseLabel": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r257", "r269", "r273", "r275", "r783" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from continuing operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r540" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Lease liability", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails", "http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r540" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liability, current portion", "negatedLabel": "Less current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r540" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability, net of current portion", "verboseLabel": "Long term portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/ScheduleOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r541", "r542" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r539" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use asset, net", "totalLabel": "Right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/ScheduleOfRight-of-useAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r92", "r149", "r651", "r652" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r196" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeNoncontrollingInterestTextBlock": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for tabular information relating to Other Comprehensive Income (OCI) as is applicable to noncontrolling interests. This text block may also include OCI relative to the filing entity, the aforementioned noncontrolling interest OCI, as well as OCI on a consolidated basis.", "label": "NONCONTROLLING INTEREST" } } }, "localname": "OtherComprehensiveIncomeNoncontrollingInterestTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterest" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r129", "r939" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "General and administrative, other" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r88", "r612", "r685", "r686", "r815", "r935" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Due to officers or stockholders" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r26", "r802" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Due to officers or stockholders, current" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForParticipationLiabilities": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments related to participation costs.", "label": "Cash payments" } } }, "localname": "PaymentsForParticipationLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Issuance cost", "terseLabel": "Stock issuance cost", "verboseLabel": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficitParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r132" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of office and computer equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred stock, convertible, conversion price" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r805", "r806", "r809", "r810", "r811", "r812", "r934", "r940" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r116", "r385" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionAmount": { "auth_ref": [ "r31", "r56" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Preferred stock, redemption amount" } } }, "localname": "PreferredStockRedemptionAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r116", "r691" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized", "verboseLabel": "Preferrd stock shares, authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r116", "r385" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued", "verboseLabel": "Preferred stock shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r116", "r691", "r710", "r940", "r941" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding", "verboseLabel": "Preferred stock shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r116", "r615", "r802" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r57", "r116" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred stock, voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r3" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock, net of costs", "terseLabel": "Issuance of common stock", "verboseLabel": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementsOfCashFlows", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r3" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from issuance of preferred stock and preference stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r3", "r655" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Payments of stock issuance costs" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails", "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProductLiabilityContingencyThirdPartyRecoveryPercentage": { "auth_ref": [ "r874" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the estimated recovery from third parties recorded in the period pertaining to product liability damages from specified products.", "label": "Product liability contingency, third-Party recovery, percentage" } } }, "localname": "ProductLiabilityContingencyThirdPartyRecoveryPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r813", "r938", "r939" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r189", "r205", "r206", "r214", "r222", "r230", "r240", "r241", "r257", "r269", "r273", "r275", "r317", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r479", "r482", "r483", "r509", "r517", "r610", "r625", "r665", "r712", "r734", "r735", "r783", "r800", "r801", "r814", "r853", "r875" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit", "http://ir.ozopsurgical.com/role/StatementsOfCashFlows", "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r138", "r174", "r177", "r178" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r140", "r194", "r622" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r611", "r622", "r802" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "verboseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r7", "r174", "r177", "r620" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, plant, and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "SCHEDULE OF PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, plant and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.", "label": "For the year ending December 31, 2023" } } }, "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedAndNonrelatedPartyStatusAxis": { "auth_ref": [ "r224", "r225", "r552", "r553", "r554", "r555", "r684", "r685", "r686", "r687", "r688", "r709", "r711", "r808" ], "lang": { "en-us": { "role": { "documentation": "Information by related and nonrelated party status.", "label": "Related and Nonrelated Party Status [Axis]" } } }, "localname": "RelatedAndNonrelatedPartyStatusAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedAndNonrelatedPartyStatusDomain": { "auth_ref": [ "r224", "r225", "r552", "r553", "r554", "r555", "r684", "r685", "r686", "r687", "r688", "r709", "r711", "r808" ], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated party status." } } }, "localname": "RelatedAndNonrelatedPartyStatusDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r422", "r552", "r553", "r684", "r685", "r686", "r687", "r688", "r709", "r711", "r743" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyMember": { "auth_ref": [ "r224", "r225", "r552", "r553", "r554", "r555", "r684", "r685", "r686", "r687", "r688", "r709", "r711", "r743" ], "lang": { "en-us": { "role": { "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.", "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r716", "r717", "r720" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r422", "r552", "r553", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r684", "r685", "r686", "r687", "r688", "r709", "r711", "r743", "r917" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r549", "r550", "r551", "r553", "r556", "r661", "r662", "r663", "r718", "r719", "r720", "r740", "r742" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r855" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.", "label": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r38" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Payments of principal of convertible note payable and notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r119", "r146", "r617", "r644", "r649", "r659", "r692", "r802" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Retained earnings accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r185", "r227", "r228", "r229", "r231", "r239", "r241", "r321", "r327", "r451", "r452", "r453", "r467", "r468", "r489", "r492", "r493", "r496", "r507", "r640", "r642", "r666", "r940" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r258", "r259", "r268", "r271", "r272", "r276", "r277", "r279", "r412", "r413", "r593" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue", "verboseLabel": "Total" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails", "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r181", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r775" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalariesWagesAndOfficersCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, Excluding Cost of Good and Service Sold", "verboseLabel": "Total" } } }, "localname": "SalariesWagesAndOfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of common stock" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "SCHEDULE OF NOTES PAYABLE" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r60", "r147" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r11", "r69", "r70", "r71", "r72", "r73", "r74", "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "SCHEDULE OF DERIVATIVE INSTRUMENTS" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r9", "r14", "r20", "r94", "r100", "r101", "r102", "r103", "r104", "r108", "r110", "r111", "r142" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DisaggregationOfRevenueDetails", "http://ir.ozopsurgical.com/role/SchedulesOfConcentrationOfRiskByRiskFactorDetails", "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://ir.ozopsurgical.com/role/ScheduleOfUsefulLifeOfPropertyAndEquipmentAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r83", "r84", "r716", "r717", "r720" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfExpensesToOfficersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "SCHEDULE OF EXPENSES TO OFFICERS" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r44", "r45", "r47", "r48", "r77", "r154" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "SCHEDULES OF CONCENTRATION OF RISK, BY RISK FACTOR" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r262", "r263", "r264", "r265", "r266", "r267", "r277", "r784" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Policy" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r849", "r850", "r879" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [ "r849", "r850", "r879" ], "lang": { "en-us": { "role": { "documentation": "Series D preferred stock.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesEPreferredStockMember": { "auth_ref": [ "r849", "r850", "r879" ], "lang": { "en-us": { "role": { "documentation": "Series E preferred stock.", "label": "Series E Preferred Stock [Member]" } } }, "localname": "SeriesEPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r4" ], "calculation": { "http://ir.ozopsurgical.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Warrant exercise" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Outstanding shares, percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetailsParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Issuance of common stock" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Beginning balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r113", "r156", "r802", "r927" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Term loan" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer.", "label": "Short-Term Debt [Member]" } } }, "localname": "ShortTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DiscontinuedOperationsDetailsNarrative", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetails", "http://ir.ozopsurgical.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r136", "r219" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r182", "r198", "r199", "r200", "r222", "r244", "r245", "r249", "r251", "r255", "r256", "r317", "r347", "r349", "r350", "r351", "r354", "r355", "r385", "r386", "r389", "r392", "r399", "r517", "r655", "r656", "r657", "r658", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r691", "r713", "r736", "r753", "r754", "r755", "r756", "r757", "r836", "r857", "r863" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r10", "r33", "r185", "r208", "r209", "r210", "r227", "r228", "r229", "r231", "r239", "r241", "r254", "r321", "r327", "r401", "r451", "r452", "r453", "r467", "r468", "r489", "r491", "r492", "r493", "r494", "r496", "r507", "r522", "r523", "r524", "r525", "r526", "r527", "r548", "r640", "r641", "r642", "r666", "r736" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r227", "r228", "r229", "r254", "r593", "r653", "r677", "r683", "r684", "r685", "r686", "r687", "r688", "r691", "r694", "r695", "r696", "r697", "r698", "r700", "r701", "r702", "r703", "r705", "r706", "r707", "r708", "r709", "r711", "r714", "r715", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r736", "r808" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r227", "r228", "r229", "r254", "r593", "r653", "r677", "r683", "r684", "r685", "r686", "r687", "r688", "r691", "r694", "r695", "r696", "r697", "r698", "r700", "r701", "r702", "r703", "r705", "r706", "r707", "r708", "r709", "r711", "r714", "r715", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r736", "r808" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative", "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common stock issued for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r10", "r116", "r117", "r146", "r655", "r736", "r754" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of shares of common stock sold, shares", "terseLabel": "Warrant issuance, value", "verboseLabel": "Stock issued during the period" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative", "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r10", "r146" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Number of restricted shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Issuance of common stock for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r10", "r116", "r117", "r146", "r666", "r736", "r754", "r814" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of shares of common stock sold, net of issuance costs of $19,110", "verboseLabel": "Stock issued during the period" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r10", "r116", "r117", "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Number of restricted stock issued, value" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r10", "r116", "r117", "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Number of share returned" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NoncontrollingInterestDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r117", "r120", "r121", "r137", "r693", "r710", "r737", "r738", "r802", "r815", "r859", "r869", "r911", "r940" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "totalLabel": "Total Ozop Energy Solutions, Inc. stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r65", "r66", "r67", "r185", "r186", "r209", "r227", "r228", "r229", "r231", "r239", "r321", "r327", "r401", "r451", "r452", "r453", "r467", "r468", "r489", "r491", "r492", "r493", "r494", "r496", "r507", "r522", "r523", "r527", "r548", "r641", "r642", "r664", "r693", "r710", "r737", "r738", "r758", "r814", "r859", "r869", "r911", "r940" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balances", "periodStartLabel": "Beginning balance, value", "totalLabel": "TOTAL STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets", "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r145", "r221", "r384", "r386", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r401", "r498", "r739", "r741", "r759" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [ "r528", "r558" ], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r528", "r558" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r528", "r558" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r528", "r558" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r528", "r558" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r557", "r559" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN AND MANAGEMENT\u2019S PLANS" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r165", "r166", "r167", "r282", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r381", "r397", "r497", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r628", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r865", "r866", "r867", "r868" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/ScheduleOfDerivativeLiabilitiesAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury stock, shares" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r32", "r58", "r59" ], "calculation": { "http://ir.ozopsurgical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost, 47,500 shares of Sereis C Preferred Stock and 18,667 shares of Series D Preferred Stock" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r183", "r184", "r185", "r186", "r187", "r230", "r231", "r232", "r233", "r242", "r285", "r286", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r340", "r451", "r452", "r453", "r465", "r466", "r467", "r468", "r475", "r476", "r477", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r514", "r515", "r518", "r519", "r520", "r521", "r529", "r530", "r534", "r535", "r536", "r537", "r544", "r545", "r546", "r547", "r548", "r594", "r595", "r596", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards." } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/OperatingLeaseRight-of-useAssetsAndOperatingLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://ir.ozopsurgical.com/role/DeferredLiabilityDetailsNarrative", "http://ir.ozopsurgical.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://ir.ozopsurgical.com/role/RelatedPartyTransactionsDetailsNarrative", "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative", "http://ir.ozopsurgical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r49", "r50", "r51", "r171", "r172", "r175", "r176" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/SummaryOfSignificantAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r805", "r806", "r809", "r810", "r811", "r812" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r910" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrant expiry date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Risk free interest exercise prices" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r243", "r251" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://ir.ozopsurgical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org//205-40/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482669/740-10-15-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org//815/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "https://asc.fasb.org//820/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "50", "Subparagraph": "(a)", "Topic": "405", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481244/470-50-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480463/815-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(17))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(5)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "47", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r816": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r817": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r818": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r819": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r821": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r822": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r823": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r824": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r825": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r826": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r827": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r828": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r829": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r831": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r832": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r833": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r834": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r835": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r841": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r842": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r843": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r844": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r845": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r846": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483170/926-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r872": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//205-20/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 78 0001493152-23-017496-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-017496-xbrl.zip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

EH.2G NID:]%#MU#]='=Q/-"ZFAB+M747)P[4NH_N

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end